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Chapter 1. Ubiquitylation: Function and Regulation 
 
1.1 Ubiquitylation  
 
1.1.1 The history of the ubiquitin discovery  
Ubiquitylation is an important post-translational modification that connects 
ubiquitin (mono- or poly-) to various substrate proteins through a covalent bond1. 
Ubiquitin was initially identified in 1975 as a heat-stable polypeptide ~8,500Da in 
size2. It was found to be able to degrade denatured globin in reticulocyte lysates in 
an ATP-dependent manner3. Ubiquitin (Ub) was so named for its ubiquitous 
expression within the cells of higher order eukaryotes. It is found with high 
sequence conservation in animals, plants and yeast. The polypeptide has later 
been discovered as an important component for ATP-dependent proteolysis and 
was named ATP-dependent proteolysis factor 1 (APF-1)4. Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion analysis revealed 
that APF-1 was covalently conjugated to numerous cellular proteins and 
demonstrated tolerance to heat and high-pH conditions. This was the first time 
that ubiquitin was considered as an essential constituent of an apparent 
proteolysis pathway. Hershko et al.5 further demonstrated APF-1 was heavily 
conjugated to authentic proteolysis substrates and for first time elucidated the 
important components of the ubiquitin system, for example, ligases (E3 ligases) 
and amidases (deubiquitinase, DUBs). These breakthrough discoveries have since 
paved the way for the identification and further deconvolution of the role and 
function of many important protein players within this ATP-dependent proteolytic 
pathway. This has allowed scientists to further elucidate and understand important 
aspects of biology and physiology through the role of this important post-
translational modification.  
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 Since the 1980s, we have learned more about ubiquitin and the proteolytic 
system in which it plays a crucial role. The structure of ubiquitin was solved by 
nuclear magnetic resonance (NMR) and X-ray crystallography by several different 
groups6-9 (Fig 1.1). Ubiquitin is composed of 76 amino acids and displays a compact 
β-grasp fold with a 3.5 turn α-helix, a short 310-helix and mixed β-sheet 
components. The conserved hydrophobic core stabilizes the globular fold and 
allows it to survive in non-physiological conditions, for example, extremes of pH 
and temperature. Conserved solvent exposed patches and a highly-flexible C-
terminal tail enable ubiquitin to covalently react and non-covalently interact with 
a huge body of proteins to progress various cell signaling pathways8. Moreover, the 
canonical Ile44 hydrophobic patch on the Ub has been demonstrated as an 
important region for interacting with E2s and multiple ubiquitin binding domains 
(UBDs)10.     
 
1.1.2 Divergent functions of Ubiquitin-like proteins (UBLs)   
The distinguished β-grasp structure of ubiquitin and its conserved amino acids 
sequence allowed the identification of further proteins which shared similar 
biochemical and structural properties. These Ub-like proteins (UBLs)11, though 
similar from a structural point of view (sharing the ubiquitin fold), however, can be 
functionally categorized into two groups. The first group includes SUMO (small Ub-
like modifier), ATG8 (autophagy-related gene 8), NEDD8 (neural precursor cell-
expressed, developmentally downregulated protein 8), ISG15 (interferon-
stimulated gene 15), FAT10 (HLA-adjacent transcript 10), and UFM1 (Ub-fold 
modifier1) (Figure 1.1). These UBLs can also be conjugated to specific substrate 
proteins via a ATP-dependent enzymatic cascade similar to ubiquitin. Despite the 
regulation of protein turnover, UBLs also control various cellular function; e.g: 
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SUMO-substrates form complexes with chromatin and regulate DNA repair12; 
NEDD8 regulates cullin RING (Really Interesting New Gene) E3 ligase activity by 
neddylation of a conserved lysine residue13; ATG8 is conjugated to 
phosphatidylethanolamine14 (PE) and determines the size of autophagosomes15 
which is the precursor of autophagy16.  
The second group consist of proteins containing a UBL domain that are 
frequently found as part of multi-protein complex structures which prevent the 
protein itself to be conjugated to substrates. Moreover, the hydrophobic property 
from UBL domain allows these UBLs to mediate various protein-protein 
interactions. For example, the UBL domain in DNA repair protein HHR23A, which 
displays high affinity towards the second ubiquitin-interacting domain of S5a in the 
proteasome, enable HHR32A to play an important role involved in nucleotide 
excision repair via UBL-binding17.  
 
 
Figure 1.1 structural comparison of ubiquitin and ubiquitin-like proteins.  
Ub and UBL in cartoon representation. α-helices are in yellow, β-strands are in grey and 
loops are in green. UBL all share the similar α-helices with Ub which make them ubiquitin-
like protein. (Figure was reproduced from Ronau et al., 201618) 
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1.1.3 The enigma of ubiquitin system 
Typically, ubiquitylation is the biochemical event describing the conjugation of the 
C-terminal Gly76 of ubiquitin to the ε-NH2 group of a Lys residue in a substrate 
protein via an isopeptide bond. In addition, the seven lysine residues in ubiquitin 
itself can also serve as substrates, allowing the formation of different types of 
ubiquitin oligomers and polymers, referred to as polyubiquitin chains. Alternatively, 
the N-terminal methionine of ubiquitin can also form a linear peptide linkage with 
ubiquitin. Combinations of all eight different possible ubiquitin chain types19 (Met1, 
K6, K11, K27, K29, K33, K48, K63) act as a complicated code system to regulate cell 
function and signaling cascades.  
  The complexity of the Ub code system exceeds that of the eight different 
chain types20. The simplest type is mono-ubiquitylation in which a single ubiquitin 
is conjugated to a single lysine ε-NH2 upon a substrate. Mono-ubiqutination has 
been demonstrated to regulate multiple cellular processes such as DNA repair, 
gene expression 21,22. The earliest mono-ubiquitylation event was found on histone 
H2A23. The most immediate effect of mono-ubiquitylationin on substrates is to 
alter protein-protein interaction which can either activate a downstream cascade24, 
or prevent the interactions between substrates and their respective binding 
partner. This principal can serve as a regulation mechanism25. On the other hand, 
mono-ubiquitylation of multiple lysines within a substrate protein is able to trigger 
endocytosis26. However, it is the role played by oligomeric and polymeric ubiquitin 
chains that make this system of biological signaling both elegant and complicated.  
 The eight different ubiquitin chain types can be further categorized into two 
main groups, homotypic chains or heterotypic chains. In homotypic ubiquitin 
chains, the ubiquitin proteins are conjugated via the same lysine position to the 
Gly76 of a ubiquitin C-terminus. In heterotypic ubiquitin chains, the ubiquitin 
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proteins can be conjugated via various lysine positions to form a so-called 
branched Ub-chain. The classical and most abundant chain type is the K48-
chain27,28 which has been traditionally associated with targeting proteins to the 
26S proteasome and their subsequent processing by proteolysis29,30. The K48 chain 
was first found to regulate the degradation of cell-cycle proteins but direct 
evidence that demonstrated the recognition of the proteasome toward K48-linked 
proteins was provided in 200031. Consistent with the vital role in proteolysis, the 
K48 chain is generated by several different E3s which are known to be involved in 
protein degradation, for example, the conserved acidic loop on the E2 cdc34 and 
the cullin RING ubiquitin ligase SCFCdc4 tightly regulate K48 chain formation upon 
the Sic1 during the cell cycle32; Lu et al. further demonstrated that cyclin-B1, the 
substrate of another cullin E3, the anaphase-promoting complex  (APC/C) E3 
ligase, is rapidly degraded by the proteasome when two lysines are both modified 
with a di-K48 chain (two ubiquitin proteins are conjugated together via the lysine 
48 position on second Ub) rather than with a single tetra-K48 chain on one lysine33. 
E2 and E3 enzymes transfer ubiquitin to substrates and will be discussed later.  
 Instead of playing a similar role to K48 chains in regulating proteolysis, K63 
chains interact with multiple proteins and have been shown to regulate various 
signaling pathways20. Li et al. first reported that the RING E3 ligase TRAF6 can 
activate IKK (IκB kinase, inhibitor of kappa B kinase) by assembling a K63 
polyubiquitin chain34. Other groups also demonstrated that K63 chains are 
involved in DNA damage repair35,36, oxidative stress responses37, anti-viral immune 
responses38,39 and can even mediate mRNA splicing and hence regulate protein 
translation40,41. Both K48 and K63 ubiquitin chains are the most well studied and 
are abundant chain types in mammalian cells. The remaining five chain types are 
classed as atypical poly-Ub chains.  
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 A series of proteomic analyses revealed enormous roles for atypical ubiquitin 
chains and additional codes have been added27,29,42. The Met-1 chain (M1) is a 
unique chain type because of its special linear structure19,43 and has been 
demonstrated thus far to be made by a single specific E3 ligase complex44 (The 
linear ubiquitylation assembly complex, LUBAC45,46) Furthermore, it was 
discovered that the coordination of LUBAC and M1 chain formation are associated 
with NF-κB activation45,47-49. An interesting feature of the M1-chain is the difficulty 
to detect M1-linked conjugates without activation of the inflammatory signaling 
cascade47. In addition to the growing body of work in the area on M1 chains in the 
NF-κB signaling pathway, the regulation in pathogen infection50,51 and cell death52 
have also been shown to be mediated by LUBAC-associated M1 chains.  
The roles of K11 chains in cells are poorly understood. One exception is that 
K11-ubiquitylation has been shown to be increased during mitosis and G1-phase. 
Depletion of APC/C E3 largely prevents K11 chain formation indicating that it is a 
major source of K11-Ub chains53. Although the K11 chains have been linked to a 
proteolytic role, the homotypic K11 chain modification is not sufficient to trigger 
proteasome-dependent protein degradation of APC/C susbtrates. Mixed K48/K11 
heterotypic ubiquitin chains have been demonstrated to accelerate proteolysis 
compared to K11 chains alone54. K11 chains have also been found to mediate the 
HIF-1α-dependent pathway,55 and immune response after viral infection56.  
 In contrast to K48, K63, K11 and M1 chains, the remaining four chain types 
(K6, K27, K29 and K33) do not seem to be made by a highly Ub-chain specific 
enzymatic system which further complicates their studies. However, certain 
regulatory roles associated with these chains have been presented. Quantitative 
proteomics has indicated that K6- and K33-Ub chains are specifically increased 
after DNA damage57. Moreover, the K6 chains have also been verified in their 
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ability to mediate proteasome-dependent protein degradation58,59 and more 
recently have been shown to play a role in the response to mitochondrial damage 
or mitochondria-specific autophagy60,61 (mitophagy). Michel et al. developed a K6-
linked affimer with high selectivity and revealed that upon mitochondrial 
depolarization, the outer mitochondrial membrane protein mitofusin-2, is 
modified with K6 chains in a HUWE1 E3-dependent manner62. Little is known 
about K27-linked chains so far and the E3 ligases responsible have only been 
revealed recently63,64. Several reports indicate that K27 chains can regulate 
neuronal protection by branching with K29 chains65, activate DNA damage 
response (DDR)64 and control autoimmunity through regulation of the NF-κB 
activity in dendritic cells66. K29 chains were initially shown to regulate the ubiquitin 
fusion degradation (UFD) pathway in yeast by branching with K48 chains67,68. Two 
different groups established methods to prepare bulk amounts of K29 chains and 
solved the crystal structure69,70. Furthermore, K29 chains are reported to mediate 
lysosomal degradation in mammalian cells71,72. Al-Hakim et al. also demonstrated 
that K29 chains accompanied with K33 chains can modulate 5' AMP-activated 
protein kinase (AMPK) activity73. Additionally, several groups have demonstrated 
that K33 chains can mediate cell trafficking74, T-cell regulation75,76 and TBK1 
degradation77.  
 The discovery and study of the various roles played by all eight ubiquitin chain 
types in the regulation of various cellular functions still requires further maturation 
and development in order to fully understand how the ubiquitin code is ‘read’ by 
the aforementioned ubiquitin-binding domains (UBDs) and how the code is 
‘written’ in an orchestrated, context dependent manner by the various E2/E3 pairs. 
Moreover, the majority of these studies are based on either protein 
overexpression systems or in-vitro biochemical strategies, thus the biological and 
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physiological relevance of these studies must be interpreted with caution. Recently, 
another interesting and important research area in the ubiquitin field was 
uncovered, the direct post translation modification (PTM) of ubiquitin78,79, this 
increases the complexity of the ubiquitin code to a higher level. The most striking 
and exciting example is phosphorylation on Ser65 in ubiquitin80-82 (Ser65-p-Ub). 
This modification serves not only to change the well-known structure of ubiquitin 
but has also been demonstrated to affect the preference of DUBs or UBDs toward 
these modified-ubiquitin moieties83-85.  
 
1.2 Regulation of the ubiquitin conjugation cascade 
There are three major steps involved in the ubiquitylation of target proteins86,87 
(Figure 1.2). First, ubiquitin is activated by an ATP-dependent ubiquitin-activating 
enzyme (E1), resulting in the reaction of an activated Ub-resulting in the formation 
of a thioester bond between the C-terminus of ubiquitin and the active site 
cysteine in E1s88 (E1~Ub, ~ refers to labile thioester bond). E1~Ub will then recruit 
an ubiquitin conjugating enzyme (E2) and promote the transfer of ubiquitin to the 
E2 (E2~Ub) forming a thioester-linked intermediate89. The E2~Ub is then recruited 
by E3 ubiquitin ligases that mediate substrate specificity90. E3s belonging to the 
RING (Really Interesting New Gene) family can transfer ubiquitin from E2~Ub to 
substrates directly91; however, E3 ligases belonging to the HECT (Homologous to 
the E6AP Carboxyl Terminus)92 and RBR (RING-Between-RING) families87 form a 
covalent thioester intermediate (E3~Ub) through E2-E3 transthiolation and 
mediate transfer of ubiquitin to the lysine residue on substrates. The enzyme trio 
(E1, E2 and E3) can be considered as a ubiquitylation ‘writers’. The ubiquitin signal 
can be decoded by downstream effector proteins. These proteins contain the 
ubiquitin binding domains (UBDs)93,94 considered as the ‘readers’; the Ub/UBLs 
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specific proteases which remove the Ub or Ub chains from substrate proteins are 
the ‘erasers’, such as deubiquitinases (DUBs)95,96. The detailed mechanism and 
function of each enzyme will be discussed below (vide infra).   
 
 
Figure 1.2 The proposed mechanism of ubiquitin transfer by E1, E2 and E3 enzymes.  
The ubiquitin transfer cascade in cartoon. Three distinct E3 ligase families perform 
differently in transferring Ub to substrates. (Figure was reproduced as a whole from Smit 
et al., 201487) 
 
Using the same analogy, if Ub or Ub chains are the ‘words’ in the ubiquitin 
code, the next question is how do cells ‘write’ the sentence to allow proteins to 
communicate with each other. The workflow of the aforementioned enzyme trio, 
‘E1-E2-E3’, perform the key reactions to accomplish ubiquitin modification. It has 
been demonstrated by multiple groups that the disruption of this cascade or 
mutation in one of the enzymes will lead to numerous diseases97-100. 
Understanding the detailed molecular mechanism of how these enzymes regulate 
ubiquitin transfer will undoubtedly expand the number of therapeutic targets for 
drug discovery against disease states where ubiquitylation or ‘E1-E2-E3’ is of vital 
importance. A key question that has puzzled the field for a long time is how the 
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activity of these key enzymes is regulated? The following is a brief review of this 
important enzyme cascade in the ubiquitin system with subsequent focus on the 
final component, the ‘E3 ligase’.  
 
1.2.1 Initiation by E1 activating enzymes 
The ubiquitin proteolysis system was discovered to be an ATP-dependent 
process4,5. ATP is an important component for triggering ubiquitin activating 
enzymes, E1s, namely UBA1 and UBA6 in vertebrates101,102. UBA1 is specific for 
ubiquitin transfer and UBA6 can transfer both Ub and FAT10103 to their cognate E2s. 
Other UBL E1s also share mechanistic but not sequence similarities in activating 
UBL cascade. All the E1s are in the range of approximately 120 kDa and feature 
three major important domains to transfer ubiquitin with high fidelity: 
pseudodimeric adenylation domain, cysteine domain with catalytic cysteine 
residue, and ubiquitin-fold domain (UFD) that interacts with downstream E2s104. 
E1s associate with Mg2+•ATP and Ub/UBL through their adenylation domain and 
adenylate the C-terminal glycine of Ub/UBL to form Ub-AMP and pyrophosphate. 
Previous structural studies have shown that the E1 is in an open conformation and 
that the catalytic cysteine residue is far from the adenylation site at this step105-107. 
After the Ub-AMP has formed, pyrophosphate will be released from the 
adenylation site. There is a significant conformational change (130° rotation) in this 
domain to allow the Cys domain to bring the E1s catalytic cysteine in close 
proximity of the C-terminal Ub/UBL108. This conformational transition is extremely 
important for ubiquitin transfer since it brings the E1s catalytic cysteine residue 
35Å closer to the Ub/UBL C-terminus. After the rotation, the catalytic cysteine 
attacks the Ub-AMP and forms a transient thioester bond between the Ub Gly76 
and the Cys sulphydryl of E1. Once the thioester bond has formed, the E1s Cys 
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domain rotates back to an open configuration and frees up the adenylation domain 
for the next round of adenylation109. Early studies into E1 activity revealed that a 
doubly loaded E1 was better in recruiting E2s, although the mechanism was 
unknown110. The transthiolation mechanism of Ub transfer between E1/E2 has 
only revealed over the last few years88,104. The mystery before these studies was 
how the E1s catalytic cysteine positioned itself in close enough proximity with the 
E2s catalytic cysteine. According to other UBL E1 structures, the doubly loaded 
NEDD8 E1/E2 structure and doubly loaded SUMO E1/E2 structure all showed that 
the two catalytic cysteines are 15-20 Å apart from each other109,111 thus 
incompatible with transthiolation. Olsen et al. compared the structure of ‘Ub 
E1/Ub/ATP,Mg’ alone with ‘Ub E1/Ub/ATP,Mg associated with Ub E2 Ubc4’ and 
revealed that a certain rotation of UFD domain on E1 is needed for E1-E2 
interaction104. In addition, the catalytic cysteine on E1 is hindered by a loop located 
in the Cys domain but this Cys cap is disordered upon contact with an E2. The E1-
E2 complex crystal structure revealed multiple contacts between the E2 and the 
E1s UFD and Cys domains, with nearly 40% of E2 surface area buried in these 
domains104. However, due to the transient nature of the thioester bond, the 
Ub~E1/E2 structure remains elusive which further emphasizes the need for a tool 
to determine the transthiolation activity of E1 enzymes.  
 Most knowledge related to E1 activity regulation has relied heavily on 
molecular biology studies, especially from a structural point of view. We still know 
little about how E1 activity is regulated in vivo. Several groups demonstrated that 
mutation or depletion of E1 in cells would affect the cell cycle and proliferation112-
115. UBA1 exists in most of mammalian cell lines and appears to be constitutivly 
active 102. Analysis of the level of Ub~E2s indicated that the E1s are activated and 
sufficient to trigger the ubiquitylation cascade. Therefore, E2-E3 and E3-substrate 
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interactions are vital steps in controlling ubiquitin modification. This thesis focuses 
on developing the tools to study E2-E3 interaction and monitoring E3 ligase activity.  
 
1.2.2 E2s are cascade intermediates   
 
1.2.2.1 General features of E2s  
There are nearly 40 Ub/UBL-conjugating E2 enzymes (E2s) in the human genome 
and most of their structures have been solved already. Transthiolation and 
aminolysis are the two major reactions which E2s perform. As the description in 
the title of Stweart et al. review116, E2s are not only middle men passing the 
message from E1s to E3s. They also play the key roles in transferring ubiquitin to 
substrate proteins, building the correct ubiquitin chains and regulating the 
function of other proteins beyond the canonical ubiquitin mechanism117,118. There 
is a conserved core structure among all E2s which contains roughly 150 amino 
acids, termed UBC domain. This domain adopts an α/β-fold composed of four α-
helices and a four stranded antiparallel β-sheet. Although UBC domain features a 
high similarity ‘core’ structure in E2s, certain E2s also have N- or C- terminal 
extensions. The function of these is poorly understood but in some cases they 
facilitate E2s interacting with the ~700 different E3s116. As stated previously, E1s 
appear to be constitutively active in proliferating cells and produce a steady 
turnover of Ub loaded E2s. Downstream E2~Ub activity is then tuned based on the 
E3 and/or substrate that is encountered in a given pathway. The interaction within 
E3s will be covered in later sections.  
 One of the E2s primary roles is to transfer thioester-linked Ub to the lysine 
residues on substrates in a RING E3 mediated manner. However, E3-independent 
discharge onto high concentration of free lysine is observed89. Therefore, 
monitoring the discharge of ubiquitin from E2s to free lysine can indicate the 
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intrinsic activity of E2s without being confused by other components used in 
different activity assays89. Although the cysteine-dependent ubiquitylation 
mediated by E2, Pex4p119,120, was not discovered by the free amino acids assay. 
Wenzel et al. obtained the exciting data that UBCH7, which supports activity of the 
presumed RING E3 HHARI cannot discharge onto lysine. This raised the possibility 
that HHARI belonged to a mechanistically novel clan of E3 that underwent 
transthiolation with E2~Ub121. The loaded UBCH7 (UBE2L3)~Ub performs exclusive 
reactivity towards cysteine rather than lysine which redefines the function of this 
E2. UBCH7 is now considered a functional E2 for HECT and RBR E3s which can 
transfer Ub from itself to the catalytic cysteine on E3s. UBCH7 distinguishes itself 
from other E2s that genuinely target lysine as their only substrate. The E2 UBE2J2 
has also been reported to undergo non-lysine ubiquitylation with RING E3 ligase 
mK3, instead modifying serine/threonine residues122.  
 
1.2.2.2 The distinct ‘closed’ and ‘open’ E2~Ub conformations   
Early crystal studies showed that a canonical binding surface on UBC domains 
direct E2s toward many different E3s. Multiple residues on helix 1 and loop 4 and 
7 mediate the E2s binding with HECT and RING E3s123,124. If the E3 binding region 
is similar on E2 enzymes, how is ubiquitin selectively transferred to lysine or 
cysteine? The highly flexible C-terminal region (72-76, RLRGG) on Ub offers the 
ability to swing the Ub molecule while conjugated with E2s. Several groups 
performed various experiments to demonstrate that Ub~E2 moves from an ‘open 
state’ to ‘closed state’ upon interaction with RING E3 ligases125-127. The Ub~E2 
conjugates react significantly faster toward lysine residues when accompanied by 
RING E3 ligase121. The E2~Ub:RING E3 crystal structures further revealed that the 
Ub is folded back toward the E2 to expose its C-terminal tail, making it favorable 
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for substrate lysine attack125. Moreover, the D87 and D117 residues on UBCH5 E2s, 
which have been indicated to be essential for the deprotonation of the poorly 
nucleophilic ε-NH2 group on the substrate lysine residue are missing in the 
HECT/RBR specific E2, UBCH7. Unlike the RING E3 ligases, the HECT or RBR E3s do 
not promote an E2~Ub closed conformation. The crystal structures of E2~Ub with 
Nedd4-2 (HECT E3) and HOIP (RBR E3) proved this theory128,129. Moreover, the 
binding with HECT or RBR prevents the E2~Ub closed conformation, which also 
blocks its intrinsic activity towards free lysines118.  
 
1.2.2.3 The ‘backside effect’ sterically activates E2s 
The E2-E3 interaction is not the only intermolecular interaction to regulate E2s 
activity. Recently, the backside attachments of ubiquitin to E2s has been shown to 
increase E2~Ub activity for transferring ubiquitin to acceptors130. This area is 
located opposite from the catalytic site and can be contacted by free Ub, the Ub 
on E2~Ub, mono or poly-Ub chains on E3s or substrates. There were some early 
studies on E2/E3 allosteric backside binding effects before the crystal structures 
were reported. These reports demonstrated low affinity of Ub toward E2~Ub but 
still showed the increase in activity of ubiquitin transfer131,132. Biochemical and 
structural data have revealed that Ser22 on UBCH5 and the Ile44 hydrophobic 
patch on Ub are the key factors in this Ub/E2~Ub interaction. However, the 
opposite result was also found by another E2, UBE2E3, for which the backside 
effect governs the ability to make polyUb chains133. Autoubiquitylation of lysine 
residues on E2 itself has also been showed to have a regulatory effect on E2 activity. 
Instead of enhancing the activity of E2s, these modifications inhibit the ubiquitin 
transfer from E2 in vitro134,135. On the whole, considering that there are more than 
600 RING E3 ligases needed to work with 40 different E2s to either make free 
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ubiquitin chains or conjugate mono- or poly- ubiquitin to substrates, the regulation 
of E2s activity may need to be controlled. However, the mechanism for E2 
regulation is poorly characterized.  
 
1.2.3 E3 confers substrate specificity 
The aim for this thesis is to study the mechanism of E3 ligases whose activity is 
clearly regulated in many cases. E3 transthiolation activity further plays a key role 
in ubiquitin transfer and regulation can occur at this step. However, a good 
mechanism-based tool to study the tranthiolation activity between E2s and E3s is 
missing. In order to develop a good tool to help us to dissect E3 activity, 
understanding how E3 ligases generally work is the first step. E3s can be 
categorized into three subfamilies based on their distinct structure and mechanism 
of how they catalyze ubiquitin transfer to substrates. In general, RING E3s interact 
with E2~Ub and regulate the ubiquitin transfer indirectly. On the other hand, 
transthiolation between E2~Ub and HECT and RBR E3s allow these E3s to transfer 
ubiquitin to substrates directly based on their activity.  
 
1.3 The E3 ligases are more than a messenger but a creator 
 
1.3.1 RING E3 ligases 
 
1.3.1.1 The RING domain binds E2s  
RING E3 ligases were first discovered with the RING motif from Ring1 protein 
(really interesting new gene 1)136. The conserved sequence in canonical RING E3s 
is Cys-X2-Cys-X(9-39)-Cys(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-Cys-X2-Cys (X can be any 
amino acid) (Figure 1.3) and adopts a cross-braced arrangement with Zn ions91. 
Structural analysis reveals that this motif resides in the core of RING E3s and the 
16 
 
association with Zn2+ yields a globular and rigid platform for recruiting E2s137. 
Considering its essential role in RING E3 composition, mutations in these Zn2+-
binding domains usually abolishes RING E3 activity. Another exception is U-Box 
proteins which adopt a RING-like structure for E2 interaction and transfer ubiquitin 
with the same mechanism as RING E3s but do not coordinate with Zn2+-ions138,139. 
Interestingly, RING E3s were not discovered as ubiquitin E3 ligases at first but were 
identified through involvment in regulating DNA damage. Many discoveries of 
RING E3s were related to DNA research91. The E3 activity was later demonstrated 
with histone ubiquitylation promoted by Rad18.  
 
 
 
Figure 1.3 RING Finger domain adopts a highly conserved cross-braced arrangement.  
(a) The sequence of RING-HC domain with Zn2+. The first cysteine coordinated with Zn2+ is 
ordered C1 and so on. The H1 refers to the histidine binding with Zn2+. (b) RING domain 
from c-Cbl in ribbon diagram with the N as N-terminus and C as C-terminus. (c) The 
alignment of different RING-like sequences with canonical RING domain. LIM and PHD 
share high similarity in sequence with RING E3 but do not retain E3 activity. (Figure was 
reproduced from Deshaies et al., 200991)  
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1.3.1.2 RING E3s work collectively  
According to bioinformatic analyses there are more than 600 RING E3s in the 
human genome and nearly half of them are not yet well understood140. The 
interesting and also difficult part to studying RING E3s is their diversity of action 
(Figure 1.4). The single functional polypeptide RING E3s (RING monomer) can be 
found in CBL123, CNOT4141 and RNF38130. However, the most-well known feature of 
RING E3s is their ability to form homodimers or heterodimers. For example, cIAP142, 
RNF4143, TRAF6144, BIRC7126, CHIP145 and Prp19146,147 are all be found as 
homodimeric RING E3s in cells. These homodimeric RING E3s have intrinsic activity 
to react with Ub~E2 but the mechanisms of dimer formation are quite different. 
The hydrophobic patches and N-terminal hairpin on CHIP RING E3 mediate the U-
box/U-box intermolecular reaction and substrate binding domain148 while others 
simply dimerize via RING domain interaction. In contrast, some E3s such as BRCA1-
BARD1, BMI1-RING1B and MDM2-MDMX are known to exist in heterodimeric form. 
BARD1 from this category does not have intrinsic activity to interact with E2s but 
is able to enhance the stability of a dimer complex or substrate recognition in 
vivo149,150. The domains on RING E3s responsible for dimerization are also varied. 
In some RING E3s, the sequence outside the RING domain plays an important role 
for dimerization, as seen in BRCA1-BARD1 and RING1-Bmi1 complexes. The others 
can form a dimer via their RING domains which are generally located in the 
extreme C-terminus of these proteins, for example, MDM2-MDMX and RNF4 
homodimer143,151. The complexity of RING E3s is more than just the dimer. The 
Cullin RING Ligase (CRLs) subfamily including the anaphase promoting 
complex/cyclosome (APC/C) are reported as huge complexes with E3 activity. CRLs 
are built up of multiple proteins including RING E3 (in most cases RBX1 or RBX2), a 
cullin protein (CUL1, CUL2, CUL3, CUL4A/4B, CUL5 or CUL7) and a substrate 
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receptor152,153. Due to the variety of the substrate receptors and the combination 
of different cullin proteins, the substrate number for CRLs is enormous. Due to the 
high variety of different RING E3s forms, the detection of RING E3s activity has 
proven to be challenging.  
 
 
Figure 1.4 RING E3 ligases work in various form from monomer to dimer. 
The crystal structure of different RING E3 in either a: monomer, CBL RING, PDB:1FBV, b: 
Homodimer, cIAP2 RING E3, PDB:3EB5, c: Heterodimer, BRCA1(orange)/BARD1(yellow) 
RING E3, PDB:1JM7. The grey sphere represents a Zn ion that coordinates with RING 
domain. The homodimer adopts a different structural architecture compared to the 
hererodimer. (Figure was reproduced from Buetow et al., 2016137)   
 
1.3.1.3 Regulation of RING E3s 
The most important function of RING E3s is to mediate ubiquitin transfer from 
E2~Ub to substrates. The mechanism of how RING E3s distinguish the loaded 
E2~Ub from unloaded E2 and how the enhanced reactivity of E2~Ub towards 
substrate lysine is promoted via RING E3s were only be reported recently. RING E3s 
used to be considered as only the cofactors for helping E2 to transfer ubiquitin to 
the correct substrate residues. The early reported crystal data showed little 
differences between E2s and E2:RING complexes123,154,155. Moreover, the catalytic 
cysteine on E2 is also far from the E2 binding site on RING E3s. Considering the 
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highly dynamic nature of E2~Ub156 and the enhancement of ubiquitin transfer from 
E2~Ub while RING E3s are presented , it was suggested that there is an unknown 
allosteric effect between RING E3s and E2s. The main shortcoming in earlier 
structures was the lack of ubiquitin on E2s which is important for E2:E3 
interaction157,158.  
The structure of the thioester-linked ubiquitin on E2 in complex with the 
dimeric RNF4 E3 demonstrated the dynamic nature of the so called ‘open’ 
conformation of this conjugate132. The significant advance in our understanding of 
RING E3 mechanism is that three landmark papers reported structures of E2-
Ub:RING E3s in 2012 and provided the molecular detail of their action125,126,159. In 
contrast to the previous E2~Ub structures which were in open conformations, the 
‘closed’ conformation was discovered by all three groups (Figure 1.5). The Ile44 
hydrophobic patch on the donor ubiquitin (the ubiquitin on E2 referred to as the 
donor, the ubiquitin as a substrate containing the target lysine is referred to as the 
acceptor) interacts with α helixes on the E2 to stabilize the ubiquitin in a folded 
back position and allows the C-terminal tail to be exposed to the substrate in the 
E2 active site. RING E3s prime the ubiquitin transfer from E2s by keeping the 
flexible ubiquitin in an active mode which allows the lysine on substrates to attack 
the thioester bond more easily. Consistent with the mechanism proposed, several 
E2:Ub interface mutations showed a decrease in ubiquitin transfer and disruption 
of the closed E2~Ub conformation159. Moreover, by forming a hydrogen bond with 
Gln92 on E2 and Arg72 on ubiquitin, the Arg residue in loop 2 which is on the RING 
domain plays a vital role in priming the ubiquitin transfer157,160,161. These findings 
greatly expand our knowledge about the mechanism of ubiquitin being transferred 
by RING E3s. However, it has been reported that several E2s which work with RING 
E3s are also capabled to transfer ubiquitin in an E3-independent manner157,160,161. 
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Further study about the detail mechanism of how these two enzymes mediate 
ubiquitin transfer is still needed.  
 
 
 
Figure 1.5 E2~Ub adopts a close conformation whilst binding with RING E3. 
The highly flexible tail on Ub makes E2~Ub highly dynamic. However, once it has bound 
with RING E3 ligase, it adopts a ‘closed’ state for incoming lysine attack from substrate 
proteins. The UBE2D2~Ub oxyester conjugate forms a closed conformation upon binding 
with a RING E3 BIRC7 (not shown) (PDBID:4AUQ). (Figure was reproduced from Stewart 
et al., 2016116) 
 
The concept that RING E3s prime the E2~Ub to transfer ubiquitin toward 
substrate is well accepted, but how these RING E3s are regulated or activated is 
still not fully understood. One of the mechanisms to regulate RING E3s is through 
dimer or complex formation, as discussed above. The post translational 
modification on RING E3s has also currently been reported. The Cbl RING E3 family 
(c-Cbl, Cbl-B and Cbl-C) is reported to be regulated by phosphorylation. 
Phosphorylation of a highly conserved tyrosine residue at position 371 (Tyr371) 
promotes a conformational change of the linker helix region (LHR) and allows the 
RING-bound E2 to present the catalytic site towards the substrate162. This 
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phosphorylation event is also involved in stabilizing the closed E2~Ub 
conformation for priming ubiquitin transfer163. Despite autoubiquitylation on RING 
E3s enhancing their ligase activity131,164, the post-translational modification on the 
subunit of CRL complex can also regulate ligase activity. All the cullin proteins have 
been reported to be modified by NEDD8, one of the UBL proteins, to regulate CRL 
activity165,166. The neddyation of cullin proteins induces a conformational change 
to potentially free up the RBX1 RING domain and allow it to bring E2~Ub in 
proximity to substrates154,167. E2~Ub levels are in sufficient supply within the cells 
which makes regulation of RING E3 activity extremely important considering the 
huge number of RING E3s (nearly 600). A good tool to measure the activity of RING 
E3s will be a big step forward to accelerate research on this topic.  
 
1.3.2 HECT E3 ligases 
 
1.3.2.1 HECT E3s  
HECT E3 ligases were the first type of E3 ligase to be discovered168 and in humans 
there are ~28 enzymes ranging between 80 kDa to more than 500 kDa in size169 
(Figure 1.6). The mechanism for ubiquitin transfer via HECT E3s is distinct to that 
of RING E3s. The ubiquitin transfer from E2 to catalytic cysteine on HECT is via a 
transthiolation reaction to a specific cysteine residing within the HECT E3 and then 
subsequent Ub transfer to a lysine side chain on a substrate via an aminolysis 
reaction. These two distinct reactions are responsible for one single ubiquitin 
transfer and as such, makes the study and deconvolution of HECT E3 activity and 
regulation challenging.  
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Figure 1.6 Overview of three subtypes of HECT E3s. 
The N- and C- terminal extensions from the HECT domain not only regulate HECT E3 
activity but also largely expand the substrate numbers for HECT E3s. Abbreviation: RCC1, 
Regulator of Chromosome Condensation 1 repeat domain; SPRY, B30.2/SPRY (SPIA and 
RYanodine Receptor) domain; WD40, WD40/YVTN repeat-like-containing domain; CYT-B5, 
Cytochrome B5-like heme/steroid binding domain; MIB, MIB-HERC2 domain; L2, 
ribosomal protein L2 domain; ZNF, zinc finger; DOC, APC10/DOC domain; AR, ankyrin 
repeat-containing domain; ARM, armadillo-type fold domain (overlaps in TRIPC with a 
predicted WWE domain); UBA, ubiquitin-associated domain; WWE, WWE domain; BH3, 
BCL-2 homology region 3 domain; UBM, ubiquitin-binding motif; MLLE, 
Mademoiselle/PABC domain; IGF, immunoglobulin-like fold; PHD, PHD-type zinc finger; 
SUN, SAD1/UNC domain (overlaps in HECTD1 with predicted galactose-binding-like 
domain); AZUL, AZUL domain/ N-terminal zinc-binding domain; IQ, IQ domain/ EF-hand 
binding site; C2, C2 domain; WW, WW domain (Figure was reproduced as a whole from 
Lorenz et al., 2018170) 
 
 There are three subtypes of HECT E3s based on their structural diversity 
within the substrate recognition domain. The Nedd4/Nedd4-like HECT E3 
subfamily contain a membrane-targeting C2 domain tethered to several WW 
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domains N-terminal to the HECT domain171,172. In contrast, six E3s (HERC1 to 6) 
within HERC subfamily contain RCC1-like domains which are N-terminal to the 
HECT domain. The remaining HECT E3s are also predicted to bear varied protein 
architectures before the HECT domain and are likely to be important for mediating 
protein-protein interactions (Fig 1.6).  
Understanding how HECT E3s work on a molecular level is currently a difficult 
task to achieve as there are no available full length structures of any HECT E3s 
(either by crystallography or NMR analysis). Also, many regions within HECT E3s 
are predicted to be disordered in nature, thereby hampering efforts towards 
complete structural characterization. However, by combining the growing body of 
biochemical data relating to HECT E3 activity and by solving and analyzing the 
structures of HECT- domain only or appropriately truncated HECT E3s, we will be 
able to better understand HECT E3 ligase activity, regulation and mechanism. 
 
1.3.2.2 Nedd4 HECT E3s 
The Nedd4 family is the most well studied category which contains nine members 
and all possess C2 and WW domains. The C2 domain was discovered in several 
different proteins including protein kinase C (PKC)173, cytosolic phospholipase A2174 
and synaptotagmin175 and was first identified as a Ca2+-dependent phospholipid 
binding domain in PKC. It contains approximately 130 amino acids and folds into 
two four-stranded β-sheets. Multiple conserved aspartate amino acids reside in 
the loop regions between these β-strands, bind Ca2+ and mediate the C2 
interaction176,177. Plant et al. reported that the C2 domain in Nedd4 is responsible 
for localizing the Nedd4 from the cytosol to specific cellular fractions such as 
membranes in response to Ca2+ treatment178. Experiments demonstrated that the 
C2 domain is able to bind not only Ca2+ but also phospholipids and even other 
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proteins. The other domain present in Nedd4 is the WW domains (2-4 repeats N-
terminal to HECT domain), which has been reported as the substrate recognition 
site179,180. The WW domain is so-named as there are two conserved tryptophan 
residues within its structure that are commonly spaced 20-22 residues apart. The 
domain adopts a compact module with three-stranded anti-parallel β-sheets that 
forms a hydrophobic ligand binding groove. It is found to bind exclusively to 
proline-rich motifs such as PPxY181 (x can be any amino acid), PPLP182, and 
phosphoserine/threonine (pSer/pThr) that are followed by a proline residue183. 
WW domains fall into four classes based on the recognized motif they interact with. 
It has been found that WW domain in Nedd4 E3s particularly favors PY motifs 
(PPxY). However, Lu et al.183 also demonstrated the possibility of WW domain to 
recognize pSer/pThr which broadens the substrate members of the Nedd4 HECT 
family. Importantly, some WW domains reside within the same E3 and may 
function with entirely different substrates. As such, these proteins architectures 
would enable these enzymes to act as an interaction hub, enabling interaction with 
various adaptor proteins and substrates for specific signaling pathways184.  
 
1.3.2.3 HERC-family and miscellaneous HECT E3s 
HERC E3s are a family of large proteins which range from 120 kDa to 500 kDa. The 
characteristic domain of HERC E3s is the chromosome condensation 1 (RCC)-like 
domain (RLD). The RLD is composed of a seven-bladed β-propeller fold which itself 
is a 51-68 amino acid repeat unit. The RLD acts as a guanine nucleotide-exchange 
factor (GEF) that interacts with GTPases or interacts with chromatin via H2A and 
H2B. However, only in the case of the large HERC E3s (HERC1 and HERC2), has the 
above function been demonstrated. The small HERC E3s do not retain GEF activity. 
Convincing experimental data concerning the function and structure of HERC E3s 
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is currently absent from literature due to their often large size and to the presence 
of multiple domains of hitherto unknown function. The miscellaneous HECT E3s, 
have divergent N-terminal domains and display preferences toward interacting 
partners not found in previously described HECT E3 families185. For example, the 
UBR5(EDD) contains a UBR 1-like zinc finger and PABC domain which allows HECT 
E3 mediated regulation of the activity of the PABP transcription factor186; HUWE1, 
has a WWE and a BH3 domain N-terminal to the HECT domain.  
 
1.3.2.4 General mechanism of Ub transfer by HECT E3s 
Ubiquitin transfer by HECT E3s involves two sequential steps. Firstly transthiolation 
occurs to transfer thioester-linked ubiquitin from E2s to HECT E3s and then 
secondly, aminolysis, enabling the Ub-modification of substrate proteins. Initial 
structural studies of E2:HECT protein complexes indicated the distance between 
the E2 catalytic cysteine and the catalytic cysteine of HECT E3 are too far from each 
other to allow cysteine-cysteine juxtaposition and subsequent transthiolation to 
occur. Significant conformational changes must be undertaken to allow a 
catalytically competent protein complex to be formed for transthiolation and 
subsequent ubiquitin transfer. It has recently been demonstrated that the 
structural movement of HECT E3s is actually regulated by two conserved lobes and 
a linker region within the HECT domain. The HECT domain is a bi-lobed structure 
that contains N-lobe which is essential for E2 binding and a C-lobe harboring the 
catalytic cysteine187. The highly flexible hinge region which connects these two 
lobes allows the C-lobe to adopt different conformations when interacting with 
substrates. The other conserved region among all HECT domains is the ‘-4Phe’ 
region which is located towards the C-terminus and is proposed to be an important 
region for HECT-mediated isopeptide bond formation188. This region is found to 
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only be structurally ordered when co-crystalized with ubiquitin and a substrate 
peptide as they enable stabilization of the N-lobe189. Mutation of the C-lobe 
Phe806 on Rsp5 dramatically impairs the polyubiquitylation process (Figure 1.7).   
 
 
 
Figure 1.7 The close-up view of the crystal structure for ‘-4Phe’ position between N- 
and C-lobe.  
The structure of the interface between Rsp5WW3-HECT, Ub and Sna3C indicated how F806 
interacts with residues on N-lobe (R461, L506 and F505). (Figure was reproduced from 
Kamadurai et al., 2013189) 
 
 The first step to transfer ubiquitin by HECT E3 is the interaction with E2~Ub. 
The crystal structures for E2:HECT187 and E2~Ub:HECT128 revealed the interface 
between them. The major differences between these two structures are the 
rotation of C-lobe in HECT domain and the non-covalent interaction between Ub 
and C-lobe when E2~Ub is bound to HECT E3. Huang et al. solved the structure of 
UBCH7:E6AP and showed that the catalytic cysteine 820 is located in the junction 
connecting the two lobes. Both lobes provide important amino acid contacts 
within this broad cleft, with N-lobe residues being broadly polar and negatively 
charged whereas C-lobe residues are widely conserved and are hydrophobic in 
nature. Comparing the two structures, the HECT-binding domain from the E2 is 
conserved among them but the E2 recognition region upon HECT binding domain 
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is varied. In addition, Phe (62 on UBH5B, 63 on UBCH7) on loop4 is important for 
E2 interaction with the hydrophobic patch on some HECT domains (Figure 1.8a). 
The mutations made at these sites often disrupt the transthiolation between E2s 
and HECT E3s but these sites appear more important and consistent with HECT E3s 
rather than RING E3s190. In addition, the wide range of this hydrophobic region 
among HECT E3s may explain the reason why the same E2 is capable of interacting 
with numerous HECT E3s. The above mentioned structures also indicate the 
selectivity of HECT E3s toward E2s. Nedd4L Trp742 which is conserved in the 
Nedd4 family has been found to form a hydrogen bonding interaction with 
UBCH5C Ser94. This is the same region within HECT E3s that enables interaction 
with the UBCH4/5 and UBE2E families191,192. Other HECT E3s such as HECTD1, 
HERC3, HERC6 and HECTD6 also have the corresponding residue acting as Trp742 
to interact with the residue homologous to Ser94 in UBCH5C. As mentioned above, 
the catalytic cysteine on the E2 is found to be >40 Å away from the catalytic 
cysteine in the HECT domain in the H7:E6AP structure, making transthiolation 
impossible. However, in UBCH5B~Ub:Nedd4L structure, the two cysteines are 
within <8 Å and implies that a certain conformational change occurred, enabling 
cysteine-cysteine juxtaposition. A complete and accurate mechanistic explanation 
of how E2~Ub triggers the rotation of the HECT E3 C-lobe and the predicted E2 
binding interactions are all likely to play an important role and contribute to 
catalysis. 
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Figure 1.8 The close-up view of the crystal structure of E2:HECT complex.  
(a) Interactions between UBCH5B (cyan, black labels) and HECT NEDD4L N lobe (magenta) 
(left) and interactions between UBCH7 (navy) and HECT E6AP (salmon), in same 
orientation (Right). The red frame highlights the F62/F63 positon on E2s which is essential 
for E3 binding. (b) The model of UBCH5B~Ub with NEDD4L HECT domain. 4° rotation on 
the hinge linker is predicted to adopt catalytic Cys on E2 in proximity with catalytic Cys on 
HECT domain. (Figure was reproduced from Kamadurai et al., 2009128) 
 
 In the predicted modeling complex reported by Kamadurai et al., the E2 can 
be positioned more closely to HECT domain in order to approach catalytic cysteine 
for competent transthiolation by rotating the hinge linker by approximately 4°128. 
Furthermore, the rotation in this model had minimal effect upon the interface of 
E2~Ub and the HECT domain. The conserved region was discovered by the 
predicted model and agreed with the results of the mutational analysis of 
important HECT E3 residues. The Leu119 on UBCH5B was found to interact with 
His920, Phe923 and catalytic Cys922 (Figure 1.8b). Although the exact role of the 
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residues found by modeling require further investigation, the interactions between 
donor ubiquitin on E2 and the HECT E3 C-lobe in the crystal structure indicate that 
the mechanism to prime ubiquitin transfer is largely mediated by the donor 
ubiquitin. Unlike the contacts made with RING E3 ligases, E2~Ub adopts as opened 
conformation when contacting with HECT E3s in the pre-transthiolation state. The 
Ub tail is then stabilized by the interaction with the C-lobe. According to the 
crystallographic data, the lle36, Leu71 and Leu73 on Ub coordinate with Leu916 
and Met943 on the HECT to enable the interface between them. Hydrogen bonds 
are also discovered between Gly35 on Ub with Lys90 on HECT and Gln40 on Ub 
with Leu916 on HECT. The hydrophobic patch on Ub including Ile36 and Leu71 both 
play important role on mediating the interaction. Mutaion of both Ile36 and Leu71 
perturb ubiquitin transfer to Nedd4L, ITCH and Rsp5128. Clearly the presence of the 
ubiquitin component in E2~Ub plays a role in inducing conformational changes in 
the E3 that are required for catalysis.  
 HECT E3s have been experimentally determined to enable both mono-
ubiquitylation and poly-ubiquitylation of protein substrates. After ubiquitin has 
been transferred to the HECT domain, the interaction between C-lobe and Ub is 
still preserved but Ub is orientated in an extended conformation and extends past 
the β-sheet of the HECT C-lobe. The C-lobe then rotates ~130° and turns it away 
from E2 binding site for thioester-linked donor ubiquitin to be attacked by 
substrate lysine189 (Figure1.9). The well-known “-4Phe, F806” resides in this region 
at the C-lobe and collaborates with Phe505 and Leu506 to orientate the two lobes 
into appropriate position for substrate ubiquitination. The mutation on Phe806 
severely impairs the ligation but can be rescued by mutating the L506W or L506F 
upon the N-lobe189 (Figure 1.7). However, the conserved region on the N-lobe is 
only preserved in Nedd4 family HECT E3s which raises the possibility for other 
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mechanisms of ubiquitin transfer being possible with respect to miscellaneous 
HECT E3s169. The HECT:substrate structure also reveals that the loop in N-lobe 
containing Asp495 is important for ubiquitin ligation. 193. The ubiquitin transfer is 
assisted by the noncovalent Ub binding sites on the N-lobe which have been 
demonstrated to be essential for chain elongation but not for transthiolation with 
E2~Ub194. This region is distal to the E3~Ub which makes unsuitable contacts with 
ubiquitin in order to accept ubiquitin from the donor. Experimental data suggests 
that this site can coordinate with ubiquitylated substrate and promote the chain 
elongation195.   
 
 
 
Figure 1.9 HECT E3s in motion.  
The C-lobe on the HECT domain is blocked by C2 domain at rest in an auto-inhibited form. 
By induction from stimuli or binding with substrates, the HECT domain is freed from 
inhibition and is able to interact with E2~Ub. C-lobe will rotate 130° upon binding with 
E2~Ub and present the donor ubiquitin toward substrates. (Figure was reproduced from 
Fajner et al., 2017185) 
 
 The intrinsic activity of HECT E3s to make poly-ubiquitin chains is independent 
of E2s although the universal mechanism for the chain type preference of HECT 
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E3s is still poorly understand. By far, only the C-terminal region from Nedd4 Rsp5 
has been shown to be critical for K63 chain formation. The replacement the last 60 
residues on Rap5 to the region corresponded to E6AP can manipulate the chain 
formation from K63 to K48196.    
 
1.3.2.5 The regulation of HECT E3s activity  
The activity of HECT E3s must be regulated since the loaded E2~Ub can adopt a 
catalytically competent orientation for ubiquitin transfer once it associates with a 
E3. As a result, in order to maintain an appropriate level of E3s or substrates within 
the cell, some HECT E3s have been found to be in an auto-inhibited state whilst at 
rest197-199. Again, the Nedd4 HECT E3 family is the most well-studied example for 
auto-inhibitory mechanisms of HECT E3s. In addition, the N-terminal C2 domain 
on Smurf2 has been demonstrated to interact with its HECT domain to prevent 
E2~Ub binding200. Through in-solution NMR studies and biochemical experiments, 
the region on the C2 domain which interacts with phosphoinositides overlaps with 
the region found to interact with the HECT domain. NMR binding assays, 
accompanied with isoleucine mutations upon the C2 domain, revealed that the C2 
domain also masks the catalytic cysteine on the HECT domain important for 
ubiquitin thioester formation. The proposed mechanism has been further 
developed and supported by the observation of increased Ub thioester formation 
using ΔC2-truncated Smurf2 in biochemical experiments. Moreover, deletion of 
the C2 domain or by interrupting the interaction of C2-HECT both enhance the 
autoubiquitylation of Smurf2200. The same laboratory further demonstrated the 
disruption of these regions protects Smurf2 from degradation in cells and 
enhances its activity towards its substrate, RhoA. Smad7, which is known to 
enhance Smurf2 activity201,202, also shows competition with C2 domain binding. 
32 
 
The PY motif on SMAD7 will interact with the WW domain on Smurf2 and release 
the C2 domain from the HECT domain for E2~Ub binding203 (Figure 1.9). The dual 
role for the C2 domain expands the possibility that other domains within HECT E3s 
might play different roles for activity regulation and expand upon the hypothesis 
that substrate binding to HECT E3s may induce E3s activation.   
 WW domains have also been demonstrated to regulate the activity of HECT 
E3s. Gallagher et al. first indicated that JNK1 binds the HECT E3 ITCH and 
phosphorylates Ser199, Ser232 and Thr222 which frees the HECT domain from 
WW and PRR domain intramolecular inhibition199. Small PY motif-containing 
membrane proteins, NDFIP1 and NDFIP2 (Nedd4 family-interacting proteins), were 
later shown to activate ITCH activity by unmasking the catalytic cysteine rather 
than through E2 binding. NDFIP is able to interact with WW domains and prime for 
ubiquitin thioester formation198. In addition to the WW domain itself, the linker 
between them also participates in the autoinhibition of HECT E3s. The recently 
solved structure indicated that the 26-residue α-helical linker (named 2,3-linker) 
between WW2 and WW3 domain on WWP2 E3 is able to inhibit WWP2 activity by 
interacting with both the N- and C- lobe204. The C-terminal part of 2,3-linker 
interacts with the hinge connecting the two lobes and significant limits the 
flexibility of the C-lobe important for ubiquitin transfer. Furthermore, 
phosphorylation of Tyr369 and Tyr392 were also found to enhance the 
autoubiquitylation of WWP2. WWP1 and ITCH share these two residues which 
implies the same inhibitory mechanism exists within this HECT E3 family205. 
However, the Nedd4 E3 also contains a structurally similar linker after the WW1 
domain but it does not retain the same auto-inhibitory effect. In conclusion, 
although the field has learned many details from HECT E3 structure studies, this 
auto-inhibitory mechanism might only apply to certain examples.  
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 Since a number of HECT E3s have been shown to have evolved an auto-
inhibitory mechanism to control enzymatic activity, the question remains, ‘how are 
they activated?’ Firstly, conformational changes are induced by E2~Ub binding. As 
discussed in an earlier section, the HECT domain itself can adopt conformations 
that are able to accept E2~Ub binding and that are compatible with transthiolation 
with E2~Ub via rotation of the hinge region. However, in general, there is no 
universal mechanism to explain the regulation of HECT E3 activity, especially one 
that encompasses the varied roles played by the extended domains N-terminal to 
the HECT domain. That is, inhibition of activity by intramolecular interaction or 
increasing activity via presenting substrates to the HECT domain. In the case of 
Nedd4, there are several mechanisms to explain the activation of this enzyme. It 
has been found that increased Ca2+ levels can activate Nedd4 by relieving of the C2 
domain inhibition effect206,207. Wang et al. demonstrated Ca2+ can compete with 
the binding of the C2 domain with the HECT domain in Nedd4-1/2 ligases by 
increasing Ca2+ levels by ionomycin treatment (which activates endogenous Nedd4 
in vivo)206. They further showed that a ligand for epidermal growth factor receptor 
(EGFR), carbachol, can also activate endogenous Nedd4 in cells. Escobedo et al. 
further discovered that Ca2+ interacts with three loops (β1-β2, β5-β6, and β7-β8) 
on the C2 domain by structural analysis207. Nedd4L is mainly located in the 
cytoplasm but will translocate to the membrane after Ca2+ stimulation. 
Phospholipase C (PLC) cleaves PIP2 and generates IP3 which can later diffuse into 
the endoplasmic reticulum (ER) and binds with IP3 receptor which is a Ca2+ gated 
channel. Interestingly, the IP3 can also interact with C2 and PH domains which 
direct HECT E3s to stay in the cytoplasm. The Nedd4-type HECT E3s can also be 
activated by ubiquitin non-covalently bound on an area called the ‘exosite’208-210. 
The conserved hydrophobic patch (IIe44 patch) and C-terminal region (Leu71 and 
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Lue73) of ubiquitin can interact with this region (micromolar-KD). The inhibitor 
which specifically targets this area abolishes the activity of Nedd4-1211. Zhang et 
al. recently developed a new tool, ubiquitin variants, to further study this 
molecular mechanism in detail212.  
 E6AP has low E3 activity in vitro but it has also been found to be activated by 
another HECT E3 ligase, HERC2, via the RCC1-like domain 2 which is independent 
of its ligase activity213. Furthermore, the E6AP HECT domain trimeric complex that 
was identified through solving the E6AP crystal structure also demonstrated the 
potential for E6AP to regulate its own activity187, although firm data to support this 
conclusion are not available to date. The mutation of the essential residues for 
trimer formation lost enzymatic ligase function214,215. The interfaces between 
trimer complex revealed that F727, R626, D543 and Y533 are all important for 
activity216. Other mechanisms of HECT E3 are not yet well characterized but the 
HECT E3 HUWE1 can undergo dimerization to inhibit enzymatic activity and might 
be activated by donor ubiquitin association. Interestingly, the tumor suppressor, 
p14ARF, showed the ability to downregulate HUWE1 activity in cells by shifting 
HUWE1 population into dimeric or oligomeric states217.  
 
1.3.2.6 The physiological role of HECT E3s  
The limited knowledge regarding regulation of HECT E3 activity does not prevent 
understanding of the physiological roles played by this family of enzymes. The 
Nedd4-like family was the first identified family of HECT E3s. In Nedd4-1 deficient 
mice, growth retardation and abnormal development in nervous and 
cardiovascular systems are observed218. The tremendous growth retardation 
observed is believed to be due to the decrease of insulin-like growth factor 1 (IGF-
1) levels and the increased level of adaptor protein Grab10. Nedd4-1 apparently 
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positively regulates the IGF-1 level and insulin signaling pathway to mediate animal 
development. Nedd4-1-/- mice also demonstrate misregulation of neuron 
formation and branching of retinal ganglion axons219,220. Nedd4 KO leads to 
increased level of thrombospondin-1 (Tsp-1) which is able to regulate 
angiogenesis221. The increased level of epithelial sodium channel (ENaC) in Nedd4-
2 KO mice causes severe lung collapse and death after birth222. The PY motifs in 
ENaC are the substrate for the WW-domain in Nedd4-2 and the interruption 
between these regions also abolish the endocytosis and degradation of ENaC 
which leads to abnormal sodium level in cells.  
 WWP1 is another HECT E3 that also contains four WW domains and the gene 
knockdown has been demonstrated to arrest tumor cell growth223. In addition, the 
knockout of WWP1 also reverses the TNF-induced osteoblast differentiation arrest 
of mesenchymal stem cells224. On the other hand, WWP2 can regulate the 
important transcription factor for cell pluripotency, OCT4, by ubiquitylation. This 
has led to studies being undertaken to ascertain whether WWP2 can be 
manipulated for cell growth225. Smurf1 and Smurf2 have also been studied and 
have been shown to regulate the TGF-β signaling pathway by directly 
ubiquitylating Smad proteins. However, knock out mice later proved the 
redundancy of Smurf1/2 in this pathway and showed no phenotype in early ages226.  
 Other HECT family HERC E3s have also demonstrated various roles in 
regulating multiple cellular function. HERC2 has recently been shown to be 
involved in DNA metabolism by collaborating with RNF8 and RNF168227. The RING 
E3 BRCA1 has also been shown to be a substrate for HERC2 which allows HERC2 to 
indirectly regulate the cell cycle228. Other miscellaneous HECT3s have also been 
shown to play important roles in the cell. For example, the expression levels of 
UBE3A contribute to the neurodevelopmental disorder Angelman syndrome and 
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autism229. HUWE1 has also been identified in multiple signaling pathways and is 
responsible for cell proliferation and apoptosis. It is overexpressed in various 
cancer types and is considered a good target for drug development especially 
through its regulation of p53 and Miz1 stability230,231. Though being the first class 
of E3s to be discovered in 1995, a huge amount of data has demonstrated that 
HECT E3s play important roles and functions in cell biology92. However, such data 
has been heavily based on structural biology or cell biology approaches. The goal 
of this thesis therefore is to apply knowledge garnered in both biological disciplines 
to help better understand the roles and functions played by HECT E3s.  
 
1.3.3 RING-Between-RING (RBR) E3 ligase  
 
1.3.3.1 General features of RBR E3s 
In contrast to the previous E3 families described, RBR E3s utilize a distinct 
RING/HECT hybrid mechanism to transfer ubiquitin from E2s to substrates. RBR E3s 
contain a RING1 domain, an IBR(In-Between-RING) domain and a RING2 domain. 
General RING1 recruits E2~Ub and positions the thioester-linked Ub in close 
proximity to the catalytic cysteine on RING2. The ubiquitin is then transferred to 
the RING2 domain and subsequently to protein substrates. Unlike RING E3s, which 
indirectly regulate ubiquitin transfer via mediation of E2 interactions, RBR E3s are 
directly involved in substrate recognition and ubiquitin transfer events87,232. RBR 
E3s were discovered from RING E3 sequence alignments where three Zn2+-binding 
domains showed a distinct alignment which was in contrast to canonical RING 
E3s68,233. Nearly a decade later Wenzel et al. determined that RBR E3s belong to 
another E3 subfamily apart from RING E3s121 since the RING1 domain shares a 
similar structure and function with canonical RINGs. The discovery of bone fide 
catalytic cysteine on different RBR E3s and the trapping of Ub-E3 intermediates 
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further emphasized the inherent structural and mechanistic differences between 
RING E3s and RBR E3s. Interestingly, to date, no isolated IBR or RING2 domain has 
been identified in a protein in nature which again highlights the unique, collective 
biological features of RBR E3s.  
 
1.3.3.2 General structure of RBR E3s 
The RBR region is the core structure of RBR E3s and is the main region responsible 
for ligase activity. It is normally located at the C-terminus of the protein and is often 
found with a variety of N-terminal extensions or domains which are used to 
interact with adaptor or substrate proteins232. (Figure 1.10) The ANKIB1 (ankyrin 
repeat- and IBR domain-containing 1) and Dorfin RBR E3s are the only two 
exceptions; where the RBR domain sits in the center or N-terminal part of protein. 
Like the HECT E3 family, the variety of N-terminal extension architectures allow 
RBR E3s to interact with different substrates, be regulated by other adaptor 
proteins, or post translational modifications. For example, the Ser65 
phosphorylation of the N-terminal UBL (ubiquitin-like) domain on Parkin activate 
its ligase activity234; the UBL domain of HOIL-1 (haem-oxidized IRP2 ubiquitin ligase 
1) on other hand recruits HOIP (HOIL-1-interacting protein) via interaction with a 
UBA (ubiquitin-associated) domain and together with SHARPIN (SHANK-associated 
RH domain interactor) forms the LUBAC complex for linear ubiquitin chain 
formation. The acidic residues on the N-terminal region of HHARI (ARIH1, Ariadne 
RBR E3 1), TRIAD1 (two RING fingers and a DRIL) and TRIAD3 enable RBR E3 
activation through association with other E3s, namely CRLs235. Instead of activating 
RBR E3 ligase activity, the domains outside of the core RBR structure adopt an 
inhibitory role. The RING0 domain on Parkin has been shown to block the 
accessibility of catalytic cysteine on RING2236. The C-terminus of the Ariadne 
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domain on HHARI, TRIAD1 and ANKIB1 also play a role in intramolecular auto-
inhibitory machinery237. Further research is needed upon structural and 
mechanistic aspects of RBR E3 function since the majority of structure-function 
studies carried out only focus on a sub-set of the RBR E3 family (that is Parkin, HOIP 
and HHARI). Little is known about other RBR E3 family members, for example, 
Dorfin, RNF144 A/B, ANKIB1 and PARC232,238.  
 
 
Figure 1.10 Domain architecture of the RBR E3 ligases. (Figure was reproduced from 
Dove et al., 2017238) 
 
 Most of the solved RBR E3 structures contain a reasonably conserved core 
RBR domain which allows some insight to be gained from their analysis. The three 
domains exist in order RING1-IBR-RING2 but might structurally display in different 
orientations depending in which form they exist (active- or inactive-conformation). 
The conserved feature of these three domains is they each are all cysteine-rich and 
coordinate two Zn2+ ions. RING1 adopts a typical C3HC4 cross-brace fold which is 
similar to canonical RINGs and enable them to functionally interact with E2s. 
Although the name, RING2, was ascribed due to the similarity of sequence to the 
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RING domain, later structural analysis revealed that neither the IBR or RING2 
adopts the same structure as RING1 or other canonical RING domain. The IBR 
domains and regions N- or C-terminal to them show extensive interaction with the 
RING2 domain in solved crystallographic structures. It has been suggested that the 
IBR domain might interact with ubiquitin during transfer or mediate the inhibitory 
domain (as the linker region is dynamic in nature), but the exact role for IBR is still 
not clear232. The RING2 domain contains the active site of RBR E3s, the catalytic 
cysteine, and it has been experimentally determined that this cysteine is not 
involved in Zn2+ coordination. The ubiquitin is transferred from E2s to the RING2 
and forms a thioester bond between C-terminal tail and catalytic cysteine. The 
detailed mechanism of subsequent ubiquitin transfer from RING2 to substrate is 
not fully understood. The RBRE3 HOIP which contains a linear ubiquitin chain 
determining domain (LDD) is the only RBR E3 where insights into substrate 
recognition have been found239.  
 
1.3.3.3 The ubiquitin transfer mechanism of RBR E3s 
As mentioned above, RBR E3s accept ubiquitin from E2~Ub and the Ub~RBR E3s 
intermediate then goes on to further react with substrates. Previous studies have 
demonstrated that E2s which are able to function with RBR E3s can also function 
with RING E3s. It has raised the question, ‘how do RBR E3s determine whether to 
undergo transthiolation or an aminolysis reactions?’. We will undoubtedly learn 
more from structural studies of E2~Ub:RBR complexes, as currently there are only 
two complexes with solved structures129,240. However, the distinct selectivity 
toward HECT/RBR E3s from the E2, UBCH7, may shed some light on this question. 
In fact, UBCH7 plays an important role in the discovery of RBR E3s not only because 
it was the very first E2 enzyme to be mapped to E3s binding partners but because 
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UBCH7~Ub shows high preference in discharging Ub toward cysteine rather than 
lysine121,123. UBCH7 has been shown to function with HECT E3s but Wenzel et al. 
later applied an E3-independent assay to demonstrate that UBCH7~Ub exclusively 
discharges Ub onto cysteine121. Together with the data showing that UBCH7 is 
functional with Parkin and HHARI further identified that RBR E3s demonstrate a 
RING/HECT hybrid mechanism. Similar results were also provided for other RBR 
members soon after their initial publication241,242.  
 E2~Ub exhibits a highly dynamic structure and reactivity profile toward 
substrates and is able to interact with both RING and RBR to elicit substrate 
ubiquitylation by different mechanism. As we know E2~Ub displays to a ‘closed’ 
conformation, once bound with canonical RING E3s. Where the ubiquitin folds 
back in a closed conformation toward the E2 and displays the ubiquitin thioester 
bond in a favorable position to be react with an incoming lysine125,126. However, 
the RBR E3s do not support this conformation to accept E2~Ub243. RING1 domain 
does not contain the linchpin Arg residue which is an important and a conserved 
region in canonical RING domain, used to anchor the closed conformation159. 
Although not explaining how RING1 domain coordinate the incoming E2~Ub to 
favor transthiolation, the recently solved E2~Ub:RBR structures showed the E2~Ub 
adopts an extended and ‘open’ conformation which reduce the likelihood of 
proceeding by aminolysis129,244. The determinant of the E2~Ub conformation that 
enable transthiolation over direct aminolysis have not yet been confirmed since 
the unbound UBCH7~Ub complex exists in a mainly closed conformation in 
solution but capable of transthiolation with free cysteine amino acid121,243. The 
UBCH7~Ub has been demonstrated to exist in an open conformation when bound 
with RING1 in the UBCH7~Ub/HHARI complex. In fact, it is not the E2 itself that 
determines the next move but the extension of the 2nd Zn2+-loop on HHARI that 
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may contribute to disfavoring of the closed E2~Ub conformation. The deletion of 
two residues in this loop abolish the ability of HHARI to stabilize the E2~Ub open 
conformation. The steric effect from the extended loop is conserved among some 
RBR E3s but not all since the extra residues do not exist in Parkin and other RBR 
E3s. In addition, the affinity toward E2s is extremely low for an inactived Parkin 
compared to a fully activated Parkin which implies that Parkin might not use the 
exact same mechanism as HHARI. However, we cannot rule out the possibility that 
other RBR E3s may use a similar mechanism to mediate E2~Ub binding with RING1 
since only two structures of complex have been solved so far.  
 In contrast to UBCH7~Ub/HHARI structure, UBCH5B~Ub/HOIP structure 
provides some complementary information about RBR E3 interactions with E2s. 
Both E2~Ubs adopt an open conformation in these structures but the Ub moiety 
on H5B contains more non-covalent contacts with HOIP. These interactions have 
been proposed to maintain the open conformation of E2~Ub since H5B~Ub is 
found to retain an open conformation when uncomplexed. Once the E2~Ub binds 
with RING1, the Ub is able to transfer to the catalytic cysteine on the RING2 domain. 
Little is known about how ubiquitin is transferred to RING2 and what kind of 
interactions occur between Ub and the RBR E3 since most of the RBR E3s are in an 
auto-inhibited state in the context of full-length protein. Furthermore, several 
crystal and NMR structures showed that the distance between catalytic cysteine 
on E2s and RBR E3s is significantly greater than would be chemically allowed for a 
successful transthiolation reaction to occur (>55 Å in Parkin case and >65 Å in 
HHARI case) (Figure 1.11). Large and specific conformational changes have to 
occur during the ubiquitin transfer to allow transthiolation. The highly dynamic IBR 
domain and its linkers support this hypothesis since different orientations of the 
IBR domain and linker have been discovered in different structures for the same 
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protein, but the various extra domains out of the core RBR domain might also 
cause the IBR domain to behave differently, from a structural point of view. The 
RING2 domain displays similar features among RBR E3s such as the catalytic triad 
(consisting of the catalytic cysteine and neighbouring His and Glu) which are found 
in Parkin236,245, HHARI237 and HOIP239. Also, these catalytic regions are all buried by 
other domains (RING0 for Parkin, Ariaden for HHARI) by hydrophobic interactions. 
A good tool to stabilize the highly flexible active RBR E3s is urgently needed for 
both structure and activity regulation studies of RBR E3s.   
 
Figure 1.11 Structures of PARKIN and HHARI with a modelled ubiquitin-conjugating 
enzyme.  
The model was built by docking RING1 domain from Parkin (PDB:5C23) or HHARI 
(PDB:4KBL) with the structure of RNF38 RING domain bound to E2 (PDB: 4V3L). The 
distance between two catalytic cysteines on E2 and E3 are presented and highlighted. In 
order for successful transthilation, a conformational change spanning nearly 60 Å is 
implied. Moreover, the clash on UBL domain on Parkin was observed when E2 was closed. 
(Figure was reproduced from Buetow et al., 2016137)   
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1.3.3.4 Activity regulation of RBR E3s 
It has been proven by biochemical assays and currently solved structures that the 
RBR E3s are in the auto-inhibited conformation at the rest stage234,241,242. 
Apparently, the extended domains N- or C-terminal to RBR core involved in either 
blocking the E2s binding or regulating the accessibility of catalytic cysteine on 
RING2. How to prime the activity of RBR E3s has been heavily studied recently 
although still focused only on few of them. Also, most of the mechanisms are based 
on structural data interpretation and domain deletion/truncation in in vitro assays. 
The up-stream stimulation for ligase activity is still poorly understood.  
 
1.3.3.4.1 Unique domain architecture inhibits Parkin activity but the dual 
phosphorylation activates it 
Parkin has been found in loss-of-function mutation for its E3 activity in various 
types of Parkinson’s disease (PD). To understand the biology behind of it, especially 
for the regulation of E3 ligase activity, many groups have contributed. Like other 
RBR E3s, the full-length Parkin structures solved to date has been indicated that it 
is in an auto-inhibited form with five domains in a tight embrace236,245. The Parkin 
protein comprises an N-terminal the UBL domain followed by a flexible short linker. 
The RING0 (or UBD) domain, which is unique to Parkin, and IBR domain reside in 
the middle of Parkin architecture. Before the RING2 domain, a disordered segment 
which contains a α-helix connects IBR with the RING2 domain. Since 2013, crystal 
structures have been solved and indicated that Parkin is inhibited and stabilized 
via several hydrophobic interactions236,245-247.  
 First, the hydrophobic region around Ile44 residue on the UBL domain, which 
share similarity with ubiquitin, interacts with the RING1 domain and block the E2 
binding with Parkin since the RING1 has been proven to be the site that recruits 
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E2~Ub (Figure 1.12). The mutation or truncation of UBL can relieve the structure 
and increase Parkin activity in vitro248. UBL has also been shown able to interact 
with SH3 and UIM (ubiquitin interacting motif) domains which indicate that the 
competition for the UBL binding may also retain Parkin activity. The following 
RING0 domain coordinates with Zn2+ in hairpin structure and this unique segment 
occludes the catalytic cysteine in RING2 domain for ubiquitin transferring. The IBR 
and RING2 domains in Parkin are quite conserved within RBR E3s but the linker 
between them, now referred to as REP domain (repressor element of Parkin), has 
been shown to bind with the RING1 domain and to block the E2s interaction. To 
overcome this effect, one single amino acid residue mutation in the REP region, 
W403A, has been shown to increase the Parkin activity both in vitro and in cells245. 
The mutations associated with PD have also been found to either disrupt the zinc 
coordination for the structure maintaining or to block the E2 binding. The G430D 
and C431F mutations on the RING2 domain even directly abolish Parkin 
activity246,249.  
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Figure 1.12 The unique domains in Parkin regulate auto-inhibition. 
Parkin is a 465 amino acids E3 ligase which adopts several different domains in structure. 
The Ubl domain outside the RBR core together with the REP domain which resides 
between the IBR and RING2 block the interaction between E2 and Parkin. The RING0 
further occludes the catalytic cysteine for ubiquitin access. *this structure is missed a.a 
86-130 for crystalization purposes. (Figure was reproduced from Sauvé et al., 2015250) 
 
 How to efficiently activate Parkin has been a question in the field for a long 
time. Early Drosophila studies indicated that PINK1 (PTEN-induced kinase-1) is 
associated with Parkin activity by serving as the up-stream protein in 
mitochondrial quality control signaling pathway251,252. Interruptions in PINK1-
Parkin pathway lead to the dysfunction of mitochondria maintenance. The 
mutations on both PINK1 and Parkin proteins have also been discovered in PD 
patients253. PINK1 is constitutively being cleaved at mitochondria by mitochondrial 
intramembrane protease PARL (Presenilins-associated rhomboid-like protein). The 
remaining PINK1 N-terminal domain will subsequently translocate to the cytosol 
and be degraded by the N-end rule proteolysis254. However, once the mitochondria 
sense the damage signal such as depolarization by harsh CCCP reagent (carbonyl 
cyanide m-cholorophenylhydrazone) treatment, PINK1 is stabilized and 
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accumulates on the outer mitochondrial membrane. Parkin is then be recruited to 
the mitochondria and phosphorylated by PINK1255-257. PINK1 directly 
phosphorylates the Ser65 on the UBL domain both in vitro and in cells and liberates 
the auto-inhibition mechanism caused by the UBL domain234,249,255. It frees the 
RING1 domain for the E2~Ub engagement. Deletion of the UBL domain also 
showed the enhancement of Parkin activity in vitro249. However, the phospho-
mimetic S65E Parkin cannot bypass the PINK1 requirement for Parkin translocation 
to mitochondria together with the data that S65A Parkin still has the trace amount 
of activity in cells80 indicated that PINK1 might work with other proteins to activate 
Parkin.  
 The breakthrough discovery was provided by three different groups that 
ubiquitin can be phosphorylated by PINK1 and the phosphorylated-ubiquitin (p-
Ub) can further prime the Parkin activity in a feed-forward pathway80-82. PINK1 
phosphorylates Ub at the same position as the UBL domain which makes isolated 
phospho-UBL also capable to activate Parkin in vitro. The introduction of Ser65 
mutation on UBL and ubiquitin both impaired Parkin activity80. Furthermore, 
Parkin has high affinity toward p-Ub by 400nM and resulted in 20-fold 
enhancement for its phosphorylation by PINK1 when p-Ub was supplied82,258. The 
PD-associated mutation site on Parkin, Lys161 and Lys211, together with the 
Arg163 residue form a pocket for p-Ub binding and was further be confirmed by 
crystal structure and in vitro assays84,258. The p-Ub interacts with the RING0 domain 
and its phospho-group and Ile44 hydrophobic patch further react with the RING1 
and IBR domain. The disruptions on the p-Ub-binding helix (pUBH) showed the 
decrease of Parkin activity84. Recently, several different Parkin structures either 
without the UBL domain (presumed as active) or conjugated with p-Ub provide the 
molecular mechanism for priming Parkin activity247,259. In brief, the p-Ub binding 
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within the Parkin can release the UBL domain from core structure which allow it 
to be phosphorylated by PINK1. Once the UBL domain is phosphorylated, it 
relieves the auto-inhibited machinery by displacing RING0 and REP domains 
allowing RING1 to interact with incoming E2~Ub. Although the structure of the 
E2~Ub:Parkin complex has not yet been solved, it has been hypothezised that 
Parkin becomes flexible in structure once activated and performs a conformational 
change to bring the RING2 domain in close proximity with the E2 catalytic site 
(Figure 1.13).  
   
 
Figure 1.13 Dual-phosphorylation on Parkin UBL domain and Ub primes Parkin activity.  
Parkin E3 exists in an auto-inhibited conformation at resting stage. In the current model, 
once Ub has been phosphorylated by PINK1, pUb is able to interact with Parkin RING1 
domain and triggers a conformational change of Parkin which frees the Ubl domain from 
Parkin core structure. The Ubl domain is then further be phosphorylated by PINK1 and 
induces another conformation change to expose the catalytic cysteine for incoming E2~Ub. 
The catalytic cysteine 431 is then no longer blocked and is ready for E2-E3 transthiolation. 
Both phosphorylation events on Parkin and Ub prime the activity of Parkin. Red star 
denotes catalytic cysteine 431 and yellow triangle denotes phospho-Ser65. (Figure was 
reproduced from Trempe et al., 2013245)  
 
It is not yet clear the order of these phosphorylation events in cells since the 
binding with p-Ub enhances the phosphorylation of Parkin; the p-Parkin also has 
higher affinity toward p-Ub. In addition, who recruits the first ubiquitin to be 
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phosphorylated by PINK1 and make this p-Ub to be able to recruit Parkin is still 
unknown. However, it is possible that the two phosphorylation events proceed 
simultaneously and with the help from other proteins. Although it is clear that the 
PINK1 activates Parkin E3 activity in vitro, most of the cellular experiments are 
accomplished by use of overexpression system. Furthermore, the lack of 
phenotype in PINK1/Parkin mutant mice also brings the attention in field. It 
remains possible that other regulation mechanisms exist in the more physiological 
relevant conditions. More mechanistic studies in how phosphorylations contribute 
to the Parkin activity will be discussed in the latter chapter.   
 
1.3.3.4.2 Activation of the only linear ubiquitin chain maker---HOIP and its 
binding partners from the LUBAC complex 
LUBAC complex composed by two RBR E3s, HOIP (also termed RNF31) and HOIL-
1L, and one adaptor protein SHARPIN. It has been the only protein which is able to 
make linear ubiquitin chain (M1-chain) in vertebrate to date44. The HOIP E3 is the 
main E3 ligase for catalyzing M1-chains assembly and is the only component from 
LUBAC to show robust E3 activity in vitro239. Similar to other RBR E3s, HOIP adopts 
an auto-inhibited state in the full-length protein. The HOIP RBR core alone can 
make a free chain in vitro but lost the activity while one N-terminus extended 
domain, UBA domain, is linked239. The isolated N-terminus domains can also inhibit 
HOIP activity in trans87. However, the detailed auto-inhibitory mechanism is still 
not yet fully understood since the lack of a full-length HOIP structure. Intriguing, 
HOIP is always coordinated with HOIL-1L and SHARPIN in cells as a LUBAC complex 
since no isolated HOIP protein has been detected after purification44. This implied 
that the intramolecular interactions between LUBAC components may regulate the 
E3 activity of HOIP.  
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 The UBL domain on HOIL-1L has been found to activate HOIP E3 activity by 
interacting with the UBA domain and exposes the RBR core on HOIP for incoming 
E2~Ub260. Several binding complexes for the UBA-UBL crystal have been solved by 
Yagi et al.260. These data combined with the deletion mapping assays further 
indicated that the helices α6, α7, α8 and α9 on HOIP UBA domain are involved in 
recognizing the UBL surface on HOIL-1L which prevents the UBA inhibitory effect 
on HOIP. Although SHARPIN has the similar UBL domain for binding with HOIP E3, 
the exact molecular mechanism studies remain to be solved. Liu et al. recently 
solved the crystal structures for UBAHOIP/UBLSHARPIN and UBAHOIP/UBLHOIL-1L and 
demonstrated that HOIL-1L and SHARPIN individually interacts with a different 
region of the UBA domain on HOIP261. Furthermore, HOIL-1L and SHARPIN are 
individually capable to activate HOIP but are also able to synergistically activate 
HOIP via enhancing the E2 loading261. In contrast to other RBR E3s which need to 
be activated from the autoinhibited state, the LUBAC complex is constitutively 
activated by HOIP/HOIL-1L or HOIP/SHARPIN interactions which mentioned above. 
However, the question remains, how is the activity of LUBAC regulated?  
LUBAC is the only E3 complex capable of making M1-chains, there are also 
only two DUBs that have been found to manage to cleave the M1-chains, OTULIN 
(OTU domain DUB with linear linkage specificity) and CYLD. In addition, it has been 
found that the N-terminal domains of HOIP E3 are able to react with these two 
DUBs to regulate the activity of the LUBAC262,263. There is also a PUB domain 
(Peptide:N-glycanase/UBA or UBX-containing proteins) in HOIP which is 
responsible for mediating interactions between the PUB interaction motifs (PIMs) 
of OTULIN DUB and spermatogenesis-associated protein 2 (SPATA2). SPATA2 is able 
to recruit CYLD to the LUBAC complex for chain cleavage once it binds with HOIP264. 
Based on the structures, these two proteins bind the same region in HOIP and both 
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regulate chain formation in vitro. The conserved tyrosine residue on the PIMs has 
even been found to be phosphorylated and may regulate the binding with the 
DUBs262,264. A proposed model of OTULIN/LUBAC regulation is once the signaling 
pathway is activated by stimuli, the phosphorylation on Tyr56 will disassociate the 
OTULIN and LUBAC interaction and lead to M1-chains accumulation. However, the 
kinase and phosphatase responsible for this event are awaited to be discovered.   
 Although the mechanism of LUBAC activity regulation is not fully understood, 
how is HOIP able to selectively make the M1-chains and how does it interact with 
E2~Ub have been demonstrate by recently solved crystal structures129,239. The 
E2~Ub:HOIPRBR-LDD is the first and to date the only solved crystal structure for the 
E2-RBR E3 complex while RBR is in active form129. It revealed that the E2~Ub is 
truly in the open conformation when engaged with RBR E3s. It also uncovered 
many interactions between the RBR domain and E2~Ub, especially for the 
ubiquitin moiety since the other E2~UB:RBR show little contact between Ub and 
the core RBR. Notably, the HOIP adopts a conformation that brings E2~Ub in 
proximity of the catalytic cysteine in the RING2 domain which is important for 
transthiolation. In addition, it demonstrated that the non-covalent contacts 
between ubiquitin and the RING1-IBR linker and IBR domain and also showed less 
E3 activity when mutated in these regions. However, this model was built on two 
separate asymmetric molecules that includes one RING1-IBR and RING2-LDD 
element respectively. In addition, the auto-inhibited HOIP structure is still 
unavailable which prevents us from comparing the differences between them. As 
a result, we still cannot formally draw an accurate model to describe how the 
RING2 domain adopts close proximity toward E2~Ub from inactivated form to 
activated form.     
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 The selectivity for linear chain formation via HOIP E3 comes from the linear 
ubiquitin chain-determining domain (LDD)241,242. The HOIPRBR-LDD domain 
complexed with a donor ubiquitin and an acceptor ubiquitin in structure indicated 
the mechanism of the M1-chains formation239. The RING2-LDD surface orientates 
the acceptor ubiquitin to the position where only the N-terminal amino group of 
it is directed toward the HOIP catalytic cysteine Cys885, but not the other lysine 
residues in ubiquitin. The ZF1 domain is also involved in presenting the acceptor 
ubiquitin to the correct position. Moreover, the conserved histidine His887 acts as 
a general base to deprotonate the N-terminal amino group on the acceptor 
ubiquitin for a nucleophilic attack of the donor ubiquitin thioester bond242. The 
donor ubiquitin hydrophobic patch and its extended C-terminal tail interact with 
the β-hairpin on LDD and RING2 domain to stabilize the Ub on the RING2 and to 
guide the Gly76 in proximity of the catalytic cysteine. In conclusion, the distinct 
structure and architecture of HOIP E3 contributes mainly to the specificity of linear 
ubiquitin chain formation, but how to coordinate the activity between LUBAC and 
DUBs for regulating the M1-chains formation is stillnor fully understood.  
 
1.3.3.4.3 RBR E3s are RING-linked--- Activity regulation of HHARI and TRIAD1 
with CRLs  
HHARI, TRIAD1, ANKIB1 and PARC/CUL9 all feature an Ariadne domain C-terminal 
to their RBR core structure. It has been proven that the Ariadne domain occludes 
the catalytic cysteine on the RING2 domain of HHARI235,237,240. The mutations or 
deletion of the Ariadne domain both activate HHARI in vitro237. Intriguingly, the 
binding with E2~Ub does not trigger a conformational change of HHARI moiety for 
bringing the RING2 domain in proximity of E2, the Ariadne domain still blocks the 
RING2 domain preventing E2-E3 transthiolation. A recent study showed the 
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W386A mutation on the RING2 domain or the Y531A on the Ariadne domain can 
both disrupt the inhibitory machinery for HHARI. The Y531A mutation can rescue 
the activity of the catalytic cysteine access and enhance the autoubiquitylation of 
HHARI, but it is still unable to transfer ubiquitin to the substrate proteins265. How 
does the RING2 domain free itself from the Ariadne domain binding is still not clear.  
 The other distinct character for these RBR E3s is the partnership with cullin 
RING E3 ligases (CRLs). It has been shown that the neddylated-CRLs can activate 
HHARI and TRIAD1 in a neddylation-dependent manner235,265. TRIAD1 can be 
activated by CUL5/RBX-2 machinery while HHARI can work with CUL1, CUL2, CUL4 
and CUL4A. Notably, RBX1 can work with all CULs but RBX-2 is only able to react 
with CUL5. There is still no hint about which CULs teams up with PARC since there 
is already a cullin domain in PARC itself. As CULs play the vital roles in 
HHARI/TRIAD1 activity regulation, it has also been demonstrated that the 
Neddylation of the CULs affects the interaction between CRLs and RBR E3s. The 
treatment of NEDD8 E1 enzyme inhibitor, MLN4924, abolishes the TRAID1/CUL5 
and HHARI/CUL1 interactions in cells but does not affect UBCH7 binding with 
TRIAD1235,265. The recent structural and biochemical studies both indicated that 
the predicted NEDD8 interacting sites on the UBA domain are important for the 
ubiquitin transfer from UBCH7 to HHARI240. As a result, the interactions between 
these two E3s are speculated to be essential to adopt the Ariadne-RBR E3s into a 
favorable conformation compatible with ubiquitin transfer265.  
 The latest discovery of HHARI E3 is the partnership with the CRLs to prime the 
substrate poly-ubiquitination265. Scott et al. reported that when HHARI was 
activated by the Neddylated-CUL1 or CUL3, HHARI then primes the first mono-
ubiquitylation on the substrates which CRLs recruit. CRLs then use their intrinsic 
RING E3 activity to extend the ubiquitin chains265. This discovery greatly broadens 
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our imagination about the regulation of E3 ligases activity since we generally 
interpretate the data by the very last step, the ubiquitylation. The outcome of the 
ubiquitylation may not simply be regulated by one E3 enzyme or one machinery 
but might involve synergetic cooperation of multiple E3s.  
 
1.3.3.4.4 Physiological role of RBR E3s and their partner proteins 
The clarification of RBR E3s as a new subfamily of E3 ligases has only recently been 
defined121. The above discussed RBR E3s are the only members which have been 
sufficiently studied. The other RBR E3s such as Dorfin, TRIAD3, RNF144A/B are not 
easy to assay for their E3 activity in vitro which makes them difficult to study. 
Furthermore, although all of them contain a RBR core structure, there is no 
universal activity regulation mechanism for them due to the divergent domains 
extensions. However, we still can gain some insight for these RBR E3s from their 
partner proteins and the cellular function which they have been involved.  
 Parkin has been demonstrated to mediate the substrates for regulating 
autophagy and neurodegeneration266,267. It has also been demonstrated to interact 
with G-protein-coupled receptors (GPCR) for the dopaminergic signalling and 
dopamine receptor268,269. Although the main study of Parkin E3 is focus on 
neurodegeneration disease and mitophagy, more studies have also indicated an 
involvement of Parkin in the cell proliferation and cancer regulation270,271. HHARI 
shares some substrates with Parkin which are PD-related but has also been shown 
to target mRNA cap-binding protein and regulate cell proliferation272,273. Less-
studied RNF144A has been shown to regulate DNA damage-induced cell apoptosis 
by regulating its dimerization274,275. The recent studies also reported that RNF144A 
can regulate cancer cells proliferation and resistance towards a PARP1 (Poly(ADP-
ribose) polymerase 1) inhibitor276,277. The RNF144B also showed the ability to 
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promote IL-1β mRNA expression by LPS (lipopolysaccharide) inducement278. The 
giant RBR E3 PARC/CUL9 contains the cullin sequence and an RBR core in the same 
polypeptide. The detailed relationship between these two domains is unknown 
but PARC has been proven to regulate the cell survival by mediating the level of 
cytochrome C279. Parkin is not the only RBR E3 to associated with 
neurodegeneration diseases, RNF19A/Dorfin has also been linked to synphilin-1 
regulation and co-localizes with Lewy bodies 280,281.  
 Clearly, RBR E3 ligases play the coordinated roles in cell biology via their 
complicated regulation mechanism. To date, we have only got a glimpse of their 
mechanism. How much impact the RBR E3s have under physiological model needs 
more careful and detailed studies. The development of an accurate and facile 
method to detect their activation state is important to achieve.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
Chapter 2. Activity-Based Probes  
 
2.1 Unravelling protein identity and function---The case for Activity Based 
Probes 
Enzymes of diverse function and biological activity are tightly orchestrated and 
regulated within cells in order to enable and maintain the complexity of life. It has 
been demonstrated that enzyme misregulation can lead to the onset of various 
diseases97,282,283. Therefore, understanding how enzyme function is regulated not 
only allows us to better understand fundamental biology, but also demands the 
development of new tools with which to address and combat human diseases. 
Directly monitoring the cellular activity of an enzyme or enzyme family is 
challenging. This is particularly important for enzymes expressed at low levels 
within the cell and which can also be subjected to regulation of their activity by 
post translational mechanism284. For example, activation via post translational 
modification or through interaction with specific cofactors285,286. As previously 
discussed, several HECT and RBR E3 ligases become activated when constituent 
intramolecular inhibitory domains become phosphorylated. For example, 
phosphorylation of the Ubl domain in Parkin relieves its autoinhibited structure, 
allowing Parkin to interact with E2~Ub. In addition, p-Ub binding to Parkin largely 
enhances the activation process of Parkin and primes the E3 for activity by altering 
the structure of Parkin E384,247. Tightly regulated protein activation machineries 
have also been found and described for various cellular protease systems287. It is 
therefore not surprising that most proteases have been found in the auto-inhibited 
forms due to their intrinsic activity is to degrade their target proteins which must 
be tightly regulated spatiotemporally. As a consequence, methods used to 
measure mRNA levels or protein abundances do not provide quantitative 
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information relating to intrinsic protein activity or function only abundance 
information that does not always correlate with activity.   
 It can be argued that the detection of a protein’s substrate(s) is an alternative 
way to study. However, the fast turnover rate of substrates, the lack of knowledge 
about bone fide substrates for a given protein, and the fact substrates can be 
regulated by different enzymes, all limit the utility of this approach288. In addition, 
substrate degradation normally involves numerous co-factors in a complex cellular 
environment which prevent clear and unambiguous data interpretation.  
The ubiquitin cascade system is a very good example of this ambiguity since 
substrate ubiquitylation is co-regulated by three different enzymes (E1s, E2s and 
E3s)86. Misregulation of the ubiquitin system often cannot be unambiguously 
attributed to the activity of a single enzyme within the cascade. This is particularly 
pertinent when the activity readout (Ub chain formation or proteosomal 
degradation) is somewhat removed from the source of the misregulation. 
Moreover, substrate ubiquitylation, often used as a method to detect and infer 
misregulation within the ubiquitin cascade might only be observed (or enhanced 
to allow substrate detection) when accompanied by proteosomal inhibition. In 
many cases, small-molecule proteosomal inhibititor has been demonstrated to 
alter or modify the activity of other enzymes, making it difficult to attribute direct 
effects upon enzyme activity289. On the other hand, there are the examples of 
substrates being regulated by several different upstream enzymes. Thus, a probe 
molecule which could target the catalytic site of specific protein family, in order to 
monitor protein activity, would be a valuable tool to better understand the 
complex interactions and relationships involved in the regulation of enzyme 
activity and function. 
 
57 
 
2.2 What are Activity-Based Probes (ABPs) and how to make them? 
 
2.2.1 Where did this concept originate? 
Activity-based probes (ABPs) are typically small-molecule chemical entities that 
aim to target an enzyme of interest in an activity-dependent manner. They are 
designed to mechanistically interact with a specific target enzymes or protein 
enzyme and frequently covalently label the protein active site as a means to 
monitor protein activity and function. The covalent labelling of a protein by ABPs 
is normally achieved by having mutually reactive chemical handles present on the 
ABPs and on the protein of interest, most commonly, an electrophilic moiety on 
the ABPs and a native nucleophilic residue within the active site of the enzyme290. 
On the other hand, photocrosslinkers can be incorporated into the probe if the 
catalytic nucleophile in the target enzyme is missing 291. The photocrosslinker 
produces a reactive radical intermediate which is capable of forming covalent 
bonds with nearby atoms when irradiated with UV light. As a consequence, the 
binding affinity of these probes toward the target proteins determines the 
selectivity and labelling efficiency of the photocrosslinker-conjugated probes.  
The idea of ABPs was first described in 1961 by Barnard et al. in which they 
demonstrated the use of a radioactive chemical probe for cytochemistry study, 
which was a forerunner to modern ABPs292. Although the term called ‘ABPs’ is 
relatively new within scientific literature293,294, researchers in the 1970s applied 
the concept of ABPs in their work. However, limitations of the technology and a 
lack of biological understanding often prevented early research at this chemical 
biological interface from adequately addressing complex biological questions295-297. 
In addition, early ABP-type studies were often based on small-molecule inhibitor 
development, for example, towards hydrolytic enzymes such as serine hydrolase, 
chymotrypsin and trypsin rather than use as discrete tools to directly address 
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biological questions related to those enzymes such as activity regulation248,298,299. 
Up until the year 2000, a wide variety of selective inhibitors targeting serine, 
cysteine and threonine proteases had been demonstrated300 which not only 
provided insight and greatly aided drug discovery programs, but also provided the 
foundational knowledge to design and synthesise activity-based probes.  
 In general, there are three essential components to an activity-based probe 
(Figure 2.1); The reactive group, which is normally referred to as a ‘warhead’, is 
responsible for covalent, irreversible attachment of the ABP to the catalytic site in 
the enzyme of interest; A recognition element is typically required to deliver the 
ABP to the catalytic site of an active enzyme; and the reporter tag, which allows 
the formed ABP-protein complexes to be retrieved, enriched or 
visualized288,290,293,301-303. The pioneering research performed by the laboratories 
of Dr. B. Cravatt and Dr. M. Bogyo have provided many of the conceptual and 
technical insights that have underpinned the ABP field. To date, multiple types of 
ABPs have been developed for targeting numerous of enzyme classes288,290,302,304-
307.   
 
2.2.2 The Warhead (Reactive functional group)  
The functionality of the warhead is an important aspect in ABP design. The choice 
of warhead is often protein-target dependent but generally a directly-reactive 
electrophile is utilised when probes are designed for labelling serine, cysteine or 
threonine amino acid side-chains within an active site. The choices of electrophile 
can also be varied based on the target amino acids. In contrast, for enzymes which 
do not contain catalytic nucleophilic residues, for example, aspartyl proteases and 
metalloproteases, photocrosslinkers have been utilised for labelling in a 
mechanism-dependent manner304,308,309. However, the majority of the ABPs to 
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date make use of an electrophilic warhead310. The key element for ‘warhead’ 
design is that it should be sufficiently reactive for targeting the specific active site 
amino acids of interest but unreactive enough to prevent off-target labelling. As a 
result, one of the main challenges for the field is to find this balance between 
selectivity and reactivity.  
 
 
Figure 2.1 Activity-based probe construction. 
Activity-based probes (ABPs) are composed of three essential elements: Reactive group, 
Recognition element and Reporter tag. A wide variety of warheads can be incorporated 
into ABPs for labelling different types of enzymes. Based on the purpose of the assays, 
affinity tags or fluorescence tags can be introduced upon ABPs for monitoring enzyme 
activity via proteomic methods or in-gel scan. In order to enhance ABPs specificity, the 
substrates peptides or full-length proteins can be used as the backbone for the ABPs. The 
introduction of bioorthogonal handles upon the ABPs allows post probe-labelling tag-
conjugation. (Figure was reproduced from Niphakis et al., 2014302)  
 
The labelling efficiency of ABPs is typically based on two factors: the affinity 
of the recognition element and the reactivity of the warhead with respect to the 
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protein target. The warhead is required to be in close proximity of the target site 
on proteins for the covalent reaction to occur between the catalytic nucleophile 
and the electrophilic ‘warhead’. The affinity of the probes toward the target 
proteins (KD) drives the recruitment of the ABP and the target protein (reversible 
interaction). If an ABP cannot contact with its target protein at the correct location 
and with suitable geometry to allow chemical crosslinking then the degree to 
which the ‘warhead’ can react is diminished significantly or completely. For 
example, the E2 binding site in the autoinhibited SMURF2 HECT E3 is blocked by 
its C2 domain which prevents the interaction with the E2~Ub 185. Therefore, if a 
chemically engineered E2 was chosen as a recognition element, the warhead in 
the ABP would not be delivered to the active site of the autoinhibited SMURF2. 
When ABPs sit in the correct region on target protein, the irreversible covalent 
attachment is then driven by the rate of the warhead reaction and the catalytic 
nucleophile. High reactivity of the electrophile enhances the labelling rate of the 
ABP but needs to be balanced with the affinity of the recognition element to 
ensure optimal selectivity. For example, a weakly reactive warhead might not work 
with a low affinity recognition element but might be sufficient if the affinity was 
relatively high. Ideally, Kon and Koff rates should also be considered311. 
Sometime, promiscuous Cys-reactive warheads with no recognition element 
have utility, for example, such ABPs can serve as positive controls in inhibitor 
screening experiments of cysteine-containing proteins and can be used in a 
competitive role in profiling the off-target sites modified by covalent inhibitors312. 
Generic cysteine-reactive ABPs have found utility in determining the reactivity 
profile of cysteine and specific cysteine residues upon proteins due to their high 
intrinsic reactivity toward thiol nucleophiles. Catalytic cysteine residues often 
display higher reactivity compared to non-catalytic cysteines with a non-catalytic 
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function312. This often comes as a consequence of being situated in proximity to 
amino acids chain residues (for example, histidine), which serve as a general base, 
rendering the cysteine thiol group more nucleophilic in character. 
PTMs or conformational changes of proteins which expose the catalytic 
cysteine for labelling result in highly reactive warheads undergoing labelling in a 
dose-dependent manner, allowing researchers to distinguish the roles of different 
cysteines within the same protein. On the other hand, the ABP AWP28, which 
contains a low reactivity acyloxymethyl ketone electrophile (Figure 2.2) as the 
warhead and the low affinity recognition element as the back bone, is a highly 
selective towards caspase-1313.  
 
 
Figure 2.2 Structures of two functionally-different ABPs.  
Iodoacetamide-based probe (left) and AOMK-based probe, AWP28 (right).    
 
 In conclusion, though we have a wide variety choice for reactive ‘warheads’ 
to date, the design of the ‘warhead’ still requires caution, thought and novel design 
when dealing with novel enzyme classes. Further discussion about ‘warhead’ 
characteristics in building different types of ABPs will discussed below.  
 
2.2.3 Design of the recognition element  
As we discussed above, the affinity of ABPs also affect the degree of labelling 
efficiency when encountering various target enzymes. Hence, recognition element 
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design is the key for enhancing the specificity of ABPs to a specific enzyme target. 
The recognition element can be a small-molecule scaffold which has affinity for 
the target protein, a substrate peptide sequence, a protein domain, or even a 
whole substrate protein. An example of the latter is the ubiquitin moiety in DUB 
ABPs303,306. In most of the protease ABPs, the recognition element requires only a 
peptide sequence corresponding to the proteases substrate. DUB ABPs require the 
whole ubiquitin protein to interact with the catalytic domains in the DUB due the 
requirement of engaging the larger Ub-binding surfaces18. This is a common 
challenge when designing ABPs for Ub system enzymes. 
 Obtaining a highly selective recognition element for ABPs is non-trivial since 
the substrate protein would normally display some degree of similarity in terms of 
primary amino acids sequence or similarity in binding mode for closely related 
enzymes. The high background (off-target labelling) generated by such probes 
largely decrease their utility in imaging applications and in the development for 
translating the ABPs into biomarkers for detecting and diagnosing disease 
states314,315. To overcome these issues, related to sub-optimal recognition 
elements, several different methods have been pursued recently. Peptide inhibitor 
library screening of fluorescence-labelled substrates has been demonstrated as a 
good system to identify the highly selective recognition elements. A recognition 
element with a 30-fold increase in selectivity for caspase-3 has been identified 
from this platform316. The phage display system also allows screening of highly 
diverse libraries317,318. Although this approach was initially applied towards 
inhibitor development, the principles are similar for ABP recognition elements.  
An obvious way to enhance the selectivity of the ABP recognition element 
towards a protein target would be to utilize the native full-length protein binding 
partner of the target protein. There are however many caveats inherent to 
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successfully following such a strategy. Even small, lower molecular proteins, for 
example, ubiquitin, or recently-developed bicyclic peptides, used as the 
recognition element for an ABP, cannot overcome cell permeability problems due 
to their size, electrostatic and steric problems (for example, bulky side chains and 
ionisable side chains). Examples of the cell-penetrating peptides have been applied 
to ABPs to address this problem and have been used for proteomic and imaging 
experiments319,320. Other strategies which have been used to enhance the cell 
permeability for small molecular inhibitors are also the options for solving this 
problem but with the concerns in disrupting reactivity and selectivity of well-
designed ABPs, for example, the liposome-coating method321. However, within the 
recent advances in peptide-based inhibitor development, it is possible to design 
an ABP with exquisite selectivity even for highly homologues target enzymes.  
 
2.2.4 Design of the reporter tag  
The great advantage for using ABPs for profiling a complex cellular proteome is the 
ability to enrich, isolate and unambiguously identify the ABP-protein adduct from 
complex biological samples. An affinity handle as reporter tag on an ABP allows 
retrieval of the ABP-protein complex for further immunoblotting or proteomic 
analysis, for example, using epitope affinity tag such as the Human influenza 
hemagglutinin tag (HA-tag), or a polyhistidine-tag (His-tag), Avidin/Streptavidin-
Biotin interaction. Bioorthogonal chemical reactivity handles (for example, azides, 
alkynes, strained alkene and tetrazine functionality301) can be used allowing two-
step procedures where a sample is treated with ABP and affinity tag (for example, 
biotin) is subsequently attached by bioorthogonal ‘click’ reaction. (Figure 2.1). The 
use of epitope tags allow the facile validation of ABP labelling efficiency or 
selectivity toward panels of recombinant protein and mutants controls322, and 
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various types of cell extracts323. The mutual reactivity of azides and alkynes is 
enabled by well-established copper-catalyzed ‘click’ reaction (Huisgen 1,3-dipolar 
cycloaddition)324. Rapid biorthogonal labeling between strained alkenes and 
tetrazine functionality, achieved by Diels-Alder cycloaddition reaction, can also be 
applied to capture and enrich ABP-protein complexes, post-ABP labelling291,310. 
Biotin-tag probes are largely applied in proteomic research since the high affinity 
of the non-covalent interaction with streptavidin can significantly reduce the non-
specific binding of background proteins to the immobilized resins291,325.    
 Apart from binding tags for enrichment purposes, fluorescence-tags also 
allow rapid analysis of ABP-protein target engagement by a simple in-gel 
fluorescence scanning323,326. Such methods allow for rapid analysis of the activity 
signatures in a particular experiment but offer little in the way of addressing target 
identification and absolute protein quantitation. The use of fluorescence-tags 
prevents time-consuming immunoblotting and MS-based analysis. It enables the 
rapid scanning and analysis of many proteins in the same assay, whether 
performing experiments with recombinant protein, or with protein lysates from 
cellular extracts. Furthermore, the high sensitivity and linearity of the fluorescence 
signal makes the study of labelling kinetics possible. For example, a fluorescence 
polarization activity-based protein profiling assay could be performed which has 
been demonstrated by Lahav et al327. A valuable application of application of 
fluorescently-tagged ABPs is exemplified in imaging assay328,329. This allows the 
tracking of enzyme activity during specific cellular stimuli or the cellular location. 
For example, tumor cells are normally found in hypoxic or low pH conditions which 
can quench the fluorescent signal. Therefore, a fluorescence signal is often 
location specific, and is only observed when the cellular conditions in which ABP 
is located are appropriate330.  
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 The choice of the tag utilized in an ABP also requires careful consideration as 
tag size and solubility affect the ABP utility. Fluorescence tags are useful reporter 
groups for ABPs but are also frequently bulky and hydrophobic molecules. Similar 
concerns have been raised for ABPs utilising biotin-tags288. Although a huge body 
of recent literature has demonstrated the utility of these ABPs, another factor to 
consider is the physiological relevance of the conclusion reached in the vast 
majority of ABPs were incubated with cell lysates or used in vitro and not in vivo 
experiments due to the problems with cell permeability. Also, relative protein 
concentration and loss of spatiotemporal organization and the biochemical 
regulation of enzymatic pathways (for example, through interaction with co-
factors or regulation of PTMs) will undoubtedly differ between intact cells and 
cellular extracts.  
 
2.3 How do ABPs detect enzyme activity: The analytical platforms of ABPs 
In the field of chemical biology, an important question is how to appropriately 
apply the tools we have to address and answer important biological questions. The 
design and synthesis of ABPs has been addressed leaving the question, ‘how are 
ABPs to be used effectively?’ The most attractive characteristic about ABPs is their 
concomitant ability of isolating, enriching and enabling read out (enzyme catalytic 
activity) target of proteins of interest from a complicated proteome. This allows 
the systematic profiling of protein enzymatic activity from differing experimental 
setups (for example, varied cells types within different stimuli, cell-free assays or 
animal models), termed activity-based protein profiling (ABPP). As a result, 
choosing the appropriate platform setup for carrying out an ABP-based experiment 
is essential and several experimental platforms can be utilized with ABPs.  
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2.3.1 Gel-based platform 
The most basic method to validate the labelling ability of ABPs toward target 
proteins is by gel-based detection. The ABPs can first react with either a 
recombinant protein mixture or a whole (or fractionated) proteome from cell 
extracts followed by resolution by using 1D or 2D SDS-PAGE293,307,331,332. The 
labelled enzymes can be visualized by in-gel fluorescence scanning (for fluorescent 
probes) or immunoblotting (for affinity-tagged ABPs, or Biotinylated-ABPs). The 
robust fluorescence signal rapidly provides a clear read-out of proteins activity. It 
allows for even an individual research group to be able to profile hundreds of 
thousand proteins (different types of proteins or various mutants) in a short period 
of time. If the probes are constructed based on a full-length protein structure, for 
example, Ub-VS (-vinyl methyl sulfone) or E2-VME (-vinyl methyl ester) 303,322,333,334, 
then the corresponding band-shift can also be easily detected by Coomassie 
staining or by affinity-tag immunoblotting such that a reporter tag is not necessary. 
Furthermore, biotinylated ABPs together with streptavidin affinity purification, gel 
separation and tandem mass spectrometry analysis can validate the identity of 
unknown labelled proteins. Although the ‘gel-free’ based assays provide a higher-
resolution and depth of information towards decrypting a complicated proteome, 
the facile and simple gel-based assay still provides us with an easily interpretable 
data set. For example, in Chapter 4, I will describe the use of the novel E3-ABPs to 
dissect the effects of dual-phosphorylation events on the activation mechanism of 
the RBR E3. Gel-based assays in this work enabled the validation of the importance 
of p-Ub in a role to prime Parkin activation in cells322. Overall, in-gel based analysis 
is still a valuable format for ABP assays that allow various (but not exhaustive) 
experimental read-outs to be compared in parallel.    
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2.3.2 Tandem-mass spectrometry   
Gel-based methods for applying ABPs are robust but often result in data which is 
‘low resolution’ and limited in terms of depth of analysis. The ‘low resolution’ 
problem often stems from similarities in protein molecular weights (leading to 
poor resolution by SDS-PAGE analysis) as well as a lack of information regarding 
protein identity. The latter problem can be addressed by MS/MS analysis322,334,335. 
However, it is clear that data obtained from ABP experiments is limited only when 
using gel-based experiments exclusively, limiting the utility of ABPs. The 
introduction of liquid chromatography-mass spectrometry (LC-MS) strategies into 
ABP work-flows enables direct analysis of complicated proteomes and as such, 
vastly increased the amount of hitherto inaccessible data obtained from ABP 
profiling experiments336.  
 There are several different ABP work flows that have been developed to 
address various biological questions. A common approach used is the generation 
of biotinylated ABPs and their subsequent incubation with a proteome of interest. 
Streptavidin facilitated capture and enrichment of ABP-protein complexes is 
followed by on-bead trypsin digestion. The digested-peptides are then analyzed by 
LC-MS/MS enabling identification of labelled proteins. This strategy has been able 
to identify more than 50-100 activated proteins from an individual proteome301,336-
339.   
Label-free mass spectrometric analysis provides semi-quantitative 
parameters (for example, peptide counts) for data analysis, whereas peptide 
labelling methodologies are able to provide quantitative data, allowing in depth 
analysis of data provided by ABP labelling experiments. Quantitative mass 
spectrometric methodologies such as SILAC291,340 (stable isotope labeling by amino 
acids in cell culture) and TMT (Tandem Mass Tag)291 are capable of comparing the 
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relative levels of activated enzymes in parallel from three to ten proteomes 
simultaneously (SILAC and TMT 10plex, respectively). The state-in-art mass 
spectrometric technology, MS/MS/MS(MS3), further provides a platform with a 
better accuracy in terms of protein quantification341-343. Parallel ABPP 
methodologies enable monitoring of protein activity in response to varied stimuli 
and form the basis of inhibitor/drug screening platforms in modern drug discovery 
efforts302,344,345. Notably, although multichannel peptide labeling technology, such 
as iTRAQ (isobaric tags for relative and absolute quantification) or TMT, enable 
multiple profiling of samples in parallel, labeling efficiency constraints and the 
resulting peptide signal loss should also be considered in such approaches346. 
Although SILAC technology offers increased efficiencies through isotope labelling, 
the limited number of parallel channels available (up to three) and the logistics and 
time employed in establishing and maintaining cultured cells are the major 
drawbacks of the method. SILAC is also incompatible with primary cells, tissues 
and biological fluids.      
 
2.3.3 Activity-based imaging platform 
The installation of a fluorescent tag on ABPs make useful tools for locating and 
tracking proteins in the context of live cell347. This technology not only provides 
the cellular location of proteins in context but is a truer representation of intrinsic 
protein activity as ABP labelling occurs in the context of native protein 
concentration and spatiotemporal localization. Moreover, protein labelling occurs 
in the presence of physiologically relevant protein-protein interactions. More 
recently, Dr. M. Bogyo’s group applied this methodology in an animal model to 
develop a noninvasive imaging system to specifically monitor tumor-associated 
cysteine proteases, cathepsins, in live mice330.  
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2.4 What can ABPs do? ---The application of ABPP 
 
2.4.1 Target discovery  
Protein target discovery and identification has been the main experimental 
application of ABPP290,348,349. Application of ABPP in comparing varied biological 
samples under differing experimental conditions has the ability to uncover protein 
candidates that are causative of a particular cellular phenotype or disease state. 
One of the advantages of comparative ABPP is that the data obtained is directly 
correlated to the intrinsic activity of protein target which might not only be 
regulated simply by varying protein expression levels but also by posttranslational 
regulation, for example, via PTMs and/or protein conformational changes. Such 
methodologies therefore are well suited to address biological questions related to 
the study of otherwise difficult to study enzymes, for example, protein proteases 
and E3 ligases. As discussed previously, these enzyme families can be often found 
in an inhibited form under resting conditions and are only activated in response to 
specific substrate localization, co-factors engagement or other specific cellular 
stimuli81,171,205,206,256,350. Furthermore, the accuracy and sensitivity of tandem mass 
spectrometry approaches used in ABPP enables the identification of hitherto 
undetected low-abundance proteins which have evaded detection by other 
methods. The application of such methods will undoubtedly provide new 
perspectives and outlooks on multiple disease-related biology which may translate 
into novel therapeutic strategies, particularly in relation to novel biomarker 
development.      
 
2.4.2 Competitive ABPP for inhibitor screening  
Competitive ABPP strategies enable the direct application ABPs towards furthering 
drug discovery. Because ABPs have been designed to specifically target the active 
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site of particular proteins and protein families, small molecules, developed 
through tradition medicinal chemistry approaches that target the same protein or 
protein families can be used in competition with ABPs for proteins labelling 
therefore allowing elucidation of inhibitor specificity and selectivity302,307,332 
(Figure 2.3). In addition, this strategy can also uncover off-target issues associated 
with small-molecule inhibitor development through comparison of parallel data-
sets with and without inhibitor treatment. Furthermore, dose-titration 
experiments using small-molecule inhibitors in ABP gel-based assays provide a 
facile way to obtain the inhibitor affinity information toward specific target 
proteins. Once again, like previously mentioned ABP approaches, the major 
advantage of competitive ABPP as applied to small-molecule inhibitor 
development is the ability to interrogate native proteomes whilst minimizing 
concerns regarding experiments carried out under non-physiologically relevant 
conditions (for example, effects related to PTMs), apparent in assays using only 
recombinant protein. Overall, competitive ABPP not only provides a platform for 
inhibitor development and screening but also generates a useful and rich protein 
target database, regardless of the target protein or inhibitor under study.  
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Figure 2.3 The work flow chart of competitive ABPP strategy.  
(a) The standard ABPP assay. Various types of cellular extracts are incubated with ABPs 
and the ABP-labeled proteome are subsequently analysed by gel-based assays or 
comprehensive proteomic strategies. (b) In contrast to the standard workflow, the cellular 
extracts or the intake cells are treated with selected inhibitor prior to the ABPs incubation. 
The leading inhibitors for targeting specific protein or protein families can be obtained via 
the comparison of the datasets from two different strategies.  
 
2.5 Case studies of different ABPs 
To date, numerous types of ABPs have been developed for the study of various 
proteins including serine hydrolases293,307,331,351,352, cysteine proteases315,330,348,353, 
DUBs303,354, metallohydrolases304,355, kinases356-358, palmitoyl transferases359and 
other examples288,302. The diverse protein families studied by ABP profiling has 
been beneficial for uncovering fundamental biology related to the proteins in 
question but has also been a significantly useful strategy for drug development 
programs302,360. Since this thesis is focussed upon on the ubiquitin system, the 
following discussion will focus on two pioneering ABP families of relevance, serine 
hydrolases and cysteine proteases ABPs. 
 
2.5.1 Serine hydrolases ABPs  
The serine hydrolases family consist of a wide variety of enzymes including 
proteases, peptidases, lipases, esterases, and amidases which are predicted to 
make up approximately 1% of mammalian genomes361. Serine hydrolases have also 
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been demonstrated to be important to numerous cellular events, for example, 
angiogenesis362, neuronal signaling363,364, inflammation365,366, and cancers367,368. 
Although the various structures and sequences among many different serine 
hydrolases are often varied, this protein family share a similar mechanism of action 
in order to hydrolyse the appropriate ester or amide bond functionality found in 
their substrates. The base-activated nucleophilic serine residue targets the 
substrate ester and amide functional group at the sp2 carbon. Most commonly, a 
tetrahedral acyl-enzyme intermediate is formed that is then subsequently 
hydrolysed by a water molecule361. In addition, serine hydrolases have been shown 
to not only target proteins as substrates, but also polar metabolites, lipids, 
posttranslational protein modifications and peptides369. The high nucleophilicity of 
the catalytic serine residue present in serine hydrolases make it an tractable 
chemical target for ‘warhead’ electrophiles, for example, aryl phosphonates, 
sulfonyl fluorides, carbamates and fluorophosphonates (FPs)290,302,368,369 (Figure 
2.1).  
 FPs had first been discovered as a mechanism-based inhibitors of serine 
hydrolases293,370. Whilst several other types of other serine hydrolase inhibitors 
have been demonstrated371-373, FPs preserve the advantages of broad coverage of 
the serine hydrolase family and often demonstrate limited cross-reactivity toward 
other enzymes361. The electrophilic FP centre is highly reactive to the serine side 
chain oxygen atom. Labelling with FPs further stabilize the probe-labelled 
intermediate by mimicking the enzyme-substrate tetrahedral intermediate as a 
stable adduct. The above features endow FPs with a broad target selectivity within 
the serine hydrolase families361. In addition, FPs higher reactivity toward activated 
serine hydrolases over inactive374. By demonstrating labelling profiles that 
distinguish active from non-active enzymes supports the statement that FPs are 
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bona fide activity based probes for serine hydrolases. A variety of FP-based ABPs 
have been shown to be able to label more than 80 distinct serine hydrolases in 
both human and mouse proteomes290,336,337,375. Notably, more than one-third of 
these serine hydrolases had remained uncharacterized before being identified by 
serine hydrolase ABPP. For example, a serine hydrolase, MAGL, that degrades 2-
arachidonoylglycerol (2-AG), an endogenous ligand for cannabinoid receptors, was 
discovered from mouse brain by FP probes349. Cravatt and colleagues have 
contributed significantly to this field and a huge body of data have been produced 
by their efforts to date.  
Comparative ABPP can be considered a straightforward proteomic method to 
proceed. Indeed, such FP-based serine hydrolase ABPs have been applied to 
different biological models for profiling studies. These models include 
atherosclerosis376, immune cell activation377, nervous system signaling378 and 
cancers336,368,375,379. There are several good cases which exemplify how to apply 
serine hydrolase ABPs to discover and validate a novel serine hydrolases and to 
apply findings from those experiments towards small-molecule inhibitor 
development. Jessani et al. first applied fluorescent FP probes to profile a panel of 
human breast carcinoma and melanoma cell lines380 from NCI-60. They performed 
in-gel fluorescent scanning assays to obtain a quantitative comparison of enzyme 
activities for serine hydrolases. The apparent increased level of some serine 
hydrolases present in the assay was demonstrated and displayed restricted activity 
patterns amongst the different cell lines analyzed. Subsequent follow up analysis 
was performed utilizing biotin-tagged FP ABPP approaches with cellular extract 
proteomes followed by LC-MS analysis for protein identification. Along with this 
approach, different groups had discovered more than 50 serine hydrolases and 
categorized them into subgroups based on their apparent activity signature. As a 
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result of such studies, it was found that the activity of certain serine hydrolases 
was consistently increased in aggressive cancer cell lines366,380. These enzymes 
included the known cancer biomarker, urokinase plaminogen activator (uPA), but 
more interestingly two enzymes, KIAA1363 and MAGL, which had not been 
previously linked to cancer malignancy290,360. Application of quantitative mass 
activities-based proteomics, further demonstrated that KIAA1363 activity is 
significantly enhanced in an aggressive cancer cell line (estrogen receptor-negative 
[ER-] primary human breast tumors). Chiang et al. later developed an inhibitor of 
KIAA1363 using the competitive ABPP strategy381. Surprisingly, by global 
metabolite profiling of inhibitor-treated cancer cell lines, levels of an unusual class 
of lipids, monoalkylglycerol ethers (MAGEs), had been found to be decreased in 
inhibitor-treated cells. It was subsequently determined that KIAA1363 is the 
hydrolase responsible for hydrolysis of the MAGE precursor, lipid 2-acetyl MAGE, 
thereby regulating the MAGE levels in cancer cells. The conversion of MAGE into 
lysophosphatidic acid (LPA) by cancer cells has also been linked to tumor 
progression382. The reduction in tumor cell growth using both KIAA1363 RNA 
interference (RNAi) or small-molecule inhibitor further indicated the role of 
KIAA1363 in aggressive cancer cell progression.  
 The other uncharacterized serine hydrolase that had been identified by FP-
probes was monoacylglycerol lipase (MAGL) which has also been found in several 
aggressive cancer cell lines with increased activity360,383. The increased activity of 
MAGL in cells was further validated by monitoring the hydrolysis level of its 
substrate, 2-Arachidonoylglycerol (2-AG) combination with MAGL inhibitor (JZL184) 
treatment 384. An elevated activity level of MAGL has been shown to be an 
important feature for aggressive tumor progression and that inhibitor treatment 
also significantly reduces the tumor growth.  
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These above examples perfectly demonstrated the utility of FP ABPs applied 
to the study of seine hydrolases to further progress fundamental and translational 
biology. The FP probes have progressed from protein identification (within disease 
or stimuli-specific model systems) to competitive ABPP approaches, aiding 
inhibitor development through to more sophisticated assay formats which enable 
discovery and validation of target biology. The success of FP probes in the serine 
hydrolase field has largely enhanced the research of ABPs application in various 
biological systems. From both a methodological and a conceptual stand point.  
 
2.5.2 Cysteine protease ABPs  
Like serine hydrolases, cysteine proteases are another huge enzyme family found 
in both prokaryotic and eukaryotic systems. These enzymes have been shown to 
be involved in regulating multiple cellular functions and having involvement in 
various diseases, for example, arthritis385, apoptosis386-388, tumor progression389,390, 
cell cycle regulation391 and even parasitic invasion392. Like serine hydrolases, the 
distinct catalytic mechanism of cysteine proteases makes them susceptible to 
labelling by differentially designed electrophiles, for example, epoxides and 
diazomethyl ketones for cathepsins315,393, α-haloketones and acyloxymethyl 
ketone for caspases348,394 and vinyl sulfones for DUBs303,305,306 (Figure 2.1). The 
histidine-activated sulfhydryl nucleophile on the catalytic cysteine forms a 
covalent intermediate with the carboxy terminus of the substrates. The 
intermediate is then cleaved by the action of a water molecule. Due to the high 
intrinsic reactivity of the catalytic cysteine of many cysteine proteases, many small-
molecule tool compounds and inhibitors (both covalent and non-covalent) have 
been developed for their study302,367.  
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 Cysteine proteases can be divided into several different clans based on their 
evolutionary origins395,396. The CA clan subgroup of cysteine proteases has 
previously been heavily studied due to the many essential roles they occupy in 
physiological regulation397,398. In 1976, a specific cysteine protease inhibitor, E-64, 
had been discovered from the cultures of Aspergillus japonicus399. The reactive 
epoxide warhead present in the E-64 displays high reactivity and specificity 
towards the papain cysteine protease family400. E-64 and its derivatives have been 
applied widely, for example, DCG-04, a E-64 derivatives which containing a P2 
leucine residue, has been used in the studies of tumor progression389 and 
prohormone processing401. E-64 has significant inhibitory effects upon cathepsins 
and has minimal cross-reactivity toward other cysteine proteases402. Clan CD 
proteases are the second largest family of cysteine protease, which include 
legumains, caspases, separases and gingipains. Caspases in particular have been 
extensively studied due to their essential role in regulating apoptosis403. In fact, 
the cysteine protease ABPs with aldehyde warheads were used to discovered the 
first caspase, caspase 1404. The early caspase ABPs were compromised of an 
acyloxymethyl ketone (AOMK) as the warhead. In 2005, the AOMK-based probes 
were demonstrated to have broader coverage of CD clan proteases, including the 
lysosomal cysteine protease, legumain and cathepsins348. 
 A central dilemma in ABP design has always been the balance to retain ABP 
diversity for broad target discovery but also display selectivity for proteins of 
interest. By incorporation of optimized peptide sequences into AOMK-based 
probes, Bogyo et al. have previously demonstrated that it is possible to tune the 
reactivity of AOMK-based probes to selectively target specific proteases 405. tAB50-
Cy5 is an AOMK-based probe which carries a fluorescent cyanine fluorophore, Cy5, 
reporter tag and also a cell penetrating peptide trans-activating transcriptional 
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activator (Tat) peptide sequcence406. It labels both caspases and legumain 
proteases. Edgington et al. applied this probe to detect and quantify the activity 
level of caspases and legumain in vivo314,405. Probe activity was validated in a 
dexamethasone-induced apoptosis model in CD4+CD8+ thymocytes of mice. Both 
caspases and legumain were labelled with the tAB50-Cy5 probe. The quantitative 
data gathered further indicated that the activity of legumain was low after 
dexamethasone treatment. However, the activity of caspase-3 was enhanced and 
reached the highest levels at 12 hour dexamethasone treatment. In addition, 
subsequent analysis by flow cytometry and comparison with ABP-fluorescence 
data, indicated that the tAB50-Cy5 was only accumulating within the apoptotic 
cells. Together, with further in-gel fluorescence scanning and biochemical assay, 
the study provided a powerful platform to monitor protease activity both in vivo 
and in vitro.   
 Cysteine protease ABPs also contributed to the understanding of 
tumorigenesis. Combined analyses of the global gene expression in conjugation 
with ABPP, Joyce et al. identified the high activity of cathepsins Z, B/L, and C in 
tumor progression processes389. The application of fluorescently-tagged ABPs 
allowed the unambiguous localization of the cathepsins within tumor cells. Taken 
together with data obtained from inhibitor treatment studies of tumor cells, 
cathepsins have been found to regulate tumor development by affecting invasive 
proliferation, tumor vascularity and angiogenic switching290,389. The other papain 
family-specific probe, DCG-04, was also applied in ABPP methodologies and 
identified that the activity of falcipain 1 is enhanced during P. falciparum 
invasion392.  
As previously discussed in the context of serine hydrolase ABPs, cysteine 
protease ABPs have also been used for inhibitor screening and development. 
78 
 
Cwp84 a papain family protease which regulates C. difficile host infection 407. The 
inhibition of Cwp84 enhances the host immune response to block the C. difficile 
invasion, making Cwp84 a good target for drug development.  
 
2.5.3 DUB ABPs  
Deubiquitinase (DUBs) are another cysteine protease family which have been 
studied extensively by ABPs303,408-410. DUBs play the ‘eraser’ role in the 
ubiquitylation system, either trimming or removing the ubiquitin chains from 
ubiquitylated substrates43. DUBs have also been shown to regulate multiple 
cellular functions411, for example, membrane trafficking412, secretory pathway 
control413, Wnt signalling, TGF-β signalling and transcription414 and RNA 
processing415. In addition, the coordination with E3 ligases to further regulate the 
downstream ubiquitin signalling pathways also serves to highlight the important 
and multi-faceted role played by DUBs activity. There are nearly ~100 DUBs in the 
human genome416 and these can be divided into two main categories based on the 
catalytic mechanism of substrate hydrolysis; cysteine protease DUBs or metallo-
protease DUBs96. The cysteine DUBs use a familiar mechanism for (iso)peptide 
bond cleavage, with similarities to other cysteine proteases where a catalytic triad 
is employed417. Structural studies have shown that the proximal histidine near the 
catalytic cysteine acts as a general base to deprotonate and activate the thiol group 
on the cysteine for the nucleophilic attack towards the carbonyl of the (iso)peptide 
bond96 (Figure 2.4). The conserved catalytic cysteine and chemical environment 
between cysteine DUBs make this nucleophile suitable for exploitation by ABPs 
approaches.  
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Figure 2.4 The mechanism of DUBs. 
The proximal histidine side chain lowers the pKa of the thiol-group of the catalytic cysteine 
upon DUBs. The nucleophilic attack towards the peptide bond is then performed and 
further releases the Ub moiety and target proteins. (Figure was reproduced from 
Komander et al., 200996)  
 
Based on the structural folds identified from analysis of DUBs by structural 
methods, they can be further classified into sevendifferent families418. Six of the 
seven families of DUBs are cysteine protease DUBs there being Ub C-terminal 
hydrolyses (UCH), Ub-specific proteases (USP), ovarian tumour proteases (OTU), 
Josephins, MINDY (for MIU-containing novel DUB family) and ZUFSP418-420. 
JAB1/MPN/MOV34 (JAMM) DUBs is belong to metallo-protease DUBs.  
The first covalent DUB ABP was developed in 2001 by Borodovsky et al. and 
contains a single full-length ubiquitin as the recognition element and a vinyl 
sulfone ‘warhead’ connected to the penultimate C-terminal Gly residue as the 
electrophile408. This first generation of DUB ABP labelled six different putative 
yeast deubiquitylating enzymes in a recombinant enzyme panel. The authors 
further identified that the mammalian homolog of yeast Ubp6p, USP14, was 
bound to the proteasome. To date, a wide variety of DUB ABPs have been 
developed and applied to different types of ubiquitin research. Ub-aldehyde (Ubal) 
and Ub-nitrile (Ub-CN) were heavily used in early DUB inhibitor development 
studies whilst Ubal was also used to solve the first DUB-Ub complex structure421. 
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The yeast UCH, Yuh1, was labelled with Ubal and mimics the tetrahedral 
intermediate during the hydrolysis pathway. The authors also demonstrated that 
the UCH undergoes a structural rearrangement upon ubiquitin binding which 
increases its enzymatic activity. However, Ubal and Ub-CN are not formally 
considered as ABPs since their labelling mechanism is reversible and limits their 
compatibility for ABP profiling. It was the Ub-vinyl methyl sulfone (Ub-VS) that was 
initially to demonstrate irreversibly label DUBs in cell lysates306. The distinct 
activity of vinyl methyl sulfone (-VS) has also been applied to the construction of 
ubiquitin-like protein probes, for example, the NEDD8, ISG-15 and SUMO-1 have 
all reported to be conjugated with –VS and used as ABPs against their respective 
(iso)peptidases422,423. Following on from the earlier success of Ub-VS, significant 
effects have been applied to warhead optimization. For example, the Ub-propargyl 
amide (Ub-Prg)333,424, Ub-vinyl ethylsulfonate (Ub-OEtVS)425, Ub-α-amino-β-
lactone (Ub-Lac)425 and more recent Ub-dehydroalanine (Ub-Dha)426 (Figure 2.5). 
However, vinyl methyl sulfones (VS) and vinyl methyl ester (VME) ‘warheads’ are 
still the two most widely used reactive groups utilised in DUB ABPs.  
 
 
Figure 2.5 Different types of DUB ABPs 
Different types of electrophiles are covalently appended to ubiquitin1-75 protein (without 
C-terminal Gly76) for making DUB ABPs.  
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Another highly reactive warhead, AOMK, is also conjugated with ubiquitin as 
the DUB ABP, UbTF3BOK. However, it labels not only DUBs but also E1s, E2s and 
E3s which also carry catalytic residues248. Therefore, the profiling data generated 
by DUB ABPs need to be interpreted with caution. Furthermore, as E2 recognition 
is a requirement for E1 and E3 activity, activity data inferred from studies on these 
enzymes should also be treated with caution. A recent report by Hewings et al. 
indicated that multiple non-catalytic cysteines on DUBs were also labelled by DUB 
ABPs420. However, HA-Ub-VS was still capable of validating the activity of USP9X in 
melanoma cells , a DUB whose activity is regulated by phosphorylation427. The 
enhancement of HA-Ub-VS labelling with USP9X was observed in stimulated CD4+ 
T cells without an increases in USP9X expression level, emphasising the value of 
ABPs.   
  DUB ABPs have been applied toward the discovery of new DUBs, 
characterization of DUB selectivity, stimuli-regulated DUB activity profiling and 
DUB inhibitor screening303. USP14 was identified by HA-Ub-VS and Ubal306 was 
used to identify OTU family DUBs, otubain 1 and otubain 2428. Pruneda et al. 
recently applied the Ub-Prg ABP in conjunction with fluorescent substrates to 
further validate the deubiquitinase and deneddylase activity of proposed bacterial 
isopeptidases429. Non-hydrolyzable DUB ABPs, diUb-AMC (Ub-7-amido-4-
methylcoumarin), combined with Ub-Prg provided the data necessary to explain 
the mechanism behind the K11 chain cleavage preference by OTUD2 and OTUD3430. 
In 2013, Gao et al. further applied the HA-Ub-VS probe to demonstrate that USP7-
regulated deubiquitylation plays a vital role in early adipogenesis which mediated 
by histone acetyltransferase, TIP60431. As previously discussed with respect to 
other proteases, ABPP approaches for DUB inhibitor screening and development 
have also heavily relied upon the use of appropriate DUB ABPs339,432. The only DUB 
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inhibitor currently in clinical trials, VLX1570, has been shown to selectively label 
USP14 but not UCHL5. The selectivity preference was verified using HA-Ub-VS in a 
competitive gel-based ABP assay. VLX1570 treatment also induces the 
accumulation of polyubiquitin conjugates and the apoptotic response in multiple 
myeloma cells433. The DUB ABPs were also applied in two individual research lab 
for USP7 inhibitor development345,434. The above examples demonstrate the 
necessity and utility of DUB ABPs for the progression of our understanding of DUB 
biology and inhibiter development.  
 
2.5.4 E1 ABPs 
As previously discussed in Chapter 1, apart from DUBs, the other enzymes involved 
in the ubiquitin system (E1s, E2s, E3s) can also transfer ubiquitin via catalytic 
cysteine residues. Compared to cysteine protease enzymes288,312, E1, E2, E3 ABP 
development has only recently been investigated, due in part to the comparatively 
suppressed reactivity of the catalytic cysteines among these enzymes (compared 
to cysteine proteases for example)288. Furthermore, unlike DUBs that recognize the 
conserved ubiquitin moiety or distinct ubiquitin chain topology for substrate 
recognition, E1s/E2s/E3s can display multiple preferred active combinations and 
have multiple substrates. The lack of a complete mechanistic and biological 
understanding of these enzymes that on some degree has delayed the 
development of suitable ABPs. However, recently, several groups have reported 
the development of ABPs for targeting these enzymes and have discrete 
demonstrated their application in the ubiquitin field303.  
 Though limited in number, the first examples of E1 ABPs have had great 
impact on ubiquitin research. Olsen et al. synthesized and conjugated a non-
hydrolysable mimic of the acyl adenylate intermediate (AMSN) onto human 
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SUMO1 to make SUMO-AMSN108 (Figure 2.6). This conjugate can mimic the 
intermediate produced during catalytic cysteine attack of the SUMO-AMP 
intermediate. SUMO1 was conjugated to a 5’-
(vinylsulphonylaminodeoxy)adenosine (AVSN) which is able to label the E1 
catalytic cysteine like a suicide substrate (Figure 2.6). The authors later incubated 
the SUMO E1, SUMO Activating Enzyme Subunit 1 (SAE1), with SUMO1-AVSN and 
resolved the conjugation product via SDS-PAGE analysis. A redox stable product 
was observed and corresponded to the approximate molecular weight of the 
E1~Ub adduct. Control reactions using catalytically dead E1 further supported the 
conclusion that the SUMO1-AVSN was covalently labelling the E1 catalytic cysteine 
residue. The subsequent solving of the E1 structure using both SUMO1-AVSN and 
SUMO1-AMSN ABPs, uncovered an required E1 conformation change for catalytic 
cysteine attack of SUMO-AMP. The E1:SUMO-AMSN (E1:SUMO-AMP mimic) 
adopts an ‘open’ conformation compared to E1:SUMO-AVSN (E1~SUMO-AMP 
trapped intermediate). The ATP-binding site is exposed and the catalytic cysteine 
is buried in the Cys domain. In contrast, E1:SUMO-AVSN adopts a ‘closed’ 
conformation and a subsequent 130° rotation of the Cys domain is required to 
allow successful ubiquitin transfer. Although the SUMO-AVSN labels the SUMO E1 
in an activity dependent manner, the lack of reporter tag renders it unsuitable 
towards profiling E1 activity in ABP-type approaches, although this could be easily 
introduced. An et al. later developed two types of E1 ABPs. Initially, small 
molecules probe, referred as ABP1 in the literauture435, was generated and is 
based on the structure of MLN4924, an inhibitor of the NEDD8 E1, NAE. An 
analogue of ABP1, ABP3, was also developed and utilized an alkyne handle for 
reporter tag conjugation. ABP1 has been demonstrated to label a variety of E1s in 
vitro but ABP3 is only able to label Ub and the NEDD8 E1.  
84 
 
 
Figure 2.6 The structures of E1-Ub mimic (Ub/Ubl-AMSN) and E1 suicide probe 
(Ub/Ubl-AVSN). 
 
 In 2016, An et al. developed a panel of Ubl–AMP electrophilic probes which 
introduced a dehydroalanine (Dha) functional group as a ‘warhead’436 (Figure 2.7a). 
The facile synthetic methods employed and the native C-terminal sequence of 
Ub/Ubl allowed these probes to be applied in ABPP experiments. Using a similar 
construction strategy, the ubiquitin-like protein, microtubule associated protein 1 
light-chain 3 (LC3)/ATG8 has also been used for making the LC3-based probe, which 
has been demonstrated to label autophagy E1-like enzyme, ATG7. The major 
drawback of these probes is the susceptibility to DUB hydrolysis by IsoT(USP5) 
which somewhat limits their utility in experiments using cell derived samples. In a 
different approach, Stanley et al. designed E2-based ABPs which were able to 
efficiently label E1 enzymes334. The novel approach developed a small-molecule, 
termed a tosyl-substituted doubly activated ene (TDAE), that can be conjugated 
with multiple E2s at their catalytic cysteine generating an electrophilic activated 
vinylsulfide (AVS) warhead which is then able to react further with a second 
nucleophile (Figure 2.7b). The AVS warhead is thereby able to conjugate two 
cysteines that come into close proximity. Such probes are useful in studying 
enzymatic reaction where cysteine-cysteine juxtaposition is a crucial requirement 
for catalytic activity. Determination of the rate of the second cysteine addition to 
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the AVS indicated that the -CN functionalised AVS reacts slower than a -VME AVS 
in the context of model reaction with glutathione (k=1.52x10-3M-1s-1 and 7.84x10-
3 M-1s-1, respectively)334, therefore showing the warhead reactivity was tunable. In 
the same study, The UBE2N-CN was demonstrated to be able to label the human 
E1, UBA1 in an activity-dependent manner that was dependent on the UBA1 
catalytic cysteine. UBA1 C632A mutation abolished probe labelling. UBA1 labelling 
assays were also performed by incubating the UBE2N-CN probe with Human 
Embryonic Kidney 293 (HEK293) cell extracts and followed by immunoblotting. The 
E2 AVS-probes labelled greater than 90% of the available UBA1 and demonstrated 
that probes unique capability of profiling the E1-E2 transthiolation event. This 
facile installation of the ‘warhead’ at the E2 catalytic cysteine in this approach 
enabled the obvious leap to testing beyond E1 enzymes to the more numerous E3 
ligase families, for example, HECT and RBR E3 ligases. The failure of HECT/RBR E3 
labelling by E2-based ABPs was convincingly attributed to the lack of the ubiquitin 
moiety upon the E2. However, sub-stoichiometric labelling was observed with non-
canonical E3s (for example, bacterial effectors such as NleL), where obviously the 
strict recognition requirement for the E2¬Ub conjugate are somewhat more 
relaxed.  
 
 
Figure 2.7 The structures of two novel E1 ABPs.  
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2.5.5 E3 ABPs  
Validation of E3 ligases activity has proved challenging as traditional assays are 
often hampered by deconvolution problems associated with the presence of other 
critical components of the ubiquitin cascade (E1, E2, Ub, ATP). However, the 
catalytic cysteines on HECT and RBR E3s, which accept Ub from E2s by 
transthiolation reactions are potentially suitable sites for labelling by an 
electrophile-containing probe. Only very recently have the first E2-based E3 ABPs 
been developed by Pao et al.322. Part of my research involved optimization of the 
ABPs where the foundations were reported in Stanley et al.334 to enable labelling 
of the RBR E3 ligase, Parkin. This research will be discussed in detail in Chapter 4. 
Different types of ABPs and strategies to monitor E3 activity were also reported 
after the initial publication of research by Virdee lab. For example, Krist et al. have 
demonstrated that the UbFluor probe could be applied to monitor and validate the 
activity of HECT and RBR E3 ligases437,438 (Figure 2.8a). Although the mechanism of 
probe labelling is not based on E2-E3 transthiolation, UbFluor can still act as a Ub-
thioester mimic to reacting with the catalytic cysteine on HECT/RBR E3s. The 
fluorescence tag on these probes can be monitored by fluorescence polarization 
assays which makes high through putscreening of E3 activity using this technique 
feasible and also potentially accelerating E3 small-molecule inhibitor/activator 
development via use of competitive ABPP approaches. Of note, this approach is 
not compatible with cell extracts and does not take into account E2 binding. 
Another strategy developed by Mulder et al. also demonstrated the ability to label 
E3 ligases both in vitro and in cell lysates439. The novel ubiquitin-based probe, Ub-
Dha, can be activated by E1s and label the downstream E2s and E3s in an ATP-
dependent manner (Figure 2.8b). The distinct design which features -Dha as a 
‘warhead’ and a native carboxy group at the ubiquitin C-terminus allows E1 
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enzymatic activations. The activated Ub-Dha is conjugated with E1 via thioester 
bond and subsequently the Ub-Dha can either form a stable E1-Ub conjugate (by 
covalent binding between -Dha and the catalytic cysteine) or perform a 
transthiolation step, transferring the activated Ub-Dha to an E2. Furthermore, the 
same reaction pathway can occur allowing the potential transfer of Ub-Dha from 
E2 to E3. In this manner, Ub-Dha is potentially able to detect the activity of all three 
enzyme families at the same time. However, there are still problems with assay 
deconvolution, suitable controls and the fact that Dha electrophiles have been 
shown to be somewhat promiscuous and non-cysteine specific under physiological 
conditions440.   
Research into the generation and application of E3 ABPs is only in its infancy 
and there are many technical problems that require addressing for many 
approaches to enable the maximum impact of these technologies. More 
comprehensive and novel assays and experimental platforms will undoubtedly be 
reported in the future.  
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Figure 2.8 The structures and working mechanism scheme of recently developed E3 
ABPs.   
(a) The UbFluor E3 ABP performs a native transthiolation step within the target E3s. It 
subsequently releases the fluorescent tag from the probe which can be used as the signal 
to indicate the activity of target E3s. (b) Ub-Dha, a ‘cascading’ ABP, which contains a native 
Ub C-terminal carboxy group and a Dha electrophile as a ‘warhead’. The Ub-Dha can either 
react within enzymes as a wild type Ub does, that is, transferring itself from E1 through E2 
to E3; or to be trapped as the stable conjugates at each step (E1-Ub, E2-Ub, E3-Ub). The 
Ub-Dha labels the E1s, E2s and E3s in an ATP-dependent manner.  
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Chapter 3. Material & Method 
 
3.1 General material 
 
3.1.1 Reagents & Chemicals list 
Table 3.1 Reagents used in this thesis 
Reagents & Chemical  Catalogue number  company  
2-mercaptoethanol (β-ME) 444203 Calbiochem 
Ac-EGXGN-NH2 (X= K, S or T) Not provided Bio-Synthesis Inc 
Acetonitrile 'HiPerSolv' for HPLC  20048.32 VWR 
Amersham ECL Prime Western 
Blotting Detection Reagent 
GERPN2232 GE healthcare 
Apyrase M0398S  New England BioLabs  
Cy3B-maleimide PA63131 GE Life Sciences 
DMEM/F-12 media 21331-046 Thermo Fisher 
EZ-link Iodoacetyl-PEG2-biotin 21334 Thermo Fisher 
Isopropyl thio-b-D-galactoside 
(IPTG) 
MB1008 MELFORD 
Na2S2O3, purum p.a., anhydrous, 
≥98.0% 
72049-250G Sigma 
Sodium fluoride S7920-100G Sigma 
(Diacetoxyiodo)benzene 178721-25G Sigma 
2-azidoethan-1-amine 
hydrochloride 
EN300-102102 Enamine 
Adenosine 5'-triphosphate 
disodium salt hydrate 
A7699-5G Sigma 
ALBUMIN FROM BOVINE SERUM 
( Fraction V ) BSA 
A7906-100G Sigma 
Ampicillin sodium salt A9518-25G Sigma 
Antimycin A A8674-50MG Sigma 
Arginine 11009-25G-F Sigma 
Benzamidine hydrochloride 434760-5G Sigma 
Carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) 
C2759-100MG Sigma 
CentriPure P2 Columns GEN-CP-0110-50 Generon 
Chitin Resin S6651L New England Biolabs 
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Complete, Mini, EDTA-free protease 
inhibitor cocktail 
11873580001 Roche 
Coomassie (Bradford) Protein Assay 
Kit 
23200 Thermo Fisher 
Copper(II) sulfate 
anhydrous, powder, ≥99.99% trace 
metals basis 
451657-10G Sigma 
Deoxyribonuclease I from bovine 
pancreas 
DN25-100MG Sigma 
Dimethyl sulfoxide 
BioReagent, for molecular biology, 
≥99.9% 
D8418-50ML Sigma 
Dithiothreitol (DTT) MB1015 Melford 
ECL Kit ( Reagent detection Western 
Blotting ) 
RPN2106 GE healthcare 
Ethyl acetate GPR RECTAPUR 23880.368 VWR 
EDTA Disodium EDTA1000 Formedium  
Hexane, Laboratory Reagent, ≥95% 208752-2.5L Sigma 
HiMark™ Pre-stained Protein 
Standard 
LC5699 Life Tech 
Hygromycin B Gold (solution) ant-hg-5 Invivogen 
Imidazole I2399-500G Sigma 
InstantBlue™ ISB1L Sigma 
iodoacetamide I1149-5G Sigma 
L-Alanine A7627-1G Sigma 
L-Ascorbic acid 
reagent grade, crystalline 
A7506-25G Sigma 
Lysine L5501-5G Sigma 
Lysozyme from chicken egg white 62971-10G-F Sigma 
Magnesium chloride L6876-5G Sigma 
MG-132 474790-5MG Merck 
Na-glycerophosphate pentahydrate S/4110/48 Thermo Fisher 
Ni-NTA affinity chromatography 30210 Qiagen 
Non-Essential Amino Acids Solution 
(100X) 
11140035 Gibco™ 
NuPAGE LDS loading buffer NP0007 Invitrogen™ 
MOPS SDS running buffer 20X NP0001 NuPage 
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MES SDS Running Buffer 20X    MES-SDS1000 Formedium  
OligomycinA 75351-5MG Sigma 
Phenylmethane sulfonyl fluoride 
(PMSF) 
P7626-25G Sigma 
Pierce™ Streptavidin Plus 
UltraLink™ Resin 
53117 Thermo Fisher 
Polyethylenimine, Linear (MW 
25,000) 
23966-2 Polysciences 
Potassium iodide P2963-100G Sigma 
Propargyl acrylate 543136-5G Sigma 
Propargyloxycarbonyl-L-lysine HAA2095 Iris Biotech GmbH 
Recombinant Human IL-1α 10ug 200-01A Peprotech 
Sequencing Grade Modified Trypsin V5111 Promega 
Serine S4500-1G Sigma 
Sodium 2-mercaptoethanesulfonate M1511-10G Sigma 
Sodium bicarbonate S8875-500G Sigma 
Sodium chloride 10241AP Merck 
Sodium Orthovanadate S6508-250G Sigma 
Sodium p-toluenesulfinate 89720-100G Sigma 
Sodium pyrophosphate tetrabasic P8010-500G Sigma 
Sodium Pyruvate (100 mM) 11360070 Thermo Fisher 
Sodium sulfate, ACS reagent, 
≥99.0%, anhydrous, powder 
238597-2.5KG-M Sigma 
Sucrose for molecular biology, 
≥99.5% (GC) 
S0389-500G Sigma 
TAMRA-azide CLK-FA008 Jena Bioscience 
Tris Acetate Running Buffer (20x) LA0041 Thermo Fisher 
TCEP Hydrochloride T2650 Melford 
Threonine T8625-10G Sigma 
Triethylamine 471283-500ML Sigma 
Trifluoroacetic acid 
CHROMASOLV®, for HPLC, ≥99.0% 
302031 Sigma 
Tween-20 437082Q VWR 
Ubiquitin vinylsulfone (Ub-VS) U-202  Boston Biochem 
QIAprep Spin Miniprep Kit 50 27104 Qiagen 
Tris(3-
hydroxypropyltriazolylmethyl)amine  
762342-100MG Sigma 
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3.1.2 Plasmids list 
Dr M. Peggie, Dr R. Toth, Dr N. Wood, Mrs M. Wightman and Mr T. Macartney 
performed the cloning, subcloning and mutagenesis of the constructs described in 
this thesis. All constructs encoded the human version of the gene unless otherwise 
indicated. 
 
Table 3.2 Plasmids used in this thesis 
Protein Expressed Plasmid DU Number 
Ubiquitin MGCSSG Ubiquitin Q2-L73-
Mxe intein/chitin binding 
domain T3C 
pTXB1 MGCSSG Ubiquitin 
Q2-L73-Mxe intein/chitin 
binding domain T3C 
DU53581 
Ubiquitin MGCSSG Ubiquitin Q2-
R74-Mxe intein/chitin 
binding domain 
pTXB1 MGCSSG Ubiquitin 
Q2-R74-Mxe intein/chitin 
binding domain 
DU53553 
Ubiquitin Ubiquitin 1-73-T3C Mxe 
intein/chitin binding 
domain 
pTXB1 Ubiquitin (delta 
R74-G75)-T3C Mxe 
intein/chitin binding 
domain 
DU24828 
Ubiquitin Ubiquitin I44A (1-73)-T3C 
Mxe intein/chitin binding 
domain 
pTXB1 Ubiquitin I44A 
(delta R74-G75)-T3C Mxe 
intein/chitin binding 
domain 
DU24902 
Ubiquitin Ubiquitin M1-R74-Mxe 
intein/chitin binding 
domain 
pTXB1 Ubiquitin M1-R74-
Mxe intein/chitin binding 
domain  
DU53503 
Ubiquitin FLAG GG Ubiquitin pET28a FLAG GG Ubiquitin DU46789 
UBCH7 6His UBCH7 C17S C137S 
TAG3 
pET156P UBCH7 C17S 
C137S TAG3 
DU24871 
UBCH7 6HIS(TAG3) UBCH7 C17S 
F63A C137S 
pET15 6HIS(TAG3) UBCH7 
C17S F63A C137S 
DU28262 
UBCH7 6His UBCH7 C17S C137S pET156P UBCH7 C17S 
C137S 
DU39196 
UBCH7 His-UbcH7 C17S C137S 
F63A 
pET156P UBCH7 C17S 
F63A C137S 
DU24883 
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UBCH5c 6His-UBCH5c C21S 107S 
C111S 
pET15b 6His C3 UBCH5c 
C21S 107S C111S 
DU24307 
UbcH5c His-UbcH5c C21S F62A 
107S C111S 
pET15b 6His C3 UBCH5c 
C21S F62A 107S C111S 
DU28781 
UBCH5b His-UBE2D2 (UBCH5b) 
C21S C107S C111S 
pET28a(+) UBE2D2 
(UBCH5b) C21S C107S 
C111S 
DU24825 
UBCH5b His-UBE2D2 (UBCH5b) 
C21S F62A C107S C111S 
pET28a(+) 6His-UBE2D2 
(UBCH5b) C21S F62A 
C107S C111S 
DU28325 
UBCH5b His-UBE2D2 (UBCH5b) 
C21S C107S C111S 
pET15b 6His C3- UBE2D2 
(UBCH5b) C21S C107S 
C111S 
DU29236 
UBCH5b His-UBE2D2 (UBCH5b) 
C21S F62A C107S C111S 
pET15b 6His C3 -UBE2D2 
(UBCH5b) C21S F62A 
C107S C111S 
DU29237 
UBCH7 6His UBCH7 pET156P UBCH7 DU12798 
UBCH5a His-UBE2D1 (UBCH5a) pET28a(+) UBE2D1 
(UBCH5a) 
DU4315 
UBCH5c His-UBE2D3 (UBCH5C) pET156P UBCH5c DU15703 
UBE2A 6His-UBE2A pET28b-UBE2A DU20178 
UBE2B 6His-UBE2B  DU20017 
UBE2C 6His UBE2C pET156P UBE2C DU32146 
UBCH6 6His UBCH6 pET156P UBCH6 DU12803 
UBE2G1 6H-UBE2G1 pET28a(+) UBE2G1 DU14055 
UBE2H 6His UBE2H pET156P UBE2H DU32149 
UBE2J2 6His-UBE2J2 1-226 pET28a-UBE2J2 1-226 DU20695 
UBC13 6His UBC13 pet156P UBC13 DU15705 
UBC1 6His-UBC1 pET156P-UBC1 DU20018 
CDC34 6His-CDC34 pET28a(+) CDC34 DU4317 
UBE2S 6His-UBE2S pET28-UBE2S DU20175 
UBE2W 6His-UBE2W pET28a-UBE2W isoform 1 DU20190 
UBE2Q1 6His-UBE2Q1 pET28-UBE2Q1 DU20176 
UBE2Q2 6His UBE2Q2 pET156P UBE2Q2 DU12801 
UbcH5c His-UbcH5c N77S pET15b His UbcH5c N77S DU28800 
UBCH5c His UBCH5C (UBE2D3) 
D87A 
pET15 6His 3C UBCH5C 
(UBE2D3) D87A 
DU28876 
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UbcH5c His-UbcH5c I88A pET15b 6His C3 UbcH5c 
I88A 
DU28799 
UbcH5c His-UbcH5c L97A pET15b 6His C3 UbcH5c 
L97A 
DU28798 
UbcH5c His-UbcH5c L104A pET15b 6His C3 UbcH5c 
L104A 
DU28796 
UBCH5c 6His 3C UBCH5C (UBE2D3) 
S108A 
pET15 6His 3C UBCH5C 
(UBE2D3) S108A 
DU28895 
UBCH5c 6His 3C UBCH5C (UBE2D3) 
D117A 
pET15 6His 3C UBCH5C 
(UBE2D3) D117A 
DU58041 
PINK1 (Pediculus) GST-PINK1 (Pediculus) 126-
end 
pGEX6P-PINK1 (Pediculus) 
126-end 
DU34798 
PINK1 (Tribolium) GST-full PINK1 (Tribolium) 
kin dead 
pGEX-6-full PINK1 
(Tribolium) Kdead 
DU38037 
USP2 GST-USP2 269-605 pGEX6P-2-USP2 269-605 DU15718 
USP21 His-USP21 aa196-565 pET156p USP21 aa196-565 DU22483 
OTUB2 GST OTUB2 pGEX6P-1-OTUB2 DU32795 
UCHL3  pGEX6P-2-UCHL3 DU15696 
Parkin 6HIS SUMO Parkin W403A pET15 6HIS SUMO Parkin 
W403A 
DU51424 
Parkin 6His-SUMO Parkin W403A 
C431S 
pET15 6HIS SUMO Parkin 
W403A C431S 
DU28120 
Parkin 6His SUMO parkin (223S) pET156P 6His SUMO 
parkin (223S) 
DU40847 
Parkin 6HIS SUMO Parkin C431S pET 6His SUMO Parkin 
C431S 
DU39796 
Parkin 6His SUMO parkin tv3 
K27N 
pET156P 6His SUMO 
parkin K27N 
DU39837 
Parkin 6HIs SUMO PArkin R33Q pET6HIS SUMO Parkin 
R33Q 
DU39824 
Parkin 6HIS SUMO Parkin R42P pET 6His SUMO Parkin 
R42P 
DU39784 
Parkin 6xHIS-SUMO-PARKIN A46P pET15b SUMO blunt 
PARKIN A46P 
DU44510 
Parkin 6His SUMO parkin S65A pET156P 6His SUMO 
parkin S65A 
DU23314 
Parkin 6xHIS-SUMO-PARKIN 
K161N 
pET15b SUMO PARKIN 
K161N 
DU44321 
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Parkin 6His SUMO parkin K211N pET156P 6His SUMO 
parkin K211N 
DU23325 
Parkin 6His SUMO parkin R275W pET156P 6His SUMO 
parkin R275W 
DU43127 
Parkin 6xHIS-SUMO-PARKIN 
G328E 
pET15b SUMO PARKIN 
G328E 
DU44322 
Parkin 6HIS SUMO Parkin T415N pET 6His SUMO Parkin 
T415N 
DU39786 
Parkin 6His SUMO parkin G430D pET156P 6His SUMO 
parkin G430D 
DU43129 
Parkin 6His SUMO parkin C431F pET 6His SUMO parkin 
C431F 
DU46232 
NEDD4L GST-NEDD4L E576-D955 pGEX_TEV-NEDD4L E576-
D955 
DU24933 
NEDD4L GST-NEDD4L E576-D955 
C922A 
pGEX_TEV-NEDD4L E576-
D955 C922A 
DU24934 
NLEL GST-TEV-NLEL 59- end pGEX-TEV-NLEL DU39419 
NLEL GST-TEV-NLEL N59- end 
C753S 
pGEX-TEV-NLEL (N59-end) 
C753S 
DU24819 
ARIH1 GST-TEV-ARIH1 aa1-394 pGEX TEV ARIH1 aa1-394 DU24260 
UBE3C GST UBE3C Q641-
S1083(end) 
pGEX6P UBE3C Q641-
S1083(end) 
DU45302 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 
DU28681 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4390S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4390S 
DU28728 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4393S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4393S 
DU28729 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4408S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4408S 
DU28730 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4416S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4416S 
DU28731 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4417S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4417S 
DU28732 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4437S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4437S 
DU28733 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4440S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4440S 
DU28734 
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MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4506S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4506S 
DU28735 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4509S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4509S 
DU28736 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4520A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4520A 
DU28828 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4520A C4572A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4520A 
C4572A 
DU28897 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4520A C4572S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4520A 
C4572S 
DU28961 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4520K 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4520K 
DU29041 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4520S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4520S 
DU28737 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4537S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4537S 
DU28738 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4540S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4540S 
DU28739 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4549S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4549S 
DU28716 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4564S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4564S 
DU28718 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4565S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4565S 
DU28726 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4572A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4572A 
DU28898 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4572A C4520S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4572A 
C4520S 
DU28964 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4572S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4572S 
DU28742 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4572S H4583N 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4572S 
H4583N 
DU29097 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4579S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4579S 
DU28719 
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MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4582S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4582S 
DU28720 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4600S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4600S 
DU28721 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4614S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4614S 
DU28727 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4631S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4631S 
DU28743 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 C4634S 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 C4634S 
DU28722 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 E4534A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 E4534A 
DU28901 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 E4534Q 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 E4534Q 
DU28899 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 E4534Q H4583N 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 E4534Q 
H4583N 
DU28904 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 F4573A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 F4573A 
DU28943 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 F4573A F4586A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 F4573A 
F4586A 
DU28941 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 F4578A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 F4578A 
DU28942 
MYCBP2 GST-MYCBP2 Ser4378-
Phe4640 F4586A 
pGEX6P-1-MYCBP2 
Ser4378-Phe4640 F4586A 
DU28900 
NMNAT2 6His SUMO-NMNAT2 pET156His SUMO-
NMNAT2 
DU28977 
MIRO1 6xHIS-SUMO-MIRO1 1-592 
K567R K572R 
pET15b 6xHIS SUMO 
Miro1 1-592 K567R K572R 
DU44247 
Parkin Parkin E321-V465 C431S pcDNA5D FRT/TO-Parkin 
E321-V465 C431S 
DU28118 
Parkin Parkin E321-V465 pcDNA5D FRT/TO-Parkin 
E321-V465 
DU28101 
Parkin parkin W403A pcDNA5 FRT/TO Parkin 
W403A 
DU51408 
MYCBP2 MYCBP2 Ser4378-Phe4640 pcDNA5-FRT/TO-DU-
MYCBP2 Ser4378-Phe4640 
DU29077 
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MYCBP2 Myc-MYCBP2 Ser4378-
Phe4640 C4520A 
pcDNA5-FRT/TO-Myc DU-
MYCBP2 Ser4378-Phe4640 
C4520A 
DU28919 
Ubiquitin HA-ubiquitin pcDNA5D frtTO HA 
UBIQUITIN 
DU48439 
 
3.1.3 Antibody list 
 
Table 3.3 Commercial antibodies used in this thesis 
Name Company Catalogue Number Host 
6xHis Monoclonal Antibody 
(Albumin Free) 
Clontech 631212 Mouse 
Parkin human SantaCruz Sc-32282 Mouse 
GAPDH (14C10) (HRP 
Conjugate) 
Cell Signaling 3683 Rabbit 
Monoclonal Anti-NMNAT2, 
clone 2E4 
Sigma WH0023057M1-
100UG 
Mouse 
Alpha Tubulin PROTEINTECH 66031-1-Ig Mouse 
 
Table 3.4 In-house antibodies used in this thesis 
Name Immunogen Sheep number Bleed number 
Parkin phospho-Ser65 RDLDQQS*IVHIVQR   
[residues 60 - 72 of 
human PARKIN] 
S210D 2nd 
MYCBP2 MYCBP2 (4378 - 4640) SA357 2nd 
 
3.1.4 Instruments  
Bacterial incubators were from Infors (Reigate, UK). Centrifuge tubes, rotors and 
centrifuges were from Beckmann Coulter (Palo Alto, USA). ÄKTA pure 
chromatography system, Superdex 200 10/300, Superdex 75 16/600 were from GE 
Healthcare (Piscataway, NJ). Thermomixer IP shakers and bench-top centrifuge 
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were purchased from Eppendorf (Cambridge, UK). SpeedVacs were from CHRIST 
(Osterode, Germany). pH meters and electrodes were from Horiba (Kyoto, Japan). 
Power packs for electrophoresis and Trans-Blot Cells were from BioRad (Herts, UK). 
Mini gel tank electrophoresis system was from Atto (Tokyo, Japan). X-Cell SureLock 
Mini-cell electrophoresis systems and X-Cell II Blot modules were from Invitrogen 
(Paisley, UK). X-omat autoradiography cassettes, with intensifying screens, were 
from Kodak (Liverpool, UK). The Konica automatic film processor was from Konica 
Corporation (Japan). CO2 incubators were from Mackay and Lynn (Dundee, UK). 
Tissue culture class II safety cabinets were from Medical Air Technology (Oldham, 
UK). The Chemidoc Gel Imaging System was from BioRad. The Mosquito Crystal, 
Dragonfly liquid handling robot and consumables were from TTP Labtech (Herts, 
UK). Prep-HPLC system components were obtained from Dionex (Camberley, UK). 
LC-MS system were obtained from Agilent Technologies. Freeze Dryers was 
obtained from LaboGene (Bjarkesvej, Danmark). The Reveleris® X2 flash 
chromatography system and The R-210/215 Rotavapor® system were obtained 
from BÜCHI Labortechnik AG. The ultrasonic cleaning baths was obtained from 
VWR.  
 
3.1.5 In-house reagents 
Primers were obtained by the University of Dundee oligonucleotide synthesis 
service. Bacterial culture medium Luria Bertani (LB) broth and LB agar plates were 
provided by the University of Dundee media kitchen facility. The Protein 
Production Team at Division of Signal Transduction and Therapy (DSTT) provided 
the affinity chromatography reagents including glutathione sepharose 4b, Ni-NTA 
agarose. The recombinant E1s, E2s, Flag-Ub, HHARI, UBE3C, USP2, USP21, OTUB2, 
UCH-L3, NleL, disease mutant Parkin, phPINK1, p-Ub, His-SUMO-Miro1, NMNAT2 
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proteins expression and purification were carried out by the Protein Production 
and Assay Development (PPAD) team led by Dr. Axel Knebel. The lp-In T-Rex HeLa 
(Life Technologies) stable cell lines (HeLa cells stably expressing untagged Parkin 
WT, S65A, H302A or IBR-RING2) were kindly provided by Dr. Miratul Muqit’s lab.  
 
3.2 Method for Chapter 4 
 
3.2.1 Synthesis of TDAEs (performed by Dr. Mattew Stanely) 
 
3.2.1.1 Synthesis of alkyne-functionalized TDAE 3 
PhI(OAc)2 (966 mg, 2 mmol) was added to a suspension of propargyl acrylate 1 (2 
mmol), sodium arenesulfinate (8.0 mmol), and KI (328 mg, 2.0 mmol) in 
acetonitrile (MeCN) (8 mL). The reaction mixture was stirred vigorously at room 
temperature for 1 h under an inert atmosphere. The reaction mixture was then 
quenched by the addition of saturated Na2S2O3 aq. (20 mL) followed by a saturated 
aqueous solution of NaHCO3 aq. (20 mL). Further stirring was followed by 
extraction with ethyl acetate (EtOAc) (3 x 50 mL). The combined organic phases 
were washed with saturated NaCl aq. (75 mL) and dried over Na2SO4. The organic 
solvent was removed in vacuo and the crude product was directly purified by flash 
chromatography using a Reveleris® X2 flash chromatography system (Grace) 
(Reveleris® 12g silica column; EA:Hexane; 15% to 25% to 100% EA gradient elution) 
to yield 3. HR-MS: observed [M-H]- 263.0361 (calculated 263.0373). 
 
3.2.1.2 Synthesis of alkyne-functionalized TDAE 4 
To synthesize 4, starting material N-propargylacrylamide, 2 was first prepared as 
previously described441. Purification was carried out by flash chromatography 
using a Reveleris® X2 flash chromatography system (Grace) (Reveleris® 12g silica 
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column; EA:Hexane; 20% to 35% EA gradient elution). Analytical data 
corresponded to literature values. PhI(OAc)2 (966 mg, 2 mmol) was added to a 
suspension of N-propargylacrylamide, 2 (2 mmol), sodium arenesulfinate (8.0 
mmol), and KI (328 mg, 2.0 mmol) in CH3CN (8 mL). The reaction mixture was 
stirred vigorously at room temperature for 1 h under an inert atmosphere. The 
reaction mixture was quenched by the addition of saturated Na2S2O3 aq. (20 mL) 
followed by a saturated aqueous solution of NaHCO3 aq. (20 mL). Further stirring 
was followed by extraction with EtOAc (3 x 50 mL). The combined organic phases 
were washed with saturated NaCl aq. (75 mL) and dried over Na2SO4. The organic 
solvent was removed in vacuo and the crude product was directly purified by flash 
chromatography using a Reveleris® X2 flash chromatography system (Grace) 
(Reveleris® 12 g silica column; Toluene:EA; 0% to 1% to 10% EA gradient elution). 
HR-MS: observed [M-H]- 262.0537 (calculated 262.0543). 
 
3.2.2 Preparation of UBE2L3*and UBE2D3*  
Full-length E2s were cloned into the pET expression vectors downstream of an N-
terminal Hisx6 tag and Precision protease site. E. coli strain BL21(DE3, Merck) 
transformed with E2 clones were cultured at 37 °C in LB medium supplemented 
with 100 g mL-1 of ampicillin. When the OD600 reached 0.6, the culture was 
induced by addition of 0.2 mM isopropyl thio--D-galactoside (IPTG) and 
incubated at 37 °C for 5.0 hours. The cells were harvested by centrifugation and 
stored at -80 °C. Cells were resuspended in ice cold lysis buffer (50 mM Tris-HCl pH 
7.5, 150 mM NaCl, 25 mM imidazole, 0.5 mg/mL lysozyme, 50 g/mL DnaseI, 
Complete, Mini, EDTA-free protease inhibitor cocktail) and incubated on ice for 30 
minutes followed by sonication. The clarified lysate was then subjected to Ni-NTA 
affinity chromatography (Qiagen) and washed with wash buffer (50 mM Tris-HCl 
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pH 7.5, 150 mM NaCl, 25 mM imidazole). Protein was eluted with elution buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 300 mM imidazole) and dialyzed into 
storage buffer (20 mM Tris, 150 mM NaCl, 1 mM DTT). The protein was then further 
purified by size exclusion chromatography using a HiLoad 16/600 Superdex 75 pg 
column (GE Life Sciences) coupled to an ÄKTA Purifier FPLC system (1.0 mL min-1, 
running buffer: 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT). Fractions were 
collected, concentrated and flash frozen for storage at -80 °C. 
 
3.2.3 Preparation of UBE2L3-ProcK 
An amber stop codon was introduced at position 3 of the open reading frame in 
pET156-UBE2L3* by Quikchange site-directed mutagenesis. This yielded the 
plasmid pET156-UBE2L3*-TAG3 (* corresponds to a C17S and C137S mutant). 
BL21(DE3) cells were transformed with plasmids pET156-UBE2L3*-TAG3 and pCDF-
PylST (plasmid harbouring constitutive copies of the MbPylRS/tRNACUA pair, a kind 
gift from Dr. Jason Chin) and used to inoculate 200 mL LB media containing 
ampicillin (100 g mL-1) and spectinomycin (50 g mL-1). After overnight 
incubation at 37 C, 6 x 1 L of LB medium containing ampicillin (100 g mL-1) and 
spectinomycin (25 g mL-1) were each inoculated with 30 mL overnight culture 
and incubated at 37 C, 200 rpm, until cell density reached OD600 = 0.8-0.9. 
Propargyloxycarbonyl-L-lysine (ProcK) (300 mM stock solution in H2O and pH 
adjusted to ~7) was then added to a final concentration of 3 mM. Cultures were 
then incubated for a further 20 min at 37 °C and then induced with IPTG (500 M). 
After 4 h cells were harvested and cell pellets were resuspended in 200 mL lysis 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 25 mM imidazole, 0.5 mg mL-1 
lysozyme, 50 g mL-1 DnaseI, 4 tablets of Complete, EDTA-free protease inhibitor 
cocktail (Roche) and incubated on ice for 30 min. The suspension was then 
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sonicated before clarification at 18,000 rpm, 30 min at 4 °C. Ni-NTA resin (600 l 
of settled resin, Qiagen) was then added to the lysates and rotated at 4 °C for 1 h. 
Resin was then washed with wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 25 
mM imidazole) and then eluted with elution buffer (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 300 mM Imidazole). The eluent was then concentrated to 2.5 mL and 
further purified by size exclusion chromatography using a HiLoad 16/600 Superdex 
75 pg column (GE Life Sciences) coupled to an ÄKTA Purifier FPLC system (running 
buffer: 100 mM Na2HPO4 pH 8, 150 mM NaCl, 0.1 mM TCEP). Fractions were 
collected and concentrated.  
 
3.2.4 TAMRA labelling of UBE2L3-ProcK by Copper-catalyzed Azide-Alkyne 
Cycloaddition (CuAAC)  
UBE2L3-ProcK was diluted in buffer (100 mM Na2HPO4 pH 8, 150 mM NaCl, 0.1 
mM TCEP) to a final concentration of 50 M. CuSO4 and Tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA)442, stock solutions were freshly 
prepared in H2O and then premixed before being added to the protein at final 
concentrations of 0.1 mM and 1.0 mM, respectively. TAMRA-azide (Jena Bioscience, 
#CLK-FA008, M.W. = 512.56 g mol-1) was then added to a final concentration of 150 
M. Ascorbic acid was added to a final concentration of 4 mM. The reaction was 
incubated at 23 C for 1-2 h (or until starting material had been consumed as 
determined by LC-MS). The reaction was then quenched with 5 mM EDTA for 15 
min at 23 C. Small molecule components were then removed by dialysis against 2 
x 1L buffer (100 mM Na2HPO4 pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1 mM TCEP) at 
4 °C over 48 h. Protein was snap frozen in liquid nitrogen and stored at -80 °C.  
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3.2.5 Preparation and purification of phospho-ubiqutin (Performed by Dr. Axel 
Knebel) 
23 μM bovine ubiquitin (SIGMA) was phosphorylated for 24 h with 3.7 μM MBP-
PINK1 at 22 °C in the presence of 100 μM ATP and 10 mM MgCl2. To replace ADP 
with ATP, the reaction was dialysed against Mg-ATP solution. Ubiquitin was filtered 
through a 30 kDa Vivaspin filter to deplete MBP-PINK1, concentrated in a 3 kDa 
MWCO filter device, washed extensively with water and loaded onto a Mono Q-
column, which bound phospho-ubiquitin but not ubiquitin. The former was 
recovered by washing the column with 50 mM Tris pH 7.5, which was sufficient to 
elute stoichiometrically phosphorylated ubiquitin 
 
3.2.6 Preparation and purification of Parkin WT, C431S, W403A and p-Parkin 
(phosphorylation of p-Parkin was performed by Dr. Cong Han) 
The wild type human Parkin and C431S mutant clones (pET15-6His-SUMO-Parkin, 
pET15-6His-SUMO-Parkin C431S and pET15-6His-SUMO-Parkin W403A) were 
transformed into Escherichia coli BL21 (DE3) (Merck) and grown in LB media 
supplemented with 200 μM ZnCl2 and 100 mg mL-1 ampicillin at 37 C until OD600 
reached 0.4. The culture was incubated at 16 C. Upon OD600= 0.8, expression was 
induced with 25 mM IPTG for 18 h. The bacterial cells were then harvested by 
centrifugation and suspended in lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 
10 mM imidazole, 1 mM TCEP) supplemented with lysozyme (0.5 mg/mL) and 
cOmplete™, EDTA-free Protease Inhibitor Cocktail Set (Roche). After sonication 
treatment on ice, the mixture was centrifuged to yield a clear supernatant, which 
was loaded onto a column with Ni-NTA resin (Qiagen) pre-equilibrated in lysis 
buffer. The fraction containing Parkin was eluted, and then dialyzed against buffer 
A (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM TCEP), then SENP1 was added to 
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cleave SUMO tag for 12 h at 4 C (100:1 w/w ratio of Parkin to SENP1). After the 
digestion, 10 mM imidazole was added to the sample, which was further applied 
onto a Ni-NTA column. The flow-thru fraction was loaded onto a HiLoad 16/60 
Superdex 75 column (GE Healthcare) with buffer B (20 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 5 mM DTT).  
The Pediculus humanus corporis PINK1 (PhPINK1) clone (pGEX6P-PINK1 126-
575) was transformed into E. coli BL21 (DE3) and grown in LB media supplemented 
with 100 mg mL-1 ampicillin at 37 C. Upon OD600= 0.8, expression was induced 
with 0.1 mM IPTG for 16 h at 26 C. The bacterial cells were then harvested by 
centrifugation and suspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 
0.5 mM EGTA, 0.5 mM EDTA, and 1 mM DTT) supplemented with 10 mg/mL 
Leupeptin and 1 mM Pefabloc. After sonication treatment on ice, the mixture was 
centrifuged to yield a clear supernatant, which was loaded onto a column with 
Glutathione Sepharose 4B resin (GE Healthcare) pre-equilibrated in lysis buffer. The 
PhPINK1 fraction was eluted, and then dialyzed against buffer C (50 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1 mM DTT, and 5% glycerol). 
The Parkin was incubated with PhPINK1 for 8 h at 27 C in 20 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 10 mM MgCl2, 5 mM ATP, and 5 mM DTT (5:1 molar ratio of 
Parkin to PhPINK1). The reaction mixture was applied to a HiLoad 16/60 Superdex 
75 column with buffer B. Subsequently, the Parkin fractions were pooled and 
concentrated by ultrafiltration with Amicon centrifugal filter device. The 
phosphorylated Parkin was identified by 8% Zn2+-Phos-tag SDS-PAGE.  
 
3.2.7 Expression and purification of NEDD4L, HOIP and NleL 
GST-NEDD4L, GST-NEDD4L C922A, HOIP, HOIP C885S, GST-NleL and GST-NleL 
C753A, were expressed and purified as previously described128,242,443 
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3.2.8 General method for ΔUb-SR preparation 
A plasmid composed of full-length Ub cloned into the pTXB1 vector444, was taken 
and the bases coding for the C-terminal Ub residues 74-76 were deleted by 
Quikchange mutagenesis. To suppress cellular intein activity, a T3C mutation in the 
GyrA intein was also introduced yielding plasmid pTXB1-Ub74-76-T3C. ER2566 E. 
coli. cells (NEB) were transformed with pTXB1-Ub1-74 and recovered with S.O.C. 
medium (250 μL). The cells were incubated for 1 h at 37 °C and then LB medium 
(100 mL) containing ampicillin (100 mg mL-1) was inoculated with the recovered 
cells (200 μL) and the culture was incubated overnight whilst shaking (230rpm) at 
37°C. LB medium (2L) containing ampicillin (100 mg mL-1) was inoculated with the 
overnight culture (50 mL) and incubated whilst shaking (230rpm) at 37°C. At 
O.D.600~ 0.4, the cells were transferred to a 25°C incubator and after 30 min the 
cells were induced with IPTG (0.2 mM). After 5 h the cells were harvested and 
suspended in 60 ml lysis buffer (20 mM Na2HPO4 pH 7.2, 200 mM NaCl, 1 mM EDTA) 
and frozen. The thawed cells were lysed by sonication on ice and were clarified by 
centrifugation (39000 x g, 30 min). An empty XK 26/20 column was filled with chitin 
beads (20 mL) (NEB) and equilibrated with lysis buffer. At 4°C the clarified lysate 
was loaded (flow rate: 1.0ml min-1) onto the column using an ÄKTA FPLC system. 
The column was then washed with lysis buffer (~400 mL) and incubated with 50 
mL of cleavage buffer (20 mM Na2HPO4 pH 6.0, 200 mM NaCl, 100 mM Sodium 
methanethiolate (MESNA), 1 mM EDTA). The flow was then stopped and the 
column was incubated for 60 h at 4°C, to allow thiolysis and concomittant S-N 
transfer. Liberated ΔUb-SH was eluted with elution buffer (20 mM Na2HPO4 pH 6, 
200 mM NaCl, 1 mM EDTA). The fractions containing ΔUb-SH were pooled and 
concentrated to ~5 mL using an Amicon Ultra-15 centrifugal filter device (Millipore). 
The protein was then further purified by semi-preparative RP-HPLC using the 
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Dionex system. A gradient of 10 % buffer A to 80 % buffer B was applied at a flow 
rate of 10 mL min-1 over 30 min (buffer A=0.1% TFA in H2O, buffer B=0.1% TFA in 
acetonitrile). After HPLC purification fractions containing ΔUb-SR were pooled and 
lyophilized yielding ~30 mg. 
 
3.2.9 Ub-N3 aminolysis reaction 
Ub-SR (25.8 mg) was reconstituted445, by the addition of DMSO (200 μL). On 
complete dissolution of ∆Ub-SR in DMSO, H2O (800 μL) was added to give a final 
DMSO concentration of 20% (v/v). 500 μL of 2-azidoethanamine (Enamine) in 50% 
(v/v) aqueous DMSO/MQ (8 M) was then added to the ∆Ub-SR solution. 60.0 μl of 
triethylamine (TEA) was then added raising the solution pH to 9 and the mixture 
was then briefly vortexed. The solution incubated at 30 °C for 16 hours and 
monitored by LC-MS. The protein (∆Ub-N3) was then further purified by semi-
preparative RP-HPLC (Column: BioBasic-4; Part number: 72305-259270). A 
gradient of 20 % buffer A to 50 % buffer B was applied at a flow rate of 10 mL min-
1 over 60 min (buffer A=0.1% TFA in H2O, buffer B=0.1% TFA in acetonitrile). 
Fractions containing ΔUb-N3 were pooled and lyophilized (Yield: 80%). 
 
3.2.10 Conjugation of ∆Ub-N3 with TDAE by CuAAC click reaction 
∆Ub-N3 (3.5 mg) was reconstituted by dissolution into 100 μl DMSO. H2O (900 μL) 
was added to give a final DMSO concentration of 10% (v/v) and a final ∆Ub-N3 
concentration of 418.6 μM. DMSO stock solutions of TDAEs 3 or 4 were prepared 
(10 mM). TDAEs 3 or 4 (200 μL) were then mixed with a pre-prepared DMSO/MQ 
solution (456.2 μL, 20% (v/v)). Phosphate buffer (50.0 μL, 100 mM Na2HPO4 pH 7.5, 
150 mM NaCl) and ∆Ub-N3 stock solution (238.6 μL, 418.6 μM) were then 
subsequently added. Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) in H2O 
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(25 μL, 12.5 eq., 50 mM stock solution) was pre-mixed with a freshly prepared 
solution of CuSO4 (aq.) (5 μL, 2.5 eq., 50 mM stock solution). The THPTA/CuSO4 
(aq.) solution (30 μL) was then added to the previously prepared TDAE/∆Ub-N3 
solution. L-ascorbic acid in H2O (25 μL, 100 mM stock solution) was then added to 
the previously mixed components. The reaction was incubated at 23 C with 
shaking (1400 rpm) for 15 minutes. The reaction was then quenched by the 
addition of EDTA (2.5 mM final concentration) and the product (7 or 8) was purified 
by semi-preparative RP-HPLC (Column: Thermo Scientific BioBasic-4; Part number: 
72305-259270) using the Dionex system. A gradient of 20 % buffer A to 50 % buffer 
B was applied at a flow rate of 10 mL min-1 over 60 minutes (buffer A=0.1% TFA in 
H2O, buffer B=0.1% TFA in acetonitrile). Fractions containing ΔUb-TDAE were 
pooled and lyophilized (Yield: 50-60%). 
 
3.2.11 Synthesis E2~Ub Probes  
ΔUb-TDAE (7, 7.0 mg) was reconstituted by the addition of 50 μl DMSO. On 
complete dissolution of ∆Ub-TDAE, H2O (450 μL) was added to give a final DMSO 
concentration of 10% (v/v) and a final ∆Ub-TDAE concentration of 1.6 mM. ∆Ub-
TDAE was then incubated with 0.5 eq. of the desired E2 in 0.8 mL phosphate buffer 
(100 mM Na2HPO4 pH 7.5, 150 mM NaCl, reducing agent free, the desired E2s were 
performed buffer exchanged before the reaction) at 23 C for two hours and 
monitored by LC-MS. For acrylamide probes 10, 10 F63A, 11, 12 and 12 F62A the 
above procedure was carried out with ΔUb-TDAE 8 and 30 °C incubation for 12 h 
was required to consistently achieve quantitative elimination to the unsaturated 
AVS species. The products were purified by gel filtration (0.5 mL min-1, 20 mM Tris-
HCl pH 7.5, 150 mM NaCl as mobile buffer, HiLoad 16/600 Superdex 75pg). 
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3.2.12 Molecular modelling of RING- and HECT-probe complexes (Performed by 
Dr. Virdee) 
The RING-E2~Ub model was generated by importing the PDB coordinates 4AP4446 
into the BioLuminate biologics modelling suite (Schrödinger). The AVS-triazole 
linker present between E2 and Ub in probe 10 was manually built and geometry 
optimized. Hydrogen atoms were then added using the Protein Preparation tool. 
The E2 residue Cys85, the Ub residue Leu73, and the linkage between them were 
selected along with all protein residues within 5Å. This substructure was then 
energy minimized using the OPLS2005 forcefield. Minimized coordinates were 
then exported as mol2 files and imported into Pymol (Schrödinger) for figure 
generation. The same procedure was repeated for the HECT-E2~Ub model using 
PDB 3JW0128. 
 
3.2.13 Parkin activity assay with UBE2L3* 
Parkin (3 μg, 760 nM) was incubated with ubiquitylation assay components in a 
final volume of 50 μl (50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 240 nM UBA1, 2 μM 
UBE2L3 variant, 2 mM ATP, 58 μM Ub and 380 nM of GST-PhPINK1 WT.  The 
reaction was incubated at 30 °C for 1 h. The reaction was quenched by the addition 
of reducing 4X LDS loading buffer, resolved by SDS-PAGE, and visualized by 
coomassie staining. 
 
3.2.14 In vitro probe-labeling assay 
The indicated E3 ligases were added into Tris buffer (20 mM Tris-HCl pH 7.5, 150 
mM NaCl). 5.0 e.q (unless otherwise indicated) of E2~Ub (probe 9 or 10) was 
incubated with E3 ligase at 30 °C for the indicated time. Reactions were quenched 
by the addition of 4X LDS loading buffer (supplemented with ~680 mM 2-
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mercaptoethanol) and samples were analyzed by SDS-PAGE (4-12% NuPage gel) 
followed by coomassie staining or immunoblotting. 
 
3.2.15 Ubiquitylation assay and in situ profiling (performed by Kristin Bulk) 
Parkin (1.3 M) was incubated with ubiquitylation assay components in a final 
volume of 30 μl (50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 0.12 μM UBA1, 2 μM UBE2L3, 
0.83 μM His-SUMO-Miro1, 2 mM ATP, 88 μM Flag-ubiquitin and 0.31 μM TcPINK1 
(WT/KD). Ubiquitylation reactions were incubated at 30 °C and 1050 rpm for 60 
min. Ubiquitylation reactions were stopped by the addition of 5 U mL-1 Apyrase 
(New England BioLabs) and incubated for 10 min at 30 °C and agitated at 1050 rpm. 
Probe profiling was carried out by the addition of 9 or 11 (8 μM) and incubated for 
10 h at 30 °C and 650 rpm. The reactions were terminated by the addition of LDS 
sample buffer containing 4 % 2-mercaptoethanol. Reaction mixtures were resolved 
by SDS-PAGE and immunoblotted with the following antibodies: anti-FLAG (Sigma, 
1:10000), anti-Parkin (Santa-Cruz, 1:500) or anti-His (1:5000). For Fluorescence 
detection, 20 μl of sample were loaded on a 4-12 % gel and subjected to SDS-PAGE. 
Gels were washed with water for 30 minutes and then visualized by scanning with 
a FLA-5100 imaging system (Filter: LPG, Laser: 532 nm, Voltage: 400, FUJIFILM Life 
Science). The gel was subsequently coomassie stained. 
 
3.2.16 DUB resistance assay (performed by Dr. Virdee) 
His-USP2259–605, His-USP21196-565, OTUB2 and GST-UCHL3 were expressed in E. coli 
and purified. The DUB-reactive ubiquitin-based probe, Ub-Alk, was used as a 
positive control and tested in parallel with probes 9 and 10. Probes were diluted 
to 40 M and DUBs were diluted to 10 M in buffer (20 mM Tris-HCl pH 7.5, 150 
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mM NaCl, 1 mM TCEP). Probe (10 L) and DUB (10 L) solutions were then mixed 
and incubated for 2 h at 30 C. Proteins were then resolved by SDS-PAGE and 
visualized by coomassie staining. 
 
3.2.17 Tryptic MS/MS sequencing of crosslinked peptides from Parkin and an ABP 
The coomassie stained SDS-PAGE band corresponding to the Parkin labeled with 
ABP 9 was excised, dehydrated and resuspended using standard procedures (In-
house protocol from Dr. David Campbell, file name: In gel digest 170221). LC-
MS/MS analysis was performed on an LTQ Orbitrap Velos instrument (Thermo 
Scientific) coupled to an Ultimate nanoflow HPLC system (Dionex). A gradient 
running from 3 % solvent A to 60 % solvent B over 45 min was applied (solvent A = 
0.1 % formic acid in H2O; solvent B = 0.08 % formic acid in 80 % MeCN). Fragment 
ions were generated by CID and 1+ and 2+ precursor ions were excluded. 
Thermo .raw data was converted to .mgf format using the MSConvert software 
(ProteoWizard). Raw data was searched using the pLink software against UBE2L3* 
and Parkin sequences with trypsin specificity (up to 3 missed cleavages) 
(Performed by Dr. Virdee). A crosslinker monoisotopic mass of 307.1644 was 
manually added which accounted for the theoretical mass difference associated 
with formation of a bisthioether between 2 Cys residues together with the acrylate 
AVS, the triazole linkage and the tryptic Leu73 remnant from the Ub C-terminus.  
 
3.2.18 Cell culture and lysis protocol 
Flp-In T-Rex HeLa (Life Technologies) stable cell lines (HeLa cells stably expressing 
untagged Parkin WT, S65A, H302A or IBR-RING2) were cultured (37 C, 10 % CO2) 
in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) Fetal 
Bovine Serum (FBS), 2.0 mM L-glutamine, 1X minimum essential medium (MEM, 
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Life Technologies), 1X non-essential amino acids (NEAA, Life Technologies), 1.0 mM 
of sodium pyruvate (Life Technologies) and antibiotics (100 units mL-1 penicillin, 
0.1 mg mL-1 streptomycin, 15 g mL-1 blasticidin, 100 g mL-1 hygromycin). At 80 % 
confluency cells were either untreated or treated with 10 M CCCP (dissolved in 
DMSO, 40mM stock solution), and incubated for a further 3 h. Cells were rinsed 
with ice-cold PBS and extracted in lysis buffer (50 mM Tris-HCl pH 7.5, 5 M EDTA, 
0.27 M sucrose, 10 mM sodium 2-glycerophosphate, 0.2 mM phenylmethane 
sulfonyl fluoride (PMSF), 1.0 mM benzamidine, 1.0 mM sodium ortho-vanadate, 
50 mM sodium fluoride, 5.0 mM sodium pyrophosphate and 10 M TCEP). Lysis 
was carried out by sonication (Sonic & Materials INC, VC 100, Jencons Scientific 
LTD, CT, USA, 55% amplitude, 12 times (1 sec on, 1 sec off)) and then clarified by 
centrifugation at 4 °C for 30 min at 14,800 rpm. Supernatants were collected (total 
cell extracts) and protein concentration determined by Bradford assay. 
SH-SY5Y (PHE Culture Collection) cells were grown in DMEM/F-12 media 
supplemented with 15% (v/v) FBS, 2.0 mM L-glutamine and antibiotics (100 units 
mL-1 penicillin, 100 g mL-1 streptomycin). To depolarize mitochondria, cells were 
treated with 10 μM CCCP, dissolved in DMSO, for the indicated time. Cell extracts 
were prepared as described for HeLa cells. All cells were cultured at 37 °C in a 5 % 
CO2 humidified atmosphere. 
 HOIP WT and C879S MEF cells were provided by Dr. Philip Cohen lab. The MEF 
cells was prepared as previously described447. The cells were cultured (37 C, 10 % 
CO2) in DMEM supplemented with 10% (v/v) FBS, 2.0 mM L-glutamine, and 
antibiotics (100 units mL-1 penicillin, 0.1 mg mL-1 streptomycin, 15 g mL-1) and 
treated within 5 ng mL-1 IL-1α for indicated time. Cell extracts were prepared as 
described for HeLa cells. Testing of cell stocks for mycoplasma contamination was 
routinely carried out in accordance with departmental protocols.   
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3.2.19 ABPP of total cell extracts 
E2~Ub probes were diluted with buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl) and 
added to total cell extracts at a final concentration of 5.0 μM (final extract 
concentration 1.6 mg mL-1). Reactions were then incubated at 30 °C for the 
indicated time. Reactions were quenched by the addition of 4X LDS loading buffer 
(supplemented with betamercaptoethanol) and samples were analyzed by SDS-
PAGE (4-12% NuPage gel) followed by immunoblotting. 
 
3.2.20 Immunoblotting 
Samples were resolved by SDS–PAGE (4–12% NuPage gel, Invitrogen) with MOPS 
or MES running buffer (without boiling) and transferred on to 0.45 μm 
nitrocellulose membranes (GE Healthcare Life Science). Membranes were blocked 
with PBS-T buffer (PBS + 0.1% Tween-20) containing 5% (w/v) non-fat dried 
skimmed milk powder (PBS-TM) at room temperature for 1 h. Membranes were 
subsequently probed with the indicated antibodies in PBS-T containing 5 % (w/v) 
Bovine Serum Albumin (BSA) overnight at 4 °C. Detection was performed using 
HRP-conjugated secondary antibodies in PBS-TM for 1 h at 23 °C. ECL Prime 
substrate (GE Life Sciences) was used for visualization in accordance with the 
manufacturers protocol. 
 
3.2.21 Antibodies 
His-tagged species were probed with 1:10000 anti-His primary antibody (Clontech, 
cat number: 631212). Anti-Parkin mouse monoclonal was obtained from Santa 
Cruz (sc-32282) at 1:2000 dilution (HeLa and SH-SY5Y samples); anti-Parkin 
phospho-serine 65 rabbit monoclonal antibody was obtained as previously 
described258, and used at 1:2500 dilution. GAPDH (14C10) rabbit mAb (HRP 
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Conjugate, Cell Signaling Technology) was used at 1:5000 dilution. For detecting 
the endogenous level of phospho-Parkin, an antibody pre-clearing step is required 
(The pre-blocked nitrocellulose membrane was incubated with anti-Parkin 
phospho-serine 65 rabbit monoclonal antibody solution (1:2500 dilution) at 4°C 
for overnight. The pre-clearing procedure was repeated)  
 
3.2.22 Parkin disease mutant in vitro profiling 
The different recombinant Parkin mutants448, (1.0 μM, 1.535 μg) were incubated 
with PhPINK1 or kinase dead PhPINK1 (0.77 μg), TCEP (1.0 mM), ATP (1.0 mM) and 
Ub (75 μM) in 1X Tris buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5.0 mM MgCl2) 
at 30 °C for 1.0 h. After 1.0 hour incubation, fluorescent probe 11 was added (5.0 
μM) and incubated for another 4 or 8 hours in the dark at 30 °C. Reactions were 
quenched by the addition of 4X LDS loading buffer (supplemented with 
betamercaptoethanol) for the indicated time point and samples were resolved by 
SDS-PAGE (4-12% NuPage gel). Gels were washed with water for 30 minutes and 
then visualized by scanning with a FLA-5100 imaging system (Filter: LPG, Laser: 532 
nm, Voltage: 400, FUJIFILM Life Science). Experiments were carried out in triplicate 
and quantification was carried out using the Fiji software variant of ImageJ. For 
each replicate the ratio of the band size relative to the WT signal was taken. The 
mean of these values were plotted on a Log2 scale using Prism 6 (GraphPad 
Software). All the disease mutant Parkin proteins were obtained from Dr. Axel 
Knebel, DSTT.  
 
3.2.23 Profiling of patient-derived fibroblasts 
Low passage fibroblasts from a PD patient carrying a Q456X mutation in the PARK6 
gene and from a healthy age-matched family member, were cultured as previously 
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described449. Fibroblasts were obtained from skin biopsies following routine 
clinical procedures, underwritten informed consent and approval by a local ethics 
committee (Comite ́ de Protection des Personnes “Ile de France”). Cell lysis, probe 
profiling and immunoblotting as carried out as described for SH-SY5Y extracts. 
These fibroblasts sample were kindly provided by Dr. Olga Corti and Dr. Jean-
Christophe Corvol (Sorbonne Universités, UPMC Univ Paris 06; and INSERM 
UMRS_1127, CIC_1422; CNRS UMR_7225; AP-HP and ICM, Hôpital Pitié-
Salpêtrière, Department of Neurology, F-75013, Paris, France). 
 
3.2.24 Ubiquitin-based probes  
Ubiquitin vinylsulfone (Ub-VS) was sourced from Boston Biochem. The Ub-Alk 
probe was prepared by Dr. Stanley as follows. Ub1-75 thioester was prepared as 
previously described except the Gly76 was deleted producing plasmid pTXB1-Ub1-
75. Pooled fractions were concentrated and adjusted to pH 8 by the careful 
addition of 1 N NaOH while mixing. Propargyl amine (250 mM) was then added 
and the reaction left to incubate at 25 °C for 1 h. Protein functionalization was 
~90% as determined by LC-MS and was further purified by semi-preparative HPLC 
and lyophilized. Probe was folded by dissolution in denaturing buffer (200 mM 
Na2HPO4 pH 7.5, 6 M guanidinium chloride) and dialyzed overnight against PBS.  
 
3.3 Method for Chapter 5 
 
3.3.1 Biotin functionalized ABP preparation 
Ub with a GCSSG N-terminal extension was expressed from plasmid pTXB1-UbΔ74-
76-T3C plasmid7. An equivalent plasmid encoding Ub residues 1-74 (pTXB1-UbΔ75-
76-T3C) was also created. Ub thioesters were obtained as described previously 
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generating cysteine tagged Cys-Ub1-73-SR and Cys-Ub1-74-SR, respectively7. The 
extended Ub1-74 was included as this retains Arg74 which forms a favorable 
electrostatic interaction with the RBR E3 HOIP31. Cys-Ub1-73-SR (30 mg) was 
reconstituted by the addition of DMSO (116 μL) followed by H2O (456 μL). An 
aqueous stock solution (48 mM) of EZ-link Iodoacetyl-PEG2-biotin (Thermofisher) 
was prepared and 200 μL was added to the Cys-Ub1-73-SR solution (580 μl) followed 
by the addition of 900 μl degased buffer (50 mM Na2HPO4 pH 7.5, 150 mM NaCl). 
The reaction was incubated at 23 C for 1 hour and monitored by LC-MS. The 
protein (Biotin-Ub1-73-SR) was then further purified by semi-preparative RP-HPLC 
(Column: BioBasic-4; Part number: 72305-259270). A gradient of 20 % buffer A to 
50 % buffer B was applied at a flow rate of 10 mL min-1 over 60 min (buffer A=0.1 
% TFA in H2O, buffer B=0.1 % TFA in acetonitrile). The above procedure was 
repeated to generate Biotin-Ub1-74-SR. HPLC fractions containing Biotin-Ub1-7X-SR 
were pooled and lyophilized (Yield: Biotin-Ub1-73-SR 75-85 %, Biotin-Ub1-74-SR 40-
50 %). Biotin-tagged ABPs containing thioacrylamide warheads were then 
prepared as previously described7 employing the E2 recognition elements 
UBE2D2*, UBE2D2* F62A, UBE2L3* and UBE2L3* F63A furnishing ABPs 13, 14, 15 
and 16. *denotes E2 where non-catalytic Cys residues were mutated to Ser. ABPs 
based on UBE2D2* and UBE2D3* bearing hexahistidine reporter tags and 
thioacrylamide warheads, were also prepared yielding ABPs 17 and 18, 
respectively.  
 
3.3.2 Activity-based proteomic profiling of SH-SY5Y cells 
SH-SY5Y total cell lysate (4.5 mg, 550 μL) was mixed with ABPs 13, 14, 15 and 16 (3 
μM) and incubated at 30 C for 4 hours. To induce Parkin activation cells were 
administered with oligomycin (5 μM) and antimycin A (10 μM) (OA, dissolved in 
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DMSO) for 3 hours. Control enrichments were also performed where probe was 
withheld. Extracts were mixed with 100 μL of Pierce™ Streptavidin Plus UltraLink™ 
Resin (ThermoFisher Scientific) and diluted with 6 % SDS solution (20 μL) to a final 
concentration of 0.2 % in phosphate buffer. Samples were incubated for 4 hours at 
4 C and resin washed (2 ml 0.2 % SDS/PBS, 2 ml PBS, 1 ml 4 M urea/PBS, 2 ml PBS) 
and then resuspended in 190 l Tris buffer (50 mM Tris pH 8, 1.5 M urea). Resin-
bound proteins were reduced with TCEP (5 mM) for 30 minutes at 37 C and then 
alkylated with iodoacetamide (10 mM) at 23 C for 20 minutes. DTT (10 mM) was 
then added followed by washing with buffer (50 mM Tris pH 8, 1.5 M urea) to a 
final volume of 300 L. Trypsin (2 μg) was then added and further incubated at 37 
C for 14 hours. Trifluoroacetic acid was added to a final concentration of 0.1 % 
and samples were desalted with a C18 MacroSpin column (The Nest Group Inc). LC-
MS/MS analysis was performed on an LTQ Orbitrap Velos instrument (Thermo 
Scientific) coupled to an Ultimate nanoflow HPLC system (Dionex). A gradient 
running from 3 % solvent B to 99 % solvent B over 345 min was applied (solvent A 
= 0.1 % formic acid and 3 % DMSO in H2O; solvent B = 0.08 % formic acid and 3 % 
DMSO in 80 % MeCN). 
 
3.3.3 Data processing  
Raw files were searched against the Swissprot database and a decoy database 
using the MASCOT server (Matrix Science). Trypsin specificity with up to three 
missed cleavages was applied. Cysteine carbamylation was set as a fixed 
modification and variable modifications were methione oxidation/dioxidation. A 
PERL script was used to extract the number of rank 1 peptides for each protein 
from the MASCOT search results and this figure was used as the number of spectral 
counts which performed by Dr. Virdee. A second PERL script filtered the data by 
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searching the human swisspfam_v30 database using the E3 domain terms RING, 
HECT, IBR and zf-UBR. Manual curation was also carried out which involved the 
addition of E1 enzymes. Any proteins with less than 3 spectral counts and less than 
14-fold spectral count enrichment, relative to control experiments where ABP was 
withheld, were omitted from the list. Pairwise datasets were then plotted as 
column charts in Prism (Graphpad Software). 
 
3.3.4 Cloning of MYCBP2cat (performed by Dr. Nicola T. Wood) 
Human MYCBP2 (NM_015057.4) sequences were amplified from full-length 
Addgene plasmid #2570. Wild type and mutant fragments were subcloned as 
BamHI/Not1 inserts into pGEX6P-1 (GE Life Sciences) for bacterial expression, or a 
modified version of pcDNA TM5/FRT/TO (ThermoFisher) containing an N-terminal 
Myc tag for mammalian expression.  
 
3.3.5 UBE1 and E2 expression and purification (Performed by Dr. Axel Knebel) 
6His-UBE1 was expressed in Sf21 cells and purified via its tag as previously 
described334. Phosphate Buffered Saline was used throughout the purification and 
hydroxy containing compounds avoided. UBE2D3 was expressed as an N-
terminally 6His-tagged protein in BL21 cells and purified over Ni-NTA-agarose and 
finally dialysed into 50 mM Na2HPO4 pH 7.5, 150 mM NaCl, 0.5 mM TCEP. UBE2A 
was expressed as a GST-fusion in E. coli and the GST tag was proteolytically 
removed. The remaining E2s were expressed as recombinant bacterial proteins 
and purified via their His-tags and buffer exchanged by size exclusion 
chromatography into running buffer (50 mM Na2HPO4 pH 7.5, 150 mM NaCl, 0.5 
mM TCEP, 0.015 % Brij-35) using a Superdex 75 column (GE Life Sciences).  
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3.3.6 Expression and purification of MYCBP2cat and GST-MYCBP2cat 
GST-tagged MYCBP2cat (Ser4378-Phe4640), wt and mutants, were expressed at 16 
°C overnight and purified against glutathione resin (Expedeon) using standard 
procedures. GST-tagged constructs were eluted with glutathione and untagged 
constructs were obtained by on-resin cleavage with Rhinovirus 3C protease. 
Proteins were buffer exchanged into 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1.0 mM 
TCEP buffer and flash frozen for storage at -80 °C.   
 
3.3.7 Expression and purification of NMNAT2 (Performed by Dr. Axel Knebel) 
NMNAT2 was expressed with a 6His-SUMO tag in BL21(DE3) cells, induced with 0.1 
mM IPTG and incubated for expression at 16 C. The cells were collected and lysed 
in buffer (50mM Tris-HCl (pH 7.5), 250 mM NaCl, 0.2 mM EGTA, 20 mM imidazole, 
20 mM L-arginine, 0.015% Brij 35, 1 mM Leupeptin, 1 mM Pefabloc, 1 mM DTT 
using standard protocols and the protein was purified over Ni-NTA-agarose. The 
eluted protein was incubated with His-SENP1 protease during dialysis against PBS, 
20 mM L-arginine, 1 mM DTT. The tag and protease were depeleted against Ni-
NTA-agarose and NMNAT2 was concentrated and subjected to chromatography on 
a Superdex 75 HR 10/30 into buffer (PBS, 20 mM L-arginine). 
 
3.3.8 Activity-based protein profiling of MYCBP2 cysteine mutants  
The indicated MYCBP2 mutant was diluted into Tris buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl) to a final concentration of 3 μM. Probe 18 was added (12 μM) and 
incubated with E3 ligase at 30 °C for four hours. Reactions were quenched by the 
addition of 4X LDS loading buffer (supplemented with ~680 mM 2-
mercaptoethanol) and samples were resolved by SDS-PAGE (4-12 % NuPage gel) 
followed by Coomassie staining or anti-His immunoblotting. 
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3.3.9 Tryptic MS/MS sequencing of probe-labelled MYCBP2 
Crosslinking MS using ABP 18 was carried out as previously described322. In 
summary Coomassie stained SDS-PAGE band corresponding to ABP-labelled WT 
MYCBP2 was analyzed by LC-MS/MS using an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Scientific) coupled to an Ultimate nanoflow HPLC system 
(Dionex). A gradient running from 0 % solvent A to 60 % solvent B over 120 min 
was applied (solvent A = 0.1 % formic acid in H2O; solvent B = 0.08 % formic acid in 
80 % MeCN). Fragment ions were generated by HCD and 1+, 2+ and 3+ precursor 
ions excluded. Raw data was searched using the pLink software against UBE2D3* 
and MYCBP2 sequences with trypsin specificity (up to 2 missed cleavages) 
(Performed by Dr. Virdee). The error window for MS/MS fragment ion mass values 
was set to the software default of 20 ppm. A crosslinker monoisotopic mass of 
306.1805 Da was manually added which accounted for the theoretical mass 
difference associated with formation of a bisthioether between 2 Cys residues 
derived from probe 6, which was based on UBE2D3* and contained a 
thioacrylamide AVS warhead322. 
 
3.3.10 Tris/glycerol-mediated E2 discharge assay  
Assays were carried out in buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM 
TCEP, 5 mM MgCl2) containing the indicated MYCBP2 mutant (15 μM), UBE1 (1.5 
μM), UBE2D3 (15 μM), Ub (37 μM) and ATP (10 mM). The reactions were incubated 
at 37 °C for 30 minutes. Reactions were terminated by the addition of 4X LDS 
loading buffer (with and without ~680 mM 2-mercaptoethanol). A C4572S sample 
was further incubated with 0.14 N NaOH at 37 °C for 20 minutes and samples were 
resolved by SDS-PAGE (4-12 % NuPage gel) and visualized by Coomassie staining.  
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3.3.11 LC-MS analysis of nucleophile discharge assays 
Reactions were prepared as described for discharge assay. After 30 minutes, the 
reaction was analyzed using an Agilent 1200/6130 LC-MS system (Agilent 
Technologies) using a 10-75 % gradient over 20 minutes (buffer A = H2O + 0.05 % 
TFA, buffer B = acetonitrile + 0.04 % TFA). 
 
3.3.12 Preparation of Cy3B-Ub 
Ub bearing a TEV protease-cleavable N-terminal hexahistidine tag followed by a 
ACG motif was expressed in bacteria from a pET plasmid (kindly provide Ronald 
Hay, University of Dundee). Protein was purified by Ni affinity chromatography, 
cleaved from the tag with TEV protease then buffer exchanged into reaction buffer 
(50 mM HEPES, pH 7.5, 0.5 mM TCEP). Protein was concentrated to 2 mg mL-1 and 
221 L (50 nmol) was mixed with Cy3B-maleimide (150 nmol, GE Life Sciences) in 
a final volume of 300 L and agitated for 2 h at 25 C. Labelled protein was then 
further purified with a P2 Centri-Pure desalting column (EMP Biotech) with 
degassed buffer (50 mM Na2HPO4, 150 mM NaCl).    
 
3.3.13 MYCBP2 thioester/ester trapping assay 
UBE1 (2 μM) was mixed with Cy3B-Ub (1 μM) in buffer (40 mM Na2HPO4-HCl pH 
7.5, 150 mM NaCl, 0.5 mM TCEP, 5 mM MgCl2) (Figure 5.4, Lane 1, 2). The reaction 
was then initiated by the addition of ATP (5 mM) and incubated for 10 minutes at 
25°C. Samples (lane 3, 4) were taken and combined with UBE2D3 (10 μM). After a 
further 10 minutes at 25°C, samples (lane 5, 6) were taken and combined with GST-
MYCBP2cat (WT, C4520S, C4520A, C4572S, C4572A, C4520A/C4572S or 
C4520S/C4572A) (15 μM). The reactions were incubated at 25 °C for 30 seconds 
and terminated by the addition of 4X LDS loading buffer (either non-reducing or 
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reducing). For Ub~GST-MYCBP2cat C4572S ester bond cleavage, 0.14 N NaOH was 
added after E3 reaction with E1/E2 mixture for 30 seconds and then further 
incubated at 37 °C for 20 minutes. The gel was then scanned with a Chemidoc Gel 
Imaging System (BioRad).  
 
3.3.14 Multiple turnover amino acid and peptide panel discharge assays 
Stock solutions (0.5 M) of amino acids were dissolved in MQ water and pH was 
adjusted to pH ~8. Peptides of the sequence Ac-EGXGN-NH2 (X= K, S or T) were 
obtained from Bio-Synthesis Inc. Stock peptide solutions (200 mM) were dissolved 
in MQ water and pH was adjusted to pH ~8. An E2 (UBE2D3) charging reaction was 
carried out in buffer (40 mM Na2HPO4-HCl pH 8.0, 150 mM NaCl, 0.5 mM TCEP) 
containing UBE1 (250-500 nM), UBE2D3 (20 M), Ub (50 M), or Cy3B-Ub (25 M), 
MgCl2 (5 mM) and ATP 10 (mM). The reaction was incubated at 37 C for 15 
minutes and then equilibrated to 23 C for 3 minutes. An equivalent volume of 
nucleophile sample containing small molecule/peptide nucleophile (100 mM) and 
GST-MYCBP2 (10 M) was then added and incubated at 23 C. Samples were taken 
at the specified time points and analyzed as described for Tris/glycerol-mediated 
E2 discharge assay. Cy3B-Ub was visualized using a Chemidoc Gel Imaging System 
(Biorad). LC-MS was carried out as described for Tris/glycerol discharge but amino 
acid substrate samples were quenched by the addition of 2:1 parts quenching 
solution (75 % acetonitrile, 2 % TFA) and peptide substrate samples were quenched 
by addition of 1:1 parts quenching solution. 
 
3.3.15 Multiple turnover E2 discharge panel  
E2s were screened for threonine discharge activity with GST-MYCBP2cat as 
described for the amino acid panel. E2s were also incubated in the presence of 
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threonine but in the absence of GST-MYCBP2cat. These samples provided a 
reference to distinguish between intrinsic E2~Ub instability and E3-dependent 
discharge. All the E2s were stored in phosphate buffer.  
 
3.3.16 Single turnover E2 mutant discharge by in-gel fluorescence 
E2 mutants126,159,242,450,451 (10 M) were charged with Cy3B-labelled Ub (12.5 M) 
in a final volume of 12 L at 37 C for 20 minutes then cooled on ice for 3 minutes. 
E2 recharging was then blocked by the addition of MLN4924 derivative, Compound 
1 (25 M)452, which inhibits E1, and then incubated for a further 15 minutes, 23 
C. The mixture was then mixed with 12 L of GST-MYCBP2cat (5 M) and 
threonine (100 mM) and incubated at 23 C for the specified time. Analysis was 
carried out as for multiple turnover assays. To account for intrinsic E2~Ub 
instability the mean % discharge (n=2) calculated against a parallel incubation 
where E3 was withheld. Data were plotted using Prism (Graphpad). 
 
3.3.17 Expression and purification of ARIH1 and UBE3C (performed by Dr. Axel 
Knebel) 
ARIH1 residues 1-394 (DU24260) was expressed as an N-terminally GST-tagged 
fusion protein in BL21 cells. UBE3C residues 641-1083 (DU45302) was expressed 
as a N-terminally GST-tagged fusion protein in Sf21 cells using the baculovirus 
infection system.  
 
3.3.18 Calculation of observed rate constants for E3-substrate dependent single 
turnover E2~Ub discharge 
UBE2D3 or UBE2L3 (5 M) were charged with Cy3B-labelled Ub (8 M) in a final 
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volume of 30 L at 37 C for 25 minutes then incubated at 23 C for 3 minutes. 
Single turnover conditions for E2~Ub discharge were achieved by E1 inhibition with 
MLN4924 derivative, Compound 1 (25 M) and then incubated for a further 15 
minutes. The mixture was then mixed with 30 L of MYCBP2cat or ARIH11-394 (HHARI) 
or UBE3C641-1083 (1 M) and threonine (100 mM) and incubated at 23 C for the 
specified time. Samples were quenched with non-reducing 4X LDS loading buffer 
and resolved by SDS-PAGE (Bis-Tris 4-12 %, MES buffer). The gel was then scanned 
with a Chemidoc Gel Imaging System (BioRad) and subsequently Coomassie 
stained. E2~Ub signals were quantified using the Fiji software. Observed rate 
constants were obtained by fitting reaction progressive curves to a single 
exponential function using Prism (Graphpad Software).  
 
3.3.19 NMNAT2 ubiquitylation assay  
NMNAT2 (5 μM) was mixed with E1 (500 nM), UBE2D3 (10 μM), MYCBP2cat (10 
μM), Ub (50 μM), ATP (10 mM) and made up with 10X pH 7.5 buffer (40 mM 
Na2H2PO4 pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5 mM TCEP). The reactions were 
incubated at 37 C for 1 hour and terminated by the addition of 4X LDS loading 
buffer (either non-reducing or reducing). For base lability test, reactions were 
supplemented with 0.14 N NaOH and then further incubated at 37 °C for 20 
minutes. 
 
3.3.20 Immunoblotting 
The immunoblotting were performed with the same method as described in 
section 2.2.20. The His-tagged species were probed with 1:10000 anti-His primary 
antibody (Clontech, #631212). Alpha tubulin (1E4C11) mouse mAb (Proteintech®) 
was used at 1:10000 dilution. The MYCBP2 antibody was used at 0.5 μg mL-1 and 
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raised by in sheep by MRC PPU Reagents and Services and affinity-purified against 
the indicated antigen: anti-MYCBP2 (2nd bleed of SA357, residues 4378-4640 of 
human MYCBP2). Mouse monoclonal NMNAT2 antibody (clone 2E4; Sigma Aldrich) 
was used at 0.5 g mL-1. 
 
3.3.21 Cell culture and lysis protocol 
SH-SY5Y cells were cultures as previously described in section 2.2.18. HEK293 were 
cultured (37 C, 5 % CO2) in DMEM supplemented with 10 % (v/v) FBS, 2.0 mM L-
glutamine, and antibiotics (100 units mL-1 penicillin, 0.1 mg mL-1 streptomycin). 
Cell transfections were performed using polyethylenimine (Polysciences) 
according to the manufacturer's instruction. PEI stock (1 mg/mL) was prepared by 
dissolving PEI powder in 20 mM Hepes (pH 7). Aliquots were filter sterilized (0.22 
μm) and stored at -80 °C. Cells were grown to 50 % confluency on 10 cm dishes; 10 
μg of DNA was mixed with 30 μL 1mg/mL PEI and 900 μL serum-free DMEM, 
vortexed for 5 secs and incubated for 20 - 40 min at room temperature before 
being added to cells. Cells were harvested 24hrs post transfection. MG-132 (50 μM) 
was added to cells two hours prior to lysis. Cells were rinsed with ice-cold PBS and 
extracted in lysis buffer (1 % NP-40, 50 mM Tris-HCl pH 7.5, 1.0 mM EGTA, 1.0 mM 
EDTA, 0.27 M sucrose, 10 mM sodium 2-glycerophosphate, 0.2 mM PMSF, 1.0 mM 
benzamidine, 1.0 mM sodium ortho-vanadate, 50 mM sodium fluoride and 5.0 
mM sodium pyrophosphate, 50 mM iodoacetamide and cOmplete, EDTA-free 
protease inhibitor cocktail (Roche)). Lysates were then clarified by centrifugation 
at 4 °C for 30 min at 14,800 rpm. Supernatants were collected (total cell extracts) 
and protein concentration determined by Bradford assay. For the base-lability test, 
indicated cell lysates were further incubated with 0.5M hydroxylamine, pH 9.0 at 
37 °C for 30 minutes. 
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3.3.22 MYCBP2cat crystallization (collaboration with Dr. Karim Ramfie and Dr. 
Daan van Aalten) 
MYCBP2 was expressed as described for untagged protein. After protease cleavage 
of the tag the protein was further purified by size exclusion chromatography using 
an ÄKTA FPLC system and a HiLoad 26/600 Superdex 75 pg column (GE Life 
Sciences). The running buffer consisted of 20 mM HEPES pH 7.4, 150 mM NaCl, 4 
mM DTT.  Combined fractions were concentrated to 10.4 mg mL-1. Sparse matrix 
screening was carried out and Bipyrimidal crystals were obtained from the 
Morpheus screen condition C1 (Molecular Dimensions). A subsequent 
optimization screen carried out by Dr. Virdee yielded multiple crystals (Buffer 
system 1 (MES/imidazole) pH 6.7, 23.3 mM Na2HPO4, 23.3 mM (NH4)2SO4, 23.3 
mM NaNO3, 18 % PEG500 MME, 9 % PEG20000). A single crystal was soaked in 
mother liquor and further cryoprotected by supplementation with 5 % PEG400 and 
frozen in liquid N2. Data were collected to 1.75 Å at the European Synchrotron 
Radiation Facility at Beamline ID23-1. Energy was set to the peak value of 9.669 
keV (1.2823 Å), as determined by an absorption edge energy scan. A total of 360 
were collected with an oscillation range of  = 0.1 . The phase problem was 
solved by locating 6 Zn2+ sites in the anomalous signal and solvent flattening with 
the SHELX suite. An initial model was built by ARP/wARP38 and subsequently 
optimized by manual building in COOT39 and refinement with REFMAC540 resulting 
in the final model with statistics as shown in Extended Data Table 1. Final 
Ramachandran statistics were favored: 95.55 %, allowed: 3.24 %, outliers: 1.21 %. 
Coordinates have been deposited with the Protein Data Bank (PDB ID: 5O6C). 
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3.3.23 Size exclusion chromatography with multi-angle light scattering (SEC-
MALS) (performed by Dr. Ramasubramanian Sundaramoorthy) 
SEC–MALS experiments were performed on a Ultimate 3000 HPLC system (Dionex) 
with an in-line miniDAWN TREOS MALS detector and Optilab T-rEX refractive index 
detector (Wyatt). In addition, the elution profile of the protein was also monitored 
by UV absorbance at 280 nm. A Superdex 75 10/300 GL column (GE Life Sciences) 
was used. Buffer conditions were 50 mM Na2HPO4 pH 7.5, NaCl 150 mM, 1.0 mM 
TCEP and a flow rate of 0.3 mL min-1 was applied. Sample (50 L, 5.5 mg mL-1) was 
loaded onto the column with a Dionex autosampler. Molar masses spanning 
elution peaks were calculated using ASTRA software v6.0.0.108 (Wyatt). 
 
3.3.24 Mediator loop modeling (performed by Dr. Peter Mabbitt and Dr. Satpal 
Virdee) 
Mediator loop residues where built and geometry optimized within the 
Bioluminate Software (Schrödinger). Side chains were modified within COOT39 and 
figures were generated with Pymol (Schrödinger). Ramachandran analysis was 
carried with the RAMPAGE server453.  
 
3.3.25 Bioinformatic analysis (performed by Dr. Kay Hofmann) 
Proteins belonging to the RCR family were identified by generalized profile 
searches. Overall 671 such sequences were identified. The sequences were aligned 
by profile-guided alignment using the pftools package. For identifying 
representative sequences from various taxa, the Belvu program (Sanger Institute) 
was used to remove sequences with >80 % identity to other sequences. Truncated 
and misassembled proteins were removed manually, resulting in 130 
representative TC domain sequences.  
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Chapter 4. Development of Novel E3 Activity-Based Probes  
 
4.1 Introduction 
The ubiquitylation cascade regulates multiple cellular functions and is involved in 
numerous diseases. The distinct transfer cascade including E1-E2-E3 enzymes 
serve as a good target for drug development. Furthermore, how ubiquitin is 
transferred from E2~Ub to E3 ligases and how substrate specificity is conferred by 
many E3 ligases are poorly understood. However, to analyze the intrinsic E3 activity 
has proven to be a challenge task in the field since there is currently no good tool 
for directly monitoring ligase activity. Furthermore, because of the short reaction 
time among ubiquitin transfer process and the transient nature of thioester bond, 
it is difficult to trap the thioester-linked ubiquitin intermediates among all three 
enzymes. New tools for validating the mechanisms of ubiquitin transfer, the 
determination of substrate selection, and the identification of E3 substrates are 
urgently needed. To dissect the regulatory mechanism of HECT/RBR E3 ligases is 
the main focus of this thesis. Furthermore, the transthiolation ability of these E3s 
has been poorly addressed even though it is a fundamental step for ubiquitin 
transfer (Figure 4.1a). In addition, currently cellular E3 activity can only be 
monitored by the autoubiquitination assay which is not typically observed for 
endogenous E3s.  
 Activity-based probes (ABPs) have shown their potential for rapidly profiling 
various enzymes activity in recent years302,454. They can also be the powerful 
structural tools by stabilizing transient enzyme intermediates108,455. A key question 
initially set at to address with a functional ABP was to study the mechanism of 
ubiquitin transfer for an RBR E3. If we could engineer a stable E2~Ub conjugate this 
could serve as a recognition element. Careful incorporation of a ‘warhead’ would 
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furnish an ABP that covalently and specifically labels the incoming catalytic 
cysteine in an active E3 (Figure 4.1b). To date, our understanding of how an RBR 
E3 ligase recruits E2~Ub and mediates transthiolation is poorly understood. 
Additionally, because this ABP is designed with the aim of specifically targeting the 
catalytic cysteine in any active E3 that functions with an E2 which the ABP was 
based on, we could simultaneously profile the E3 activities in complex cellular 
extracts.   
  
 
Figure 4.1 Transthiolation between E1s to E3s through juxtaposition of active site 
cysteine could be abrogated by warhead introduction.  
(a) Reaction scheme depicting native transthiolation between E2~Ub and HECT/RBR E3 
ligases. (b) Incorporation of a warhead in E2~Ub makes it as a probe to trap E2-E3 
intermediate. Validation of these complexes can be achieved by various methods including 
mass spectrometry.   
 
Previous research has demonstrated that ABPs consisting of an E2 and a 
warhead on them can only specifically and efficiently target the catalytic cysteine 
in E1 and is able to trap an E1-E2 complex in the in vitro and in situ assays456. The 
chemistry used for probe targeting here ensures the warhead on the probe can 
only target cysteine residues which come into close proximity to allow crosslinking 
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to occur. However, the first generation E2-conjugated activity based probes barely 
labeled any recombinant HOIP RBR E3 ligase in vitro, which consists of only the 
active RBR domain456. Ubiquitin itself also seems to play an important role in E2-
E3 binding processes and generation of a transthiolation competent conformation. 
We therefore believed the first generation probes were missing a vital component, 
the ubiquitin molecule. As a result, developing a E2-ubiquitin-conjugated E3 
activity-based probe (E2~Ub*ABP; ubiquitin stably conjugated to an E2 displaying 
a proximal thiol-reactive warhead) for detecting E3 activity is therefore the first 
step and the main focus of this project. 
 
4.2 Strategies for preparation of E2-ubiquitin-conjugated E3 Activity-Based 
Probes 
Cysteine−cysteine juxtaposi on is the prerequisite for transthiola on ac vity. The 
catalytic cysteine that resides in the middle of the E2 polypeptide is the essential 
residue for thiol-reactive warhead installation and E1/E3 activity-based probe 
construction. Putting the warhead on E2 ensures the E2 is the recognition element 
of the probe. A strategy for generating an E3 ABP would be to prepare a stable 
E2~Ub conjugate with a warhead in place of the thioester bond. We reasoned this 
could be done by using a trifunctional component that could link E2 to the C-
terminus of Ub and also allow warhead attachment.  
 
4.2.1 E3 ABPs synthesis strategy 1: Genetic code expansion technology 
In order to introduce the tri-functional molecule linker into ubiquitin and E2s, the 
first strategy was to use genetic code expansion technology for incorporating an 
unnatural amino acid containing a δ-thiol lysine457 in place of the catalytic cysteine 
of E2 enzymes (Figure 4.3). In this instance, the genetic incorporation of the 
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unnatural amino acid into the E2 backbone could be considered the first 
functionalization step. Mediated by the δ-thiol group, the ε-amino group could 
then be reacted with a thioester group on ubiquitin to form a stable ubiquitin-
loaded E2 enzyme by formation of an isopeptide bond125. This can serve as a stable 
mimic of a E2~Ub thioester125. Subsequent introduction of a thiol-reactive 
warhead on the proximal δ-thiol group by reaction with a TDAE (Tosyl substituted-
Doubly Activated Ene, Figure 4.2), a bifunctional thiol reactive molecule, could 
then be carried out456. As we discussed in Chapter 2, TDAE is a novel compound 
which allows us to introduce an activated vinylsulfide (AVS) on the E2 catalytic 
cysteine by an unexpected addition-elimination mechanism458. However, the 
synthetic route for this particular unnatural amino acid bearing a δ-thiol lysine was 
non-trivial457. Herein, I successfully reduced the number of synthetic steps from 
nine to five for getting the δ-thiol-Nε-(p-nitrocarboxybenzyloxy)lysine (CBZ-Lys)445 
(Scheme 4.1). I successfully incorporated the Nα-(tert-Butoxycarbonyl)-L-lysine 
(Boc-Lys) into the position 85 (catalytic cysteine) of UBCH5C; however, I failed with 
the CBZ-Lys incorporation (data not shown). The incorporation of derivative δ-
thiol-Nε-(((allyloxy)carbonyl)amino)lysine, which is structurally similar to the CBZ-
Lys, into UBCH5C was also failed. We reasoned that it was the required δ-thiol 
group in these lysines that was not tolerated at the catalytic cysteine position in 
the E2 enzyme. Although this approach was unsuccessful, the optimized route for 
synthesizing CBZ-Lys should prove to be valuable as incorporation of this amino 
acid allows traceless and site-specific ubiquitylation of recombinant proteins457. 
Because I did not further apply these compounds in my project, the related data 
are not included.  
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Figure 4.2 TDAE is a powerful molecule for targeting cysteine-containing proteins. 
The trans activated vinylsulfide (AVS) is obtained by the reaction of a tosyl-substituted 
doubly activated ene (TDAE) with a thiol affords. The reactivity-tunable AVS then acts as a 
warhead to covalently reacts with a cysteine in close proximity. Addition of a second thiol 
to the AVS is slower than the first reaction which enabling an orthogonal thiol 
functionalization (OTF).  
 
 
Figure 4.3 Genetically introduction of an unnatural amino acid as a tri-functional linker 
to E2 and construction of an E3 ABP. 
The proposed synthetic route for constructing E3 ABPs by unnatural amino acids 
incorporation. The incorporation of CBZ-lysine on the position of catalytic cysteine on E2 
allows us to generate a stable E2~Ub conjugate. The thiol group on the CBZ-lysine then 
reacts with TDAE in a mild buffer condition and affords a novel E3 ABP. The asterisk 
corresponds to the cysteine reactive carbon atom in the ABP.   
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Scheme 4.1 The application of different protecting group (9-BBN) reduced the 
synthetic steps for obtaining δ-thiol-Nε-(p-nitrocarbobenzyloxy)lysine. 
 
4.2.2 E3 ABPs synthesis strategy 2: Construction of ubiquitin-conjugated E3 ABPs 
via trifunctional TDAE  
Since we failed to incorporate a chemical handle into E2 which should allow us to 
link the ubiquitin molecule and ligate a cysteine-specific warhead, we designed 
and synthesized a different trifunctional molecule. We reasoned that appending a 
tosyl-substituted doubly activated ene (TDAE)334 to the C-terminus of Ub would 
generate a highly electrophilic, but thiol-specific, protein conjugate that could 
undergo addition-elimination with the catalytic cysteine residue of recombinant 
E2s allowing the production of a stable mimetic of E2~Ub harboring a tried and 
tested warhead. To achieve this the TDAE would need to be a tri-functional 
molecule that I would first react with the C-terminus of Ub and then subsequently 
link to the E2 forming a conjugate containing a mechanistically positioned 
warhead. We reasoned that an alkyne moiety attached to a TDAE would satisfy 
this requirement (Scheme 4.2a). The Ub-TDAE conjugate could then be prepared 
by triazole formation between azide-functionalized Ub, that could be prepared 
using the procedure used for DUB probes, and alkyne-functionalized, TDAEs using 
Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC)459.  
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Scheme 4.2 Synthesis of alkyne-functionalized TDAEs and their utility for assembling 
E2~Ub-based probes for profiling E3 transthiolation activity.  
(a) Alkyne-functionalized, electron-deficient acrylate 1 and acrylamide 2 were used to 
prepare trifunctional TDAEs 3 and 4, respectively. This was achieved by PhI(OAc)2/KI-
mediated reaction of 1 and 2 with sodium arenesulfinate. (b) Probe construction involved 
production of Ub truncated to residues 1-73 bearing a C-terminal thioester (Ub1-73-SR). 
(Next page)  
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Ub1–73-SR was prepared by thiol (R-SH) treatment of a recombinant intein fusion protein. 
A truncated Ub species was chosen for molecular modeling, based on RING-E2~Ub and 
HECT-E2~Ub co-crystal structures, indicated that the AVS-triazole linker would 
satisfactorily mimic the Ub C terminus and serve as a surrogate for residues 74–76 (Figure 
4.4). Preparation of Ub1–73-SR 5 was achieved by thiolysis of an intein fusion protein. 
Aminolysis of the Ub1–73-SR with azidoaminoethane afforded azide-functionalized Ub 
(Ub1–73-N3) 6. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) between 6 and 
TDAEs 3 and 4 yielded TDAE-functionalized Ub molecules (Ub-TDAEs) 7 and 8. Mild 
incubation of Ub-TDAEs 7 or 8 with recombinant reporter tagged E2 generated E2~Ub-
based probes bearing thioacrylate and thioacrylamide electrophiles poised for actvity-
based labeling of catalytic cysteine nucleophiles in E3 ligases. Reporter tags were either a 
Hisx6 epitope or a 5-carboxytetramethylrhodamine (TAMRA) fluorophore. Ub in E2~Ub 
makes noncovalent contacts with E3 that are likely to be involved in coordinating a 
catalytically competent conformation. 
  
 We designed and synthesized the trifunctional-TDAE 3 and 4 molecules 
(Extended figure 4.1- 4.4) which incorporated an additional alkyne appendage 
(TDAE-alkyne) that serves as a vital chemical handle for the click reaction and also 
harbors latent thioacrylate and thioacrylamide AVS electrophiles, respectively 
(Scheme 4.2a). To obtain the azide-functionalized Ub, different lengths of 
ubiquitin-thioesters were produced by an intein system444 with excellent yields 
after optimization (>10mg protein per Liter LB). Instead of full-length ubiquitin, C-
terminal truncations were generated so as to spatially mimic the native E2-Ub 
conjugate upon incorporation of the warhead and triazole linkage by successful 
‘click’ ligation. A computational model based on Ub-loaded UBCH5B in complex 
with various E3 ligase (Figure 4.4) suggested that the truncated ubiquitin1-73 was 
the best choice for building the probe. Unfortunately, poor yields of ubiquitin 1-
73-SR (thioester) were obtained initially due to the in vivo auto-cleavage of the 
intein fusion that released truncated ubiquitin during protein expression. This was 
remedied by mutation of a threonine to cysteine at position 3 of the intein protein 
which prevents the auto-cleavage from occurring460. Ubiquitin1-73 thioester, 5, 
136 
 
could then be successfully generated after modification of the intein system and 
was purified by preparative reversed phase high-performance liquid 
chromatography (RP-HPLC) (Figure 4.5a).  
 
 
Figure 4.4 Molecular modeling of RING-, HECT- and RBR-E3 ABP complexes. (Next page) 
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(a) Crystal structure of RING E3 ligase in complex with E2~Ub (PDB ID 4AP4, thioester 
linkage was stabilized by mutation of E2 catalytic cysteine to lysine and an isopeptide was 
formed)125. E2 (salmon), RING (light teal) and Ub (light gray) are in cartoon format. Ub 
residues 74-76 are in gray stick format. The computational model, where residues 74-76 
have been substituted for the AVS-triazole linkage (blue stick notation) in probe 10, is 
superposed. In the computational model E2 (firebrick), RING (dark teal) and Ub (dark gray) 
are in cartoon format. The modeling suggests that the AVS-triazole satisfies (next page)  
the conformational requirements of E2~Ub for RING engagement. (b) Crystal structure of 
HECT E3 ligase in complex with E2~Ub (PDB ID 3JW0, thioester linkage was stabilized by 
mutation of E2 catalytic cysteine to serine and an ester was formed128). E2 (salmon), HECT 
(light teal) and Ub (light gray) are in cartoon format. Ub residues 74-76 are in gray stick 
format. In the computational model E2 (firebrick), HECT (dark teal) and Ub (dark gray) are 
in cartoon format. The modeling suggests that the AVS-triazole also satisfies the 
conformational requirements of E2~Ub for HECT engagement. (c) Crystal structure of RBR 
E3 ligase (HOIP) in complex with E2~Ub (PDB ID 3EDV, thioester linkage was stabilized by 
mutation of E2 catalytic cysteine to lysine and an isopeptide was formed129). E2 (salmon), 
RBR (light teal) and Ub (light gray) are in cartoon format. Ub residues 74-76 are in gray 
stick format. In the computational model E2 (firebrick), RBR (dark teal) and Ub (dark gray) 
are in cartoon format. The modeling suggests that the AVS triazole also satisfies the 
conformational requirements of E2~Ub for HOIP engagement. The incoming cysteine 
nucleophile in RING 2 (C885) is 2.9 Å from the reactive center in the AVS electrophile. (The 
figures are provided by Dr. Virdee) 
 
To obtain the necessary azide-functionalized ubiquitin for click reaction, 
ubiquitin 1-73 thioester 5, underwent on aminolysis reaction with 2-
azidoethanamine in the presence of triethylamine at 30°C for 16 hours yielding 
ubiquitin-azide 6 (Scheme 4.2b & Figure 4.5b). Conjugation of ubiquitin-azide 6 
with TDAE-alkyne 3 and 4 was successfully achieved by developing optimized 
conditions for CuAAC yielding ubiquitin-TDAE 7, 8 (Scheme 4.2b & Figure 4.5c). 
E2~Ub*ABP (E3 ABP) was then made by treating ubiquitin-TDAE with different E2s 
under native but non-reducing condition (Figure 4.6a-c). To ensure that the TDAE 
only reacts with the catalytic cysteine, C17S and C137S on E2 UBE2L3* (UBCH7) 
were introduced. These mutations on E2s did not compromise activity as the 
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mutant supported Parkin activity the same as wild-type (Figure 4.7). UBE2L3* was 
then successfully conjugated with ubiquitin-TDAE 7, 8 and became novel E3 
activity-based probes 9 and 10 (Figure 4.6a-c). In conclusion, we have developed 
a facile, modular and scalable method for synthesizing ubiquitin-conjugated E2 as 
E3 activity-based probes. Herein, I would also like to highlight the user-friendly 
method we had developed for probe construction since it largely enhances the 
possibility for large scale production for future applications. It is extremely 
important for method development since we would like to apply the ABP in crystal 
structure studies which generally require large milligram amounts of proteins for 
condition-screening.   
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Figure 4.5 Characterization data for the preparation of intermediates (5), (6) and (7).  
(a) Left panel, Ub thioester 5 (blue) underwent near quantitative aminolysis with 
azidoaminoethane (green), in aqueous DMSO buffer containing 4 % triethylamine, after 
16 hincubation at 30 °C. The peak denoted with an asterisk corresponds to hydrolysis 
product of 5. Reaction was monitored by HPLC at 214 nm. (Next page)  
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Right panel, ESI-MS mass spectrum for starting thioester 5. Inset, deconvoluted mass 
spectrum (observed mass = 8,417 Da; calculated mass = 8,418 Da). (b) Left panel, 
analytical HPLC analysis of purified aminolysis product 6. Right panel, ESI-MS mass 
spectrum of 6. Inset, deconvoluted mass spectrum (observed mass = 8,361 Da; calculated 
mass = 8,362 Da). (c) HPLC analysis of the purified Ub-TDAE conjugate 7 obtained by 
Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC) between azide-functionalized Ub 6 
and TDAE 3 in pH 7.5 phosphate buffer, CuSO4 and Tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) after 15 min incubation at 23 °C. Right panel, 
ESI-MS mass spectrum of 7. Inset, deconvoluted mass spectrum (observed mass = 8,625 
Da; calculated mass = 8,626 Da). 
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Figure 4.6 Characterization data for the preparation of ABP (9), (10) and (11). 
(a) Efficient addition-elimination reaction between 7 (lane 2) and E2 (His-UBE2L3*) (lane3)  
to produce E2~Ub conjugate, probe 9 (lane 4). 5 (2 eq.) was added to His-UBE2L3* in 
phosphate buffered saline and incubated for 2 h at 23 °C). Probe 9 was then purified by 
size exclusion chromatography (lane 5). (b) Left panel, HPLC analysis of purified probe 9. 
Right panel, ESI-MS spectrum of 9 (observed mass = 26,593 Da; calculated mass = 26,598 
Da). The N-terminal Hisx6 tag has been proteolytically cleaved for clarity. (c) Left panel, 
LC-MS characterization of probe 10 prepared by reaction between 6 and His-UBE2L3*. 
Observed mass = 26,592 Da; theoretical mass = 26,597 Da (N-terminal Hisx6 tag cleaved). 
(d) SDS-PAGE analysis of fluorescent TAMRA-conjugated probe 11. Left lane is a coomassie 
stain and the right lane is a scan of in-gel fluorescence using an imaging system (excitation 
λ = 532nm). 
142 
 
 
Figure 4.7 Tagged and untagged forms of double mutant C17S C137S UBE2L3 (UBE2L3*) 
support Parkin activity.  
The His-tagged form of UBE2L3* that probes 9, 10 and 11 were based on was tested for 
its ability to support Parkin activity (N.B. probe 11 contained a Ser to ProcK mutation N-
terminal of the His-tag that was labelled with a TAMRA fluorophore). Both His-UBE2L3* 
and UBE2L3* (where the N-terminal Hisx6 tag was removed with Rhinovirus C3 protease) 
demonstrated activity comparable to WT protein in a qualitative SDS-PAGE gel-based 
activity assay. Unless otherwise labeled, 50 μL reactions consisted of 50 mM Tris-HCl pH7.5, 
MgCl2 (5 mM), ATP (2 mM), UBA1 (240 nM), UBE2L3 variant (2 μM), Ub (58 μM), Parkin 
(1.2 μM), GST-PhPINK1 (383 nM). Reactions were incubated at 30 °C for 1 h, resolved by 
SDS-PAGE, and visualized by coomassie staining. 
 
4.2.3 Construction of fluorophore-tagged E3 ABP for systematically profiling  
In order to expand the application of our ABPs, I focused on the reporter tag 
replacement which provide us choices for different readout based on the native of 
the assay. Furthermore, by simply introducing a biotin-tag it could make this probe 
a very powerful tool for activity-based proteomics. A versatile handle on probes 
also allows us to swap various tags via facile reactions. We therefore genetically 
incorporated a bio-orthogonal alkyne handle into UBE2L3* through the unnatural 
amino acid propargyloxycarbonyl-L-lysine (ProcK). This was positioned N-terminal 
to the hexahistidine (Hisx6) tag (UBE2L3*-ProcK). The alkyne group allows us to 
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use well-developed CuAAC click reaction for tag conjugation. Azide-functionalized 
5-carboxytetramethylrhodamine (TAMRA) was then used to label UBE2L3*-ProcK, 
yielding UBE2L3*-TAMRA. The fluorescent probe 11 was then generated via 
conjugated Ub-TDAE 6 with UBE2L3*-TAMRA by the same method I used in probe 
9 and 10 construction. (Figure 4.6d, Extended Figure 4.5: the LC-MS data for ABP 
11).  
 
4.3 Validation of novel synthesized E3 Activity-Based Probes with the RBR E3 
Parkin 
 
4.3.1 RBR E3 ligase, Parkin, is labeled with novel E3 ABPs in an activity-dependent 
manner  
In order to validate the functionality of our probes, we attempted a labeling assay 
with probe 9 and 10 with recombinant Parkin. Since the dual phosphorylation on 
both Parkin and ubiquitin might be required for optimal activity, we generated 
phosphorylated-Parkin (p-Parkin) and phosphorylated-ubiquitin (p-Ub) via 
incubation with PINK1 and ATP. We obtained nearly 60% p-Parkin and quantitative 
p-Ub. Purification was by size exclusion chromatography and we confirmedthe 
purity by LC-MS and Phos-tag SDS-PAGE. The activity of p-Parkin was then further 
tested by auto-ubiquitylation assay (data not shown). We then incubated probe 9 
and 10 with either non phosphorylated-Parkin or p-Parkin at 30°C for four hours in 
the presence of p-Ub. The reaction was resolved by SDS-PAGE and validated by 
Coomasie staining or immunoblotting (Figure 4.8a). The only protein bearing Hisx6 
tag is our probes which allowed me to use highly specific Hisx6 antibody to analyze 
the labeling. In Figure 4.8a, probe 9 and 10 obtained efficient labeling with p-
Parkin but not with non- phosphorylated Parkin (lane 2,3 versus lane 4,5). The 
probe 10 likely gained more efficient labeling with p-Parkin due to the greater 
electrophilicity of the acrylamide electrophile, to it being a closer mimic of the Ub 
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C terminus, or due to a combination of both. Moreover, to dissect whether probe 
labeling was attributable to E2 engagement of the RING1 domain on Parkin, we 
also generated a mutant version of probe 9 (9 F63A) containing a Phe63Ala 
mutation in the UBE2L3* component of the ABP (Extended Figure 4.6). 
Aforementioned in chapter 1, E2 Phe63 is important for RING, HECT and RBR E3 
ligase binding129,461. The loss of p-Parkin labeling within probe 9 F63A indicated 
that the mechanism for our probe labeling is based on a canonical E2-E3 
interaction. Although we expected the decrease labeling in non-phosphorylated 
Parkin group, it was not consistent with the findings that the p-Ub alone is able to 
sterically activate Parkin82. We doubted that the weak activation came from the 
low concentration of p-Ub since Parkin is activated when a molar excess of p-Ub 
was presented60. Indeed, I observed the probe labeling with non-phosphorylated 
Parkin in a dose dependent manner while increasing p-Ub up to 0.2 and 1mM 
concentration (Figure 4.8a).  
 Since we observed the probes label Parkin in an activity dependent manner, 
we wanted to know whether the probe is labeling to catalytic cysteine in Parkin. 
We applied probe 10 to WT p-Parkin or catalytic mutant C431S p-Parkin 
accompanied with tryptic MS/MS sequencing of the corsslinked WT p-Parkin to 
confirm the labeling position. As shown in Figure 4.8b and 4.8c, probe 10 only 
labeled WT p-Parkin but not the C431S mutant. The MS/MS peptide sequence data 
and F63A experiment further indicated that our probes label Parkin via a 
mechanism consistent with the proposed E2-RBR E3 mechanism where the 
catalytic Cys85 in UBE2L3 and Cys431 in Parkin are in juxtaposed to perform 
transthiolation.  
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Figure 4.8 E2~Ub-based probes label the RBR E3 ligase Parkin in an activity-dependent 
manner.  
(a) Coomassie stained reducing SDS-PAGE and anti-His immunoblotting reveal that 9 and 
10 (10 μM) form a covalent adduct with p-Parkin (2 μM) in the presence of p-Ub (2 μM) 
(lanes 2 and 3). Probe 9 F63A (predicted to abolish E3 binding) failed to label Parkin under 
the same conditions (lane 4). (Nex page)  
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Non-phosphorylated Parkin failed to undergo labeling with probe 9 in the presence of p-
Ub (2 μM) (lane 5). Labeling could be affected by the inclusion of molar excess levels of p-
Ub (lanes 6 and 7). * corresponds to contaminating band from p-Ub preparation. (b) Probe 
10 does not label p-Parkin C431S in the presence of p-Ub (lane 8 versus lane 5). All Parkin 
species and p-Ub were prephosphorylated by treatment with PhPINK1. (c) Annotated 
tryptic MS/MS spectrum for a tryptic 5+ charged precursor ion of the crosslinked peptide 
derived from labeling of Parkin with 9 (observed m/z = 625.7106; expected m/z = 625.7126) 
further confirms probe labeling of Parkin Cys431. (d) In situ probe labeling of reconstituted 
substrate ubiquitylation assays. Parkin and FLAG-Ub in the reactions were phosphorylated 
by pre-incubation with TcPINK1. Parkin labeling with fluorescent probe 11 and probe 9 
was strictly consistent with the Parkin activity readouts of His-SUMO-Miro1 substrate 
ubiquitylation, parkin autoubiquitylation and free polyubiquitin chains formation. In all 
cases, activity was strictly dependent on TcPINK1 activity. (Performed by Kristin Balk) 
Consistent results were obtained over three replicate experiments. 
 
 
4.3.2 In vitro Parkin labelling by probes is dependent on PINK1 kinase activity  
To further confirm the probe labelling with Parkin is dependent on Parkin activity, 
we performed post-probe labeling of a Parkin ubiquitylation assay reaction 
mixture which provided me with these independent readouts for Parkin activity. 
In Figure 4.8d, the Parkin was incubated with either WT Tribolium castaneum 
PINK1 (TcPINK1 WT) or kinase inactivated PINK1 (TcPINK1 KI) and supplied with E1, 
UBE2L3, FLAG-tagged Ub, ATP and the substrate for Parkin, Miro1249,462. As shown 
in Figure 4.8d, the ubiquitylation on Miro1 was detected and depended on PINK1 
kinase. After the kinase reaction, probe 10 or 11 was further reacted with mixtures 
and observed by either His-tag blot or in-gel fluorescent scan. Again, we observed 
probe labelling with activated Parkin consistent with the kinase activity of the 
respective mixtures. Fluorescent-tag containing probe, 11, provided another rapid 
and independent readout since the His-tag was both present in probe 10 and 
Miro1 which we used in the assay which might lead to confusion during data 
interpretation.  
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4.4 Applying novel E3-ABPs for RBR E3 activity studies 
RBR E3 ligase, Parkin, has been proven to be involved in Parkinson’s disease. The 
huge body of data suggested that Parkin has 100’s of substrates and its activity 
could associated with neurodegeneration463-465. However, the transthiolation 
activity of Parkin itself in cells is less well addressed, herein, I provide a tool that 
can monitor Parkin activity directly from its transthiolation ability.  
 
4.4.1 Dual phosphorylation events on Parkin and ubiquitin are both essential 
for Parkin activity 
We had demonstrated that our probes are compatible to label Parkin E3 in an 
activity-dependent manner, we next would like to gain more biological insight 
about Parkin activation mechanism. Since we were unable to isolate each 
phosphorylation step of Parkin and Ub under cellular level to dictate their effect 
toward Parkin activity, we then incubated the recombinant p-Ub and p-Parkin or 
non-phosphorylated Parkin individually with our probes. Intriguingly, appreciable 
labeling was observed only with probe 10 and p-Parkin in the presence of p-Ub, 
suggesting that both phosphorylation events are critical for optimal Parkin 
transthiolation activity (Figure 4.9). Probe 10 still labeled p-Parkin in low level 
without p-Ub supplement, however, the labeling greatly enhanced when p-Ub was 
present. Consistent with the previous data that probe 10 labeled non-
phosphorylated Parkin when p-Ub was supplied. Another interesting finding from 
Figure 4.9 was that wild-type ubiquitin can also increase p-Parkin activity based on 
probe labeling. One explanation is that the non-phospho Ub still interacts with the 
p-Ub binding helix (pUBH)84 but with less affinity. The lack of phospho-Ser65 
maybe makes non-phospho Ub unable to position its Ile44 patch correctly to react 
with extended helix in the RING1 domain, or, the Ub structure is not as dynamic as 
p-Ub which allow its extended C-terminal tail to interact with the IBR domain. The 
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other possibility might be that the excess of ubiquitin acts a substrate (as an 
acceptor ubiquitin for chain formation) for Parkin and further primes Parkin 
activity although there is no similar data to support this hypothesis. This result 
suggests that p-Ub is not redundant to Parkin activation after Parkin 
phosphorylation. Therefore, maintaining p-Ub dependence on sustained Parkin 
activity could continuously ensure that Parkin activity correlates closely with the 
levels of the p-Ub primary signal. 
 
 
Figure 4.9 Optimized parkin transthiolation activity requires phosphorylation of both 
p-Parkin and p-Ub.   
Prephosphorylated p-Parkin (3 μM) underwent significant labeling with probe 9 only in 
the presence of p-Ub (6 μM). Substantially reduced labeling was observed in the presence 
of Ub. Parallel profiling with probe 10 demonstrated that 10 was more sensitive than 9. 
Labeling was consistently more efficient with probe 10, enabling detectable parkin 
labeling in the presence of individual phosphorylation sites. 
 
 
 
 
 
149 
 
4.4.2 Determinants of Parkin activity in the context of PINK1-Parkin signaling in 
cells 
As mentioned, I next wanted to validate ABP functionality within cells by profiling 
the activity of Parkin using probes 9 and 10 via analysis of HeLa cells (that do not 
express endogenous Parkin) stably expressing untagged Parkin WT, Parkin S65A 
and Parkin H302A. Parkin S65A cannot be phosphorylated by PINK1 and the H302A 
mutation significantly impairs p-Ub binding84,250,258. Therefore, in combination 
with S65A, the effects of Ub and Parkin phosphorylation in the context of PINK1-
Parkin signaling could be assessed. The cells were either treated with or without 
CCCP (carbonyl cyanide m-cholorophenylhydrazone) to impair the mitochondrial 
membrane potential which activates Parkin. The cells were then lysed under a mild 
conditions using sonication and further treated with probe 9 or 10 (5μM) for 4 
hours at 30°C. In parallel, the E2 only probe (no ubiquitin) containing vinylmethyl 
ester (VME) (UBE2L3-VME) as a warhead was also added in the same assay as a 
control. According to total Parkin immunoblotting, it revealed a fraction of Parkin 
WT (~40%) was activated, as judged by the presence of new bands corresponding 
to Parkin WT labeled with probes 9 or 10 in the presence of CCCP (Figure 4.10). 
Furthermore, according to pSer65-Parkin specific immunoblotting, the 
phosphorylated pool of WT Parkin was labeled with probe 10 nearly 100%. 
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Figure 4.10 Activity-based profiling of cellular Parkin provides insights into the hierachy 
of Parkin and Ub phosphorylation in the context of PINK1-Parkin signaling.  
HeLa cells stably expressing Parkin WT, Parkin S65A and Parkin H302A were untreated or 
treated with the CCCP (10 μM) for 3 h and labeling of Parkin WT was only observed with 
probes 9 and 10 in response to CCCP treatment. Probe labeling correlated with Parkin 
phosphorylation and labeling of the phosphorylated pool was more efficient than that of 
the total Parkin pool. Non-phosphorylatable Parkin S65A did not undergo labeling with 
probe 9 or 10. Parkin H302A with significantly impaired p-Ub binding ability exhibited 
drastically reduced phosphorylation and no detectable labeling with 9 or 10.  
 
In contrast, we did not see any labeling of S65A highlighting the importance 
of Parkin phosphorylation in cells. Furthermore, no labeling was observed with the 
H302A mutant, and, p-Parkin levels were substantially reduced (Figure 4.10). The 
fact that the total pool of H302A Parkin is unchanged after CCCP treatment and p-
Parkin is drastically reduced suggesting that phosphorylation of Ub by endogenous 
PINK1 contributes to Parkin activation (Figure 4.10). Moreover, this shows that p-
Ub and p-Parkin are required for optimal activity, this result supports a model 
whereby the primary mechanism of Parkin activation in response to mitochondrial 
depolarization in cells involves initial p-Ub binding to Parkin that primes it for 
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PINK1 phosphorylation, by disrupt the auto-inhibition between Ubl domain and 
RING1 domain, and optimal activation. To further explore the possibility that 
Parkin phosphorylation was also associated with RING0 displacement, we carried 
out profiling of HeLa cells stably expressing Parkin WT, Parkin S65A and a 
truncated Parkin IBR-RING2 construct (residues 321-465, which missing the Ubl, 
RING0 and RING1 domain) with our probes (Figure 4.11). The IBR-RING2 construct 
enabled further verification that Ub access to C431 is inhibited by RING0 in cells. 
Contrary to Parkin WT, Parkin S65A did not undergo CCCP-dependent labelling 
with Ub-VS which can measure C431 accessibility466. Profiling of cells stably 
expressing the IBR-RING2 construct with Ub-VS revealed significantly enhanced 
labelling efficiency relative to full-length Parkin, that was CCCP independent. 
Taken together, this indicates that RING0 does inhibit Ub accessibility to C431 and 
suggests that Parkin phosphorylation mediates Ub accession to C431, most likely 
by allosteric displacement of RING0. This latter point requires further validation as 
we cannot decouple the feed-forward aspect that is activity, and therefore S65 
dependent. Furthermore, IBR-RING2 did not undergo labelling with probe 10 and 
is therefore not proficient to undergo transthiolation with E2~Ub. In conclusion, 
these results support a model where the primary mechanism of Parkin activation 
in response to mitochondrial depolarization involves initial p-Ub binding to Parkin 
that primes it for PINK1 phosphorylation that is essential for its sustained 
activation84,250,258.  
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Figure 4.11 Parkin phosphorylation may also mediate RING0 displacement.  
Profiling HeLa cells stably expressing Parkin WT, Parkin S65A and a truncated 
Parkin IBR-RING2 construct (residues 321-465) by our probes was performed. The 
cells were either treated with CCCP or not and lysed by the same method we used 
in Figure 4.9. No labelling from probe 10 with IBR-RING2 Parkin was observed 
under CCCP treatment but Ub-VS did. Ub-VS underwent a catalytic Cys431 
dependent labelling with Parkin. The result further supported a model whereby 
parkin phosphorylation allosterically mediates Cys431 accession in addition to 
displacement of the REP element. These findings also demonstrate that Ub-VS can 
only be used as a tool to assess C431 accessibility but not native E3 transthiolation 
activity. 
 
4.4.3 Profiling of endogenous Parkin activity in domaminergic SH-SY5Y cells 
As we discussed in the Chapter 1 that to date the majority of data for Parkin 
research is based on overexpression systems (the N-terminal tag might even 
aberrantly activate it234). Furthermore, since optimal activity of Pakin needs both 
phosphorylation on Parkin and ubiquitin, it also raised the question whether the 
concentration of PINK1 and ubiquitin is sufficient to activate Parkin in the 
overexpression system. Therefore, we would like to use probe 10 to determine 
the activation status of endogenous parkin in response to mitochondrial 
uncoupling in undifferentiated dopaminergic SH-SY5Y neuroblastoma cells. The 
cells were untreated or treated with CCCP (10 μM) for 3, 6 and 9 h and then lysed 
as with the above method. Profiling was then carried out with probe 10 and probe 
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10 F63A as a further control, and validated by immunoblotting against total-Parkin 
and p-Parkin. Again, I did not observe probe labeling and Parkin phosphorylation 
in untreated group. However, the labeling by probe 10 was detected after CCCP 
treatment and peaked at the 3 hour time point (Figure 4.12). Notably, the probe 
could label nearly 95% of p-Parkin in repeated assays and while the F63A control 
probe failed to label any p-Parkin. Our data is consistent with the finding that 
Parkin proceeds to undergo autoubiquitylation and destabilization since detected 
Parkin decreases in a time-dependent way. Moreover, based on the fact that 
probes nearly label the total pool of p-Parkin, the fraction of probe-labeled total-
Parkin can be considered as the pool of fully-activated Parkin in SH-HY5Y cells. 
Hence 75% of total Parkin is activated in SH-HY5Y cells in response to CCCP 
treatment. The data also suggests that the parkin activation signal is attenuated 
through degradation of parkin in the activated state rather than through its 
deactivation as probe labelling stoichiometry remains approximately constant.  
 
 
 
154 
 
 
Figure 4.12 Activity-based profiling of endogenous Parkin in SH-SY5Y cells directly 
reveals Parkin phosphorylation and activation of transthiolation.  
In response to CCCP treatment, labeling of the total parkin pool is more efficient than with 
overexpressed Parkin. Labeling efficiency of the p-Parkin pool approached nearly 100%. 
Labeling was not observed with the control probes UBE2L3*-VME or 10 F63A. Over the 
time course, probe labeling efficiency of parkin remained unchanged while parkin levels 
declined, suggestive of Parkin clearance in the activated state. Asterisk (*) corresponds to 
non-specific bands. Consistent results were obtained over three replicate experiments.  
 
 The failure to label Parkin with UBE2L3-VME (Figure 4.12) further indicated 
that the contact between Ub moiety on E2 and RBR E3s is essential for ubiquitin 
transfer. We hypothesized that the interaction between E3 and Ub triggers a Parkin 
conformational change required for transthiolation. To confirm this was the case 
and that E2~Ub engineering did not inadvertently alter the warhead properties, I 
made an E2~Ub probe with an IIe44Ala mutation in the Ub. Consistent with our 
hypothesis, probe 10 (Ub-I44A) failed to label recombinant p-Parkin in the 
presence of p-Ub nor endogenous Parkin in CCCP-treated SH-HY5Y cells (Figure 
4.13a and 4.13b). 
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Figure 4.13 The ubiquitin Ile44A mutation on probes disrupts the binding ability of E3 
ABPs toward Parkin.  
(a) The probe 10 or 10 (Ub-I44A) was treated with either WT or C431S p-parkin. The WT 
probe 10 as a positive control labeled p-parkin while 10 (Ub-I44A) did not. (b) Ubiquitin 
Ile44A mutation on E3 ABP also abolish its ability to label endogenous Parkin in SH-HY5Y 
cell lysate.  
 
4.4.4 Profiling of endogenous Parkin activity in primary fibroblasts derived from 
PD patients  
To explore the translational potential of our probes we used probe 10 to profile 
primary fibroblasts derived from a skin biopsy from PD patients carrying a 
homozygous Q456X mutation in the PARK6 gene and an exon 5 deletion/C441R 
(Δex5/C441R) compound heterozygous mutation in the PARK2 gene. The Q456X 
mutation disrupts PINK1 activity and the PARK2 compound heterozygous 
mutation would be predicted to result in aberrant Parkin expression and/or 
stability449. As expected, I did observe significant probe labeling in healthy control 
cells in response to CCCP treatment whereas probe 10 failed to label Parkin in 
PINK1 Q456X mutation cells (Figure 4.14). Parkin was undetectable in the 
Δex5/C441R sample and as expected, no probe labelling signals were observed. 
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These data provide the first quantitative assessment of Parkin activity in patient-
derived cells and indicate that our probes can be deployed to determine the 
general functionality of the PINK1-Parkin signaling pathway in PD patients. We are 
excited about the potential of our probes for identifying individuals who might be 
predisposed to PD, and stratifying patients suffering from idiopathic PD for 
treatment with future therapeutics.  
 
Figure 4.14 Activity-based profiling of PD patient-derived fibroblasts reveals biomarker 
potential.  
Low passage primary fibroblasts derived from skin biopsies from a healthy age-matched 
family member, a PD patient harbouring a Q456X homozygous mutation in the PARK6 
gene, and a PD patient harboring a Δex5/C441R compound heterozygous mutation in the 
PARK2 gene were profiled with probe 10. Control cells undergo robust Parkin 
phosphorylation and activation. In contrast, Parkin in either PARK6 or PARK2 mutant PD 
patient cells cannot be activated in response to CCCP treatment. With expectation, probe 
10 only labeled Parkin in the positive control group. Both mutation on PARK6 or PARK2 
abolishes Parkin activity. 
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4.4.5 Parkin phosphorylation displaces the REP element 
The repressor element of Parkin (REP) that blocks the RING1 domain for recruiting 
E2~Ub is one of the Parkin autoinhibitory mechanisms236,245. The side chain of 
Trp403, located in this element of Parkin, inserts into a pocket in RING1 and masks 
the predicted E2 docking site on Parkin245. A W403A mutation in the REP region 
disrupt this inhibition and results in increased Parkin autoubiquitylation activity 
and accelerated Parkin recruitment to damaged mitochondria upon activation of 
PINK1 kinase activity245. However, the mechanism behind the relief of REP element 
by PINK1 phosphorylation is not clear. We then explored whether relief of the 
autoinhibitory REP element was associated with phosphorylation of Parkin at 
Ser65 by performing a probe labelling assay with the non-phosphorylated Parkin 
W403A mutant in parallel with Parkin and p-Parkin, in the presence and absence 
of p-Ub (Figure 4.15a). Probe 10 only labelled non-phosphorylated Parkin W403A 
in the presence of p-Ub but not Parkin W403A alone. This finding was consistent 
with the data that Parkin W403A activity was still dependent on PINK1 and CCCP 
treatment in cells but retained activity in vitro when supplied with p-Ub. 
Apparently, without activating PINK1 to phosphorylate ubiquitin in cell, Parkin is 
unable to maintain in full-activated form. However, according to the obtained data, 
we concluded that Parkin phosphorylation was only partially recapitulated by the 
W403A mutation upon consideration of the stoichiometric nature of the W403A 
mutation and the substoichiometry of Parkin phosphorylation (~60%). In addition, 
it has been shown that the enhanced affinity of Parkin toward E2 enzyme via 
phosphorylation on Ubl domain was only emulated when Parkin W403A mutation 
and Ubl domain deletion coexist250. For further confirm the probe was being 
labelled with the correct position, we carried out probe labelling with Parkin 
W403A/C431S double mutant (Figure 4.15b). These data suggest that parkin 
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phosphorylation is directly associated with relief of the autoinhibitory constraints 
imposed by the REP element through an allosteric mechanism, thereby facilitating 
E2 binding, and REP displacement is independent of p-Ub binding.   
 
 
Figure 4.15 REP domain blocks the E2~Ub contact with Parkin and attenuates Parkin 
activity.  
(a) ABP 10 was used to determine whether a distinct phosphorylation event contributed 
to displacement of the autoinhibitory REP element. Non-phosphorylated Parkin W403A, 
in the presence of p-Ub, underwent robust labeling (lane 18). The first-generation E2-
based probe UBE2L3*-VME, which contains a chemically analogous electrophile to 9 but 
lacks the Ub component, failed to label Parkin under any of the conditions tested. 
Consistent results were obtained over two replicate experiments. (b) Profiling of Parkin 
mutants was carried in the presence of p-Ub with control probe UBE2L3*-VME and ABP 
10. Importantly, the Parkin W403A C431S double mutant, in the presence of p-Ub, does 
not undergo labeling. This confirms that labeling remains activity dependent in the context 
of the W403A mutation. Asterisk (*) indicates a non-specific band. 
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4.4.6 Rapid profiling of Parkin disease mutants 
In order to translate our probes into clinical application, we built fluorescent probe 
11 by conjugation of the fluorophore TAMRA with E3 ABP (Scheme 4.2, Figure 4.6d) 
and profiled a panel of recombinant Parkin disease mutants (K27N, R33Q, R42P, 
A46P, K161N, K211N, R275W, G328E, T415N, G430D and C431F, Figure 4.16a) in 
parallel, with Parkin WT and the phosphorylation defective S65A mutant. This was 
achieved by incubating probe 11 with the panel of mutants that had been 
phosphorylated with WT Pediculus humanus corporis PINK1 (PhPINK1) in the 
presence of Ub (Figure 4.16 b-c). Among these Parkin mutants, 8 of 12 were 
inactivate. The K27N mutant was reduced 0.7-fold and the R33Q mutant was found 
to activate Parkin 2.2-fold. As these disease mutants are located through out the 
Parkin polypeptide, this suggests that transthiolation activity is dependent on all 
of the domains within Parkin and leads towards a unifying pathogenic basis. 
However, we cannot formally exclude the possibility that the mutations may also 
affect the latter step of Ub transfer to substrate249. 
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Figure 4.16 Quantitative and direct activity-based Protein Profiling of transthiolation 
activity of Parkin patient mutations reveals distinct activity signature.  
(a) Amino acid boundaries of the multidomain architecture of parkin. (b) Recombinant 
Parkin mutants were incubated with PhPINK1 in presence of Ub and ATP. Mutations 
resided throughout the multi-domain architecture of Parkin. Incubations were then 
directly profiled for Parkin transthiolation activity with ABP 11. Mutations mildly 
perturbed, activated or abolished transthiolation activity as determined by fluorescence 
of labeled Parkin. (c) Fold-change of mutant Parkin transthiolation activity relative to WT 
represented on a Log2 scale (n.d. means no detectable labeling. Data represent mean 
values and error bars correspond to ± s.d, n = 3). (* the doublet bands in K27N and R33Q 
are the impurity band from the ABP 11.) 
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4.5 Further validation of E3 ABP specificity and compatibilty 
Since we established the activity-based probe for RBR E3 ligases by profiling Parkin, 
to build a platform for E3s activity-based proteomic is an important next step. In 
addition, the details of activity regulation for most of E3s are still poorly 
understood, our probes are able to provide more biological insight into this field. 
However, before we carried out more sophisticated assays for E3 activity profiling, 
we need to confirm that the E3s are the major target for our probes and also to 
demonstrate that more E3s can be labelled by our probes.  
 
4.5.1 DUBs profiling with E3 ABPs 
DUBs play an important role in ubiquitin system by editing ubiquitin chain level in 
cells. They also cooperate with E3s to regulate various cellular functions. 
Intriguingly, DUBs can also have a catalytic cysteine as the catalytic reside for their 
activity. As a result, we next tested whether probe 9 and 10 cross reacted with 
DUBs and whether they were susceptible to DUB mediated hydrolytic degradation, 
either of which would restrict the utility of the probes activity-based proteomics. 
We found that although the potential control DUB ABP propargylated-Ub (Ub-
Alk)333 efficiently labeled DUBs from three different subfamilies (USP, OTU and 
UCH), probes 9 and 10 exhibited no labeling, nor were they degraded by DUB 
isopeptidase activity (Figure 4.17a). These data further indicated the selectivity of 
our probes toward E3s.  
 
4.5.2 Profiling HECT E3 ligase with E3 ABPs 
In order to expand the utility of our probes, we next tested the compatibility of 
probes against another catalytic cysteine-containing E3 ligase family, HECT E3s. 
Again, labelling of probe 9 and 10 with activated forms of the HECT E3 NEDD4128 
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and the bacterial HECT-like E3 NleL443 was observed in all cases and the efficiency 
was dependent on the catalytic cysteine nucleophiles (Figure 4.17b-c). It 
demonstrated that our probes are able to target a different E3 family and indicated 
the potential of our probes for systematic profiling.  
 
 
 
Figure 4.17 E3 ABPs have no affinity toward DUBs but retain activity for HECT E3s.  
(a) DUB ABP, Ub-Alk, showed great labelling efficiency with USP2, USP21, OTUB2 and UCH-
L3. In contrast, the labelling of these DUBs by E3 ABPs 9 and 10 was missing further 
indicated the specificity of E3 ABPs is strict with E3 only. (b-c) Probe 9 and 10 labelled HECT 
and HECT-like E3, NEDD4L and NleL, in an activity dependent manner.  
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4.5.3 In situ profiling of HOIP in complex proteomes of mouse embryonic 
fibroblasts (MEFs) cells 
HOIL-1L (haem-oxidized iron-regulatory protein 2 ubiquitin ligase-1) and HOIP 
(HOIL- 1L-interacting protein) are important RBR E3 ligases that form a complex 
with SHARPIN called LUBAC (The linear ubiquitin chain assembly complex)242. 
Although the LUBAC complex is involved in regulating several cell signaling 
pathways467 447,468, and binding of either HOIL-1L or SHARPIN to HOIP is required 
for HOIP E3 activity, the regulation of HOIL-1 or HOIP RBR E3 ligase activity in 
response to dynamic signaling is still not well understood. Recently, the co-crystal 
structure of UBCH5B with HOIP was solved129. It showed that the Arg 74 on 
ubiquitin might be important for ubiquitin transfer as it forms a salt bridge with 
E976 on HOIP. This interaction was also observed in a truncated HOIP structure 
published by Stieglitz et al.239. By building probes on alternative E2s and including 
Ub Arg74, we built a new type of ABP, based on Ub 1-74 and UBCH5B (Probe 12). 
We also built a control version of this probe containing an F62A mutation in the 
E2 component that would be predicted to abolish RBR E3 recognition. In parallel, 
we profiled mouse embryonic fibroblasts (MEFs) and catalytically inactive HOIP 
879S knock-in MEFs (provided by Dr. Philip Cohen’s lab) with probe 12 (Figure 
4.18). Labeling of HOIP was only observed in WT MEFs and F62A mutant probe did 
not undergo HOIP labeling in either cell line. As the probe signal was dependent 
on the catalytic cysteine and the F62 residue in E2, this suggests that our probe 
labeling signal provides a physiological measure of endogenous HOIP 
transthiolation activity. 
In a previous study, the linear ubiquitin chain made by the LUBAC complex 
was shown to be dependent on IL-1α stimulation447. However, the same group 
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also claimed that HOIP activity is not correlated, suggesting that perhaps an 
opposing activity to HOIP (e.g. the linear Ub chain-specific DUB, OTULIN) is 
deactivated in response to IL-1α treatment. This latter argument is consistent with 
our results. Our data suggested that HOIP might be constitutively active in mouse 
embryonic fibroblasts. However, probe labeling indicated that activation of the 
endogenous HOIP pool was substoichiometric. Therefore our probe should be a 
valuable tool for determining whether HOIP can be further activated, or 
deactivated, under certain conditions. A hypothesis we could test is whether HOIP 
activity is not binary but rather behaves like a rheostat where different levels of 
activity illicit distinct cellular processes.   
 
 
Figure 4.18. HOIP E3 is constitutively active in MEFs.  
HOIL-1Land HOIP are important RBR E3 ligases which form a complex with SHARPIN 
called LUBAC. Wild-type (WT) HOIP and catalytic dead mutant HOIP [C879S] knock-in 
MEFs were treated with 5 ng/mL IL-1α for certain time points. Cellular extracts were 
incubated with either probe 12 or control probe 12 (F62A). HOIP labeling was only 
observed in WT MEFs with probe 12 and was dependent on Cys879. However, labeling 
of HOIP was independent of IL-1α stimulation which suggested that HOIP was 
constitutive active.  
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4.6 Conclusion & Discussion 
A useful tool to study Ub transfer from E2s to E3s has remained elusive in the field. 
Herein, we present methodology to synthesize novel ABPs that profile HECT/RBR 
E3 transthiolation activity. The utility of these ABPs was demonstrated by profiling 
the transthiolation activity of the PD-associated RBR E3 ligase Parkin both in vitro 
and in cellular extracts. Our study revealed that Parkin phosphorylation displaces 
the inhibitory REP element and suggests that p-Ub binding to Parkin occurs 
upstream of Parkin phosphorylation in cells. Furthermore, our probes enabled 
direct and quantitative measurement of endogenous Parkin activation in neuronal 
cell lines as well as in PD-derived patient fibroblasts. We also demonstrated the 
compatibility of our ABPs with another RBR E3 HOIP, and HECT E3s. In conclusion, 
our findings show the potential of this new technology as a robust readout of 
PINK1-Parkin signaling, as a novel biomarker of PD patient-derived samples, and a 
powerful tool for profiling the transthiolation activity of E3s in general. 
 
4.6.1 The Parkin mechanism  
The mechanism for regulating Parkin activity has been heavily studied in recent 
years. I have already discussed the model based on the current discoveries in 
chapter 1. Our data supports the model that initial binding of p-Ub to Parkin 
renders Parkin a more effective PINK1 substrate in cells, and both phosphorylation 
events are then absolutely required for sustained Parkin activity, as judged by 
transthiolation. However, Parkin is located in cytoplasm when cells are in the 
resting stage, how does Parkin get recruited to mitochondria is still in debate80,469. 
Some data support a model where Parkin will be recruited to mitochondria by p-
Ub but how the very first p-Ub or p-Ub chains are made that recruit Parkin is still 
unknown. Although people in the field are now more aware of the fact that the 
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large body of data about Parkin research are based on overexpression systems, 
there is still little attention on the reagents we used. CCCP or O/A (oligomycin 
A/Antimycin A) treatment is a facile and fast method to depolarize mitochondria. 
The consequences provide us a good model to monitor mitochondria damage and 
the PINK1/Parkin signaling pathway. However, since there was a subtle phenotype 
from either PINK1 or Parkin KO mice248,470, I doubt that neurons will encounter the 
same level of damage imparted by CCCP treatment. Based on this hypothesis, does 
the PINK1/Parkin pathway still play a major role in neuron cell protein quality 
control? The recent study by McWilliams et al. has demonstrated that the mice 
basal mitophagy is regulated in a PINK1 independent manner471.  
 Although our probes might not be able to answer all of the above questions, 
we still can follow up one more important issue in Parkin research. What is the role 
of Parkin in the cytoplasm? Since the major pool of Parkin is in the cytoplasm, does 
Parkin retain its ligase activity in this location? Activation of Parkin by Ubl domain 
phosphorylation and p-Ub interaction is a well-accepted model to date. If Parkin 
can become activated in the cytoplasm, what is the kinase responsible for Parkin 
phosphorylation or is there an alternative activation mechanism? We can first use 
our probes to detect Parkin activity differences in mitochondria and cytoplasm 
since our probes only labels fully activated Parkin. It can also allow us to screen 
various mild stimuli to activate Parkin in cells. I believe our probes can bring more 
insight into Parkin research.  
 
4.6.2 Probes can do more than measure Parkin activity  
There is a longstanding interest in the conformational changes and mechanistic 
aspects of Ub transfer throughout the Ub conjugation cascade. Although several 
different groups solved the Parkin structures recently, none of them are in complex 
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with E2s. Furthermore, albeit we know the phosphorylation events that activate 
Parkin in vitro and in vivo, there is still no data to explain how conformational 
changes brings the RING2 domain on Parkin in close proximity of the catalytic Cys 
in E2s. Overall, it is the transient nature of the E2~Ub~E3 complex that keeps us in 
dark. However, a working theory of our probes is that they can stabilize the 
transient E2~Ub~E3 complex which could be used to facilitate its structural 
characterization. Moreover, our probes can also serve as a E2~Ub intermediate 
which also has been proven to be unstable or difficult to make. As a result, we can 
measure the affinity differences between E2 or E2~Ub toward different E3s. 
Moreover, the methodology for making the probes allows us to replace the E2 
component without difficulty, we can easily build a library to screen different 
E2~Ub affinities towards a wide variety of E3s.  
 
4.6.3 E3 ABPs in activity-based protein profiling (ABPP)  
It is certainly possible to profile more RBR or HECT E3 ligase activities by our probes. 
Dr. Julien Licchesi’s group have demonstrated that our probes can also label 
multiple HECT E3 ligases in vitro and in cell lysate, for example NEDD4, UBE3C, and 
HECTD1248. However, to validate all the RBR and HECT E3s one by one is not 
realistic and time consuming. As a result, we applied our probes in the activity-
based protein profiling (ABPP) system within mass spectrometry302. We modified 
our probes by adding a biotin-tag on to them which allow us to immobilize the 
probe-E3 complexes with streptavidin beads. The detail will be discussed in next 
chapter (Chapter 5).   
 
4.6.4 The future optimization of E3 ABP construction 
In this chapter, I already demonstrated that the ability and potential of our novel 
E3 ABPs. They can detect the endogenous Parkin in an activity-dependent manner 
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and distinguish the activity of WT Parkin among Parkin mutants. However, the 
probes are not in perfection yet. First, the linker which connects ubiquitin and E2 
does not mimic the native E2~ubiquitin thioester linkage. Although the distance 
between them is similar to the native conjugate according to modeling software 
(Figure 4.4), we still cannot ignore the impact from the differences between 
triazole linker and wild type peptide bond. In addition, the E2~Ub adopt an ‘open’ 
conformation when they encounter HECT/RBR E3s but a ‘closed’ conformation 
with RING E3s. Whether the linkage between Ub and E2s in our probe permits this 
conformational change is still unknown.  
The truncation on the ubiquitin might be tolerated by some E3s but certainly 
may interfere with the interaction with others (discussed already in section 
4.5.3129). In fact, the probes containing Ub1-73 did not have good selectivity and 
labeling efficiency toward HOIP E3 ligase in the early test. As a result, how to 
optimize the tri-functional TDAE to preserve the native ubiquitin C-terminus is a 
question we might need to address in the future.  
 The other drawback of the probes I demonstrated in this section is that they 
work only with RBR/HECT type E3 ligases which contain catalytic cysteine on them. 
The lack of reactivity toward RING E3s limits the coverage of possible E3 activity 
profiling since there are nearly 600 RING E3s in the human genome. There is no 
catalytic nucleophile on RING E3s, we cannot apply the same chemistry to label 
RING E3s in an activity dependent manner. Introducing a photocrosslinker into a 
stabilized E2~Ub conjugate may be one strategy for making RING E3 ABPs.   
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4.7 Extend Figures 
 
 
 
Extended Figure 4.1 1H NMR spectrum for TDAE 3. 
1H NMR (500 Mhz, CDCl3) δ 7.79 (2H, d, 8.4 Hz), 7.35-7.40 (3H, m), 6.81 (1H, d, 15.2 Hz), 
4.78 (2H, d, 2.5 Hz), 2.51 (1H, t, 2.5 Hz), 2.46 (3H, s).  
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Extended Figure 4.2 13C NMR spectrum for TDAE 3. (Provided by Dr. Mathew Stanley) 
13C NMR (126 MHz, CDCl3) δ 162.75, 145.83, 144.60, 135.21, 130.32, 129.19, 128.48, 
76.50, 75.87, 53.23, 21.74. 
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Extended Figure 4.3 1H NMR spectrum for TDAE 4. 
1H NMR (500 Mhz, CDCl3) δ 7.78 (2H, d, 8.3 Hz), 7.37 (2H, d, 8.5 Hz), 7.34 (1H, d, 14.9 
Hz), 6.98 (1H, d, 14.8 Hz), 6.60 (1H, t, 5.1 Hz), 4.10-4.12 (2H, dd, 5.3, 2.6 Hz), 2.45 (3H, s), 
2.23 (1H, t, 2.6 Hz). 
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Extended Figure 4.4 13C NMR spectrum of TDAE 4. (Provided by Dr. Mathew Stanley) 
13C NMR (126 MHz, CDCl3) δ 161.70, 145.60, 141.00, 135.58, 132.38, 130.25, 128.23, 
78.28, 72.39, 29.77, 21.72. 
 
 
Extended Figure 4.5 LC-MS characterization of ABP 11.  
Observed mass = 29,288 Da; theoretical mass = 29,290.3 (+Ac) Da. Mass of 29,311 Da is a 
putative Na+ adduct. 
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Extended Figure 4.6 LC-MS characterization of ABP 9 F63A.  
Observed mass = 28,534 Da; theoretical mass = 28,537.5 Da. Additional species with an 
observed mass of 28,711 Da (+177) corresponds to gluconoylated form of 9 F63A. 
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Chapter 5. Activity-based proteomics and discovery of a 
new class of E3 ligase  
Activity-based protein profiling (ABPP) has been proven to be a powerful platform 
for studying protein activity. In addition, as I discussed in the Chapter 2 &4, it has 
also enabled the discovery of new proteins and drug screening288,302,360. However, 
activity-based E3 ligase profiling has not yet be reported. In chapter 4, I discussed 
and demonstrated a facile way to generate RBR/HECT E3 ABPs. These probes have 
been shown their ability to dissect the activity of comprehensive Parkin E3 system 
and are able to detect the endogenous level of Parkin E3322. Moreover, our probes 
can also label endogenous HOIP from cell extract or HECT-domain only Nedd4L, 
UBE3C, HECTD1472 recombinant proteins in an activity-dependent manner. On the 
other hand, the low reactivity toward DUBs further indicated the selectivity of our 
E3 ABPs. As a result, we reasoned that our probes can be applied in E3s ABPP. There 
are nearly 700 different E3s in the human genome which can be further subgroup 
into three families: RING, HECT and RBR E3 ligases. HECT and RBR E3s possess a 
catalytic cysteine nucleophile that undergoes transthiolation reactions with E2~Ub 
forming a covalent intermediate that subsequently transfers Ub to 
substrate92,473,474. Alternatively, RING E3s recruit Ub~E2s and position them 
proximal to substrates and mediate direct ubiquitin transfer via RING 
domains125,126,159. Interestingly, the presence of the RING domain does not indicate 
the conserved RING E3-like function. The RBR E3s also contain the canonical RING 
domain but have characteristics of the HECT family which transfer ubiquitin to 
substrates via a covalently-linked E3~Ub intermediate121,242. RING E3s are the 
biggest family among E3s with more than 600 predicted members and the detailed 
mechanism behind E3s possessing a RING domain is not fully understood.  
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5.1 Activity-based proteomics of E3 ligases 
  
5.1.1 Development of biotin-conjugated E3 ABPs 
The mechanism of E3 labeling by our probes involves trapping of the native 
ubiquitin E2-E3 transthiolation intermediate (Figure 5.1a-b). In order to retrieve 
ABP-E3 complexes from cell extracts and to perform the proteomic analysis, I 
prepared biotinylated variants of our recently developed ABPs. In the Chapter 4, I 
described the attachment of a TAMRA reporter tag by genetic encoding of an 
unnatural amino acid at E2 N-terminus. Here we simplified reporter tag 
attachment by introducing a GCSSG sequence between the Met1 and Gln2 of C-
terminally truncated Ub plasmid, I obtained the N-terminal cysteine tagged Ub 
thioester Cys-Ub1-73-SR and Cys-Ub1-74-SR322 (Figure 5.1b). These Cys-tagged Ub 
thioesters were then conjugated with iodoacetyl-PEG2-biotin and obtained biotin- 
Ub1-7x-SR (Extended Figure 5.1 and 5.4). It has been demonstrated that different 
E3s have distinct E2 preference20,116,244. In order to obtained broad coverage of E3s, 
we generated the biotin tagged ABPs based on the promiscuous E2, UBE2D2, 
(UBE2D2-ABP 13) (Extended Figure 5.2), and the HECT/RBR specific E2, UBE2L3, 
(UBE2L3-ABP 15) (Extended Figure 5.5), by the same method I described in 
chapter 4. As an E2-E3 labeling control, I also prepared mutant biotin tagged ABPs 
predicted to disrupt or impair E3 ligase binding (UBE2D2-F62A-ABP 14 and 
UBE2L3-F63A-ABP 16, respectively) (Extended Figure 5.3 and 5.6). The biotin 
tagged ABPs have been widely used in protein proteomic profiling340,475,476 due to 
their extremely high binding affinity and selectivity with streptavidin. The high 
tolerance of this interaction toward extreme conditions allowed me to perform 
harsh washing methods to eliminate the off-target binding with the immobilized 
beads. The newly developed biotin tagged ABPs (ABP 13 and 15) both labeled 
Parkin E3 with the same efficiency as His tagged ABPs (ABP 10) (data not shown).  
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Figure 5.1 Activity-based Proteomics of E3 ligases. 
(a) Native transthiolation between thioester-linked E2~Ub and E3. (b) The ABP acts like a 
suicide substrate and covalently traps E3s that demonstrate transthiolation activity. Biotin-
tagged ABPs enable streptavidin enrichment of labelled proteins from extracted 
proteomes. Proteins can then be identified by semi-quantitative mass spectrometry-
based spectral counting. The wavy bond represents triazole linkage to a truncated 
ubiquitin molecule (as described322; Extended Figure 5.1 and 5.4). (c) Number of spectral 
counts obtained from activity-based proteomic profiling of OA-treated SH-SY5Y 
neuroblastoma cells for proteins currently annotated as E3 ligases and E1s (E1s are 
labelled because they also demonstrate transthiolation activity with E2s). Proteins with 
less than 3 spectral counts were rejected. (Next page)  
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(d) Total number of HECT, RBR and RING E3 ligases detected from the different probes. As 
the mutations (E2 F62/63A mutation) introduced into control ABPs 14 and 16 are likely to 
impair rather than abolish E3 labelling, proteins with less than half the number of spectral 
counts of those obtained with their parent ABP (13 and 15, respectively) were not plotted. 
The asterisk highlights the RBR E3 ligase Parkin (PRKN2) which is only detected when OA 
is added to cells, further suggestive of activity-dependent labelling. (e) Numbers of E3 
ligases detected using ABPs 13 and 15. 22 HECT E3s were detected, 21 of which could be 
recovered with ABP 13 alone (HERC3 was only detected with ABP 15). 11 RBRs were 
detected with ABP 15 alone. In aggregate 33 RING E3 ligases were detected, 28 of which 
could be recovered with ABP 13 alone (CBL, TRI23, MEX3C, DTX3 and TRI55 were only 
detected with ABP 15, Extended Figure 5.8 & 5.10). 
 
5.1.2 Profiling of endogenous E3 ligase activity by MS-based proteomics  
Since our probe, ABP10, has been demonstrated to label endogenous RBR E3 
Parkin in an activity-based manner, I applied the same model system to validate 
my biotin tagged ABPs. Neuroblastoma SH-SY5Y cells were left untreated or 
treated with the inhibitors of oxidative phosphorylation, oligomycin and antimycin 
A (OA) which leads to ABP-detectable activation of the RBR E3 Parkin by 
depolarizing mitochondria60,477. Parallel profiling of SH-SY5Y cell extracts was 
performed with our biotin tagged ABPs (ABP 13-16) and labelled proteins were 
enriched against streptavidin resin. Stringent washing conditions were applied 
followed by on-bead trypsin digestion (Figure 5.1b). ABP-enriched protein 
peptides were analyzed by an LC-MS/MS platform which based on an LTQ Orbitrap 
Velos instrument coupled to an Ultimate nanflow HPLC system. Data was 
processed by the MRC proteomics Facility, Dr. Virdee and me. The E3s were filtered 
against PFAM domain term searches combined with manual curation. E3s that 
showed less than 14-fold spectral count enrichment compared to control 
purifications, where biotin tagged ABP was not supplied, were excluded (Figure 
5.1c). As expected, we observed > 50 % reduction of the number of spectral counts 
for the majority of HECT/RBR E3s when the E2 binding-defective control ABPs 14 
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and 16 were supplied in the reactions (Figure 5.1d and Extended Figure 5.7 & 5.8). 
These data demonstrate that members from all E3 subtypes can be sensitive to the 
E2 F62/F63A mutation, especially for the RBR family (almost all of them are 
sensitive to the mutation), suggestive of activity-dependent labelling. We cannot 
formally exclude whether the detection of mutation insensitive E3s is activity-
independent or whether these E3s are simply permissive to the F62A/F63A 
mutation. The retaining E3 reactivity of E2 binding-defective ABP 14 and 16 may 
due to unknown E2-E3 binding mechanisms or off-target labelling by incorrect 
positioning of the probes on the E3s (false E2-E3 pairs). The exact probe labeling 
sites should be further identified in the future by crosslinking MS. Notably, Parkin 
peptides were only be observed from the cells treated with OA (Extended Figure 
5.9 & 5.10). This was consistent with the immunoblotting data (data not shown) 
and previous research. Taken together, this demonstrated that for at least a subset 
of detected E3s, spectral counts correlated with E3 activity. 
 ABP 13 and 15 are constructed with two different E2 (promiscuous UBE2D2 
and HECT/RBR favored UBE2L3 respectively), as expected, they retrieved distinct 
and overlapping E3 subsets which was reflective of their different E3 preferences 
(Figure 5.1c). The aggregate number of recovered HECT/RBR E3s from probes 13 
and 15 was 33 (22 HECT and 11 RBR) thus representing ~80 % of the currently 
annotated HECT/RBR E3s (Figure 5.1e). However, we also observed in total 33 RING 
E3s from our dataset, which was unexpected. RING E3s do not contain a catalytic 
cysteine so in theory, should not be labeled by our probes. One explanation is that 
mechanistically off-target labeling was taking place and due to the high sensitivity 
of MS-based detection, these aberrantly labelled E3 were being recorded. 
Alternatively, these RING E3s may display an unknown mechanism to interact with 
E2 enzymes for ubiquitin transfer. Notably, some of the labelled RING E3s are 
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poorly characterized and all that is known about them is the presence of a 
predicted RING domain, for example, RNF181, DTX3, ZN598 and MYCBP2. The 
RING E3 with the highest number of spectral counts was MYCBP2 (myc-binding 
protein 2, also termed Phr-1478) which prompted us to explore this putative RING 
E3 further (Figure 5.1c).  
 
5.2 Characterization of the neuron-associated protein, MYCBP2 
Among various batches of sample we tested, a giant 0.5 MDa neuron-associated 
E3 MYCBP2, which has a C-terminal RING domain, was unexpectedly labeled by 
our ABPs. As MYCBP2 does not contain any domains known to be involved in 
transthiolation (its C-terminal RING domain is devoid of HECT or IBR/RING2 
domains), we hypothesized that it was a novel class of E3 ligase. MYCBP2 and its 
orthologues are collectively termed PHR (PAM-Highwire-Rpm-1) proteins (PAM in 
Human, Phr1 in mouse, Esrom/Phr1 in zebrafish, Highwire in Drosophila and RPM-
1 in C. elegans478). Although there are quite a few papers describing the functions 
of MYBCP2, research on the function of the isolated domains on MYBCP2 is missing. 
The large size of MYCBP2 is likely to have made its study challenging.   
MYCBP2 was first isolated by a phage screen for binding proteins of the 
protooncogene MYC479. The authors further demonstrated that MYCBP2 is widely 
expressed in human tissue samples but with particularly high levels in brain. The 
RCC-1 domain and Myc protein binding site were also identified in the same 
report479. However, it was later demonstrated as a neuron-associated protein by 
studies in Drosophila480-482. It has also been shown to regulate synapse formation 
and axon termination in mice and fish483-485. The embryonic lethal effect of Phr1 
knock-out mice, due to respiratory distress, further heighted its importance486. 
Although MYCBP2 is less studied in human models, it has been shown that the loss 
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of Highwire exclusively impairs the motor neurons in Drosophila481. The RPM1 
mutants in C. elegans was also observed to have impairment of the neuron-neuron 
synaptic connection480. Moreover, this mutant also causes severe axon termination 
defects in C. elegans480,487,488. Consistent with their functions in regulating neuron 
development, PHR proteins are often found in presynaptic terminals487,489,490.  
PHR proteins have been shown to regulate several signaling pathways478. It 
has been shown that MYCBP2 can regulate mTOR signaling pathway by regulating 
TSC2 (Tuberous Sclerosis Complex (TSC) gene) ubiquitylation levels in an over-
expression system 491. MYCBP2 has also been indicated to form a non-canonical 
SCF ubiquitin ligase complex with Fbxo45, a putative E3 substrate receptor, and 
Skp1492,493. The orthologue of this complex is found in Drosophila490. In addition, 
MYCBP2 has also been found to mediate the activity of p38 MAPK via regulation 
of transient receptor potential vanilloid receptor 1 (TRPV1)494.  
MYCBP2 is also a positive regulator of Wallerian axon degeneration where it 
promotes the degradation of the axonal neuroprotectant, Nicotinamide 
Mononucleotide Adenyl Transferase (NMNAT2)493,495,496. Consequently, MYCBP2 
mutant animals demonstrate potent neuroprotection in response to axonal 
injury493,495. Above reports all demonstrate the importance of MYBCP2 in cells; 
these synaptic and neuroprotective phenotypes are observed with RING domain 
mutants and those pertaining to a structurally uncharacterized cysteine-rich region 
immediately C-terminal to the RING domain482,495. Since there is no elegant 
biological report on C-terminal region containing the RING domain, and our probes 
labelled this protein, we suspected an unknown mechanism for MYCBP2 E3 activity.  
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5.2.1 Profiling of neuron-associated protein, MYCBP2, by E3 ABPs 
Since we obtained the highest number of spectral counts for a RING E3 was MYCBP2, 
we carried out an in vitro probe labelling assay with recombinant MYCBP2. We 
expressed a C-terminal version of MYCBP2 encompassing the RING domain in E. 
coli (residues 4378-4640; MYCBP2cat; Figure 5.2b). MYCBP2cat underwent robust 
ABP labelling (Figure 5.2a) with an efficiency comparable to that observed with E3 
ligases known to demonstrate transthiolation activity322,472. This implied that 
MYCBP2 might be a novel class of RING-linked E3 ligase which used a different 
mechanism to transfer ubiquitin to the substrates.  
 We speculated that if a novel domain was present that contained an active 
site cysteine it would be C-terminal to the RING domain. We carried out structure 
prediction using the Phyre2 and I-TASSER servers and both predicted low 
confidence similarity to RBR E3 ligases. Immediately after the RING domain is an 
unannotated region that contains 16 cysteine residues, many of which reside in 
Cys-X-X-Cys motifs, characteristic of structural Zn-binding sites497. In order to clarify 
the category of MYCBP2 without any structural information on this region, I next 
set out to identify the possible catalytic cysteine in this region. Since the ABP 
undergoes mechanism-based labelling of the active site cysteine sulfhydryl group 
in HECT/RBR E3s, identifying a Cys mutant that abolished ABP labelling would allow 
me to figure out the catalytic cysteine (Figure 5.1b)121,168,242. I systematically 
generated a panel of cysteine to serine MYCBP2cat mutants and reacted with the 
ABP 18 (Figure 5.2c). We validated the labelling efficiency by both Coomassie 
staining and immunoblotting against the primary His-tag antibody. Three cysteine 
residues (C4506S, C4520S and C4537S) in MYCBP2cat were found to abolish ABP 
labeling (Figure 5.2c). Since C4506 and C4537 were located in a Cys-X-X-Cys motif 
and were likely to have a structure role, C4520 became the most promising 
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candidate as the catalytic cysteine. To further confirm our hypothesis, we 
subsequently carried out tandem mass spectrometry322 of ABP-labelled wild type 
MYCBP2cat and the data supported the role of C4520 as an active site nucleophile 
(Figure 5.2d). We observed 38 spectral matches corresponding to probe labelling 
sites from MS result and 36 of which were assigned to C4520 (Extended Figure 
5.11). This further indicated that C4520 might be a catalytic cysteine in a new class 
of E3. 
 
 
Figure 5.2 MYCBP2cat is labelled by activity-based probes that profile transthiolaiton 
activity. 
(a) A C-terminal version of MYCBP2 (residues 4378-4640) is labelled by ABPs based on the 
E2s UBE2D2 (17) and UBE2D3 (18)322. (Next page)  
 
183 
 
(b) Domain architecture of MYCBP2. Abbreviations: RCC1-like GEF domain (RLD), two PHR 
family-specific (PHR) domains, a RAE1 binding domain (RBD), a F-box binding domain 1 
(FBD1), a Myc binding domain (MBD), and a C-terminal RING domain478. (c) Putative active 
site cysteines in MYCBP2cat were determined by ABP profiling of a panel of cysteine to 
serine mutants. MYCBP2cat mutant (3M) was incubated with ABP 18 (12 M) at 30 C 
for 4 hours. ABP-treated samples were resolved by SDS-PAGE and visualized by Coomassie 
staining and immunoblotting against the hexahistidine reporter tag on the ABP. (d) C4520 
was underscored as the active site cysteine residue following tryptic digestion of the ABP-
labelled protein and MS/MS sequencing. The spectrum is for a 5+ precursor ion that was 
within 1 ppm of its theoretical m/z value (observed m/z = 614.5088; expected m/z = 
614.5094). 
 
5.2.2 Catalytic cysteine-dependent esterification activity of MYCBP2 
Based on the above data and the software structure prediction, we speculated that 
MYCBPcat displays RBR E3 characteristics. Furthermore, as RBR E3s were first 
considered as RING E3s, it seemed plausible that MYCBP2 was another new class 
of RING-linked E3. One of the features of RBR E3s is that they undergo auto-
ubiquitylation Ub chain formation dependent on their catalytic cysteine121,159,242. 
In order to further dissect the role of C4520 in MYCBP2cat, I established an in-vitro 
E3 activity assay by using E1, UBE2D3 and Ub121. Surprisingly, I could not detect 
any ubiquitin chain formation or even auto-ubiquitylation of MYCBP2cat (Figure 
5.3a and Extended Figure 5.12). However, rapid MYCBP2cat-dependent ubiquitin 
discharge from E1 and E2 were observed and were dependent on C4520 (Figure 
5.3a and Extended Figure 5.12). Since there was no nucleophile present that is 
known to become modified by E3 ligases, such as lysine and cysteine121, the high 
level of ubiquitin discharge was unexpected. We therefore analyzed the whole 
reaction by liquid chromatography-mass spectrometry (LC-MS). This demonstrated 
that the ubiquitin was been quantitatively modified by 
tris(hydroxymethyl)aminomethane (Tris) and glycerol (8639 and 8668 Da), both of 
which were present in our assay buffer at concentrations of 50 mM and ~65 mM, 
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respectively (Figure 5.3c-d). I assayed activity for all of the generated cysteine 
mutants and found it to be dependent on the active site cysteine (Extended Figure 
5.12), C4520S (a characteristic of E3s that form a thioester-linked E3~Ub 
intermediate) thereby underscoring its catalytic role. Consistent with the result I 
found earlier, the C4520S mutation abolished the ubiquitin ester adducts which 
further emphasized the catalytic role for C4520 (Figure 5.3a).  
 In the E2 discharge assay, I found that another cysteine mutation, C4572S, 
had slightly reduced E3 activity but formed a mono-Ub MYCBP2 adduct (Figure 
5.3a). In addition, the mono-Ub adduct was resistant to reducing agent (2-
mercaptoethanol, BME) but was labile to base environment after treatment with 
0.14 N NaOH (Figure 5.3b). This demonstrated that the mono-Ub adduct was 
probably linked via an oxyester bond to S4572. The striking discovery from these 
data suggested to us that C4572 may also play a catalytic role in ubiquitin transfer.  
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Figure 5.3 MYCBP2cat C4520 plays an essential role in E2~Ub discharge reaction.  
(a) Multiple turnover E2 discharge assay onto Tris (50 mM)/glycerol (~65 mM). In the 
absence of the thiol 2-mercaptoethanol (BME; left panel), E2 (15M) is loaded with Ub. 
In the presence of untagged MYCBP2cat wild type (WT) (15M), E2~Ub undergoes 
quantitative discharge due to progressive covalent attachment to threonine, which 
depletes the activatable pool of Ub. A MYCBP2cat C4520S mutant abolishes E3-mediated 
discharge of Ub from E2~Ub whereas a MYCBP2cat C4572S mutant demonstrates a 
modest reduction in activity and forms a Ub adduct. In the presence of BME (right panel), 
E2~Ub undergoes thiolysis whereas the Ub adduct formed on the C4572S mutant is thiol 
resistant. Discharge reactions were incubated at 37 C for 30 minutes. (b) The Ub adduct 
on MYCBP2 C4572S is base labile (0.14 N NaOH) indicative of the formation of an 
engineered (oxy)ester linkage between Ub and the S4572 residue. (c) Mass spectrum of 
condensation productions between Ub and glycerol and, Ub and Tris. Expected mass for 
Ub condensation with glycerol is 8,639 Da (found = 8,637 Da). Expected mass for Ub 
condensation with Tris is 8,668 Da (found = 8,666 Da). (d) Chemical structure of 
tris(hydroxymethyl)aminomethane (Tris) and glycerol. 
 
5.2.3 MYCBP2 operates via a cysteine relay mechanism 
BME-resistant but base-labile MYCBP2cat C4572S Ub-adducts could be obtained 
in repeated assays. An explanation for this observation is that the serine mutant 
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was contributing to catalysis via formation of a less transient (oxy)ester-linked 
intermediate between Ub that was still functionally active. This suggested that in 
addition to C4520, C4572 may have a catalytic contribution to E3 activity. We 
hypothesized that C4520 and C4572 were both catalytic residues that functioned 
in tandem and relayed Ub from one cysteine to the other by undergoing an 
intramolecular transthiolation reaction. To further test this hypothesis, I 
established a gel-based thioester/ester trapping assay242 using fluorescently 
labelled Ub, (Cy3B-Ub), and GST tagged MYCBP2cat (Figure 5.4). After removal of 
all traces of hydroxyl components in my buffers, I managed to trap a ubiquitin 
thioester on wild type MYCBP2cat (Figure 5.4, lane 7) and it was labile to BME 
treatment (Figure 5.4, lane 8). In contrast, MYCBP2 C4520S did not form a 
detectable thioester adduct (Figure 5.4, lane 9). Within my expectation, the 
C4520A mutant was not able to form a mono-ub adduct (Figure 5.4, lane 11). 
Consistent with earlier experiments (Figure 5.3b), I obtained a C4572S adduct 
which was thiol-resistant but base labile (Figure 5.4, lanes 13 - 15). Moreover, if a 
transient thioester intermediate was being formed between Ub and C4520, then a 
proposed unreactive C4572A mutant should trap it and enhance the MYCBP2~Ub 
level. The data was consistent with this hypothesis; compared with wild type 
MYCBP2cat we observed more Ub adduct formation on the C4572A mutant and 
the adduct was thiol-labile (Figure 5.4, lane 16-17). I did not observe any adduct 
on the C4520A/C4572S mutant further supporting the idea that the intermediate 
adduct was indeed formed on the C4520 residue.  
In light of the above data, we proposed a novel E3 ubiquitin transfer 
mechanism with dual catalytic cysteines, C4520 and C4572. A plausible model was 
that they were both catalytic residues that functioned in tandem and relayed Ub 
from one cysteine to the other by undergoing an unprecedented intramolecular 
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transthiolation reaction. The inability to render S4520 catalytic was likely to be 
reflective of C4520 and C4572 residing in distinct chemical environments. The 
intrinsic nucleophilicity reactivity of C4520, that cannot be copied with serine, 
might be essential at this position.   
 
 
Figure 5.4 MYCBP2 E3 ligase activity is dependent on a cysteine relay mechanism.  
In the absence of hydroxy substrates, a BME-sensitive Ub adduct can be detected on 
MYCBP2cat WT indicative of it being thioester-linked (lanes 7 and 8). Mutation of C4520 
to serine (lanes 9 and 10), or alanine (lanes 11 and 12), abolishes thioester adduct 
formation. MYCBP2cat C4572S forms a stable adduct that is resistant to BME but labile in 
the presence of 0.14 N NaOH (lanes 13-15). The MYCBP2cat C4572A mutant forms a BME 
labile adduct that is more stable than that formed with MYCBP2cat WT (lanes 16 and 17 
vs. lanes 7 and 8). A C4520A/C4572S double mutant abolishes adduct formation entirely 
indicating that the intermediate adduct is formed on C4520. (Commasie stained-gel is in 
Extended Figure 5.13) 
 
5.2.4 MYCBP2 ubiquitylates threonine with high selectivity 
Since we discovered that MYCBP2 has high ubiquitylation activity towards hydroxyl 
groups, we speculated that it may not ubiquitylate lysine residues like conventional 
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E3 ligases498. We followed up with a screen with MYCBP2cat mediated ubiquitin 
discharge onto a panel of amino acids including alanine, lysine, arginine, serine and 
threonine121. Glycerol was applied in the screen as a positive control. We first 
loaded E2 with Ub via a standard Ub charging assay by incubation with E1, E2, Ub 
and ATP. MYCBP2cat and amino acids mixtures were then supplied into the 
reaction. With surprise, the discharge activity of MYCBP2 was high toward 
threonine rather than the canonical ubiquitin substrate lysine (Figure 5.5a). LC-MS 
data further confirmed the adduct of ubiquitin-threonine and the product 
formation was also dependent on catalytic cysteine C4520 (Figure 5.5b). In order 
to further validate the selectivity of MYCBP2 towards these amino acids, I 
performed the discharge assay under long time course contains and quantified the 
modified and unmodified species by LC-MS. I observed nearly 10-fold selectivity 
for the amino acid threonine over serine based on the time point when 50% (t1/2) 
of ubiquitin was modified by amino acid (Figure 5.5c, ~5 mins for Thr and ~50 mins 
for Ser). The lysine-modified Ub was observed by LC-MS but it was independent of 
MYCBP2cat. It implied that the modification may most likely be due to direct 
transfer from E2121.  
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Figure 5.5 MYCBP2 is a threonine selective E3 ligase. 
(a) E3-mediated multiple turnover discharge reaction with UBE2D3 (10 M) and GST-
MYCBP2cat (5M) against glycerol (50 mM) as a positive control, and a panel of amino 
acids (50 mM). Discharge was carried out at 23 C for the indicated time. (b) The discharge 
assay was analyzed by LC-MS revealing that Ub was being converted to a product with a 
molecular weight corresponding to the condensation product with threonine (observed 
molecular weight=8,664 Da; theoretical= 8,666 Da). With MYCBP2cat C4520S, Ub remained 
unmodified (observed molecular weight = 8,563; theoretical = 8,565 Da). (c) Deconvoluted 
mass spectra for ubiquitin species in the presence of amino acid (50 mM). The intensities 
of the Ub reactant and product are reflective of their relative abundance. Ubiquitinated 
serine (Ub-Ser) observed molecular weight = 8,650 Da; theoretical = 8,652 Da. Observed 
mass at 8,591 Da corresponds to a side product that is only observed after extended 
incubation. Ubiquitinated lysine (Ub-Lys) observed molecular weight = 8,691 Da; 
theoretical = 8,693 Da. Assuming exponential Ub consumption, t1/2 is ~5min for threonine. 
For serine, t1/2 is 10-fold slower. Lysine ubiquitylation is E3-independent as a similar degree 
of modification is observed in the absence of E3. 
 
 In order to validate whether the threonine activity and selectivity were 
retained in a peptide context or not, we firstly carried out time course analysis for 
ubiquitylation of a panel of model peptides of the sequence Ac-EGXGN-NH2 (X=Lys, 
Ser or Thr). The random single peptide sequences were chosen due to the lack of 
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knowledge for the proper MYCBP2 substrates (papers published to date did not 
indicate the ubiquitylation sites within substrates for MYCBP2). By supplying 
fluorescent Ub, Cy3B-Ub, into the reaction, I was able to quantify the activity of 
MYCBP2 toward peptides. The MYCBP2cat threonine selectivity over serine for the 
peptide context was retained approximately 3-fold (Figure 5.6, higher panel 
Extended Figure 5.14). Although the ubiquitylation of the Lys-peptide was low as 
expected, we observed its ubiquitylation was partially inhibited in the presence of 
MYCBP2cat. Since free Lys-ubiquitylation was found to be E3-independent in our 
previous LC-MS data, similarly I presumed the inhibition was due to MYCBP2 
transthiolation activity competing with E2 lysine aminolysis activity. This 
underscores the absence of MYCBP2cat lysine reactivity (Figure 5.6, lower panel). 
Taken together, the above experimental data revealed that MYCBP2 was not only 
a novel class of E3 enzyme that operates via a cysteine relay mechanism, it 
specifically esterifies threonine with Ub. Because of its novel mechanism we 
termed it a RING Cys-Relay (RCR) E3 ligase. 
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Figure 5.6 MYCBP2 retains threonine selectivity in a peptide context.  
In-gel fluorescence scan of peptide modification with fluorescently labeled Ub. The t1/2 for 
Ub modification with the threonine and serine peptides is ~20 min and ~60 min, 
respectively. Observed mass of Cy3B-Ub = 9,534 Da; theoretical mass = 9,537 Da. 
Observed mass of Cy3B-Ub modified threonine peptide = 10,033 Da; theoretical mass = 
10,036 Da. Observed mass of Cy3B-Ub modified serine peptide = 10,019 Da; theoretical 
mass = 10,022 Da (Extended Figure 5.14). Inefficient modification of the lysine peptide is 
observed which is moderately enhanced in the absence of E3. 
 
5.2.5 MYCBP2 ubiquitylates NMNAT2 by esterification 
MYCBP2 has been demonstrated to promote Wallerian degeneration through 
destabilization of NMNAT2 protein493,495. Furthermore, it has also been 
demonstrated that the level of NMNAT2 was increased in the Phr1 (MYCBP2 
orthologue in mice) KO primary neurons493. I suspected the NMNAT2 is the 
downstream substrate for MYCBP2. In order to validate whether MYCBP2 retains 
the same esterification reactivity towards NMNAT2 ubiquitylation, we expressed 
and purified recombinant NMNAT2 and carried out ubiquitylation assays by 
incubating NMNAT2 within E1, E2 (UBE2D3) and MYCBP2cat. Mono-ubiquitinated 
NMNAT2 was observed and it was performed in an E3-dependent manner. 
Moreover, the mono-ubiquitylated NMNAT2 adduct was resistant to reducing 
agent but was hydroxide labile (Figure 5.7a). It was further demonstrated that 
MYCBP2 had non-lysine ubiquitylation activity because there are 13 lysine residues 
in NMNAT2.  
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To recapitulate the ubiquitinated-NMNAT2 under cellular conditions was 
challenging since NMNAT2 ubiquitylation is mediated by a Skp1/Fbox45 substrate 
receptor co-complex that binds to a site ~1940 residues N-terminal to the 
MYCBP2cat region493. The activation mechanism for the endogenous MYCBP2 is 
also poorly understood. In addition, NMNAT2 undergoes palmitoylation and rapid 
axonal transport making reconstitution and cellular study of its ubiquitylation 
extremely difficult. Considering the entirely different pathways non-lysine 
ubiquitylated proteins may take, the inhibition of proteasome activity which is the 
standard procedure to facilitate the detection of ubiquitylated species in cells, may 
not contribute the same effects to non-lysine ubiquitylated proteins. However, in 
order to confirm that the non-lysine esterification activity by MYCBP2 occurs in 
cells, the overexpression of myc-tagged MYCBP2cat in HEK (human embryonic 
kidney) 293 cell either with or without HA-Ub were performed. A mono-
ubiquitylated form of MYCBP2 was observed and that was dependent on C4520. 
Furthermore, the mono-Ub adduct was also resistant to thiolysis after BME 
treatment but labile under basic treatment, suggestive of the Ub being ester-linked 
to the protein (Figure 5.7b). These data demonstrate that MYCBP2 can retain 
specificity for hydroxy amino acids in mammalian cells.  
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Figure 5.7 Non-lysine ubiquitylation specificity of MYBCP2 is retained in mammalian 
cells. 
(a) Recombinant NMNAT2 undergoes base-labile ubiquitylation in a MYCBP2cat 
dependent manner. The NMNAT2 protein was incubated with E1, UBE2D3, MYCBP2cat, 
Ub and ATP at 37°C for 30mins. The mixtures were resolved by SDS-PAGE and performed 
immunoblotting with NMNAT2 primary antibody. (b) MYCBP2cat transiently transfected 
into HEK293 cells undergoes hydroxy ubiquitylation that is dependent on C4520. The 
discrete ester-linked species that corresponded to the molecular weight of MYCBP2cat 
plus the addition of Ub (or HA-Ub) were observed. These species were also resistant to 
reducing agent but labile to hydroxide. The mono H3NO corresponds to treatment with 
0.5 M hydroxylamine at pH 9.0. 
 
5.2.6 MYCBP2cat performs as a monomer for ubiquitin transfer 
As I discussed in Chapter 1, some RING E3s have been demonstrated as a dimer 
when they are activated248. In order to validate whether C4520 and C4572 in 
MYCBP2 relay Ub intramolecularly (cis) or via a dimeric intermolecular (trans) 
mechanism, I used untagged MYCBP2cat and initially demonstrated that a C4572A 
mutation abolished threonine discharge activity (Figure 5.8a). If the dimeric 
intermolecular mechanism was taking place, I should be able rescue MYCBP2 
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C4572A activity by supplying MYBCP2 C4520S which I previously showed was 
inactive in solution (Figure 5.8a). However, the threonine discharge activity was 
not restored when two mutants were incubated together (Figure 5.8a). The same 
result was obtained even after the concentration of MYBCP2 mutants were 
doubled. Moreover, the data from size exclusion chromatography-multi angle 
light scattering (SEC-MALS) of MYCBP2cat revealed a single species consistent with 
the mass of the monomeric protein which further supported the intramolecular 
monomeric relay mechanism (Figure 5.8b). The full-length MYBCP2 protein is 
nearly 500 kDa which contains multiple different domains with different roles. As 
a result, it is reasonable for MYBCP2 to retain as a monomer under physiological 
conditions. However, we still cannot formally rule out other possible mechanisms 
but we cannot think of any other models that are consistent with the data.   
  
 
Figure 5.8 MYCBP2cat performs threonine discharge activity via intramolecular Ub 
realy transthiolation.  
(a) The RCR E3 ligase activity is dependent on both C4520 and C4572. These residues relay 
Ub via an intramolecular transthiolation reaction rather than an intermolecular reaction 
as negligible threonine discharge activity is observed when the MYCBP2cat C4520S and 
MYCBP2cat C4572A mutants are combined (*corresponds to elevated concentrations of 
E3 mutants). (b) SEC-MALS analysis for untagged MYCBP2cat. MYCBP2cat ran as a 
monodisperse species with a calculated molecular weight of 30.06 (6) kDa (theoretical = 
30.08 kDa). For the note, the SEC-MALS assay was performed by Dr. Ramasubramanian 
Sundaramoorthy.  
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5.2.7 The catalytic efficiency of MYCBP2cat 
Since MYBCP2 adopts an unprecedented mechanism and a distinct preference 
towards substrate, I next wanted to further test the efficiency of this newly 
discovered machinery. In order to assess activity towards threonine I compared it 
to established HECT/RBR E3 lysine aminolysis activity. To do this, I developed a 
single-turnover E2~Ub discharge assay using fluorescently tagged Ub. The E2 
UBE2D3 was preloaded with Cy3B-Ub by E1 enzyme. To prevent E1 reloading the 
reaction was treated with a highly specific E1 inhibitor452. The reaction was then 
incubated with indicated E3s (5:1 molar ratio for E2~Ub:E3) and amino acids. The 
observed rate constants (kobs) for E3-substrate dependent single turnover E2~Ub 
discharge for UBE3C-mediated discharge was too low to be quantified. However, 
MYCBP2cat activity towards threonine was 22-fold lower than that of HHARI 
(Figure 5.9). Notably, the HHARI RBR E3 displays the auto-ubiquitylation activity 
which further enhanced the observed rate constants for HHARI. Since MYCBP2 
does not contain the intrinsic auto-ubiquitylation activity, the comparison of 
threonine activity between lysine activity is not perfectly fair. In order to obtain the 
accurate MYCBP2 threonine reactivity, the direct protein substrates are needed.   
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Figure 5.9 Observed rate constants (kobs) for E3-substrate dependent single turnover 
E2~Ub discharge.  
(a) Observed rate constant (0.024 min-1) for MYCBP2cat-threonine mediated single 
turnover E2~Ub discharge determined by in-gel fluorescence of Cy3B labelled Ub. E2 was 
UBE2D3 and threonine (50 mM) was the substrate. The reaction was terminated on the 
indicated time points by supplied with non-reducing loading buffer. (b) Observed rate 
constant for UBE3C-lysine mediated single turnover E2~Ub discharge was too slow to 
measure. E2 was UBE2L3 and lysine (50 mM) was the substrate. (c) Observed rate constant 
(0.52 min-1) for HHARI-lysine mediated single turnover E2~Ub discharge. E2 was UBE2L3 
and lysine (50 mM) was the substrate. The major component of this rate is attributable to 
auto-ubiquitylation of lysine residues within HHARI because when lysine is withheld, kobs 
HHARI mediated E2~Ub discharge is 0.39 min-1 and this is only partially outcompeted by 
the addition of lysine. 
 
5.2.8 MYCBP2 displays distinct E2 requirements  
In order to verify whether MYCBP2cat E3 ligase activity is exclusively attributed to 
E3~Ub thioester intermediate formation, or if it can perform direct Ub transfer 
from E2~Ub like RING E3s91, I tested MYCBP2cat E3 activity with the HECT/RBR 
specific E2 UBE2L3121 and a number of UBE2D3 mutants. Surprisingly, we observed 
negligible activity of the HECT/RBR specific E2, UBE2L3, with MYCBP2 cat (Figure 
5.11). Considering the UBE2L3 is involved in mediating HECT/RBR~Ub thioester 
formation, the weak activity with MYCBP2cat RCR E3 may imply a different E2 
requirement for MYCBP2cat E3 ligase. We then carried out the analysis with a 
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panel of UBE2D3 mutants (N77S, D87A, I88A, L97A, L104A, S108A and 
D117A)125,126,159 to gain more insight about the E2 requirements for MYCBP2cat 
(Figure 5.10). The N77 and D117 mutants have been found to disrupt the amino 
acids in E2 required for suppressing the pKa of the acceptor nucleophile which are 
the essential residues for RING E3. In contrast to the requirement for in RING E3 
activity, D117A showed negligible effect on MYCBP2 transthiolation while the 
N77S mutant activity was massively reduced. In addition, the E2 residues D87, I88, 
L97, L104 and S108 are involved in adopting the ‘closed’ conformation of E2~Ub 
which is required for RING E3 mediated ubiquitin transfer125,126,159. Unlike the 
canonical E2 requirement for RING E3s, S108A mutant retained the transthiolation 
activity with MYCBP2cat whereas I88A showed reduced activity. D87A, L97A and 
L104A mutants demonstrated the low transthiolation activity with MYCBP2cat. 
Moreover, the L104A mutant has been found to be permissive to RBR E3 activity129 
which was not the case for MYCBP2cat activity transthiolation (Figure 5.10). Taken 
together, the above data show that MYCBP2cat has evolved distinct E2 
requirements that are neither consistent with a HECT/RBR-like mechanism nor a 
RING-like mechanism. We certainly cannot formally exclude the possibility that 
MYCBP2cat induces a closed E2~Ub conformation during contact with MYCBP2cat. 
The structure of the E2:MYCBP2cat complex is required for the answer.  
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Figure 5.10 MYCBP2cat has a distinct E2 requirement. 
(a) SDS-PAGE analysis of single turn over E2~Ub discharge assays employing Cy3B 
labelled Ub demonstrate that MYCBP2 has E2 requirements that are neither consistent 
with a HECT/RBR nor a RING mechanism. (b) Quantification of the different E2 mutant 
activities (n=2).  
 
We would also like to discover the other E2 partners for MYCBP2 as many E3s 
have been found to work with several different E2 enzymes499,500. We carried out 
threonine discharge assays with a further 15 E2 conjugating enzymes. We 
observed the highly homologous UBE2D1 isoform had similar activity to UBE2D3. 
In addition, UBE2E1 (UbcH6) was the only other that was showed activity with 
MYCBP2cat (Figure 5.11).  
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Figure 5.11 MYCBP2cat only works with UBE2D1, UBE2D3 and UBE2E1 enzymes. 
17 E2s were tested for threonine discharge activity with GST-MYCBP2cat by Dr. Virdee. 
UBE2D1, UBE2D3 and UBE2E1 were the only E2s that demonstrated detectable activity. -, 
position of unmodified E2; *ubiquitin-charged E2. Unexpectedly, the HECT/RBR-specific 
E2 UBE2L3 shows negligible activity with MYCBP2. Certain E2s undergo E3-independent 
polyubiquitin chain formation and/or autoubiquitylation. In the presence of UBE2Q2, GST-
MYCBP2 undergoes minor degradation resulting in the appearance of two lower 
molecular weight species. Consequently, we also carried out the assay with untagged 
MYCBP2 that did not undergo degradation; this produced similar results, showing that 
UBE2Q2 does not support MYCBP2 activity. 
 
5.3 The crystal structure of MYCBPcat explains its distinct activity for Ub 
transfer 
 
5.3.1 Structural characterization provides molecular basis of RCR E3 ligase 
activity 
In order to understand the detailed molecular mechanism of the RING-Cys-relay 
machinery, we crystallized MYCBPcat (residues 4378-4640). We collected 
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synchrotron diffraction data to 1.75 Å. To clarify the contribution for the crystal-
relevant works, the protein preparation and crystal-plate screening was 
performed by me. Dr. Virdee optimized crystals and Karim Rafie mounted crystals 
and collected synchrotron diffraction data. Daan van Aalten solved the MYCBP2cat 
crystal structure (PDB: 5O6C).  
 The 6 highly ordered Zn ions in the MYCBP2cat structure addressed the 
phasing issue during structure solving (data collection and refinement statistics 
shown in Extended Table 5.1). MYCBP2cat is composed of four distinct regions 
which was observed in a single MYCBP2cat molecule present in the asymmetric 
unit (Figure 5.12a and Extended Figure 5.15). The predicted cross-brace C3H2C3 
RING domain was found at the N-terminal area spanning residues 4388-4441 
(Figure 5.12c). A long α-helix (residues 4447-4474) follows the RING domain that 
leads into small helix-turn-helix motif (residues 4475-4500) (Figure 5.12d). A 
structurally unprecedented globular domain that binds four ions (residues 4501-
4638) was found at the C-terminal region (Figure 5.12b). Dr. Virdee superposed 
known RING domains with the RING domain in MYCBP2 and observed high 
similarity among them (RING E3 RNF4125 and RBR E3 HOIP129). Notably, MYCBP2cat 
resembles the extended architecture adopted by HOIP RING1 domain (Figure 
5.12c). This region may play an important role for the distinct E2 requirement of 
MYCBP2cat. The following Zn-binding region adopts a unique unprecedented 
architecture which does not resemble any known protein folds (as determined 
using the EBI ePDB server). We termed this domain the TC (Tandem Cysteine) 
domain since the two catalytic cysteines, C4520 and C4572, reside at this region 
(Figure 5.12b). Notably, the predicted Zn binding residues C4506 and C4537 were 
found to have structural roles as they coordinate Zn ions. Mutations of the 
residues in earlier experiments must have caused a structural defect explaining 
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the poor probe labelling result (Figure 5.12e-f and Figure 5.2c). An unstructured 
region (4519-4526) was observed between the βA2 strand and helix 310A. The first 
proposed catalytic cysteine C4520, which undergoes transthiolation with E2~Ub, 
existed in this region. With the flanking residues around it, this region forms a 
mobile loop which we termed the mediator loop. Considering the high quality and 
high resolution of the crystal structure we obtained, we suspected that this loop 
is dynamic in nature. This dynamic nature could facilitate relay of the Ub from 
C4520 to C4572. The Zn coordination configuration (C5HC7HC2) of the TC domain 
is semi-contiguous and does not adopt cross-brace architecture (Figure 5.12e). 
Moreover, the residues E4534 (located at the end of the 310A helix) and H4583 
(located in the αA1 helix) together with C4572 were be observed as an apparent 
catalytic triad. We referred this region as the esterification site (Figure 5.12b). 
Since histidine has been found to act as a general base to suppress the pKa of the 
sulfydryl group on cysteine239,361, we suspected that H4583 could also play a 
similar role.  
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Figure 5.12 Molecular basis for the Ub relay mechanism utilized by the RCR E3 ligase.  
(a) Surface and cartoon representation of the MYCBP2cat structure refined to 1.75 Å. 
C4520 begins Ub relay by undergoing transthiolation with E2~Ub and resides within a 
disordered region (residues 4519-4526) which form part of a region termed the mediator 
loop. (b) The tandem cysteine (TC) domain contains four short two-stranded β-sheets 
(βA1-βA2, βB1-697 βB2, βC1-βC2 and βD1-βD2), two short 310-helices (310A and 310B) 
and extensive loop regions. Inserted directly within the domain between the βA2 strand 
and helix 310A is the mediator loop which harbors the first catalytic cysteine residue, 
C4520. The second catalytic cysteine residue, C4572, is located within the esterification 
site at the end of the βC1 strand. The sulfhydryl group of C4572 is positioned between α1 
and βC1 and is encircled by 5 Phe residues which flank C4572 (F4570, F4571, and F4573), 
emanate from the end of the βC1 strand (F4578), or emanate from the turn between αA1 
and αA2 (F4586). Inset is a close up of the esterification site where C4572S forms an 
apparent catalytic triad-like arrangement with E4534 and H4583. (c) Superposition of 
MYCBP2 RING domain with the RING domain from the canonical RING E3 ligase RNF4125, 
and from the RBR E3 ligase HOIP129. (d) The linker helix and helix-turn-helix motif that 
connect the RING domain to the Tandem Cysteine (TC) domain. (e) Diagram depicting Zn 
coordination network for the TC domain. Catalytic residues (numbered) (nex page)    
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are distributed throughout the TC polypeptide. (f) The Tandem Cysteine (TC) domain that 
confers threonine specificity is present in all MYCBP2 orthologues. All residues shown to 
be required for threonine esterification activity are conserved. Asterisks correspond to Zn-
binding residues, grey arrows correspond to β-strands, gold rectangles correspond to 310-
helices, and red cylinder corresponds to α-helix. (The figures are provided by Dr. Virdee) 
 
5.3.2 Structural basis for threonine selectivity 
The obtained MYCBP2cat crystal structure not only uncovers the unprecedented 
TC domain providing an insightful glimpse of the Ub-relay system, but also provide 
a hint to explain its preference for threonine. Crystal packing revealed that the N-
terminus of a symmetry-related MYCBP2cat molecule was packed against the 
esterification site of the molecule in the asymmetric unit. A threonine in this 
terminus (T4380sym) forms a number of substrate-like interactions (Figure 5.13a-
b). The β-hydroxy group of T4380sym, like the sulfhydryl group of C4572, forms an 
apparent triad with E4534 and H4583 (Figure 5.13a). However, we observed that 
the β-hydroxy group of T4380sym is closer to the imidazole nitrogen atom than 
the sulfur atom of C4572 (2.7 Å vs. 3.8 Å) (Figure 5.13a). It indicated that the 
H4583 can act as a general base to deprotonate the β-oxygen atom of T4380sym 
for the nucleophilic attack and the triad centred on T4380sym has more ideal 
geometry than C4572. Since the Ub relayed toward C4572 would form a thioester-
linked intermediate, the Ub C-terminus is a productive electrophile for 
nucleophilic attack from threonine. Although the ubiquitin moiety is absent in our 
structure, the sulfur atom on C4572 is only 3.8 Å away form β-oxygen atom of 
T4380sym. This structural feature supports the specific esterification reactivity 
from MYCBP2cat. Moreover, the nearby residues (F4573, F4578 and F4586) are 
also found to form a sub-cluster which is proximal to the β-methyl group of 
T4380sym (Figure 5.13b). These three continuous Phe residues perform a well-
defined hydrophobic pocket which the T4380sym β-methyl group docks into 
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(Figure 5.13b). The sub-cluster pocket stabilizes the threonine residue via a 
hydrophobic interaction with the methyl-group side chain on Thr. This proposed 
model may explain MYCBP2 high selectivity toward threonine rather than serine.   
 
 
Figure 5.13 Structural basis for threonine selectivity. 
(a) A threonine residue at the N-terminus of a symmetry related molecule (T4380sym) in 
an Ala-Thr-Ser sequence motif (grey ball and stick representation) is docked into the 
esterification site (orange stick). The β-oxygen atom of T4380sym is 2.7 Å from the 
imidazole nitrogen atom of H4583. The β-oxygen atom is also 3.8 Å away from the C4572 
sulfur atom. In light blue is a schematic of Ub thioester-linked to C4572. The electrophilic 
center of the Ub thioester carbonyl carbon atom (*) is a single bond-length away from the 
C4572 sulfur atom. (b) Electrostatic potential of the esterification site (blue represents 
positive potential, red represents negative potential, and grey represents neutral 
potential). Residues F4573, F4578 and F4586 form a hydrophobic pocket which the Thr β-
methyl group docks into. (The structral figures are provided by Dr. Virdee) (c) Residues 
deemed important for catalysis were mutated and tested in threonine discharge assays. 
(d) The H4583N mutant undergoes near quantitative Ub adduct formation. The adduct is 
largely removed after thiol treatment indicating that Ub is thioester-linked to the E3. The 
diffuse nature of the upper band might be due to the presence of a trapped thioester-
linked Ub on C4520, and C4572, as the H4583N mutation prevents substrate 
deprotonation. In addition, S4572/H4583N double mutant does not form an stabilized 
ester adduct, rather increased formation of thiol-sensitive adduct. 
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In order to test the proposed model we observed from the crystal structure, 
I expressed a panel of MYCBP2cat mutants and compared their threonine activity 
with WT MYCBP2cat via the E2~Ub discharge assay. Consistent with the proposed 
role for H4583 to act as a general base to deprotonate threonine, the H4583N 
mutants abolished the MYCBP2cat threonine activity and ceased the ubiquitin 
transfer cascade (Figure 5.13c). As a consequence, the ubiquitin should stay upon 
two catalytic cysteines as the thioester adducts. The increased level of thiol-
sensitive MYCBP2~Ub was observed with the H4583N mutant (Figure 5.13d). On 
the other hand, the C4572S/H4583N mutant only forms a discrete Ub adduct that 
is thioeser-linked. The H4583 residue is crucial for suppressing the pKa of S4572 
and thereby rendering it catalytic. In its absence, Ub remains trapped as a 
thioester-linked species on the upstream C4520 residue. To test the roles of the 
three Phe residues in the sub-cluster, the threonine activity of the individual Phe 
mutants was also tested. Strikingly, the F4573A, F4578A and F4586A mutants all 
abolished the MYCBP2cat threonine activity (Figure 5.13c). The role of E4534 was 
uncertain since the E4534 mutants did not decrease the MYCBP2cat activity. The 
findings show that E4534 residue is not part of a catalytic triad and establishing its 
precise role needs further study.  
 
5.3.3 The proposed RCR E3 mechanism 
Although the structure of MYCBP2cat was obtained and solved, how MYCBP2 
binds E2 was unknown. However, the high similarity of the RING domain structures 
among MYCBP2cat and RING E3 and RBR E3, together with their largely conserved 
mode of binding to E2123,125,126,159,501,502 allow us to perform the modelling of an 
E2-RCR E3 ligase complex. Dr.Virdee carried out the modeling via superposition of 
the MYCBP2cat RING domain with the RING1 domain from the RBR E3 HOIP bound 
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to the E2 complex structure (PDB ID: 5EDV)129. It allowed us to place the E2 with 
our currently solved MYCBP2cat structure. The modeling results showed that the 
E2 catalytic Cys residue falling immediately proximal to the mediator loop, which 
contains the catalytic C4520 residue (Figure 5.14a-b). Notably, it would appear 
that no significant conformational change is needed for MYCBP2cat to perform 
the E2-E3 transthiolation based on the structure model we obtained (Figure 5.14a). 
The proposed dynamic mediator loop should be able to bring the C4520 in the 
close proximity of Cys85 in E2.  
 The missing structure of the mediator loop prevents us from conclusively 
explaining the Ub-relay mechanism. As a result, to simulate the conformation 
required for Ub relay from C4520 to C4572, Dr. Virdee and Dr. Mabbitt modelled 
the missing mediator loop residues with a GlyGly dipeptide thioester linked to 
C4520, representative of the Ub C-terminus that would be transferred via 
transthiolation with E2~Ub (Figure 5.14b). The carbonyl C atom of the Ub thioester 
on C4520 was observed in a position ~3.3 Å of the C4572 sulfhydryl sulfur atom. 
This modeling result supported the mechanism of the ubiquitin relay from C4520 
to C4572 although the clashes were observed between mediator loop residues 
further C-terminal. The most notable were R4533, E4534, N4580, H4583 and 
D4584. However, these events could be largely relieved by rotations of their 
sidechains into available space (Figure 5.14b). In addition, the modeling result 
further supported the dynamic nature of the mediator loop since the large 
positional movement was required to bring the C4520 in close proximity with 
C4572. This may also explain the failure to trap a C4520S ester intermediate in my 
earlier experiments. Furthermore, the lack of a general base around the C4520 
was also consistent with the result for the inability to transfer ubiquitin onward 
C4572S in C4572S/H4583N mutant (Figure 5.13d). We believe that catalytic 
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activity at the C4520 position is strictly dependent on the chemical properties of 
cysteine.  
 
Figure 5.14 The modelling of an E2-MYBCP2cat intermediate and Ub relay.  
(a) Superposition of the RING domain from the RBR E3 ligase HOIP in complex with E2 (Ub 
linked to E2 has been omitted due to direct clash with the TC domain; PDB ID: 5EDV129) 
allows modelling of the E2 into our structure (grey cartoon representation). The catalytic 
C85 residue in E2 (mutated in silico from Lys to Cys43) is proximal to C4520 which 
undergoes transthiolation with E2~Ub. The right-hand panel is a top-down close up of the 
mediator loop region. The eight missing residues that form the mediator loop are 
schematically shown in brown text. (b) Modeling of the Ub relay intermediate. For the 
experimental structure, TC domain residues are in orange and mediator loop residues are 
in dark brown. For the model, TC domain residues are in light orange and mediator loop 
residues are in mauve. The modeled E2, based on the superposition in (a), is in grey 
cartoon. Upstream (C4520) and downstream (C4572) catalytic residues are in yellow and 
colored by atom type. (Nex page)                                            
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Ub residues (G75-G76) are in blue ball and stick notation and are colored by atom type. 
Gly residues in the mediator loop that are likely to be important for loop mobility are 
displayed in mauve ball and stick and colored by atom type. N4570 and H4583 side chains 
have been rotated by the specified angles to relieve steric clash (Extended Figure 5.16). 
(The figures are provided by Dr. Virdee) 
 
 
Figure 5.15 Schematic representation of the proposed model of the RCR E3 ligase 
mechanism.  
Cartoon illustrating the proposed cysteine-relay and threonine esterification mechanism 
of RCR E3 ligases.  
 
5.4 Conclusion & Discussion 
Herein, I applied novel E3 activity-based probes to profile E3 activity in cell extracts 
(Activity-based protein profiling, ABPP). Combining two different E3 ABPs in this 
powerful platform, the system has been demonstrated to be able to label 80% of 
HECT and RBR E3 ligases. In addition, by profiling different types of cells in parallel 
(only SH-HY5Y data shown), we also identified many RING E3s or RING domain-
containing proteins which are poorly characterized. MYCBP2 (PHR protein) was 
one of these proteins and yielded with the highest number of spectral counts in 
the mass spectrometry assay. Unexpectedly, we identified MYCBP2 as a novel 
subtype of E3 ligase which adopts a distinct catalytic cysteine relay mechanism 
(Figure 5.15) for ubiquitin transfer. It also displays different amino acids substrate 
preference with high selectivity for threonine esterification. I successfully 
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demonstrated the utility of our E3 ABPs by revealing a novel ubiquitin transfer 
mechanism by a poorly characterized E3, MYCBP2. This is note the first time the 
power of ABPs has been applied to discover new enzymes288,290,302. The discovery 
of this new E3 category not only expands the knowledge of the ubiquitin system 
but also provides a potential new target for drug development and the treatment 
of various neurological disorders.   
 
5.4.1 What can E3 ABPP achieve?  
In this thesis, I proved the concept that the E3 ABPs invented by the Virdee lab 
could be used in a comprehensive ABPP platform. The next question is how can I 
apply them for further research? There are several assays which are currently 
under investigation. Firstly, performing the E3s activity profiling among different 
biological models. The activity of serine hydrolases has been shown to display 
differences between tumor and non-tumor cells368. The systematic profiling of E3 
activity among such models is still missing. Although the profiling platform has not 
yet been optimized for high throughput, the broad coverage of E3 (nearly all 
HECT/RBR E3s) labelling by our probes, combined with the multi-plex labelling tags 
(TMT-sixplex or TMT-tenplex), it is feasible to potentially compare up to 50 E3 
activities across 10 different samples in a single LC-MS/MS run. For example, the 
cell lysates which treated with 10 different reagents individually can be reacted 
with biotin-probes and then the complexes are further be immobilized by 
streptavidin resins. After the on-beads trypin digestion, the trypsinized peptides 
can be labelled by TMT-tenplex tags. The 10 different tag-labelled samples are then 
pooled together which can further analyze by one single LC-MS/MS run. Various 
agents such as CCCP, Oligomycin A, Antimycin A, Rotenone, Valinomycin or 
deferiprone (DFP)503 , have been shown to interrupt mitochondrial functions. 
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However, are these reagents all capable of inducing the activity of Parkin in 
mitochondrial quality control? Or, does the disruption of mitochondria regulate 
the activity of other E3s via an unknown signaling pathway? Our probes may be 
able to address these questions. Understanding the aging process is key for 
treating neurodegeneration diseases. Tau protein, β-amyloid and α-synuclein have 
been proven to be associated with Parkinson’s disease504,505. The misregulation of 
the level of these proteins has been believed to be one of the key causal reasons 
for PD. However, the responsible E3s for these proteins or how the E3s regulate 
theses proteins are not fully understood. Systematic profiling of E3 activities for 
immature cells, mature cells and aging cells should help us understand more about 
this disease.  
 Kinases have been valuable drug targets for treating cancers for a long 
time506,507. In contrast, there is not a lot of research targeting ubiquitin cascade 
enzymes for drug development508,509. E3 ligases should be good targets for drug 
development, but the lack of tools to systematically profile the pattern for E3 
activity among various cancer types, and other models of diseases, prevent the 
access to this research. Furthermore, the difficulties for obtaining good antibodies 
against the protein of interest also hinder studies. The sensitivity of our probes, 
which has been demonstrated as being able to detect endogenous Parkin from PD 
patients322, should provide the inventory of E3s which are associated with 
tumorigenesis. For example, HECT E3 Nedd4L has been shown to mediate prostate 
cancer510, lung cancer511 and melanoma512. RBR E3 Parkin has also been found to 
be associated with glioma513, colorectal cancer514, ovarian cancer and breast 
cancer515. In addition, competitive ABPP can be performed for inhibitor screening 
once we know the target E3s. An alternative strategy is to develop an E3-focused 
inhibitor library and use this for phenotype-screening within the tumor models 
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and then perform ABPP. This should uncover the potential targets for the chosen 
inhibitors and also reveal the possible off-target proteins. One of the biggest 
advantages for using the ABPP is that there should be no bias on the protein hits. 
Discovering the inhibitors for E3s is not the only thing which ABPs can achieve. By 
applying fluorescent-E3 ABPs and the competitive ABPP strategy, quantitative 
inhibitory activity toward the target E3 by the selected inhibitors should be 
obtained by dose-response experiments.  
 In addition to the application in drug screening, the discovery of potential E3 
pairs for the E2s can also be studied by our E3 ABPs. There are nearly 700 E3s in 
the human genome but only 40 E2s have been identified to date. As we discussed 
in the chapter 1, it is possible for one E2 to work with several E3s or one E3 to work 
with several E2s. Since the E3 ABPs are composed of an E2s backbone that serves 
as a recognition element, the application of various E3 ABPs, built on different E2 
backbones, should uncover the unappreciated E2-E3 pairs.  
By performing the ABPP with different proteomes, our E3 ABPs unexpectedly 
labelled multiple RING E3s as identified by mass spectrometry analysis. MYCBP2 is 
the only one of these RING E3s we have studied to date. Is there another RING E3 
that adopts the same ubiquitin relay mechanism as MYBCP2? Or do these poorly 
characterized RING E3s belong undiscovered classed of RING-linked E3? More 
comprehensive studies on these E3s need to be performed since many E3s that 
contain a poorly characterized cysteine-rich region after their conserved RING 
domain.   
 Multiple Ubl systems also use a homologous E2-E3 cascade and use 
transthiolation for transferring Ubl protein toward substrates516, but little is known 
about their function or even which enzymes are responsible for these events. Since 
the delicate methodology for making the E3 ABP allows us to replace not only back 
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bone E2 but also the ubiquitin, the various Ubl E3 ABPs should be able to build. 
Notably, there are only few SUMO, NEDD8, and ISG15 E3s discovered; only one E3 
for ATG8 and UFM1 and no E3 has been identified to date for FAT10, URM1, and 
ATG12516. Combined with the ABPP strategy, the Ubl E3 ABPs which based on 
Ubl¬E2s, should be able to identify the Ubl E3s which are currently missing to date. 
Together with the Ub E3 ABPs, we should be able to draw an elegant map for the 
Ub/Ubl system.  
 
5.4.2 The limitation of E3 ABPs  
ABPP is definitely a powerful platform for protein activity study, but certain issues 
are must be currently considered when interpreting data. First, the concentration 
of the probe we use in the assay. How do we determine the ‘correct’ concentration 
for the target proteomes is always a dilemma since the level of proteins vary 
among different samples. If the concentration was too low, we may not be able to 
detect differences in protein activity. For example, if there were only 100 probe 
molecules in the reactions but the activated protein molecules went from 100 to 
200 after stimuli treatment, the activity of this protein would remain the same 
from the data interpretation. Furthermore, the affinity of the protein-based ABPs 
toward their target protein, changes in which might be a regulatory mechanism, 
usually affect their reactivity, the ABPs may not be able to label the target proteins 
at the low concentration. However, supplying too much probe in the reaction may 
also cause the off-target labelling since it may produce a physiologically irrelevant 
environment for the ABPs and target proteins. Moreover, the presence of too 
much protein-based ABPs in the samples for mass spectrometry analysis may also 
generate the high abundant peaks during the assay which may mask the signal 
from low abundance proteins.  
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  The other obvious drawback for our E3 ABPs is their inability to interact with 
the intact cells. The E2-Ub backbone is certainly a benefit for the selectivity but 
the size of the protein also decreases the cell permeability of E3 ABPs. It has 
already been proven that the ABPs can distinguish differences in protein activity in 
cell extracts368,410,439. However, it could also be argued that the local E3 
concentration in the intact cells would be dramatically different than in the cell 
extracts. Apparently, the relative concentration between ABPs and target protein 
would affect the labelling efficiency which may mislead the research focus. 
Furthermore, whole cell extracts may also increase the relative concentration of 
DUBs, kinases, phosphatases and proteases toward the target E3s which may 
eliminate a regulatory PTM and inactivate the E3s of interest. As a result, 
optimizing the cell permeability of our E3 ABPs should be addressed in the near 
future. For example, Mulder et al. reported the introduction of Cy5–Ub-Dha into 
HeLa cells via electroporation439. The electroporation method should be tested 
with our E3 ABPs. In addition, by conjugating the cell-penetrating peptides (CPPs) 
upon our probes517, for example, trans-activator of transcription (TAT) protein 
peptide of HIV-1, might be able to deliver our probes into the intact cells518. The 
only concern of this strategy is whether the size and properties of the additional 
peptide sequences would affect the probe labeling or not.  
 
5.4.3 Why the ubiquitin relay? 
The newly discovered cysteine relay mechanism for ubiquitin transfer indeed 
expands the knowledge of the field. It is not immediately clear why this mechanism 
has evolved. In fact, MYCBP2 is not the only protein which regulates its activity by 
two cysteines wihtin the same protein. The two cysteine residues with catalytic 
properties, Cys46 and Cys165, on peroxidatic AhpC protein regulate the protein 
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activity by forming a disulfide bond519. However, individual mutation of cysteine in 
AhpC protein, only C165S abolished its activity. Apparently, the cysteine relay 
mechanism is not the case for this protein. We did not observe the disulfide bond 
formation in the MYCBP2 crystal structure. Furthermore, the transition of the 
ubiquitin from the first catalytic cysteine to the second one is extremely fast since 
I did not observe any doubly-loaded MYCBP2cat, not using wild type or the C4572S 
mutant (Figure 5.4). The only doubly-loaded MYCBP2cat was observed with the 
H4583N mutant where the ubiquitin was unable to be transferred to threonine 
due to the lack of a general base H4583 (Figure 5.13). These results indicated that 
the intramolecular transthiolation of MYBCP2 is the process which provides a facile 
means to shuttle Ub throughout the ubiquitin system.  
 The other explanation for the cysteine relay mechanism is the esterification 
activity of MYBCP2. The special structural features of the esterification site and the 
TC domain, which are distinct in MYCBP2 differing greatly from conventional E3s 
that undergo transthiolation with E2~Ub. In order to allow Ub transthiolation with 
E2 and esterification ubiquitin towards substrates, we propose the necessity of the 
cysteine relay mechanism. As we discussed above, in order to keep the 
esterification reactivity, the C4572 residue and Phe sub-cluster together adopt a 
distinct esterification site (Figure 5.12b). I speculate that the rigid and highly 
conserved E2 ubiquitin conjugating domain (Ubc)520 is not able to perform the E2-
E3 transthiolation reaction at this site for ubiquitin transfer. Therefore, a region 
which is capable of accepting ubiquitin from E2 via the conserved E2-E3 
transthiolation is needed. According to our modeling result (Figure 5.14a), the first 
catalytic cysteine C4520 can feasibly accept the ubiquitin from E2 via the contact 
between E2 and the RING domain in MYCBP2. The biochemical experimental data 
also support this hypothesis. Apparently, the remaining question is why the 
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ubiquitin is transferred to the non-lysine residue521.  
 From our collaboration with Dr. Hofmann, we observed two other cysteine-
rich domains N-terminal to the RCR domain. These two domains may adopt Zn-
binding regions which are currently under investigation. MYCBP2 is a huge protein 
which also contains multiple additional domains, for example, the RCC-1 domain 
and Myc protein binding domain478. Although the individual function of these 
domains have been demonstrated already478, how these domains might affect E3 
activity of MYCBP2 is still unknown. It has been shown that MYCBP2 forms a 
complex with Fbxo45/Skp1 for substrate ubiquitylation478,492,493. Since we 
discovered the ability for MYCBP2 to transfer the ubiquitin to the substrates 
directly via its catalytic cysteine, it raised the question that who is the E3 ligase 
machinery in the MYCBP2/Fbxo45/Skp1 complex responsible for ubiquitin transfer? 
In addition, is the ubiquitylation event from the MYCBP2/Fbxo45/Skp1 complex 
also non-lysine ubiquitylation? Based on the data from biochemistry experiments, 
the mono-Ub adducts are the only product from MYCBP2cat E3 ligase. I propose 
that the complex formation may be essential for physiological substrate 
ubiquitylation.    
 
5.4.4 Non-lysine ubiquitylation  
The ubiquitin esterification reactivity of MYCBP2 is not the first example of non-
lysine ubiquitylation. It has already been reported by different groups for cysteine, 
serine and threonine521,522. The early evidence for non-lysine ubiquitylation was 
discovered with viral E3 ligases MARCH (membrane-associated RING-CH) 523. One 
of these MARCH E3, the viral ligase kK3, has been found to ubiquitinate cysteine, 
a residue on the major histocompatibility complex (MHC) class I. An engineered 
Lys-less cytoplasmic tail of MHCI heavy chain (HC) was unexpectedly ubiquitylated 
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and downregulated by kK3 E3524,525. Although the ubiquitin-thioester linkage has 
already been demonstrated by E2~Ub conjugates, the kK3-mediated substrate 
cysteine ubiquitylation was still the first evidence for non-lysine ubiquitylation in a 
substrate protein. Furthermore, the homologue of kK3 E3 in murine virus, mK3, 
has later been demonstrated to have ubiquitin esterification reactivity towards 
serine and threonine in substrate proteins498. Furthermore, the serine residue on 
theses substrates has been shown to be the primary residue for ubiquitylation 
even with lysine in proximity. It further indicated that non-lysine ubiquitylation is 
not simply a compensation event for the shortage of lysine residue on substrate 
proteins498.  
 The mono-ubiquitylation on the conserved Cys residue upon Pex5p has been 
found to be a key regulators for releasing Pex5p from the peroxisome membrane119. 
The Pex4p and Pex10 have also been found as the E2 and E3 enzymes for this Cys-
mono-ubiquitylation events119,526. Surprisingly, Platta et al. observed that two 
conserved lysine residues in Pex5p were ubiquitylated by E2 Ubc4 working with 
the E3 Pex2p when the releasing cascade was blocked. 527. In addition, the cysteine 
residue in the proneural transcription factor, Ngn2, has also been demonstrated to 
be ubiquitylated as well528. In mammalian cells, the N-terminal region (tBid-N) of 
the Bid protein has been found to be ubiquitylated for freeing the C-terminal 
proapoptotic Bcl-2 homology 3 (BH3) domain on Bid protein when sensing the 
apoptotic signal529. However, no lysine residue has been identified on tBid-N 
domain. In 2007, Tait et al. demonstrated that the multiple mutations on Cys, Ser 
and Thr residues in tBid-N abolish the ubiquitylation of this domain530. The tail of 
the T-cell antigen receptor α-chain (TCRα) has also been shown to undergo non-
lysine ubiquitylation. The mutation on the two evolutionarily conserved Ser 
residues to Arg massively reduces the ubiquitylation and the rate of degradation 
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of TCRα531. Interestingly, the mutation of these two Ser residues to either Cys, Thr, 
or Lys had no effect on the ubiquitylation level. NS-1 immunoglobulin (NS-1 lg) has 
also been found to be ubiquitylated via Ser and Thr residues by HRD1 E3 (a major 
ERAD-associated E3 ligase in yeast and mammals)532. Unexpectedly, HRD1 E3 was 
found to be able to ubiquitylate the Lys residue on NS-1 when all Ser and Thr 
residues were mutated533.  
 The above examples indicated that non-lysine ubiquitylation is not just an 
‘exception’ to the canonical ubiquitylation events but also an important regulation 
mechanism. However, most of these E3s perform the ubiquitylation by a RING E3 
mechanism implying that the E2 is the enzymes which mediate ubiquitin 
esterification522. As a result, MYCBP2 is the first discovered human E3 which 
displays autonomous non-lysine ubiquitylation activity. Furthermore, from the 
bioinformatics analysis, the RCR machinery which gives E3 activity to MYCBP2 has 
been well-conserved in higher eukaryotes (from C. elegans, Drosophila to mouse 
and human). 
 In conclusion, several features of non-lysine ubiquitylation have been 
discovered521,522. Although MYBCP2 shows negligible activity towards free lysine 
amino acids, other non-lysine ubiquitylation examples indicated the possibility for 
the coexistence of the non-lysine and lysine ubiquitylation events. This intrinsic 
activity toward Lys, Cys, Ser, and Thr makes the identification of the specific 
ubiquitylation site extremely difficult. Interestingly, apart from MYBCP2, the non-
lysine ubiquitylation activity is not determined by a single E2 or E3. mK3 E3 has 
been found to collaborate with the E2 Ube2j2 for both Lys and Ser/Thr 
ubiquitylation. It means that the Ube2j2 is not the E2 specific for Ser or Thr residue. 
In other words, mK3 E3 should play a role in determining the substrate preference 
of Ube2j2. It has been shown that the context of the substrate sequence is not the 
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determinant for the ubiquitin conjugation534. It is likely the three-dimensional 
location of the targeting residues determines the outcome of ubiquitylation534. The 
targeting residues have to be in close proximity of the E2 active site which is 
positioned by a paired E3154,155. Although the proximity between E2 and substrates 
may play an important role in selecting the substrate amino acid residues, it is not 
the only factor to affect the reaction. It has been found that the mK3/Ube2j2 can 
enhance Lys or Thr/Ser ubiquitylation in both cases, however, mK3/Ube2d1 can 
only target Lys residues in the substrate122. Taken together, these proposed 
mechanisms further implied the importance of the cysteine relay mechanism and 
the structural distinct esterification site for MYCBP2 threonine esterification. The 
cysteine relay mechanism can make sure that the ubiquitin is correctly being 
transferred to the MYCBP2 C4572 residue which is the catalytic cysteine 
responsible for stringent esterification (Figure 5.12b and 5.13a).  
 
5.4.5 What is the role for threonine ubiquitylation?  
To date, non-lysine ubiquitylation has only been discovered on the substrate 
residues but not upon ubiquitin itself122. It is consistent with the biochemical data 
we obtained from MYCBP2 assays. We did not observe any free-ubiquitin chain 
formation even under hydroxyl-group free conditions. It is not clear why the non-
lysine polyubiquitin chains have not been found yet. The isopeptide (amide) bond 
on the ubiquitin conjugates has been demonstrated as the most stable linkage 
compared to oxyester or thioester linkages521,535. The instability of these non-lysine 
linked ubiquitin conjugates may provide the explanation for the missing non-lysine 
DUBs. Validation of the redox environment of cells and the change of the Ser/Thr 
pKa all affect the linkage stability of these Ub conjugates. It is plausible for the 
deubiquitylation occurs via a non-enzymatic pathway. In other words, it also 
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provides a quick response mechanism for stabilizing non-lysine ubiquitin 
conjugates. For example, MYCBP2 has been demonstrated to mediate the 
internalization of transient receptor potential vanilloid receptor 1 (TRPV1)494,536. 
The loss of MYCBP2 caused the constitutive p38 MAPK activation and prevented 
the internalization of TRPV1. Furthermore, p38 MAPK has been shown to play an 
important role in the sensibilization procedures of nociceptive neurons (sensory 
neurons for damage respons)537. It is possible that the MYCBP2-dependant 
threonine ubiquitylation is also involved in the fast stimuli-induced responses of 
nociceptive neurons. MAPK kinase kinase 12 (MAP3K12, also known as dual 
leucine zipper bearing kinase, DLK) has been indicated as the MYCBP2 substrate 
for regulating this p38 MAPK-TRPV1 pathway538.  
 The actual physiological role for the MYCBP2-meidated ubiquitin 
esterification is still unknown. It is plausible that the MYCBP2-mediated Thr-
ubiquitylation performs as a competitor with Thr-phosphorylation, considering the 
high selectivity of MYCBP2 toward the threonine amino acid. Furthermore, the 
reported substrate candidates for MYCBP2, for example, DLK1539 and TSC2540, have 
also been shown to be phosphorylated by kinases. Whether MYCBP2 can regulate 
the activity of these proteins via ubiquitylation requires further study541.  
 It has proven challenging to study non-lysine ubiquitylation due to instability 
of the oxy-ester or thio-ester linkage521,522. The supplement of thiol-containing 
agents in typical biochemistry experiments simply eliminates the observation of 
cysteine-based ubiquitylation. The combination of heating and reducing 
environment may also break the oxyester-linked ubiquitin conjugates. Mass 
spectrometry analysis has been frequently used in discovering ubiquitinated 
proteins542,543. However, the frequently used ‘trypsin digestion’ step has to be 
performed under basic conditions for long incubation which may hinder the 
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detection of the oxyester-linked diGlyGly peptides544. Although the oxyester-bond 
should be reasonable stable under pH 8.0 buffer condition, the appropriate buffer 
condition for performing oxyester-linked diGlyGly peptides digestion should be 
further studied in very near future. Furthermore, we cannot rule out the possibility 
that the ubiquitin esterification is independent of the proteasome degradation 
machinery. It makes proteasome inhibitor treatment, which is frequently applied 
for stabilizing ubiquitin-conjugates, unable to trap the ester-linked ubiquitin 
conjugates.  
  To date, ubiquitylation has only been discovered in a polypeptide context. 
Since the high esterification reactivity of MYBCP2 has been demonstrated in this 
thesis, the possibility of lipid or carbohydrate ubiquitylation exist. Furthermore, 
the ubiquitylation on lipoproteins545 or N-glycosylated proteins546 have been 
demonstrated already. It is plausible that we may have missed some critical data 
due to limitations of the detection method. The development of a delicate method 
to study the non-lysine ubiquitylation is therefore urgently needed.  
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5.5 Extended Figures 
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Extended Figure 5.1 LC-MS characterization of biotin-Ub1-74-SR. 
Biotin-Ub1-74-SR. HPLC chromatogram monitoring UV absorbance at 214 nm. ESI mass 
spectrum (inset left) and deconvoluted mass spectrum (inset right). Expected mass = 
9249.2 (-Met); found = 9,247 Da. 
 
 
Extended Figure 5.2 LC-MS characterization of biotin-ABP 13.  
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UBE2D2 ABP 13. HPLC chromatogram monitoring UV absorbance at 214 nm. ESI mass 
spectrum (inset left) and deconvoluted mass spectrum (inset right). Expected mass = 
29,268 Da (-Met); found = 29,264 Da 
 
 
Extended Figure 5.3 LC-MS characterization of biotin-ABP 14.  
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UBE2D2 F62A ABP 14. HPLC chromatogram monitoring UV absorbance at 214 nm. ESI 
mass spectrum (inset left) and deconvoluted mass spectrum (inset right). Expected mass 
= 29,192 Da (-Met); found = 29,186 Da. 
 
Extended Figure 5.4 LC-MS characterization of biotin-Ub1-73-SR. 
Biotin-Ub1-73-SR. HPLC chromatogram monitoring UV absorbance at 214 nm. ESI mass 
spectrum (inset left) and deconvoluted mass spectrum (inset right). Expected mass = 9093 
(-Met); found = 9091 Da.  
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Extended Figure 5.5 LC-MS characterization of biotin ABP 15. 
UBE2L3 ABP 15. HPLC chromatogram monitoring UV absorbance at 214 nm. ESI mass 
spectrum (inset left) and deconvoluted mass spectrum (inset right). Expected mass = 
29286.9 (-Met); found = 29282 Da. 
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Extended Figure 5.6 LC-MS characterization of biotin ABP 16. 
UBE2L3 F63A ABP 16. HPLC chromatogram monitoring UV absorbance at 214 nm. ESI mass 
spectrum (inset left) and deconvoluted mass spectrum (inset right). Expected mass = 
29210.8 (-Met); found = 29206 Da. 
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Extended Figure 5.7 The E3 spectral counts by LC-MS/MS analysis. (next page) 
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Control probes containing F62A mutation recover fewer E3s which is consistent with 
activity-based labelling. To induce Parkin activation SH-SY5Y cells were administered with 
oligomycin (5μM) and antimycin A (10 μM) (OA) for 3 hours. Extracted proteomes were 
then incubated with UBE2D2 ABP 13 and the control probe, UBE2D2 F62A 14 and ABP-
labelled proteins were enriched against streptavidin resin followed by on-resin tryptic 
digestion. Obtained peptides were analyzed by data dependent LC-MS/MS. Recovered 
proteins were filtered against the pfam domain terms (RING, HECT, IBR, zf-UBR) and 
proteins with <3 spectral counts were excluded. E1s were also included as these undergo 
transthiolation and are highly enriched by our ABPs. The number of spectral counts for 
the recovered E1/E3 proteins plotted against protein ID for 13 and 14. 
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Extended Figure 5.8 The E3 spectral counts by LC-MS/MS analysis.  
The same analysis as in the extended figure 5.7 was carried out using UBE2L3 ABP 15 and 
is respective control ABP, UBE2L3 F63A 16. 
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Extended Figure 5.9 The E3 spectral counts by LC-MS/MS analysis. 
SH-SY5Y cells were untreated or administered with oligomycin (5M) and antimycin A (10 
M) (OA) for 3 hours. Extracted proteomes were then incubated with UBE2D2 ABP 13. 
The data was analyzed by the same method used in extended figure 5.7.  
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Extended Figure 5.10 The E3 spectral counts by LC-MS/MS analysis. 
SH-SY5Y cells were untreated or administered with oligomycin (5M) and antimycin A (10 
M) (OA) for 3 hours. Extracted proteomes were then incubated with UBE2D2 ABP 15. 
The data was analyzed by the same method used in extended figure 5.7.  
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Extended Figure 5.11 Expected and found fragment ions in the MS2 spectrum for the 
predominant cysteine residue labelled with the ABP.  
Using the pLink software, 38 spectral matches corresponding to cysteine labelling sites in 
MYCBP2cat were identified. 36 of these corresponded to C4520. Figure 5.2d is a 
representative MS2 spectrum. Above, is the predicted and found fragment ions for the 
representative spectrum. The spectrum is for a 5+ precursor ion (observed m/z = 614.5088; 
expected m/z = 614.5094). A mass tolerance of 20 ppm was applied for fragment ion 
assignment. 
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Extended Figure 5.12 Discharge activity towards Tris/glycerol for all of the tested 
MYCBP2cat cysteine to serine mutants.  
The C4506S mutation abolishes discharge activity but because C4506S resides within a 
Cys-X-X-Cys Zn-binding motif, this was assumed to be due to disruption of the protein fold 
and not a catalytic defect. The C4561S mutation undergoes aberrant thioester adduct 
formation. An explanation is that C4561S mutation (also in a structurally important Cys-X-
X-Cys Zn-binding motif) unfolds the protein and liberates Cys residues, that would 
otherwise be occupied as Zn ligands, that undergo aberrant transthiolation. 
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Extended Figure 5.13 Coomassie stain of the thioester/ester trapping assay with GST-
MYCBP2cat. 
After in-gel fluorescence scan, as shown in Figure 5.4, the gel was Coomassie stained. 
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Extended Figure 5.14 Coomassie stain of peptide-assay gel.  
(a) Coomassie stain of threonine gel presented in Figure. 5.6. Also shown is the 
deconvoluted mass spectrum representative of all ubiquitin species at the 60 min time 
point. Observed mass of Cy3B-Ub modified threonine peptide = 10,033 Da; theoretical 
mass = 10,036 Da. (b) Coomassie stain of the serine gel presented in Figure 5.6. Also 
shown is the deconvoluted mass spectrum representative of all ubiquitin species at the 
60-min time point. Observed mass of Cy3B-Ub = 9,534 Da; theoretical mass = 9,537 Da. 
Observed mass of Cy3B-Ub modified serine peptide = 10,019 Da; theoretical mass = 
10,022 Da. (c) Coomassie stain of lysine gels, in the presence and absence of E3, presented 
in Figure 5.6. Inefficient modification of the lysine peptide is observed, which is 
moderately enhanced in the absence of E3. Experiments shown in a-c were repeated more 
than three times. 
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Extended Figure 5.15 Representative stereo views of the MYCBP2cat crystallographic 
model.  
The distinct regions are colored in stick representation: RING domain (blue), linker helix 
(purple), helix-turn-helix motif (green) and tandem cysteine (TC) domain (orange). The 
mesh represents the experimental 2|Fobs|-|Fcalc| electron density map contoured at 1.5 . 
(a) Wide field view. C4572 is the downstream active cysteine residue in the esterification 
site. The mediator loop region is formed between A4518 and G4527 and is disordered in 
the structure. (b) Close up of the mediator loop region. (c) Close up of the esterification 
site. Threonine 4380 motif from the symmetry related molecule (T4380sym) is shown and 
represented in grey ball and stick. (The figures are provided by Dr. Virdee) 
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Extended Figure 5.16 Modelling of mediator loop.  
(a) Model of the proposed ubiquitin relay intermediate as shown in Figure 5.14 but from 
aalternative perspective. In the experimental structure, tandem-cysteinedomain residues 
are shown in orange and mediator-loop residues are in dark brown. In the model, tandem-
cysteine-domain residues are in light orange and mediator-loop residues are in mauve. 
The modelled E2, based on the superposition in a, is in grey cartoon. Essential cysteines 
C4520 and C4572 are in yellow and coloured by atom type. Ubiquitin residues G75-G76 
are in blue ball-and-stick representation and are coloured by atom type. Gly residues in 
the mediator loop that are likely to be important for loop mobility are displayed in mauve 
ball and stick and coloured by atom type. N4570 and H4583 side chains have been rotated 
by the specified angles to relieve steric clash. (b) As in a, but amino acid side chains that 
have been flipped to relieve steric clash with the modelled mediator loop are labelled in 
blue (c) All phi and psi angles in the modelled structure fall within accepted values as 
determined by Ramachandran analysis with the RAMPAGE server. (The figures are 
provided by Dr. Virdee and Dr. Mabbitt) 
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Extended Table 5.1 Data collection and refinement statistics of MYBCP2cat (The 
table is provided by Dr. Virdee) 
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Perspectives 
In this thesis, I demonstrated a sophiscated method to generate E3 ABPs322. I 
further applied the ABPs using the activity-based prteomic strategy to uncover a 
novel E3 mechanism, RING-Cysteine-Relay, for ubiquitin transfer547. Furthermore, 
poorly characterized E3, MYBCP2, contains distinct ubiquitin esterification 
reactivity to selectively transfer ubiquitin upon the threonine amino acid. Taken 
together, this thesis provides the first example for discovering and profiling E3 
activity via novel E3 activity-based probes. However, in order to broadly apply this 
platform across multiple research areas, there were a few issues that need to be 
addressed.  
 Although the methodology for producing the E2-based E3 ABPs is straight 
forward, the hydrolysis of the truncated Ub1-74-SR during the aminolysis step 
resulted in a low yield for making this specific type of ABP (the E3 ABPs with a Ub1-
74 moiety). The CuAAC click reaction though is a quick route for conjugating TDAE 
compounds with the ubiquitin-azide moiety, the 40-50% product loss during the 
reaction and purification step is a major drawback for producing ABPs on a large 
scale. Moreover, the last two or three residues missing (-GlyGly or –ArgGlyGly) in 
the ubiquitin moiety (Ub1-74 ABP or Ub1-73 ABP, respectively) of the E3 ABPs may 
still affect the activity or selectivity of our ABPs. Therefore, optimization of the 
TDAE compounds for making the E3 ABPs is required. In addition, despite the 
molar concentration of the ABPs being used at a 4:1 ratio towards target E3s, the 
labeling efficiency of E3 ABPs toward some E3s in the in vitro activity profiling assay 
is still low.  
The generally used strategies to determine E3 activity are either by observing 
E3 autoubiquitylation, ubiquitin chain formation, or by measuring the E2~Ub 
240 
 
discharge rate82,121,239. However, the above methods may not accyrately reflect the 
‘genuine’ E3 activity since these reactions are normally supplied with excess E1, E2 
and ubiquitin. It is possible that the small amount of activated E3 enzyme is 
sufficient to make siginificant amoniuts of ubiquitin chains (that might give a 
disproportionate refecltion of E3 activity). Furthermore, the highly sensitive 
immunoblotting and silver-staining method that are broadly applied in these 
assays may also overestimate the activity of the E3s. However, the labeling 
mechanism of our E3 ABPs is by detecting the transthiolation activity of the target 
E3322,334. The chemistry associated with native E2-E3 transthiolaiton and E3 ABs 
labelling are different. As a result, it is not appropriate to claim that specific E3 is 
‘fully-active’ when it catalyzed the ubiquitin chains formation under in vitro assays.  
The conditions for our E3 ABP labelling assay is also an issue that needs to be 
considered. The availability of the catalytic cysteine on HECT/RBR/RCR E3s is an 
imporatant criterion for E3 ABP labelling. Oxidation of the cysteine or formation of 
a disulfide may prohibit the ABP labeling. The supply reducing agents in the 
reactions can be performed but side reactions of the reducing agents toward E3 
ABPs were observed. The excess reducing agents (DTT or TCEP) are able to react 
with the ‘warhead’ on our ABPs which could abolish the activity of the E3 ABPs 
(data not shown). In addition, how much reducing agent is defined as a ‘sufficient 
level’ for keeping the catalytic cysteine available for E3 activity? To estimate the 
required reducing agent concentration for cellular extracts is especially challenging.  
The incubation time for the in situ probe labeling assay is considerably long 
(4.0 hours) compared to the autoubiquitylation assay (0.5-1.0 hours). Albeit TCEP 
is relatively stable, the degradation of these reducing agents can still happen 
during the long incubation time, especially at 30°C or 37°C conditions. 
Furthermore, insufficient reducing agent in the reaction buffer may disrupt the 
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integrity of the Zn-binding domain on E3s since zinc ions are coordinated by 
cysteine residues in E3 proteins (the RING and IBR domains in RBRs236 , or RCR E3 
and the TC domain in RCR E3547). This may decrease the stability of the target E3s 
and abolish ABP labelling.  
 How to correctly apply E3 ABP to E3 research is also another important issue 
for follow-up work. Despite the ABPP strategy and the crystallography which are 
discussed previously, what kinds of assays can we design and perform to obtain 
more insight about E3 activity regulation? Furthermore, it has been demonstrated 
that the interactions between cofactors and E3s can activate or enhance certain 
types of E3s. How to dissect such complicated components behind such E3 
activation mechanisms that coulde be detected by our E3 ABPs needs to be 
addressed.  
 The other part of this thesis is the discovery of a novel E3 mechanism perform 
by a giant E3, MYCBP2. Potentially, this is an exciting discovery which could open a 
new dimension to the ubiquitin field. However, the most important concern for 
this project is the missing MYCBP2 ubiquitin esterification substrate in cells. We 
clearly observed base labile Ub-conjugated adducts in cellular extract samples but 
it was largely attributed to auto-ubiquitylated MYCBP2cat. The identity of the 
genuine protein substrates of MYCBP2 which are conjugated within the ubiquitin 
via an oxyester-bond is under investigating. Obviously, the main question is that 
how should we perform the substrate search. Optimized biochemical conditions 
for assays are required due to the unstable nature of the oxyester-bond521. For 
example, maintaining the correct pH for the cell lysis buffer, protein digestion 
buffer for mass spectrometry, or even the sample loading buffer for SDS-PAGE; 
preparing the lysis buffer with suitable protease/phosphatase inhibitors (the 
inhibitors which have been proven to be unable to react with oxyester-bond). 
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Moreover, the algorithm of the mass spectrometry software for searching the 
peptides PTM sites also requires modification. Based on the current settings in the 
software, the predicated molecular weight (typically +144 Da) of the non-lysine 
ubiquitination modification is often not included in the search software. As a result, 
we may still be unable to detect the peptides which contain the ubiquitylated 
Thr/Ser residues even we perform the assay under a idealised biochemical 
conditions.  
 Finding the direct substrate for a protein has been proven to be challenging 
in many fields. Performing MYCBP2 immunoprecipitation with mass spectrometry 
analysis could provide the candidate substrates. However, a good antibody for 
MYCBP2 with high selectivity is required for this strategy. Furthermore, choosing a 
correct biological model for MYCBP2 substrate research is required since MYCBP2 
is highly expressed in brain and cerebellum478. It has also been proved to regulate 
axon and synapse development484,488. As a result, performing the 
immunoprecipitation in physiologically-irrelevant but frequently used cell lines 
such as HEK293, U2OS or HeLa cells may not provide the correct information on 
MYCBP2 substrates. MYCBP2 KO or ligase-dead KI primary neuronal cells, or 
differentiated neuroblastoma cells, should be studied in future research. Another 
strategy which has already been applied in searching for substrates is by 
performing immunoprecipitation and mass spectrometry using ‘ubiquitin remnant 
motif antibody K-ε-GG’27,548. The analogous di-GlyGly-threonine based antibody is 
also being developed by our lab. This tool should provide an informative dataset 
for threonine ubiquitination.  
 
 
 
243 
 
References: 
1 Kerscher, O., Felberbaum, R. & Hochstrasser, M. Modification of proteins 
by ubiquitin and ubiquitin-like proteins. Annual review of cell and 
developmental biology 22, 159-180, 
doi:10.1146/annurev.cellbio.22.010605.093503 (2006). 
2 Goldstein, G. et al. Isolation of a polypeptide that has lymphocyte-
differentiating properties and is probably represented universally in living 
cells. Proc Natl Acad Sci U S A 72, 11-15 (1975). 
3 Ciehanover, A., Hod, Y. & Hershko, A. A heat-stable polypeptide 
component of an ATP-dependent proteolytic system from reticulocytes. 
Biochem Biophys Res Commun 81, 1100-1105 (1978). 
4 Ciechanover, A., Heller, H., Elias, S., Haas, A. L. & Hershko, A. ATP-
dependent conjugation of reticulocyte proteins with the polypeptide 
required for protein degradation. Proc Natl Acad Sci U S A 77, 1365-1368 
(1980). 
5 Hershko, A., Ciechanover, A., Heller, H., Haas, A. L. & Rose, I. A. Proposed 
role of ATP in protein breakdown: conjugation of protein with multiple 
chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad 
Sci U S A 77, 1783-1786 (1980). 
6 Harrison, J. S., Jacobs, T. M., Houlihan, K., Van Doorslaer, K. & Kuhlman, B. 
UbSRD: The Ubiquitin Structural Relational Database. J Mol Biol 428, 679-
687, doi:10.1016/j.jmb.2015.09.011 (2016). 
7 Lenkinski, R. E., Chen, D. M., Glickson, J. D. & Goldstein, G. Nuclear 
magnetic resonance studies of the denaturation of ubiquitin. Biochim 
Biophys Acta 494, 126-130 (1977). 
8 Perica, T. & Chothia, C. Ubiquitin--molecular mechanisms for recognition 
of different structures. Curr Opin Struct Biol 20, 367-376, 
doi:10.1016/j.sbi.2010.03.007 (2010). 
9 Vijay-Kumar, S., Bugg, C. E. & Cook, W. J. Structure of ubiquitin refined at 
1.8 A resolution. J Mol Biol 194, 531-544 (1987). 
10 Winget, J. M. & Mayor, T. The diversity of ubiquitin recognition: hot spots 
and varied specificity. Mol Cell 38, 627-635, 
doi:10.1016/j.molcel.2010.05.003 (2010). 
11 Hochstrasser, M. Origin and function of ubiquitin-like proteins. Nature 
458, 422-429, doi:10.1038/nature07958 (2009). 
12 Gareau, J. R. & Lima, C. D. The SUMO pathway: emerging mechanisms 
that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 
244 
 
11, 861-871, doi:10.1038/nrm3011 (2010). 
13 Rabut, G. & Peter, M. Function and regulation of protein neddylation. 
'Protein modifications: beyond the usual suspects' review series. EMBO 
Rep 9, 969-976, doi:10.1038/embor.2008.183 (2008). 
14 Geng, J. & Klionsky, D. J. The Atg8 and Atg12 ubiquitin-like conjugation 
systems in macroautophagy. 'Protein modifications: beyond the usual 
suspects' review series. EMBO Rep 9, 859-864, 
doi:10.1038/embor.2008.163 (2008). 
15 Xie, Z., Nair, U. & Klionsky, D. J. Atg8 controls phagophore expansion 
during autophagosome formation. Mol Biol Cell 19, 3290-3298, 
doi:10.1091/mbc.E07-12-1292 (2008). 
16 Stolz, A. et al. Fluorescence-based ATG8 sensors monitor localization and 
function of LC3/GABARAP proteins. EMBO J 36, 549-564, 
doi:10.15252/embj.201695063 (2017). 
17 Mueller, T. D. & Feigon, J. Structural determinants for the binding of 
ubiquitin-like domains to the proteasome. EMBO J 22, 4634-4645, 
doi:10.1093/emboj/cdg467 (2003). 
18 Ronau, J. A., Beckmann, J. F. & Hochstrasser, M. Substrate specificity of 
the ubiquitin and Ubl proteases. Cell Res 26, 441-456, 
doi:10.1038/cr.2016.38 (2016). 
19 Komander, D. & Rape, M. The ubiquitin code. Annu Rev Biochem 81, 203-
229, doi:10.1146/annurev-biochem-060310-170328 (2012). 
20 Yau, R. & Rape, M. The increasing complexity of the ubiquitin code. Nat 
Cell Biol 18, 579-586, doi:10.1038/ncb3358 (2016). 
21 Hicke, L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 
195-201, doi:10.1038/35056583 (2001). 
22 Ulrich, H. D. & Walden, H. Ubiquitin signalling in DNA replication and 
repair. Nat Rev Mol Cell Biol 11, 479-489, doi:10.1038/nrm2921 (2010). 
23 Goldknopf, I. L., French, M. F., Musso, R. & Busch, H. Presence of protein 
A24 in rat liver nucleosomes. Proc Natl Acad Sci U S A 74, 5492-5495 
(1977). 
24 Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. & Jentsch, S. 
RAD6-dependent DNA repair is linked to modification of PCNA by 
ubiquitin and SUMO. Nature 419, 135-141, doi:10.1038/nature00991 
(2002). 
25 Dupont, S. et al. FAM/USP9x, a deubiquitinating enzyme essential for 
TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136, 123-135, 
doi:10.1016/j.cell.2008.10.051 (2009). 
245 
 
26 Haglund, K. et al. Multiple monoubiquitination of RTKs is sufficient for 
their endocytosis and degradation. Nat Cell Biol 5, 461-466, 
doi:10.1038/ncb983 (2003). 
27 Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-
modified proteome. Mol Cell 44, 325-340, 
doi:10.1016/j.molcel.2011.08.025 (2011). 
28 Kaiser, S. E. et al. Protein standard absolute quantification (PSAQ) method 
for the measurement of cellular ubiquitin pools. Nat Methods 8, 691-696, 
doi:10.1038/nmeth.1649 (2011). 
29 Xu, P. et al. Quantitative proteomics reveals the function of 
unconventional ubiquitin chains in proteasomal degradation. Cell 137, 
133-145, doi:10.1016/j.cell.2009.01.041 (2009). 
30 Saeki, Y. Ubiquitin recognition by the proteasome. J Biochem 161, 113-
124, doi:10.1093/jb/mvw091 (2017). 
31 Thrower, J. S., Hoffman, L., Rechsteiner, M. & Pickart, C. M. Recognition of 
the polyubiquitin proteolytic signal. EMBO J 19, 94-102, 
doi:10.1093/emboj/19.1.94 (2000). 
32 Petroski, M. D. & Deshaies, R. J. Mechanism of lysine 48-linked ubiquitin-
chain synthesis by the cullin-RING ubiquitin-ligase complex SCF-Cdc34. 
Cell 123, 1107-1120, doi:10.1016/j.cell.2005.09.033 (2005). 
33 Lu, Y., Lee, B. H., King, R. W., Finley, D. & Kirschner, M. W. Substrate 
degradation by the proteasome: a single-molecule kinetic analysis. 
Science 348, 1250834, doi:10.1126/science.1250834 (2015). 
34 Deng, L. et al. Activation of the IkappaB kinase complex by TRAF6 requires 
a dimeric ubiquitin-conjugating enzyme complex and a unique 
polyubiquitin chain. Cell 103, 351-361 (2000). 
35 Doil, C. et al. RNF168 binds and amplifies ubiquitin conjugates on 
damaged chromosomes to allow accumulation of repair proteins. Cell 
136, 435-446, doi:10.1016/j.cell.2008.12.041 (2009). 
36 Lee, B. L., Singh, A., Mark Glover, J. N., Hendzel, M. J. & Spyracopoulos, L. 
Molecular Basis for K63-Linked Ubiquitination Processes in Double-Strand 
DNA Break Repair: A Focus on Kinetics and Dynamics. J Mol Biol 429, 
3409-3429, doi:10.1016/j.jmb.2017.05.029 (2017). 
37 Silva, G. M., Finley, D. & Vogel, C. K63 polyubiquitination is a new 
modulator of the oxidative stress response. Nat Struct Mol Biol 22, 116-
123, doi:10.1038/nsmb.2955 (2015). 
38 Gack, M. U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for 
RIG-I-mediated antiviral activity. Nature 446, 916-920, 
246 
 
doi:10.1038/nature05732 (2007). 
39 Martin-Vicente, M., Medrano, L. M., Resino, S., Garcia-Sastre, A. & 
Martinez, I. TRIM25 in the Regulation of the Antiviral Innate Immunity. 
Front Immunol 8, 1187, doi:10.3389/fimmu.2017.01187 (2017). 
40 Song, E. J. et al. The Prp19 complex and the Usp4Sart3 deubiquitinating 
enzyme control reversible ubiquitination at the spliceosome. Genes Dev 
24, 1434-1447, doi:10.1101/gad.1925010 (2010). 
41 Spence, J. et al. Cell cycle-regulated modification of the ribosome by a 
variant multiubiquitin chain. Cell 102, 67-76 (2000). 
42 Emanuele, M. J. et al. Global identification of modular cullin-RING ligase 
substrates. Cell 147, 459-474, doi:10.1016/j.cell.2011.09.019 (2011). 
43 Komander, D. et al. Molecular discrimination of structurally equivalent Lys 
63-linked and linear polyubiquitin chains. EMBO Rep 10, 466-473, 
doi:10.1038/embor.2009.55 (2009). 
44 Kirisako, T. et al. A ubiquitin ligase complex assembles linear polyubiquitin 
chains. EMBO J 25, 4877-4887, doi:10.1038/sj.emboj.7601360 (2006). 
45 Ikeda, F. et al. SHARPIN forms a linear ubiquitin ligase complex regulating 
NF-kappaB activity and apoptosis. Nature 471, 637-641, 
doi:10.1038/nature09814 (2011). 
46 Tokunaga, F. et al. SHARPIN is a component of the NF-kappaB-activating 
linear ubiquitin chain assembly complex. Nature 471, 633-636, 
doi:10.1038/nature09815 (2011). 
47 Tokunaga, F. et al. Involvement of linear polyubiquitylation of NEMO in 
NF-kappaB activation. Nat Cell Biol 11, 123-132, doi:10.1038/ncb1821 
(2009). 
48 Gerlach, B. et al. Linear ubiquitination prevents inflammation and 
regulates immune signalling. Nature 471, 591-596, 
doi:10.1038/nature09816 (2011). 
49 Rahighi, S. et al. Specific recognition of linear ubiquitin chains by NEMO is 
important for NF-kappaB activation. Cell 136, 1098-1109, 
doi:10.1016/j.cell.2009.03.007 (2009). 
50 Jing, H. et al. Porcine Reproductive and Respiratory Syndrome Virus 
nsp1alpha Inhibits NF-kappaB Activation by Targeting the Linear Ubiquitin 
Chain Assembly Complex. J Virol 91, doi:10.1128/JVI.01911-16 (2017). 
51 Wang, L. et al. The Linear Ubiquitin Assembly Complex Modulates Latent 
Membrane Protein 1 Activation of NF-kappaB and Interferon Regulatory 
Factor 7. J Virol 91, doi:10.1128/JVI.01138-16 (2017). 
52 Lafont, E. et al. The linear ubiquitin chain assembly complex regulates 
247 
 
TRAIL-induced gene activation and cell death. EMBO J 36, 1147-1166, 
doi:10.15252/embj.201695699 (2017). 
53 Matsumoto, M. L. et al. K11-linked polyubiquitination in cell cycle control 
revealed by a K11 linkage-specific antibody. Mol Cell 39, 477-484, 
doi:10.1016/j.molcel.2010.07.001 (2010). 
54 Meyer, H. J. & Rape, M. Enhanced protein degradation by branched 
ubiquitin chains. Cell 157, 910-921, doi:10.1016/j.cell.2014.03.037 (2014). 
55 Bremm, A., Moniz, S., Mader, J., Rocha, S. & Komander, D. Cezanne 
(OTUD7B) regulates HIF-1alpha homeostasis in a proteasome-
independent manner. EMBO Rep 15, 1268-1277, 
doi:10.15252/embr.201438850 (2014). 
56 Qin, Y. et al. RNF26 temporally regulates virus-triggered type I interferon 
induction by two distinct mechanisms. PLoS Pathog 10, e1004358, 
doi:10.1371/journal.ppat.1004358 (2014). 
57 Elia, A. E. et al. Quantitative Proteomic Atlas of Ubiquitination and 
Acetylation in the DNA Damage Response. Mol Cell 59, 867-881, 
doi:10.1016/j.molcel.2015.05.006 (2015). 
58 Cripps, D. et al. Alzheimer disease-specific conformation of 
hyperphosphorylated paired helical filament-Tau is polyubiquitinated 
through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 281, 
10825-10838, doi:10.1074/jbc.M512786200 (2006). 
59 Shang, F. et al. Lys6-modified ubiquitin inhibits ubiquitin-dependent 
protein degradation. J Biol Chem 280, 20365-20374, 
doi:10.1074/jbc.M414356200 (2005). 
60 Ordureau, A. et al. Defining roles of PARKIN and ubiquitin phosphorylation 
by PINK1 in mitochondrial quality control using a ubiquitin replacement 
strategy. Proc Natl Acad Sci U S A 112, 6637-6642, 
doi:10.1073/pnas.1506593112 (2015). 
61 Durcan, T. M. et al. USP8 regulates mitophagy by removing K6-linked 
ubiquitin conjugates from parkin. EMBO J 33, 2473-2491, 
doi:10.15252/embj.201489729 (2014). 
62 Michel, M. A., Swatek, K. N., Hospenthal, M. K. & Komander, D. Ubiquitin 
Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin 
Signaling. Mol Cell 68, 233-246 e235, doi:10.1016/j.molcel.2017.08.020 
(2017). 
63 Wang, Q. et al. The E3 ubiquitin ligase RNF185 facilitates the cGAS-
mediated innate immune response. PLoS Pathog 13, e1006264, 
doi:10.1371/journal.ppat.1006264 (2017). 
248 
 
64 Gatti, M. et al. RNF168 promotes noncanonical K27 ubiquitination to 
signal DNA damage. Cell Rep 10, 226-238, 
doi:10.1016/j.celrep.2014.12.021 (2015). 
65 Nucifora, F. C., Jr. et al. Ubiqutination via K27 and K29 chains signals 
aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun 7, 
11792, doi:10.1038/ncomms11792 (2016). 
66 Liu, J. et al. Rhbdd3 controls autoimmunity by suppressing the production 
of IL-6 by dendritic cells via K27-linked ubiquitination of the regulator 
NEMO. Nat Immunol 15, 612-622, doi:10.1038/ni.2898 (2014). 
67 Johnson, E. S., Ma, P. C., Ota, I. M. & Varshavsky, A. A proteolytic pathway 
that recognizes ubiquitin as a degradation signal. J Biol Chem 270, 17442-
17456 (1995). 
68 Koegl, M. et al. A novel ubiquitination factor, E4, is involved in 
multiubiquitin chain assembly. Cell 96, 635-644 (1999). 
69 Michel, M. A. et al. Assembly and specific recognition of k29- and k33-
linked polyubiquitin. Mol Cell 58, 95-109, 
doi:10.1016/j.molcel.2015.01.042 (2015). 
70 Kristariyanto, Y. A. et al. K29-selective ubiquitin binding domain reveals 
structural basis of specificity and heterotypic nature of k29 polyubiquitin. 
Mol Cell 58, 83-94, doi:10.1016/j.molcel.2015.01.041 (2015). 
71 Chastagner, P., Israel, A. & Brou, C. Itch/AIP4 mediates Deltex degradation 
through the formation of K29-linked polyubiquitin chains. EMBO Rep 7, 
1147-1153, doi:10.1038/sj.embor.7400822 (2006). 
72 Zotti, T. et al. TRAF7 protein promotes Lys-29-linked polyubiquitination of 
IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and 
p65/RelA protein and represses NF-kappaB activation. J Biol Chem 286, 
22924-22933, doi:10.1074/jbc.M110.215426 (2011). 
73 Al-Hakim, A. K. et al. Control of AMPK-related kinases by USP9X and 
atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J 411, 249-
260, doi:10.1042/BJ20080067 (2008). 
74 Yuan, W. C. et al. K33-Linked Polyubiquitination of Coronin 7 by Cul3-
KLHL20 Ubiquitin E3 Ligase Regulates Protein Trafficking. Mol Cell 54, 586-
600, doi:10.1016/j.molcel.2014.03.035 (2014). 
75 Huang, H. et al. K33-linked polyubiquitination of T cell receptor-zeta 
regulates proteolysis-independent T cell signaling. Immunity 33, 60-70, 
doi:10.1016/j.immuni.2010.07.002 (2010). 
76 Yang, M. et al. K33-linked polyubiquitination of Zap70 by Nrdp1 controls 
CD8(+) T cell activation. Nat Immunol 16, 1253-1262, doi:10.1038/ni.3258 
249 
 
(2015). 
77 Lin, M. et al. USP38 Inhibits Type I Interferon Signaling by Editing TBK1 
Ubiquitination through NLRP4 Signalosome. Mol Cell 64, 267-281, 
doi:10.1016/j.molcel.2016.08.029 (2016). 
78 Swatek, K. N. & Komander, D. Ubiquitin modifications. Cell Res 26, 399-
422, doi:10.1038/cr.2016.39 (2016). 
79 Herhaus, L. & Dikic, I. Expanding the ubiquitin code through post-
translational modification. EMBO Rep 16, 1071-1083, 
doi:10.15252/embr.201540891 (2015). 
80 Kane, L. A. et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 
ubiquitin ligase activity. J Cell Biol 205, 143-153, 
doi:10.1083/jcb.201402104 (2014). 
81 Koyano, F. et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. 
Nature 510, 162-166, doi:10.1038/nature13392 (2014). 
82 Kazlauskaite, A. et al. Parkin is activated by PINK1-dependent 
phosphorylation of ubiquitin at Ser65. Biochem J 460, 127-139, 
doi:10.1042/BJ20140334 (2014). 
83 Okatsu, K. et al. Phosphorylated ubiquitin chain is the genuine Parkin 
receptor. J Cell Biol 209, 111-128, doi:10.1083/jcb.201410050 (2015). 
84 Wauer, T., Simicek, M., Schubert, A. & Komander, D. Mechanism of 
phospho-ubiquitin-induced PARKIN activation. Nature 524, 370-374, 
doi:10.1038/nature14879 (2015). 
85 Wauer, T. et al. Ubiquitin Ser65 phosphorylation affects ubiquitin 
structure, chain assembly and hydrolysis. EMBO J 34, 307-325, 
doi:10.15252/embj.201489847 (2015). 
86 Hershko, A. & Ciechanover, A. The ubiquitin system. Annu Rev Biochem 
67, 425-479, doi:10.1146/annurev.biochem.67.1.425 (1998). 
87 Smit, J. J. & Sixma, T. K. RBR E3-ligases at work. EMBO Rep 15, 142-154, 
doi:10.1002/embr.201338166 (2014). 
88 Schulman, B. A. & Harper, J. W. Ubiquitin-like protein activation by E1 
enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell 
Biol 10, 319-331, doi:10.1038/nrm2673 (2009). 
89 Pickart, C. M. & Rose, I. A. Functional heterogeneity of ubiquitin carrier 
proteins. J Biol Chem 260, 1573-1581 (1985). 
90 Berndsen, C. E. & Wolberger, C. New insights into ubiquitin E3 ligase 
mechanism. Nat Struct Mol Biol 21, 301-307, doi:10.1038/nsmb.2780 
(2014). 
91 Deshaies, R. J. & Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu 
250 
 
Rev Biochem 78, 399-434, 
doi:10.1146/annurev.biochem.78.101807.093809 (2009). 
92 Scheffner, M. & Kumar, S. Mammalian HECT ubiquitin-protein ligases: 
biological and pathophysiological aspects. Biochim Biophys Acta 1843, 61-
74, doi:10.1016/j.bbamcr.2013.03.024 (2014). 
93 Dikic, I., Wakatsuki, S. & Walters, K. J. Ubiquitin-binding domains - from 
structures to functions. Nat Rev Mol Cell Biol 10, 659-671, 
doi:10.1038/nrm2767 (2009). 
94 Scott, D., Oldham, N. J., Strachan, J., Searle, M. S. & Layfield, R. Ubiquitin-
binding domains: mechanisms of ubiquitin recognition and use as tools to 
investigate ubiquitin-modified proteomes. Proteomics 15, 844-861, 
doi:10.1002/pmic.201400341 (2015). 
95 Heideker, J. & Wertz, I. E. DUBs, the regulation of cell identity and disease. 
Biochem J 467, 191 (2015). 
96 Komander, D., Clague, M. J. & Urbe, S. Breaking the chains: structure and 
function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563, 
doi:10.1038/nrm2731 (2009). 
97 Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in disease pathogenesis 
and treatment. Nat Med 20, 1242-1253, doi:10.1038/nm.3739 (2014). 
98 Cohen, P. Immune diseases caused by mutations in kinases and 
components of the ubiquitin system. Nat Immunol 15, 521-529, 
doi:10.1038/ni.2892 (2014). 
99 Senft, D., Qi, J. & Ronai, Z. A. Ubiquitin ligases in oncogenic 
transformation and cancer therapy. Nat Rev Cancer 18, 69-88, 
doi:10.1038/nrc.2017.105 (2018). 
100 Atkin, G. & Paulson, H. Ubiquitin pathways in neurodegenerative disease. 
Front Mol Neurosci 7, 63, doi:10.3389/fnmol.2014.00063 (2014). 
101 Ciechanover, A., Heller, H., Katz-Etzion, R. & Hershko, A. Activation of the 
heat-stable polypeptide of the ATP-dependent proteolytic system. Proc 
Natl Acad Sci U S A 78, 761-765 (1981). 
102 Jin, J., Li, X., Gygi, S. P. & Harper, J. W. Dual E1 activation systems for 
ubiquitin differentially regulate E2 enzyme charging. Nature 447, 1135-
1138, doi:10.1038/nature05902 (2007). 
103 Chiu, Y. H., Sun, Q. & Chen, Z. J. E1-L2 activates both ubiquitin and FAT10. 
Mol Cell 27, 1014-1023, doi:10.1016/j.molcel.2007.08.020 (2007). 
104 Olsen, S. K. & Lima, C. D. Structure of a ubiquitin E1-E2 complex: insights 
to E1-E2 thioester transfer. Mol Cell 49, 884-896, 
doi:10.1016/j.molcel.2013.01.013 (2013). 
251 
 
105 Walden, H., Podgorski, M. S. & Schulman, B. A. Insights into the ubiquitin 
transfer cascade from the structure of the activating enzyme for NEDD8. 
Nature 422, 330-334, doi:10.1038/nature01456 (2003). 
106 Lois, L. M. & Lima, C. D. Structures of the SUMO E1 provide mechanistic 
insights into SUMO activation and E2 recruitment to E1. EMBO J 24, 439-
451, doi:10.1038/sj.emboj.7600552 (2005). 
107 Lee, I. & Schindelin, H. Structural insights into E1-catalyzed ubiquitin 
activation and transfer to conjugating enzymes. Cell 134, 268-278, 
doi:10.1016/j.cell.2008.05.046 (2008). 
108 Olsen, S. K., Capili, A. D., Lu, X., Tan, D. S. & Lima, C. D. Active site 
remodelling accompanies thioester bond formation in the SUMO E1. 
Nature 463, 906-912, doi:10.1038/nature08765 (2010). 
109 Huang, D. T. et al. Basis for a ubiquitin-like protein thioester switch 
toggling E1-E2 affinity. Nature 445, 394-398, doi:10.1038/nature05490 
(2007). 
110 Haas, A. L., Bright, P. M. & Jackson, V. E. Functional diversity among 
putative E2 isozymes in the mechanism of ubiquitin-histone ligation. J Biol 
Chem 263, 13268-13275 (1988). 
111 Wang, J. et al. The intrinsic affinity between E2 and the Cys domain of E1 
in ubiquitin-like modifications. Mol Cell 27, 228-237, 
doi:10.1016/j.molcel.2007.05.023 (2007). 
112 Finley, D., Ciechanover, A. & Varshavsky, A. Thermolability of ubiquitin-
activating enzyme from the mammalian cell cycle mutant ts85. Cell 37, 
43-55 (1984). 
113 Ciechanover, A., Finley, D. & Varshavsky, A. Mammalian cell cycle mutant 
defective in intracellular protein degradation and ubiquitin-protein 
conjugation. Prog Clin Biol Res 180, 17-31 (1985). 
114 Schlabach, M. R. et al. Cancer proliferation gene discovery through 
functional genomics. Science 319, 620-624, doi:10.1126/science.1149200 
(2008). 
115 Kulkarni, M. & Smith, H. E. E1 ubiquitin-activating enzyme UBA-1 plays 
multiple roles throughout C. elegans development. PLoS Genet 4, 
e1000131, doi:10.1371/journal.pgen.1000131 (2008). 
116 Stewart, M. D., Ritterhoff, T., Klevit, R. E. & Brzovic, P. S. E2 enzymes: more 
than just middle men. Cell Res 26, 423-440, doi:10.1038/cr.2016.35 
(2016). 
117 Wiener, R. et al. E2 ubiquitin-conjugating enzymes regulate the 
deubiquitinating activity of OTUB1. Nat Struct Mol Biol 20, 1033-1039, 
252 
 
doi:10.1038/nsmb.2655 (2013). 
118 Pruneda, J. N. et al. E2~Ub conjugates regulate the kinase activity of 
Shigella effector OspG during pathogenesis. EMBO J 33, 437-449, 
doi:10.1002/embj.201386386 (2014). 
119 Williams, C., van den Berg, M., Sprenger, R. R. & Distel, B. A conserved 
cysteine is essential for Pex4p-dependent ubiquitination of the 
peroxisomal import receptor Pex5p. J Biol Chem 282, 22534-22543, 
doi:10.1074/jbc.M702038200 (2007). 
120 Leon, S. & Subramani, S. A conserved cysteine residue of Pichia pastoris 
Pex20p is essential for its recycling from the peroxisome to the cytosol. J 
Biol Chem 282, 7424-7430, doi:10.1074/jbc.M611627200 (2007). 
121 Wenzel, D. M., Lissounov, A., Brzovic, P. S. & Klevit, R. E. UBCH7 reactivity 
profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 474, 
105-108, doi:10.1038/nature09966 (2011). 
122 Wang, X. et al. Ube2j2 ubiquitinates hydroxylated amino acids on ER-
associated degradation substrates. J Cell Biol 187, 655-668, 
doi:10.1083/jcb.200908036 (2009). 
123 Zheng, N., Wang, P., Jeffrey, P. D. & Pavletich, N. P. Structure of a c-Cbl-
UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 
102, 533-539 (2000). 
124 Brzovic, P. S. et al. Binding and recognition in the assembly of an active 
BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A 100, 
5646-5651, doi:10.1073/pnas.0836054100 (2003). 
125 Plechanovova, A., Jaffray, E. G., Tatham, M. H., Naismith, J. H. & Hay, R. T. 
Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. 
Nature 489, 115-120, doi:10.1038/nature11376 (2012). 
126 Dou, H., Buetow, L., Sibbet, G. J., Cameron, K. & Huang, D. T. BIRC7-E2 
ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer 
by a RING dimer. Nat Struct Mol Biol 19, 876-883, doi:10.1038/nsmb.2379 
(2012). 
127 Soss, S. E., Klevit, R. E. & Chazin, W. J. Activation of UbcH5c~Ub is the 
result of a shift in interdomain motions of the conjugate bound to U-box 
E3 ligase E4B. Biochemistry 52, 2991-2999, doi:10.1021/bi3015949 
(2013). 
128 Kamadurai, H. B. et al. Insights into ubiquitin transfer cascades from a 
structure of a UbcH5B approximately ubiquitin-HECT(NEDD4L) complex. 
Mol Cell 36, 1095-1102, doi:10.1016/j.molcel.2009.11.010 (2009). 
129 Lechtenberg, B. C. et al. Structure of a HOIP/E2~ubiquitin complex reveals 
253 
 
RBR E3 ligase mechanism and regulation. Nature 529, 546-550, 
doi:10.1038/nature16511 (2016). 
130 Buetow, L. et al. Activation of a primed RING E3-E2-ubiquitin complex by 
non-covalent ubiquitin. Mol Cell 58, 297-310, 
doi:10.1016/j.molcel.2015.02.017 (2015). 
131 Ranaweera, R. S. & Yang, X. Auto-ubiquitination of Mdm2 enhances its 
substrate ubiquitin ligase activity. J Biol Chem 288, 18939-18946, 
doi:10.1074/jbc.M113.454470 (2013). 
132 Sakata, E. et al. Crystal structure of UbcH5b~ubiquitin intermediate: 
insight into the formation of the self-assembled E2~Ub conjugates. 
Structure 18, 138-147, doi:10.1016/j.str.2009.11.007 (2010). 
133 Nguyen, L. et al. The ubiquitin-conjugating enzyme, UbcM2, is restricted 
to monoubiquitylation by a two-fold mechanism that involves backside 
residues of E2 and Lys48 of ubiquitin. Biochemistry 53, 4004-4014, 
doi:10.1021/bi500072v (2014). 
134 Machida, Y. J. et al. UBE2T is the E2 in the Fanconi anemia pathway and 
undergoes negative autoregulation. Mol Cell 23, 589-596, 
doi:10.1016/j.molcel.2006.06.024 (2006). 
135 Schumacher, F. R., Wilson, G. & Day, C. L. The N-terminal extension of 
UBE2E ubiquitin-conjugating enzymes limits chain assembly. J Mol Biol 
425, 4099-4111, doi:10.1016/j.jmb.2013.06.039 (2013). 
136 Freemont, P. S., Hanson, I. M. & Trowsdale, J. A novel cysteine-rich 
sequence motif. Cell 64, 483-484 (1991). 
137 Buetow, L. & Huang, D. T. Structural insights into the catalysis and 
regulation of E3 ubiquitin ligases. Nat Rev Mol Cell Biol 17, 626-642, 
doi:10.1038/nrm.2016.91 (2016). 
138 Ohi, M. D., Vander Kooi, C. W., Rosenberg, J. A., Chazin, W. J. & Gould, K. L. 
Structural insights into the U-box, a domain associated with multi-
ubiquitination. Nat Struct Biol 10, 250-255, doi:10.1038/nsb906 (2003). 
139 Aravind, L. & Koonin, E. V. The U box is a modified RING finger - a common 
domain in ubiquitination. Curr Biol 10, R132-134 (2000). 
140 Li, W. et al. Genome-wide and functional annotation of human E3 
ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the 
organelle's dynamics and signaling. PLoS One 3, e1487, 
doi:10.1371/journal.pone.0001487 (2008). 
141 Dominguez, C. et al. Structural model of the UbcH5B/CNOT4 complex 
revealed by combining NMR, mutagenesis, and docking approaches. 
Structure 12, 633-644, doi:10.1016/j.str.2004.03.004 (2004). 
254 
 
142 Mace, P. D. et al. Structures of the cIAP2 RING domain reveal 
conformational changes associated with ubiquitin-conjugating enzyme 
(E2) recruitment. J Biol Chem 283, 31633-31640, 
doi:10.1074/jbc.M804753200 (2008). 
143 Liew, C. W., Sun, H., Hunter, T. & Day, C. L. RING domain dimerization is 
essential for RNF4 function. Biochem J 431, 23-29, 
doi:10.1042/BJ20100957 (2010). 
144 Yin, Q. et al. E2 interaction and dimerization in the crystal structure of 
TRAF6. Nat Struct Mol Biol 16, 658-666, doi:10.1038/nsmb.1605 (2009). 
145 Xu, Z. et al. Interactions between the quality control ubiquitin ligase CHIP 
and ubiquitin conjugating enzymes. BMC Struct Biol 8, 26, 
doi:10.1186/1472-6807-8-26 (2008). 
146 Vander Kooi, C. W. et al. The Prp19 U-box crystal structure suggests a 
common dimeric architecture for a class of oligomeric E3 ubiquitin ligases. 
Biochemistry 45, 121-130, doi:10.1021/bi051787e (2006). 
147 de Moura, T. R. et al. Prp19/Pso4 Is an Autoinhibited Ubiquitin Ligase 
Activated by Stepwise Assembly of Three Splicing Factors. Mol Cell 69, 
979-992 e976, doi:10.1016/j.molcel.2018.02.022 (2018). 
148 Zhang, M. et al. Chaperoned ubiquitylation--crystal structures of the CHIP 
U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell 20, 
525-538, doi:10.1016/j.molcel.2005.09.023 (2005). 
149 Joukov, V., Chen, J., Fox, E. A., Green, J. B. & Livingston, D. M. Functional 
communication between endogenous BRCA1 and its partner, BARD1, 
during Xenopus laevis development. Proc Natl Acad Sci U S A 98, 12078-
12083, doi:10.1073/pnas.211427098 (2001). 
150 Brzovic, P. S., Rajagopal, P., Hoyt, D. W., King, M. C. & Klevit, R. E. Structure 
of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 8, 
833-837, doi:10.1038/nsb1001-833 (2001). 
151 Linke, K. et al. Structure of the MDM2/MDMX RING domain heterodimer 
reveals dimerization is required for their ubiquitylation in trans. Cell Death 
Differ 15, 841-848, doi:10.1038/sj.cdd.4402309 (2008). 
152 Lydeard, J. R., Schulman, B. A. & Harper, J. W. Building and remodelling 
Cullin-RING E3 ubiquitin ligases. EMBO Rep 14, 1050-1061, 
doi:10.1038/embor.2013.173 (2013). 
153 Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING 
ubiquitin ligases. Nat Rev Mol Cell Biol 6, 9-20, doi:10.1038/nrm1547 
(2005). 
154 Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin 
255 
 
ligase complex. Nature 416, 703-709, doi:10.1038/416703a (2002). 
155 Schulman, B. A. et al. Insights into SCF ubiquitin ligases from the structure 
of the Skp1-Skp2 complex. Nature 408, 381-386, doi:10.1038/35042620 
(2000). 
156 Pruneda, J. N., Stoll, K. E., Bolton, L. J., Brzovic, P. S. & Klevit, R. E. 
Ubiquitin in motion: structural studies of the ubiquitin-conjugating 
enzyme approximately ubiquitin conjugate. Biochemistry 50, 1624-1633, 
doi:10.1021/bi101913m (2011). 
157 Saha, A., Lewis, S., Kleiger, G., Kuhlman, B. & Deshaies, R. J. Essential role 
for ubiquitin-ubiquitin-conjugating enzyme interaction in ubiquitin 
discharge from Cdc34 to substrate. Mol Cell 42, 75-83, 
doi:10.1016/j.molcel.2011.03.016 (2011). 
158 Plechanovova, A. et al. Mechanism of ubiquitylation by dimeric RING 
ligase RNF4. Nat Struct Mol Biol 18, 1052-1059, doi:10.1038/nsmb.2108 
(2011). 
159 Pruneda, J. N. et al. Structure of an E3:E2~Ub complex reveals an 
allosteric mechanism shared among RING/U-box ligases. Mol Cell 47, 933-
942, doi:10.1016/j.molcel.2012.07.001 (2012). 
160 Hamilton, K. S. et al. Structure of a conjugating enzyme-ubiquitin 
thiolester intermediate reveals a novel role for the ubiquitin tail. Structure 
9, 897-904 (2001). 
161 Wickliffe, K. E., Lorenz, S., Wemmer, D. E., Kuriyan, J. & Rape, M. The 
mechanism of linkage-specific ubiquitin chain elongation by a single-
subunit E2. Cell 144, 769-781, doi:10.1016/j.cell.2011.01.035 (2011). 
162 Dou, H. et al. Structural basis for autoinhibition and phosphorylation-
dependent activation of c-Cbl. Nat Struct Mol Biol 19, 184-192, 
doi:10.1038/nsmb.2231 (2012). 
163 Dou, H., Buetow, L., Sibbet, G. J., Cameron, K. & Huang, D. T. Essentiality 
of a non-RING element in priming donor ubiquitin for catalysis by a 
monomeric E3. Nat Struct Mol Biol 20, 982-986, doi:10.1038/nsmb.2621 
(2013). 
164 Ben-Saadon, R., Zaaroor, D., Ziv, T. & Ciechanover, A. The polycomb 
protein Ring1B generates self atypical mixed ubiquitin chains required for 
its in vitro histone H2A ligase activity. Mol Cell 24, 701-711, 
doi:10.1016/j.molcel.2006.10.022 (2006). 
165 Saha, A. & Deshaies, R. J. Multimodal activation of the ubiquitin ligase SCF 
by Nedd8 conjugation. Mol Cell 32, 21-31, 
doi:10.1016/j.molcel.2008.08.021 (2008). 
256 
 
166 Deshaies, R. J., Emberley, E. D. & Saha, A. Control of cullin-ring ubiquitin 
ligase activity by nedd8. Subcell Biochem 54, 41-56, doi:10.1007/978-1-
4419-6676-6_4 (2010). 
167 Angers, S. et al. Molecular architecture and assembly of the DDB1-CUL4A 
ubiquitin ligase machinery. Nature 443, 590-593, 
doi:10.1038/nature05175 (2006). 
168 Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. A family of 
proteins structurally and functionally related to the E6-AP ubiquitin-
protein ligase. Proc Natl Acad Sci U S A 92, 2563-2567 (1995). 
169 Wang, M. & Pickart, C. M. Different HECT domain ubiquitin ligases employ 
distinct mechanisms of polyubiquitin chain synthesis. EMBO J 24, 4324-
4333, doi:10.1038/sj.emboj.7600895 (2005). 
170 Lorenz, S. Structural mechanisms of HECT-type ubiquitin ligases. Biol 
Chem 399, 127-145, doi:10.1515/hsz-2017-0184 (2018). 
171 Ingham, R. J., Gish, G. & Pawson, T. The Nedd4 family of E3 ubiquitin 
ligases: functional diversity within a common modular architecture. 
Oncogene 23, 1972-1984, doi:10.1038/sj.onc.1207436 (2004). 
172 Rotin, D. & Kumar, S. Physiological functions of the HECT family of 
ubiquitin ligases. Nat Rev Mol Cell Biol 10, 398-409, doi:10.1038/nrm2690 
(2009). 
173 Coussens, L. et al. Multiple, distinct forms of bovine and human protein 
kinase C suggest diversity in cellular signaling pathways. Science 233, 859-
866 (1986). 
174 Clark, J. D. et al. A novel arachidonic acid-selective cytosolic PLA2 contains 
a Ca(2+)-dependent translocation domain with homology to PKC and GAP. 
Cell 65, 1043-1051 (1991). 
175 Perin, M. S., Brose, N., Jahn, R. & Sudhof, T. C. Domain structure of 
synaptotagmin (p65). J Biol Chem 266, 623-629 (1991). 
176 Sutton, R. B., Davletov, B. A., Berghuis, A. M., Sudhof, T. C. & Sprang, S. R. 
Structure of the first C2 domain of synaptotagmin I: a novel 
Ca2+/phospholipid-binding fold. Cell 80, 929-938 (1995). 
177 Essen, L. O., Perisic, O., Cheung, R., Katan, M. & Williams, R. L. Crystal 
structure of a mammalian phosphoinositide-specific phospholipase C 
delta. Nature 380, 595-602, doi:10.1038/380595a0 (1996). 
178 Plant, P. J., Yeger, H., Staub, O., Howard, P. & Rotin, D. The C2 domain of 
the ubiquitin protein ligase Nedd4 mediates Ca2+-dependent plasma 
membrane localization. J Biol Chem 272, 32329-32336 (1997). 
179 Zarrinpar, A. & Lim, W. A. Converging on proline: the mechanism of WW 
257 
 
domain peptide recognition. Nat Struct Biol 7, 611-613, 
doi:10.1038/77891 (2000). 
180 Macias, M. J., Wiesner, S. & Sudol, M. WW and SH3 domains, two 
different scaffolds to recognize proline-rich ligands. FEBS Lett 513, 30-37 
(2002). 
181 Chen, H. I. & Sudol, M. The WW domain of Yes-associated protein binds a 
proline-rich ligand that differs from the consensus established for Src 
homology 3-binding modules. Proc Natl Acad Sci U S A 92, 7819-7823 
(1995). 
182 Bedford, M. T., Chan, D. C. & Leder, P. FBP WW domains and the Abl SH3 
domain bind to a specific class of proline-rich ligands. EMBO J 16, 2376-
2383, doi:10.1093/emboj/16.9.2376 (1997). 
183 Lu, P. J., Zhou, X. Z., Shen, M. & Lu, K. P. Function of WW domains as 
phosphoserine- or phosphothreonine-binding modules. Science 283, 
1325-1328 (1999). 
184 Persaud, A. et al. Comparison of substrate specificity of the ubiquitin 
ligases Nedd4 and Nedd4-2 using proteome arrays. Mol Syst Biol 5, 333, 
doi:10.1038/msb.2009.85 (2009). 
185 Fajner, V., Maspero, E. & Polo, S. Targeting HECT-type E3 ligases - insights 
from catalysis, regulation and inhibitors. FEBS Lett 591, 2636-2647, 
doi:10.1002/1873-3468.12775 (2017). 
186 Yoshida, M. et al. Poly(A) binding protein (PABP) homeostasis is mediated 
by the stability of its inhibitor, Paip2. EMBO J 25, 1934-1944, 
doi:10.1038/sj.emboj.7601079 (2006). 
187 Huang, L. et al. Structure of an E6AP-UbcH7 complex: insights into 
ubiquitination by the E2-E3 enzyme cascade. Science 286, 1321-1326 
(1999). 
188 Salvat, C., Wang, G., Dastur, A., Lyon, N. & Huibregtse, J. M. The -4 
phenylalanine is required for substrate ubiquitination catalyzed by HECT 
ubiquitin ligases. J Biol Chem 279, 18935-18943, 
doi:10.1074/jbc.M312201200 (2004). 
189 Kamadurai, H. B. et al. Mechanism of ubiquitin ligation and lysine 
prioritization by a HECT E3. Elife 2, e00828, doi:10.7554/eLife.00828 
(2013). 
190 Nuber, U. & Scheffner, M. Identification of determinants in E2 ubiquitin-
conjugating enzymes required for hect E3 ubiquitin-protein ligase 
interaction. J Biol Chem 274, 7576-7582 (1999). 
191 Fotia, A. B., Cook, D. I. & Kumar, S. The ubiquitin-protein ligases Nedd4 
258 
 
and Nedd4-2 show similar ubiquitin-conjugating enzyme specificities. Int J 
Biochem Cell Biol 38, 472-479, doi:10.1016/j.biocel.2005.11.006 (2006). 
192 Debonneville, C. & Staub, O. Participation of the ubiquitin-conjugating 
enzyme UBE2E3 in Nedd4-2-dependent regulation of the epithelial Na+ 
channel. Mol Cell Biol 24, 2397-2409 (2004). 
193 Maspero, E. et al. Structure of a ubiquitin-loaded HECT ligase reveals the 
molecular basis for catalytic priming. Nat Struct Mol Biol 20, 696-701, 
doi:10.1038/nsmb.2566 (2013). 
194 Maspero, E. et al. Structure of the HECT:ubiquitin complex and its role in 
ubiquitin chain elongation. EMBO Rep 12, 342-349, 
doi:10.1038/embor.2011.21 (2011). 
195 Kim, H. C., Steffen, A. M., Oldham, M. L., Chen, J. & Huibregtse, J. M. 
Structure and function of a HECT domain ubiquitin-binding site. EMBO 
Rep 12, 334-341, doi:10.1038/embor.2011.23 (2011). 
196 Kim, H. C. & Huibregtse, J. M. Polyubiquitination by HECT E3s and the 
determinants of chain type specificity. Mol Cell Biol 29, 3307-3318, 
doi:10.1128/MCB.00240-09 (2009). 
197 Mund, T. & Pelham, H. R. Control of the activity of WW-HECT domain E3 
ubiquitin ligases by NDFIP proteins. EMBO Rep 10, 501-507, 
doi:10.1038/embor.2009.30 (2009). 
198 Riling, C. et al. Itch WW Domains Inhibit Its E3 Ubiquitin Ligase Activity by 
Blocking E2-E3 Ligase Trans-thiolation. J Biol Chem 290, 23875-23887, 
doi:10.1074/jbc.M115.649269 (2015). 
199 Gallagher, E., Gao, M., Liu, Y. C. & Karin, M. Activation of the E3 ubiquitin 
ligase Itch through a phosphorylation-induced conformational change. 
Proc Natl Acad Sci U S A 103, 1717-1722, doi:10.1073/pnas.0510664103 
(2006). 
200 Wiesner, S. et al. Autoinhibition of the HECT-type ubiquitin ligase Smurf2 
through its C2 domain. Cell 130, 651-662, doi:10.1016/j.cell.2007.06.050 
(2007). 
201 Kavsak, P. et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that 
targets the TGF beta receptor for degradation. Mol Cell 6, 1365-1375 
(2000). 
202 Ogunjimi, A. A. et al. Regulation of Smurf2 ubiquitin ligase activity by 
anchoring the E2 to the HECT domain. Mol Cell 19, 297-308, 
doi:10.1016/j.molcel.2005.06.028 (2005). 
203 Aragon, E. et al. Structural basis for the versatile interactions of Smad7 
with regulator WW domains in TGF-beta Pathways. Structure 20, 1726-
259 
 
1736, doi:10.1016/j.str.2012.07.014 (2012). 
204 Chen, Z. et al. A Tunable Brake for HECT Ubiquitin Ligases. Mol Cell 66, 
345-357 e346, doi:10.1016/j.molcel.2017.03.020 (2017). 
205 Zhu, K. et al. Allosteric auto-inhibition and activation of the Nedd4 family 
E3 ligase Itch. EMBO Rep 18, 1618-1630, doi:10.15252/embr.201744454 
(2017). 
206 Wang, J. et al. Calcium activates Nedd4 E3 ubiquitin ligases by releasing 
the C2 domain-mediated auto-inhibition. J Biol Chem 285, 12279-12288, 
doi:10.1074/jbc.M109.086405 (2010). 
207 Escobedo, A. et al. Structural basis of the activation and degradation 
mechanisms of the E3 ubiquitin ligase Nedd4L. Structure 22, 1446-1457, 
doi:10.1016/j.str.2014.08.016 (2014). 
208 French, M. E., Kretzmann, B. R. & Hicke, L. Regulation of the RSP5 
ubiquitin ligase by an intrinsic ubiquitin-binding site. J Biol Chem 284, 
12071-12079, doi:10.1074/jbc.M901106200 (2009). 
209 French, M. E. et al. Mechanism of ubiquitin chain synthesis employed by a 
HECT domain ubiquitin ligase. J Biol Chem 292, 10398-10413, 
doi:10.1074/jbc.M117.789479 (2017). 
210 Ogunjimi, A. A. et al. The ubiquitin binding region of the Smurf HECT 
domain facilitates polyubiquitylation and binding of ubiquitylated 
substrates. J Biol Chem 285, 6308-6315, doi:10.1074/jbc.M109.044537 
(2010). 
211 Kathman, S. G. et al. A Small Molecule That Switches a Ubiquitin Ligase 
From a Processive to a Distributive Enzymatic Mechanism. J Am Chem Soc 
137, 12442-12445, doi:10.1021/jacs.5b06839 (2015). 
212 Zhang, W. et al. System-Wide Modulation of HECT E3 Ligases with 
Selective Ubiquitin Variant Probes. Mol Cell 62, 121-136, 
doi:10.1016/j.molcel.2016.02.005 (2016). 
213 Kuhnle, S. et al. Physical and functional interaction of the HECT ubiquitin-
protein ligases E6AP and HERC2. J Biol Chem 286, 19410-19416, 
doi:10.1074/jbc.M110.205211 (2011). 
214 Huibregtse, J. M., Scheffner, M. & Howley, P. M. A cellular protein 
mediates association of p53 with the E6 oncoprotein of human 
papillomavirus types 16 or 18. EMBO J 10, 4129-4135 (1991). 
215 Martinez-Zapien, D. et al. Structure of the E6/E6AP/p53 complex required 
for HPV-mediated degradation of p53. Nature 529, 541-545, 
doi:10.1038/nature16481 (2016). 
216 Ronchi, V. P., Klein, J. M., Edwards, D. J. & Haas, A. L. The active form of 
260 
 
E6-associated protein (E6AP)/UBE3A ubiquitin ligase is an oligomer. J Biol 
Chem 289, 1033-1048, doi:10.1074/jbc.M113.517805 (2014). 
217 Sander, B., Xu, W., Eilers, M., Popov, N. & Lorenz, S. A conformational 
switch regulates the ubiquitin ligase HUWE1. Elife 6, 
doi:10.7554/eLife.21036 (2017). 
218 Cao, X. R. et al. Nedd4 controls animal growth by regulating IGF-1 
signaling. Sci Signal 1, ra5, doi:10.1126/scisignal.1160940 (2008). 
219 Kawabe, H. et al. Regulation of Rap2A by the ubiquitin ligase Nedd4-1 
controls neurite development. Neuron 65, 358-372, 
doi:10.1016/j.neuron.2010.01.007 (2010). 
220 Drinjakovic, J. et al. E3 ligase Nedd4 promotes axon branching by 
downregulating PTEN. Neuron 65, 341-357, 
doi:10.1016/j.neuron.2010.01.017 (2010). 
221 Fouladkou, F. et al. The ubiquitin ligase Nedd4-1 is required for heart 
development and is a suppressor of thrombospondin-1. J Biol Chem 285, 
6770-6780, doi:10.1074/jbc.M109.082347 (2010). 
222 Boase, N. A. et al. Respiratory distress and perinatal lethality in Nedd4-2-
deficient mice. Nat Commun 2, 287, doi:10.1038/ncomms1284 (2011). 
223 Zhi, X. & Chen, C. WWP1: a versatile ubiquitin E3 ligase in signaling and 
diseases. Cell Mol Life Sci 69, 1425-1434, doi:10.1007/s00018-011-0871-7 
(2012). 
224 Zhao, L. et al. Tumor necrosis factor inhibits mesenchymal stem cell 
differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem 
Cells 29, 1601-1610, doi:10.1002/stem.703 (2011). 
225 Xu, H. et al. WWP2 promotes degradation of transcription factor OCT4 in 
human embryonic stem cells. Cell Res 19, 561-573, 
doi:10.1038/cr.2009.31 (2009). 
226 Yamashita, M. et al. Ubiquitin ligase Smurf1 controls osteoblast activity 
and bone homeostasis by targeting MEKK2 for degradation. Cell 121, 101-
113, doi:10.1016/j.cell.2005.01.035 (2005). 
227 Bekker-Jensen, S. et al. HERC2 coordinates ubiquitin-dependent assembly 
of DNA repair factors on damaged chromosomes. Nat Cell Biol 12, 80-86; 
sup pp 81-12, doi:10.1038/ncb2008 (2010). 
228 Wu, W. et al. HERC2 is an E3 ligase that targets BRCA1 for degradation. 
Cancer Res 70, 6384-6392, doi:10.1158/0008-5472.CAN-10-1304 (2010). 
229 Yi, J. J. et al. An Autism-Linked Mutation Disables Phosphorylation Control 
of UBE3A. Cell 162, 795-807, doi:10.1016/j.cell.2015.06.045 (2015). 
230 Yang, Y. et al. E3 ubiquitin ligase Mule ubiquitinates Miz1 and is required 
261 
 
for TNFalpha-induced JNK activation. Proc Natl Acad Sci U S A 107, 13444-
13449, doi:10.1073/pnas.0913690107 (2010). 
231 Zhong, Q., Gao, W., Du, F. & Wang, X. Mule/ARF-BP1, a BH3-only E3 
ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates 
apoptosis. Cell 121, 1085-1095, doi:10.1016/j.cell.2005.06.009 (2005). 
232 Spratt, D. E., Walden, H. & Shaw, G. S. RBR E3 ubiquitin ligases: new 
structures, new insights, new questions. Biochem J 458, 421-437, 
doi:10.1042/BJ20140006 (2014). 
233 van der Reijden, B. A., Erpelinck-Verschueren, C. A., Lowenberg, B. & 
Jansen, J. H. TRIADs: a new class of proteins with a novel cysteine-rich 
signature. Protein Sci 8, 1557-1561, doi:10.1110/ps.8.7.1557 (1999). 
234 Chaugule, V. K. et al. Autoregulation of Parkin activity through its 
ubiquitin-like domain. EMBO J 30, 2853-2867, 
doi:10.1038/emboj.2011.204 (2011). 
235 Kelsall, I. R. et al. TRIAD1 and HHARI bind to and are activated by distinct 
neddylated Cullin-RING ligase complexes. EMBO J 32, 2848-2860, 
doi:10.1038/emboj.2013.209 (2013). 
236 Wauer, T. & Komander, D. Structure of the human Parkin ligase domain in 
an autoinhibited state. EMBO J 32, 2099-2112, 
doi:10.1038/emboj.2013.125 (2013). 
237 Duda, D. M. et al. Structure of HHARI, a RING-IBR-RING ubiquitin ligase: 
autoinhibition of an Ariadne-family E3 and insights into ligation 
mechanism. Structure 21, 1030-1041, doi:10.1016/j.str.2013.04.019 
(2013). 
238 Dove, K. K. & Klevit, R. E. RING-Between-RING E3 Ligases: Emerging 
Themes amid the Variations. J Mol Biol 429, 3363-3375, 
doi:10.1016/j.jmb.2017.08.008 (2017). 
239 Stieglitz, B. et al. Structural basis for ligase-specific conjugation of linear 
ubiquitin chains by HOIP. Nature 503, 422-426, doi:10.1038/nature12638 
(2013). 
240 Dove, K. K. et al. Structural Studies of HHARI/UbcH7 approximately Ub 
Reveal Unique E2 approximately Ub Conformational Restriction by RBR 
RING1. Structure 25, 890-900 e895, doi:10.1016/j.str.2017.04.013 (2017). 
241 Smit, J. J. et al. The E3 ligase HOIP specifies linear ubiquitin chain 
assembly through its RING-IBR-RING domain and the unique LDD 
extension. EMBO J 31, 3833-3844, doi:10.1038/emboj.2012.217 (2012). 
242 Stieglitz, B., Morris-Davies, A. C., Koliopoulos, M. G., Christodoulou, E. & 
Rittinger, K. LUBAC synthesizes linear ubiquitin chains via a thioester 
262 
 
intermediate. EMBO Rep 13, 840-846, doi:10.1038/embor.2012.105 
(2012). 
243 Dove, K. K., Stieglitz, B., Duncan, E. D., Rittinger, K. & Klevit, R. E. 
Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. 
EMBO Rep 17, 1221-1235, doi:10.15252/embr.201642641 (2016). 
244 Yuan, L., Lv, Z., Atkison, J. H. & Olsen, S. K. Structural insights into the 
mechanism and E2 specificity of the RBR E3 ubiquitin ligase HHARI. Nat 
Commun 8, 211, doi:10.1038/s41467-017-00272-6 (2017). 
245 Trempe, J. F. et al. Structure of parkin reveals mechanisms for ubiquitin 
ligase activation. Science 340, 1451-1455, doi:10.1126/science.1237908 
(2013). 
246 Fiesel, F. C. et al. Structural and Functional Impact of Parkinson Disease-
Associated Mutations in the E3 Ubiquitin Ligase Parkin. Hum Mutat 36, 
774-786, doi:10.1002/humu.22808 (2015). 
247 Kumar, A. et al. Parkin-phosphoubiquitin complex reveals cryptic 
ubiquitin-binding site required for RBR ligase activity. Nat Struct Mol Biol 
24, 475-483, doi:10.1038/nsmb.3400 (2017). 
248 Jansen, E. F., Curl, A. L. & Balls, A. K. Reaction of alpha-chymotrypsin with 
analogues of diisopropyl fluorophosphate. J Biol Chem 190, 557-561 
(1951). 
249 Kazlauskaite, A. et al. Phosphorylation of Parkin at Serine65 is essential 
for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 
ligase activity. Open Biol 4, 130213, doi:10.1098/rsob.130213 (2014). 
250 Sauve, V. et al. A Ubl/ubiquitin switch in the activation of Parkin. EMBO J 
34, 2492-2505, doi:10.15252/embj.201592237 (2015). 
251 Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function 
and interacts genetically with parkin. Nature 441, 1162-1166, 
doi:10.1038/nature04779 (2006). 
252 Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is 
complemented by parkin. Nature 441, 1157-1161, 
doi:10.1038/nature04788 (2006). 
253 Winklhofer, K. F. & Haass, C. Mitochondrial dysfunction in Parkinson's 
disease. Biochim Biophys Acta 1802, 29-44, 
doi:10.1016/j.bbadis.2009.08.013 (2010). 
254 Yamano, K. & Youle, R. J. PINK1 is degraded through the N-end rule 
pathway. Autophagy 9, 1758-1769, doi:10.4161/auto.24633 (2013). 
255 Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited 
selectively to impaired mitochondria and promotes their autophagy. J Cell 
263 
 
Biol 183, 795-803, doi:10.1083/jcb.200809125 (2008). 
256 Narendra, D. P. et al. PINK1 is selectively stabilized on impaired 
mitochondria to activate Parkin. PLoS Biol 8, e1000298, 
doi:10.1371/journal.pbio.1000298 (2010). 
257 Vives-Bauza, C. et al. PINK1-dependent recruitment of Parkin to 
mitochondria in mitophagy. Proc Natl Acad Sci U S A 107, 378-383, 
doi:10.1073/pnas.0911187107 (2010). 
258 Kazlauskaite, A. et al. Binding to serine 65-phosphorylated ubiquitin 
primes Parkin for optimal PINK1-dependent phosphorylation and 
activation. EMBO Rep 16, 939-954, doi:10.15252/embr.201540352 (2015). 
259 Tang, M. Y. et al. Structure-guided mutagenesis reveals a hierarchical 
mechanism of Parkin activation. Nat Commun 8, 14697, 
doi:10.1038/ncomms14697 (2017). 
260 Yagi, H. et al. A non-canonical UBA-UBL interaction forms the linear-
ubiquitin-chain assembly complex. EMBO Rep 13, 462-468, 
doi:10.1038/embor.2012.24 (2012). 
261 Liu, J. et al. Structural Insights into SHARPIN-Mediated Activation of HOIP 
for the Linear Ubiquitin Chain Assembly. Cell Rep 21, 27-36, 
doi:10.1016/j.celrep.2017.09.031 (2017). 
262 Elliott, P. R. et al. Molecular basis and regulation of OTULIN-LUBAC 
interaction. Mol Cell 54, 335-348, doi:10.1016/j.molcel.2014.03.018 
(2014). 
263 Elliott, P. R. & Komander, D. Regulation of Met1-linked polyubiquitin 
signalling by the deubiquitinase OTULIN. FEBS J 283, 39-53, 
doi:10.1111/febs.13547 (2016). 
264 Elliott, P. R. et al. SPATA2 Links CYLD to LUBAC, Activates CYLD, and 
Controls LUBAC Signaling. Mol Cell 63, 990-1005, 
doi:10.1016/j.molcel.2016.08.001 (2016). 
265 Scott, D. C. et al. Two Distinct Types of E3 Ligases Work in Unison to 
Regulate Substrate Ubiquitylation. Cell 166, 1198-1214 e1124, 
doi:10.1016/j.cell.2016.07.027 (2016). 
266 Bernardini, J. P., Lazarou, M. & Dewson, G. Parkin and mitophagy in 
cancer. Oncogene 36, 1315-1327, doi:10.1038/onc.2016.302 (2017). 
267 Harper, J. W., Ordureau, A. & Heo, J. M. Building and decoding ubiquitin 
chains for mitophagy. Nat Rev Mol Cell Biol 19, 93-108, 
doi:10.1038/nrm.2017.129 (2018). 
268 Imai, Y. et al. An unfolded putative transmembrane polypeptide, which 
can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 
264 
 
891-902 (2001). 
269 Imai, Y. et al. CHIP is associated with Parkin, a gene responsible for familial 
Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 10, 
55-67 (2002). 
270 Gupta, A., Anjomani-Virmouni, S., Koundouros, N. & Poulogiannis, G. 
PARK2 loss promotes cancer progression via redox-mediated inactivation 
of PTEN. Mol Cell Oncol 4, e1329692, 
doi:10.1080/23723556.2017.1329692 (2017). 
271 Wahabi, K., Perwez, A. & Rizvi, M. A. Parkin in Parkinson's Disease and 
Cancer: a Double-Edged Sword. Mol Neurobiol, doi:10.1007/s12035-018-
0879-1 (2018). 
272 Tan, N. G. et al. Human homologue of ariadne promotes the 
ubiquitylation of translation initiation factor 4E homologous protein, 
4EHP. FEBS Lett 554, 501-504 (2003). 
273 Elmehdawi, F. et al. Human Homolog of Drosophila Ariadne (HHARI) is a 
marker of cellular proliferation associated with nuclear bodies. Exp Cell 
Res 319, 161-172, doi:10.1016/j.yexcr.2012.10.002 (2013). 
274 Ho, S. R., Lee, Y. J. & Lin, W. C. Regulation of RNF144A E3 Ubiquitin Ligase 
Activity by Self-association through Its Transmembrane Domain. J Biol 
Chem 290, 23026-23038, doi:10.1074/jbc.M115.645499 (2015). 
275 Ho, S. R., Mahanic, C. S., Lee, Y. J. & Lin, W. C. RNF144A, an E3 ubiquitin 
ligase for DNA-PKcs, promotes apoptosis during DNA damage. Proc Natl 
Acad Sci U S A 111, E2646-2655, doi:10.1073/pnas.1323107111 (2014). 
276 Zhang, Y., Liao, X. H., Xie, H. Y., Shao, Z. M. & Li, D. Q. RBR-type E3 
ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent 
degradation and regulates PARP inhibitor sensitivity in breast cancer cells. 
Oncotarget 8, 94505-94518, doi:10.18632/oncotarget.21784 (2017). 
277 Zhang, Y. et al. Epigenetic silencing of RNF144A expression in breast 
cancer cells through promoter hypermethylation and MBD4. Cancer Med, 
doi:10.1002/cam4.1324 (2018). 
278 Ariffin, J. K. et al. The E3 ubiquitin ligase RNF144B is LPS-inducible in 
human, but not mouse, macrophages and promotes inducible IL-1beta 
expression. J Leukoc Biol 100, 155-161, doi:10.1189/jlb.2AB0815-339R 
(2016). 
279 Lopez, J. & Tait, S. W. Killing the Killer: PARC/CUL9 promotes cell survival 
by destroying cytochrome C. Sci Signal 7, pe17, 
doi:10.1126/scisignal.2005619 (2014). 
280 Hishikawa, N. et al. Dorfin localizes to the ubiquitylated inclusions in 
265 
 
Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, 
and amyotrophic lateral sclerosis. Am J Pathol 163, 609-619 (2003). 
281 Ito, T. et al. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J 
Biol Chem 278, 29106-29114, doi:10.1074/jbc.M302763200 (2003). 
282 Le Quesne, J. P., Spriggs, K. A., Bushell, M. & Willis, A. E. Dysregulation of 
protein synthesis and disease. J Pathol 220, 140-151, 
doi:10.1002/path.2627 (2010). 
283 Paul, S. Dysfunction of the ubiquitin-proteasome system in multiple 
disease conditions: therapeutic approaches. Bioessays 30, 1172-1184, 
doi:10.1002/bies.20852 (2008). 
284 Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of 
the body. Annu Rev Immunol 27, 229-265, 
doi:10.1146/annurev.immunol.021908.132715 (2009). 
285 Appella, E. & Anderson, C. W. Post-translational modifications and 
activation of p53 by genotoxic stresses. Eur J Biochem 268, 2764-2772 
(2001). 
286 Giangrande, P. H., Kimbrel, E. A., Edwards, D. P. & McDonnell, D. P. The 
opposing transcriptional activities of the two isoforms of the human 
progesterone receptor are due to differential cofactor binding. Mol Cell 
Biol 20, 3102-3115 (2000). 
287 Twining, S. S. Regulation of proteolytic activity in tissues. Critical reviews 
in biochemistry and molecular biology 29, 315-383, 
doi:10.3109/10409239409083484 (1994). 
288 Sanman, L. E. & Bogyo, M. Activity-based profiling of proteases. Annu Rev 
Biochem 83, 249-273, doi:10.1146/annurev-biochem-060713-035352 
(2014). 
289 Kisselev, A. F., van der Linden, W. A. & Overkleeft, H. S. Proteasome 
inhibitors: an expanding army attacking a unique target. Chem Biol 19, 99-
115, doi:10.1016/j.chembiol.2012.01.003 (2012). 
290 Cravatt, B. F., Wright, A. T. & Kozarich, J. W. Activity-based protein 
profiling: from enzyme chemistry to proteomic chemistry. Annu Rev 
Biochem 77, 383-414, doi:10.1146/annurev.biochem.75.101304.124125 
(2008). 
291 Wright, M. H. & Sieber, S. A. Chemical proteomics approaches for 
identifying the cellular targets of natural products. Nat Prod Rep 33, 681-
708, doi:10.1039/c6np00001k (2016). 
292 Ostrowski, K. & Barnard, E. A. Application of isotopically labelled specific 
inhibitors as a method in enzyme cytochemistry. Exp Cell Res 25, 465-468 
266 
 
(1961). 
293 Liu, Y., Patricelli, M. P. & Cravatt, B. F. Activity-based protein profiling: the 
serine hydrolases. Proc Natl Acad Sci U S A 96, 14694-14699 (1999). 
294 Kobe, B. & Kemp, B. E. Active site-directed protein regulation. Nature 402, 
373-376, doi:10.1038/46478 (1999). 
295 Tipper, D. J. & Strominger, J. L. Mechanism of action of penicillins: a 
proposal based on their structural similarity to acyl-D-alanyl-D-alanine. 
Proc Natl Acad Sci U S A 54, 1133-1141 (1965). 
296 Suginaka, H., Blumberg, P. M. & Strominger, J. L. Multiple penicillin-
binding components in Bacillus subtilis, Bacillus cereus, Staphylococcus 
aureus, and Escherichia coli. J Biol Chem 247, 5279-5288 (1972). 
297 Iwaya, M., Goldman, R., Tipper, D. J., Feingold, B. & Strominger, J. L. 
Morphology of an Escherichia coli mutant with a temperature-dependent 
round cell shape. J Bacteriol 136, 1143-1158 (1978). 
298 Balls, A. K. & Jansen, E. F. Stoichiometric inhibition of chymotrypsin. Adv 
Enzymol Relat Subj Biochem 13, 321-343 (1952). 
299 Balls, A. K. & Jansen, E. F. Proteolytic enzymes. Annu Rev Biochem 21, 1-
28, doi:10.1146/annurev.bi.21.070152.000245 (1952). 
300 Powers, J. C., Asgian, J. L., Ekici, O. D. & James, K. E. Irreversible inhibitors 
of serine, cysteine, and threonine proteases. Chem Rev 102, 4639-4750 
(2002). 
301 Willems, L. I., Overkleeft, H. S. & van Kasteren, S. I. Current developments 
in activity-based protein profiling. Bioconjug Chem 25, 1181-1191, 
doi:10.1021/bc500208y (2014). 
302 Niphakis, M. J. & Cravatt, B. F. Enzyme inhibitor discovery by activity-
based protein profiling. Annu Rev Biochem 83, 341-377, 
doi:10.1146/annurev-biochem-060713-035708 (2014). 
303 Hewings, D. S., Flygare, J. A., Bogyo, M. & Wertz, I. E. Activity-based 
probes for the ubiquitin conjugation-deconjugation machinery: new 
chemistries, new tools, and new insights. FEBS J 284, 1555-1576, 
doi:10.1111/febs.14039 (2017). 
304 Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B. F. 
Activity-based probes for the proteomic profiling of metalloproteases. 
Proc Natl Acad Sci U S A 101, 10000-10005, 
doi:10.1073/pnas.0402784101 (2004). 
305 Hemelaar, J. et al. Chemistry-based functional proteomics: mechanism-
based activity-profiling tools for ubiquitin and ubiquitin-like specific 
proteases. J Proteome Res 3, 268-276 (2004). 
267 
 
306 Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel 
members of the deubiquitinating enzyme family. Chem Biol 9, 1149-1159 
(2002). 
307 Kidd, D., Liu, Y. & Cravatt, B. F. Profiling serine hydrolase activities in 
complex proteomes. Biochemistry 40, 4005-4015 (2001). 
308 Chan, E. W., Chattopadhaya, S., Panicker, R. C., Huang, X. & Yao, S. Q. 
Developing photoactive affinity probes for proteomic profiling: 
hydroxamate-based probes for metalloproteases. J Am Chem Soc 126, 
14435-14446, doi:10.1021/ja047044i (2004). 
309 Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K. & Martoglio, B. 
Identification of signal peptide peptidase, a presenilin-type aspartic 
protease. Science 296, 2215-2218, doi:10.1126/science.1070925 (2002). 
310 Yang, P. & Liu, K. Activity-based protein profiling: recent advances in probe 
development and applications. Chembiochem 16, 712-724, 
doi:10.1002/cbic.201402582 (2015). 
311 Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using 
isotope-coded affinity tags. Nat Biotechnol 17, 994-999, 
doi:10.1038/13690 (1999). 
312 Weerapana, E. et al. Quantitative reactivity profiling predicts functional 
cysteines in proteomes. Nature 468, 790-795, doi:10.1038/nature09472 
(2010). 
313 Puri, A. W., Broz, P., Shen, A., Monack, D. M. & Bogyo, M. Caspase-1 
activity is required to bypass macrophage apoptosis upon Salmonella 
infection. Nat Chem Biol 8, 745-747, doi:10.1038/nchembio.1023 (2012). 
314 Edgington, L. E., Verdoes, M. & Bogyo, M. Functional imaging of 
proteases: recent advances in the design and application of substrate-
based and activity-based probes. Curr Opin Chem Biol 15, 798-805, 
doi:10.1016/j.cbpa.2011.10.012 (2011). 
315 Fonovic, M. & Bogyo, M. Activity based probes for proteases: applications 
to biomarker discovery, molecular imaging and drug screening. Curr 
Pharm Des 13, 253-261 (2007). 
316 Vickers, C. J., Gonzalez-Paez, G. E. & Wolan, D. W. Selective detection of 
caspase-3 versus caspase-7 using activity-based probes with key unnatural 
amino acids. ACS Chem Biol 8, 1558-1566, doi:10.1021/cb400209w 
(2013). 
317 Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded 
combinatorial chemical libraries based on bicyclic peptides. Nat Chem Biol 
5, 502-507, doi:10.1038/nchembio.184 (2009). 
268 
 
318 Baeriswyl, V. et al. Development of a selective peptide macrocycle 
inhibitor of coagulation factor XII toward the generation of a safe 
antithrombotic therapy. J Med Chem 56, 3742-3746, 
doi:10.1021/jm400236j (2013). 
319 Fan, F. et al. Protein profiling of active cysteine cathepsins in living cells 
using an activity-based probe containing a cell-penetrating peptide. J 
Proteome Res 11, 5763-5772, doi:10.1021/pr300575u (2012). 
320 Pan, D. et al. A general strategy for developing cell-permeable photo-
modulatable organic fluorescent probes for live-cell super-resolution 
imaging. Nat Commun 5, 5573, doi:10.1038/ncomms6573 (2014). 
321 Deshpande, P. P., Biswas, S. & Torchilin, V. P. Current trends in the use of 
liposomes for tumor targeting. Nanomedicine (Lond) 8, 1509-1528, 
doi:10.2217/nnm.13.118 (2013). 
322 Pao, K. C. et al. Probes of ubiquitin E3 ligases enable systematic dissection 
of parkin activation. Nat Chem Biol 12, 324-331, 
doi:10.1038/nchembio.2045 (2016). 
323 Kornahrens, A. F. et al. Design of Benzoxathiazin-3-one 1,1-Dioxides as a 
New Class of Irreversible Serine Hydrolase Inhibitors: Discovery of a 
Uniquely Selective PNPLA4 Inhibitor. J Am Chem Soc 139, 7052-7061, 
doi:10.1021/jacs.7b02985 (2017). 
324 Martell, J. & Weerapana, E. Applications of copper-catalyzed click 
chemistry in activity-based protein profiling. Molecules 19, 1378-1393, 
doi:10.3390/molecules19021378 (2014). 
325 Schiapparelli, L. M. et al. Direct detection of biotinylated proteins by mass 
spectrometry. J Proteome Res 13, 3966-3978, doi:10.1021/pr5002862 
(2014). 
326 Tully, S. E. & Cravatt, B. F. Activity-based probes that target functional 
subclasses of phospholipases in proteomes. J Am Chem Soc 132, 3264-
3265, doi:10.1021/ja1000505 (2010). 
327 Lahav, D. et al. A Fluorescence Polarization Activity-Based Protein Profiling 
Assay in the Discovery of Potent, Selective Inhibitors for Human 
Nonlysosomal Glucosylceramidase. J Am Chem Soc 139, 14192-14197, 
doi:10.1021/jacs.7b07352 (2017). 
328 Kawaguchi, M., Ikegawa, S., Ieda, N. & Nakagawa, H. A Fluorescent Probe 
for Imaging Sirtuin Activity in Living Cells, Based on One-Step Cleavage of 
the Dabcyl Quencher. Chembiochem 17, 1961-1967, 
doi:10.1002/cbic.201600374 (2016). 
329 Verdoes, M. et al. Improved quenched fluorescent probe for imaging of 
269 
 
cysteine cathepsin activity. J Am Chem Soc 135, 14726-14730, 
doi:10.1021/ja4056068 (2013). 
330 Blum, G., von Degenfeld, G., Merchant, M. J., Blau, H. M. & Bogyo, M. 
Noninvasive optical imaging of cysteine protease activity using 
fluorescently quenched activity-based probes. Nat Chem Biol 3, 668-677, 
doi:10.1038/nchembio.2007.26 (2007). 
331 Patricelli, M. P., Giang, D. K., Stamp, L. M. & Burbaum, J. J. Direct 
visualization of serine hydrolase activities in complex proteomes using 
fluorescent active site-directed probes. Proteomics 1, 1067-1071, 
doi:10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4 
(2001). 
332 Greenbaum, D. C. et al. Small molecule affinity fingerprinting. A tool for 
enzyme family subclassification, target identification, and inhibitor design. 
Chem Biol 9, 1085-1094 (2002). 
333 Ekkebus, R. et al. On terminal alkynes that can react with active-site 
cysteine nucleophiles in proteases. J Am Chem Soc 135, 2867-2870, 
doi:10.1021/ja309802n (2013). 
334 Stanley, M. et al. Orthogonal thiol functionalization at a single atomic 
center for profiling transthiolation activity of E1 activating enzymes. ACS 
Chem Biol 10, 1542-1554, doi:10.1021/acschembio.5b00118 (2015). 
335 Adam, G. C., Burbaum, J., Kozarich, J. W., Patricelli, M. P. & Cravatt, B. F. 
Mapping enzyme active sites in complex proteomes. J Am Chem Soc 126, 
1363-1368, doi:10.1021/ja038441g (2004). 
336 Jessani, N. et al. A streamlined platform for high-content functional 
proteomics of primary human specimens. Nat Methods 2, 691-697, 
doi:10.1038/nmeth778 (2005). 
337 Okerberg, E. S. et al. High-resolution functional proteomics by active-site 
peptide profiling. Proc Natl Acad Sci U S A 102, 4996-5001, 
doi:10.1073/pnas.0501205102 (2005). 
338 Speers, A. E. & Cravatt, B. F. A tandem orthogonal proteolysis strategy for 
high-content chemical proteomics. J Am Chem Soc 127, 10018-10019, 
doi:10.1021/ja0532842 (2005). 
339 Kramer, H. B., Nicholson, B., Kessler, B. M. & Altun, M. Detection of 
ubiquitin-proteasome enzymatic activities in cells: application of activity-
based probes to inhibitor development. Biochim Biophys Acta 1823, 2029-
2037, doi:10.1016/j.bbamcr.2012.05.014 (2012). 
340 Galmozzi, A., Dominguez, E., Cravatt, B. F. & Saez, E. Application of 
activity-based protein profiling to study enzyme function in adipocytes. 
270 
 
Methods Enzymol 538, 151-169, doi:10.1016/B978-0-12-800280-3.00009-
8 (2014). 
341 Jiang, X. et al. Sensitive and Accurate Quantitation of Phosphopeptides 
Using TMT Isobaric Labeling Technique. J Proteome Res 16, 4244-4252, 
doi:10.1021/acs.jproteome.7b00610 (2017). 
342 Ting, L., Rad, R., Gygi, S. P. & Haas, W. MS3 eliminates ratio distortion in 
isobaric multiplexed quantitative proteomics. Nat Methods 8, 937-940, 
doi:10.1038/nmeth.1714 (2011). 
343 Berberich, M. J., Paulo, J. A. & Everley, R. A. MS3-IDQ: Utilizing MS3 
Spectra beyond Quantification Yields Increased Coverage of the 
Phosphoproteome in Isobaric Tag Experiments. J Proteome Res 17, 1741-
1747, doi:10.1021/acs.jproteome.8b00006 (2018). 
344 Kemp, M. Recent Advances in the Discovery of Deubiquitinating Enzyme 
Inhibitors. Prog Med Chem 55, 149-192, 
doi:10.1016/bs.pmch.2015.10.002 (2016). 
345 Kategaya, L. et al. USP7 small-molecule inhibitors interfere with ubiquitin 
binding. Nature 550, 534-538, doi:10.1038/nature24006 (2017). 
346 Ulintz, P. J. et al. Comparison of MS(2)-only, MSA, and MS(2)/MS(3) 
methodologies for phosphopeptide identification. J Proteome Res 8, 887-
899, doi:10.1021/pr800535h (2009). 
347 Wiedner, S. D. et al. Organelle-specific activity-based protein profiling in 
living cells. Angew Chem Int Ed Engl 53, 2919-2922, 
doi:10.1002/anie.201309135 (2014). 
348 Kato, D. et al. Activity-based probes that target diverse cysteine protease 
families. Nat Chem Biol 1, 33-38, doi:10.1038/nchembio707 (2005). 
349 Blankman, J. L., Simon, G. M. & Cravatt, B. F. A comprehensive profile of 
brain enzymes that hydrolyze the endocannabinoid 2-
arachidonoylglycerol. Chem Biol 14, 1347-1356, 
doi:10.1016/j.chembiol.2007.11.006 (2007). 
350 Turk, B., Turk, D. & Turk, V. Protease signalling: the cutting edge. EMBO J 
31, 1630-1643, doi:10.1038/emboj.2012.42 (2012). 
351 Ortega, C. et al. Systematic Survey of Serine Hydrolase Activity in 
Mycobacterium tuberculosis Defines Changes Associated with 
Persistence. Cell Chem Biol 23, 290-298, 
doi:10.1016/j.chembiol.2016.01.003 (2016). 
352 Gillet, L. C. et al. In-cell selectivity profiling of serine protease inhibitors by 
activity-based proteomics. Mol Cell Proteomics 7, 1241-1253, 
doi:10.1074/mcp.M700505-MCP200 (2008). 
271 
 
353 Uhlmann, F., Wernic, D., Poupart, M. A., Koonin, E. V. & Nasmyth, K. 
Cleavage of cohesin by the CD clan protease separin triggers anaphase in 
yeast. Cell 103, 375-386 (2000). 
354 Borodovsky, A. et al. Small-molecule inhibitors and probes for ubiquitin- 
and ubiquitin-like-specific proteases. Chembiochem 6, 287-291, 
doi:10.1002/cbic.200400236 (2005). 
355 Sieber, S. A., Niessen, S., Hoover, H. S. & Cravatt, B. F. Proteomic profiling 
of metalloprotease activities with cocktails of active-site probes. Nat 
Chem Biol 2, 274-281, doi:10.1038/nchembio781 (2006). 
356 Patricelli, M. P. et al. Functional interrogation of the kinome using 
nucleotide acyl phosphates. Biochemistry 46, 350-358, 
doi:10.1021/bi062142x (2007). 
357 Yee, M. C., Fas, S. C., Stohlmeyer, M. M., Wandless, T. J. & Cimprich, K. A. A 
cell-permeable, activity-based probe for protein and lipid kinases. J Biol 
Chem 280, 29053-29059, doi:10.1074/jbc.M504730200 (2005). 
358 Wilke, K. E., Francis, S. & Carlson, E. E. Activity-based probe for histidine 
kinase signaling. J Am Chem Soc 134, 9150-9153, doi:10.1021/ja3041702 
(2012). 
359 Garland, M. et al. Development of an activity-based probe for acyl-protein 
thioesterases. PLoS One 13, e0190255, 
doi:10.1371/journal.pone.0190255 (2018). 
360 Heal, W. P., Dang, T. H. & Tate, E. W. Activity-based probes: discovering 
new biology and new drug targets. Chem Soc Rev 40, 246-257, 
doi:10.1039/c0cs00004c (2011). 
361 Evans, M. J. & Cravatt, B. F. Mechanism-based profiling of enzyme 
families. Chem Rev 106, 3279-3301, doi:10.1021/cr050288g (2006). 
362 Mignatti, P. & Rifkin, D. B. Plasminogen activators and angiogenesis. Curr 
Top Microbiol Immunol 213 ( Pt 1), 33-50 (1996). 
363 Lane, R. M., Potkin, S. G. & Enz, A. Targeting acetylcholinesterase and 
butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9, 101-
124, doi:10.1017/S1461145705005833 (2006). 
364 Yoshida, S. & Shiosaka, S. Plasticity-related serine proteases in the brain 
(review). Int J Mol Med 3, 405-409 (1999). 
365 Nomura, D. K. et al. Endocannabinoid hydrolysis generates brain 
prostaglandins that promote neuroinflammation. Science 334, 809-813, 
doi:10.1126/science.1209200 (2011). 
366 Long, J. Z. & Cravatt, B. F. The metabolic serine hydrolases and their 
functions in mammalian physiology and disease. Chem Rev 111, 6022-
272 
 
6063, doi:10.1021/cr200075y (2011). 
367 DeClerck, Y. A. et al. Proteases and protease inhibitors in tumor 
progression. Adv Exp Med Biol 425, 89-97 (1997). 
368 Nomura, D. K., Dix, M. M. & Cravatt, B. F. Activity-based protein profiling 
for biochemical pathway discovery in cancer. Nat Rev Cancer 10, 630-638, 
doi:10.1038/nrc2901 (2010). 
369 Simon, G. M. & Cravatt, B. F. Activity-based proteomics of enzyme 
superfamilies: serine hydrolases as a case study. J Biol Chem 285, 11051-
11055, doi:10.1074/jbc.R109.097600 (2010). 
370 Pineiro-Sanchez, M. L. et al. Identification of the 170-kDa melanoma 
membrane-bound gelatinase (seprase) as a serine integral membrane 
protease. J Biol Chem 272, 7595-7601 (1997). 
371 Glynn, P., Read, D. J., Guo, R., Wylie, S. & Johnson, M. K. Synthesis and 
characterization of a biotinylated organophosphorus ester for detection 
and affinity purification of a brain serine esterase: neuropathy target 
esterase. Biochem J 301 ( Pt 2), 551-556 (1994). 
372 Kam, C. M., Fujikawa, K. & Powers, J. C. Mechanism-based isocoumarin 
inhibitors for trypsin and blood coagulation serine proteases: new 
anticoagulants. Biochemistry 27, 2547-2557 (1988). 
373 Winkler, U. et al. Characterization, application and potential uses of 
biotin-tagged inhibitors for lymphocyte serine proteases (granzymes). Mol 
Immunol 33, 615-623 (1996). 
374 Bouma, B. N., Miles, L. A., Beretta, G. & Griffin, J. H. Human plasma 
prekallikrein. Studies of its activation by activated factor XII and of its 
inactivation by diisopropyl phosphofluoridate. Biochemistry 19, 1151-
1160 (1980). 
375 Jessani, N. et al. Carcinoma and stromal enzyme activity profiles 
associated with breast tumor growth in vivo. Proc Natl Acad Sci U S A 101, 
13756-13761, doi:10.1073/pnas.0404727101 (2004). 
376 Milner, J. M. et al. Fibroblast activation protein alpha is expressed by 
chondrocytes following a pro-inflammatory stimulus and is elevated in 
osteoarthritis. Arthritis Res Ther 8, R23, doi:10.1186/ar1877 (2006). 
377 Mahrus, S. & Craik, C. S. Selective chemical functional probes of 
granzymes A and B reveal granzyme B is a major effector of natural killer 
cell-mediated lysis of target cells. Chem Biol 12, 567-577, 
doi:10.1016/j.chembiol.2005.03.006 (2005). 
378 Nomura, D. K. et al. A brain detoxifying enzyme for organophosphorus 
nerve poisons. Proc Natl Acad Sci U S A 102, 6195-6200, 
273 
 
doi:10.1073/pnas.0501915102 (2005). 
379 Madsen, M. A., Deryugina, E. I., Niessen, S., Cravatt, B. F. & Quigley, J. P. 
Activity-based protein profiling implicates urokinase activation as a key 
step in human fibrosarcoma intravasation. J Biol Chem 281, 15997-16005, 
doi:10.1074/jbc.M601223200 (2006). 
380 Jessani, N., Liu, Y., Humphrey, M. & Cravatt, B. F. Enzyme activity profiles 
of the secreted and membrane proteome that depict cancer cell 
invasiveness. Proc Natl Acad Sci U S A 99, 10335-10340, 
doi:10.1073/pnas.162187599 (2002). 
381 Chiang, K. P., Niessen, S., Saghatelian, A. & Cravatt, B. F. An enzyme that 
regulates ether lipid signaling pathways in cancer annotated by 
multidimensional profiling. Chem Biol 13, 1041-1050, 
doi:10.1016/j.chembiol.2006.08.008 (2006). 
382 Lu, J., Xiao Yj, Y. J., Baudhuin, L. M., Hong, G. & Xu, Y. Role of ether-linked 
lysophosphatidic acids in ovarian cancer cells. J Lipid Res 43, 463-476 
(2002). 
383 Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid 
network that promotes cancer pathogenesis. Cell 140, 49-61, 
doi:10.1016/j.cell.2009.11.027 (2010). 
384 Long, J. Z. et al. Selective blockade of 2-arachidonoylglycerol hydrolysis 
produces cannabinoid behavioral effects. Nat Chem Biol 5, 37-44, 
doi:10.1038/nchembio.129 (2009). 
385 Iwata, Y., Mort, J. S., Tateishi, H. & Lee, E. R. Macrophage cathepsin L, a 
factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis 
Rheum 40, 499-509 (1997). 
386 Lavrik, I. N., Golks, A. & Krammer, P. H. Caspases: pharmacological 
manipulation of cell death. J Clin Invest 115, 2665-2672, 
doi:10.1172/JCI26252 (2005). 
387 Crawford, E. D. & Wells, J. A. Caspase substrates and cellular remodeling. 
Annu Rev Biochem 80, 1055-1087, doi:10.1146/annurev-biochem-061809-
121639 (2011). 
388 Pop, C. & Salvesen, G. S. Human caspases: activation, specificity, and 
regulation. J Biol Chem 284, 21777-21781, doi:10.1074/jbc.R800084200 
(2009). 
389 Joyce, J. A. et al. Cathepsin cysteine proteases are effectors of invasive 
growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 
443-453 (2004). 
390 Yan, S., Sameni, M. & Sloane, B. F. Cathepsin B and human tumor 
274 
 
progression. Biol Chem 379, 113-123 (1998). 
391 Goulet, B. et al. A cathepsin L isoform that is devoid of a signal peptide 
localizes to the nucleus in S phase and processes the CDP/Cux 
transcription factor. Mol Cell 14, 207-219 (2004). 
392 Greenbaum, D. C. et al. A role for the protease falcipain 1 in host cell 
invasion by the human malaria parasite. Science 298, 2002-2006, 
doi:10.1126/science.1077426 (2002). 
393 Mason, R. W., Wilcox, D., Wikstrom, P. & Shaw, E. N. The identification of 
active forms of cysteine proteinases in Kirsten-virus-transformed mouse 
fibroblasts by use of a specific radiolabelled inhibitor. Biochem J 257, 125-
129 (1989). 
394 Thornberry, N. A. et al. Inactivation of interleukin-1 beta converting 
enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33, 3934-3940 
(1994). 
395 Rawlings, N. D. & Barrett, A. J. Families of cysteine peptidases. Methods 
Enzymol 244, 461-486 (1994). 
396 Barrett, A. J. & Rawlings, N. D. Evolutionary lines of cysteine peptidases. 
Biol Chem 382, 727-733, doi:10.1515/BC.2001.088 (2001). 
397 Turk, V., Turk, B. & Turk, D. Lysosomal cysteine proteases: facts and 
opportunities. EMBO J 20, 4629-4633, doi:10.1093/emboj/20.17.4629 
(2001). 
398 Yasuda, Y., Kaleta, J. & Bromme, D. The role of cathepsins in osteoporosis 
and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv 
Rev 57, 973-993, doi:10.1016/j.addr.2004.12.013 (2005). 
399 Razzaque, A., Hanada, Y., Mukai, J. I., Murao, S. & Nishino, T. NAD- and 
FAD-3'-pyrophosphates--enzymic synthesis and inertness. FEBS Lett 93, 
335-338 (1978). 
400 Barrett, A. J. et al. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane 
(E-64) and its analogues as inhibitors of cysteine proteinases including 
cathepsins B, H and L. Biochem J 201, 189-198 (1982). 
401 Yasothornsrikul, S. et al. Cathepsin L in secretory vesicles functions as a 
prohormone-processing enzyme for production of the enkephalin peptide 
neurotransmitter. Proc Natl Acad Sci U S A 100, 9590-9595, 
doi:10.1073/pnas.1531542100 (2003). 
402 Greenbaum, D., Medzihradszky, K. F., Burlingame, A. & Bogyo, M. Epoxide 
electrophiles as activity-dependent cysteine protease profiling and 
discovery tools. Chem Biol 7, 569-581 (2000). 
403 McIlwain, D. R., Berger, T. & Mak, T. W. Caspase functions in cell death and 
275 
 
disease. Cold Spring Harb Perspect Biol 5, a008656, 
doi:10.1101/cshperspect.a008656 (2013). 
404 Thornberry, N. A. et al. A novel heterodimeric cysteine protease is 
required for interleukin-1 beta processing in monocytes. Nature 356, 768-
774, doi:10.1038/356768a0 (1992). 
405 Blum, G., Weimer, R. M., Edgington, L. E., Adams, W. & Bogyo, M. 
Comparative assessment of substrates and activity based probes as tools 
for non-invasive optical imaging of cysteine protease activity. PLoS One 4, 
e6374, doi:10.1371/journal.pone.0006374 (2009). 
406 Green, M. & Loewenstein, P. M. Autonomous functional domains of 
chemically synthesized human immunodeficiency virus tat trans-activator 
protein. Cell 55, 1179-1188 (1988). 
407 Kirby, J. M. et al. Cwp84, a surface-associated cysteine protease, plays a 
role in the maturation of the surface layer of Clostridium difficile. J Biol 
Chem 284, 34666-34673, doi:10.1074/jbc.M109.051177 (2009). 
408 Borodovsky, A. et al. A novel active site-directed probe specific for 
deubiquitylating enzymes reveals proteasome association of USP14. 
EMBO J 20, 5187-5196, doi:10.1093/emboj/20.18.5187 (2001). 
409 Gopinath, P., Ohayon, S., Nawatha, M. & Brik, A. Chemical and 
semisynthetic approaches to study and target deubiquitinases. Chem Soc 
Rev 45, 4171-4198, doi:10.1039/c6cs00083e (2016). 
410 Altun, M. et al. Activity-based chemical proteomics accelerates inhibitor 
development for deubiquitylating enzymes. Chem Biol 18, 1401-1412, 
doi:10.1016/j.chembiol.2011.08.018 (2011). 
411 Clague, M. J., Coulson, J. M. & Urbe, S. Cellular functions of the DUBs. J 
Cell Sci 125, 277-286, doi:10.1242/jcs.090985 (2012). 
412 Hicke, L. & Dunn, R. Regulation of membrane protein transport by 
ubiquitin and ubiquitin-binding proteins. Annual review of cell and 
developmental biology 19, 141-172, 
doi:10.1146/annurev.cellbio.19.110701.154617 (2003). 
413 Hassink, G. C. et al. The ER-resident ubiquitin-specific protease 19 
participates in the UPR and rescues ERAD substrates. EMBO Rep 10, 755-
761, doi:10.1038/embor.2009.69 (2009). 
414 Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway 
for p53 stabilization. Nature 416, 648-653, doi:10.1038/nature737 (2002). 
415 Sowa, M. E., Bennett, E. J., Gygi, S. P. & Harper, J. W. Defining the human 
deubiquitinating enzyme interaction landscape. Cell 138, 389-403, 
doi:10.1016/j.cell.2009.04.042 (2009). 
276 
 
416 Clague, M. J. et al. Deubiquitylases from genes to organism. Physiol Rev 
93, 1289-1315, doi:10.1152/physrev.00002.2013 (2013). 
417 Amerik, A. Y. & Hochstrasser, M. Mechanism and function of 
deubiquitinating enzymes. Biochim Biophys Acta 1695, 189-207, 
doi:10.1016/j.bbamcr.2004.10.003 (2004). 
418 Mevissen, T. E. T. & Komander, D. Mechanisms of Deubiquitinase 
Specificity and Regulation. Annu Rev Biochem 86, 159-192, 
doi:10.1146/annurev-biochem-061516-044916 (2017). 
419 Kwasna, D. et al. Discovery and Characterization of ZUFSP/ZUP1, a Distinct 
Deubiquitinase Class Important for Genome Stability. Mol Cell 70, 150-164 
e156, doi:10.1016/j.molcel.2018.02.023 (2018). 
420 Hewings, D. S. et al. Reactive-site-centric chemoproteomics identifies a 
distinct class of deubiquitinase enzymes. Nat Commun 9, 1162, 
doi:10.1038/s41467-018-03511-6 (2018). 
421 Johnston, S. C., Riddle, S. M., Cohen, R. E. & Hill, C. P. Structural basis for 
the specificity of ubiquitin C-terminal hydrolases. EMBO J 18, 3877-3887, 
doi:10.1093/emboj/18.14.3877 (1999). 
422 Hemelaar, J., Lelyveld, V. S., Kessler, B. M. & Ploegh, H. L. A single 
protease, Apg4B, is specific for the autophagy-related ubiquitin-like 
proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L. J Biol Chem 278, 
51841-51850, doi:10.1074/jbc.M308762200 (2003). 
423 Hemelaar, J. et al. Specific and covalent targeting of conjugating and 
deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol 24, 84-95 
(2004). 
424 Sommer, S., Weikart, N. D., Linne, U. & Mootz, H. D. Covalent inhibition of 
SUMO and ubiquitin-specific cysteine proteases by an in situ thiol-alkyne 
addition. Bioorg Med Chem 21, 2511-2517, 
doi:10.1016/j.bmc.2013.02.039 (2013). 
425 Love, K. R., Pandya, R. K., Spooner, E. & Ploegh, H. L. Ubiquitin C-terminal 
electrophiles are activity-based probes for identification and mechanistic 
study of ubiquitin conjugating machinery. ACS Chem Biol 4, 275-287, 
doi:10.1021/cb9000348 (2009). 
426 Whedon, S. D. et al. Selenocysteine as a latent bioorthogonal electrophilic 
probe for deubiquitylating enzymes. J Am Chem Soc, 
doi:10.1021/jacs.6b05688 (2016). 
427 Naik, E. & Dixit, V. M. Usp9X Is Required for Lymphocyte Activation and 
Homeostasis through Its Control of ZAP70 Ubiquitination and PKCbeta 
Kinase Activity. J Immunol 196, 3438-3451, 
277 
 
doi:10.4049/jimmunol.1403165 (2016). 
428 Balakirev, M. Y., Tcherniuk, S. O., Jaquinod, M. & Chroboczek, J. Otubains: 
a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep 4, 
517-522, doi:10.1038/sj.embor.embor824 (2003). 
429 Pruneda, J. N. et al. The Molecular Basis for Ubiquitin and Ubiquitin-like 
Specificities in Bacterial Effector Proteases. Mol Cell 63, 261-276, 
doi:10.1016/j.molcel.2016.06.015 (2016). 
430 Flierman, D. et al. Non-hydrolyzable Diubiquitin Probes Reveal Linkage-
Specific Reactivity of Deubiquitylating Enzymes Mediated by S2 Pockets. 
Cell Chem Biol 23, 472-482, doi:10.1016/j.chembiol.2016.03.009 (2016). 
431 Gao, Y. et al. Early adipogenesis is regulated through USP7-mediated 
deubiquitination of the histone acetyltransferase TIP60. Nat Commun 4, 
2656, doi:10.1038/ncomms3656 (2013). 
432 Harrigan, J. A., Jacq, X., Martin, N. M. & Jackson, S. P. Deubiquitylating 
enzymes and drug discovery: emerging opportunities. Nat Rev Drug 
Discov 17, 57-78, doi:10.1038/nrd.2017.152 (2018). 
433 Wang, X. et al. The proteasome deubiquitinase inhibitor VLX1570 shows 
selectivity for ubiquitin-specific protease-14 and induces apoptosis of 
multiple myeloma cells. Sci Rep 6, 26979, doi:10.1038/srep26979 (2016). 
434 Turnbull, A. P. et al. Molecular basis of USP7 inhibition by selective small-
molecule inhibitors. Nature 550, 481-486, doi:10.1038/nature24451 
(2017). 
435 An, H. & Statsyuk, A. V. Development of activity-based probes for 
ubiquitin and ubiquitin-like protein signaling pathways. J Am Chem Soc 
135, 16948-16962, doi:10.1021/ja4099643 (2013). 
436 An, H. & Statsyuk, A. V. Facile synthesis of covalent probes to capture 
enzymatic intermediates during E1 enzyme catalysis. Chem Commun 
(Camb) 52, 2477-2480, doi:10.1039/c5cc08592f (2016). 
437 Krist, D. T., Park, S., Boneh, G. H., Rice, S. E. & Statsyuk, A. V. UbFluor: A 
Mechanism-Based Probe for HECT E3 Ligases. Chem Sci 7, 5587-5595, 
doi:10.1039/C6SC01167E (2016). 
438 Park, S., Foote, P. K., Krist, D. T., Rice, S. E. & Statsyuk, A. V. UbMES and 
UbFluor: Novel probes for ring-between-ring (RBR) E3 ubiquitin ligase 
PARKIN. J Biol Chem 292, 16539-16553, doi:10.1074/jbc.M116.773200 
(2017). 
439 Mulder, M. P. et al. A cascading activity-based probe sequentially targets 
E1-E2-E3 ubiquitin enzymes. Nat Chem Biol 12, 523-530, 
doi:10.1038/nchembio.2084 (2016). 
278 
 
440 Freedy, A. M. et al. Chemoselective Installation of Amine Bonds on 
Proteins through Aza-Michael Ligation. J Am Chem Soc 139, 18365-18375, 
doi:10.1021/jacs.7b10702 (2017). 
441 Dadova, J. et al. Vinylsulfonamide and acrylamide modification of DNA for 
cross-linking with proteins. Angew Chem Int Ed Engl 52, 10515-10518, 
doi:10.1002/anie.201303577 (2013). 
442 Hong, V., Presolski, S. I., Ma, C. & Finn, M. G. Analysis and optimization of 
copper-catalyzed azide-alkyne cycloaddition for bioconjugation. Angew 
Chem Int Ed Engl 48, 9879-9883, doi:10.1002/anie.200905087 (2009). 
443 Lin, D. Y., Diao, J., Zhou, D. & Chen, J. Biochemical and structural studies of 
a HECT-like ubiquitin ligase from Escherichia coli O157:H7. J Biol Chem 
286, 441-449, doi:10.1074/jbc.M110.167643 (2011). 
444 Virdee, S., Ye, Y., Nguyen, D. P., Komander, D. & Chin, J. W. Engineered 
diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU 
deubiquitinase. Nat Chem Biol 6, 750-757, doi:10.1038/nchembio.426 
(2010). 
445 El Oualid, F. et al. Chemical synthesis of ubiquitin, ubiquitin-based probes, 
and diubiquitin. Angewandte Chemie 49, 10149-10153, 
doi:10.1002/anie.201005995 (2010). 
446 Plechanovova, A., Jaffray, E. G., Tatham, M. H., Naismith, J. H. & Hay, R. T. 
Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. 
Nature, doi:10.1038/nature11376 (2012). 
447 Emmerich, C. H. et al. Activation of the canonical IKK complex by K63/M1-
linked hybrid ubiquitin chains. Proc Natl Acad Sci U S A 110, 15247-15252, 
doi:10.1073/pnas.1314715110 (2013). 
448 Kazlauskaite, A. et al. Phosphorylation of Parkin at Serine65 is essential 
for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 
ligase activity. Open biology 4, 130213, doi:10.1098/rsob.130213 (2014). 
449 Lai, Y. C. et al. Phosphoproteomic screening identifies Rab GTPases as 
novel downstream targets of PINK1. EMBO J 34, 2840-2861, 
doi:10.15252/embj.201591593 (2015). 
450 Wu, P. Y. et al. A conserved catalytic residue in the ubiquitin-conjugating 
enzyme family. EMBO J 22, 5241-5250, doi:10.1093/emboj/cdg501 
(2003). 
451 Yunus, A. A. & Lima, C. D. Lysine activation and functional analysis of E2-
mediated conjugation in the SUMO pathway. Nat Struct Mol Biol 13, 491-
499, doi:10.1038/nsmb1104 (2006). 
452 Brownell, J. E. et al. Substrate-assisted inhibition of ubiquitin-like protein-
279 
 
activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-
AMP mimetic in situ. Mol Cell 37, 102-111, 
doi:10.1016/j.molcel.2009.12.024 (2010). 
453 Lovell, S. C. et al. Structure validation by Calpha geometry: phi,psi and 
Cbeta deviation. Proteins 50, 437-450, doi:10.1002/prot.10286 (2003). 
454 Dominguez, E. et al. Integrated phenotypic and activity-based profiling 
links Ces3 to obesity and diabetes. Nat Chem Biol 10, 113-121, 
doi:10.1038/nchembio.1429 (2014). 
455 Lu, X. et al. Designed semisynthetic protein inhibitors of Ub/Ubl E1 
activating enzymes. Journal of the American Chemical Society 132, 1748-
1749, doi:10.1021/ja9088549 (2010). 
456 Stanley, M. et al. Orthogonal Thiol Functionalization at a Single Atomic 
Center for Profiling Transthiolation Activity of E1 Activating Enzymes. ACS 
chemical biology, doi:10.1021/acschembio.5b00118 (2015). 
457 Virdee, S. et al. Traceless and site-specific ubiquitination of recombinant 
proteins. J Am Chem Soc 133, 10708-10711, doi:10.1021/ja202799r 
(2011). 
458 Strickson, S. et al. The anti-inflammatory drug BAY 11-7082 suppresses 
the MyD88-dependent signalling network by targeting the ubiquitin 
system. Biochem J 451, 427-437, doi:10.1042/BJ20121651 (2013). 
459 Hong, V., Presolski, S. I., Ma, C. & Finn, M. G. Analysis and optimization of 
copper-catalyzed azide-alkyne cycloaddition for bioconjugation. 
Angewandte Chemie 48, 9879-9883, doi:10.1002/anie.200905087 (2009). 
460 Cui, C., Zhao, W., Chen, J., Wang, J. & Li, Q. Elimination of in vivo cleavage 
between target protein and intein in the intein-mediated protein 
purification systems. Protein expression and purification 50, 74-81, 
doi:10.1016/j.pep.2006.05.019 (2006). 
461 Weissman, A. M. Themes and variations on ubiquitylation. Nat Rev Mol 
Cell Biol 2, 169-178, doi:10.1038/35056563 (2001). 
462 Sarraf, S. A. et al. Landscape of the PARKIN-dependent ubiquitylome in 
response to mitochondrial depolarization. Nature 496, 372-376, 
doi:10.1038/nature12043 (2013). 
463 Dawson, T. M. & Dawson, V. L. The role of parkin in familial and sporadic 
Parkinson's disease. Mov Disord 25 Suppl 1, S32-39, 
doi:10.1002/mds.22798 (2010). 
464 Pickrell, A. M. & Youle, R. J. The roles of PINK1, parkin, and mitochondrial 
fidelity in Parkinson's disease. Neuron 85, 257-273, 
doi:10.1016/j.neuron.2014.12.007 (2015). 
280 
 
465 Martinez, A. et al. Quantitative proteomic analysis of Parkin substrates in 
Drosophila neurons. Mol Neurodegener 12, 29, doi:10.1186/s13024-017-
0170-3 (2017). 
466 Riley, B. E. et al. Structure and function of Parkin E3 ubiquitin ligase 
reveals aspects of RING and HECT ligases. Nat Commun 4, 1982, 
doi:10.1038/ncomms2982 (2013). 
467 Mackay, C. et al. E3 ubiquitin ligase HOIP attenuates apoptotic cell death 
induced by cisplatin. Cancer research 74, 2246-2257, doi:10.1158/0008-
5472.CAN-13-2131 (2014). 
468 Schaeffer, V. et al. Binding of OTULIN to the PUB domain of HOIP controls 
NF-kappaB signaling. Molecular cell 54, 349-361, 
doi:10.1016/j.molcel.2014.03.016 (2014). 
469 Heo, J. M., Ordureau, A., Paulo, J. A., Rinehart, J. & Harper, J. W. The 
PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of 
OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy. 
Mol Cell 60, 7-20, doi:10.1016/j.molcel.2015.08.016 (2015). 
470 Perez, F. A. & Palmiter, R. D. Parkin-deficient mice are not a robust model 
of parkinsonism. Proc Natl Acad Sci U S A 102, 2174-2179, 
doi:10.1073/pnas.0409598102 (2005). 
471 McWilliams, T. G. et al. Basal Mitophagy Occurs Independently of PINK1 in 
Mouse Tissues of High Metabolic Demand. Cell Metab 27, 439-449 e435, 
doi:10.1016/j.cmet.2017.12.008 (2018). 
472 Byrne, R., Mund, T. & Licchesi, J. D. F. Activity-Based Probes for HECT E3 
Ubiquitin Ligases. Chembiochem 18, 1415-1427, 
doi:10.1002/cbic.201700006 (2017). 
473 Scheffner, M., Nuber, U. & Huibregtse, J. M. Protein ubiquitination 
involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373, 
81-83, doi:10.1038/373081a0 (1995). 
474 Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. A family of 
proteins structurally and functionally related to the E6-AP ubiquitin-
protein ligase. Proceedings of the National Academy of Sciences of the 
United States of America 92, 5249 (1995). 
475 Speers, A. E. & Cravatt, B. F. Activity-Based Protein Profiling (ABPP) and 
Click Chemistry (CC)-ABPP by MudPIT Mass Spectrometry. Curr Protoc 
Chem Biol 1, 29-41, doi:10.1002/9780470559277.ch090138 (2009). 
476 Salisbury, C. M. & Cravatt, B. F. Activity-based probes for proteomic 
profiling of histone deacetylase complexes. Proc Natl Acad Sci U S A 104, 
1171-1176, doi:10.1073/pnas.0608659104 (2007). 
281 
 
477 Carroll, R. G., Hollville, E. & Martin, S. J. Parkin sensitizes toward apoptosis 
induced by mitochondrial depolarization through promoting degradation 
of Mcl-1. Cell Rep 9, 1538-1553, doi:10.1016/j.celrep.2014.10.046 (2014). 
478 Grill, B., Murphey, R. K. & Borgen, M. A. The PHR proteins: intracellular 
signaling hubs in neuronal development and axon degeneration. Neural 
Dev 11, 8, doi:10.1186/s13064-016-0063-0 (2016). 
479 Guo, Q., Xie, J., Dang, C. V., Liu, E. T. & Bishop, J. M. Identification of a 
large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad 
Sci U S A 95, 9172-9177 (1998). 
480 Schaefer, A. M., Hadwiger, G. D. & Nonet, M. L. rpm-1, a conserved 
neuronal gene that regulates targeting and synaptogenesis in C. elegans. 
Neuron 26, 345-356 (2000). 
481 Wan, H. I. et al. Highwire regulates synaptic growth in Drosophila. Neuron 
26, 313-329 (2000). 
482 Zhen, M., Huang, X., Bamber, B. & Jin, Y. Regulation of presynaptic 
terminal organization by C. elegans RPM-1, a putative guanine nucleotide 
exchanger with a RING-H2 finger domain. Neuron 26, 331-343 (2000). 
483 D'Souza, J. et al. Formation of the retinotectal projection requires Esrom, 
an ortholog of PAM (protein associated with Myc). Development 132, 247-
256, doi:10.1242/dev.01578 (2005). 
484 Bloom, A. J., Miller, B. R., Sanes, J. R. & DiAntonio, A. The requirement for 
Phr1 in CNS axon tract formation reveals the corticostriatal boundary as a 
choice point for cortical axons. Genes Dev 21, 2593-2606, 
doi:10.1101/gad.1592107 (2007). 
485 Lewcock, J. W., Genoud, N., Lettieri, K. & Pfaff, S. L. The ubiquitin ligase 
Phr1 regulates axon outgrowth through modulation of microtubule 
dynamics. Neuron 56, 604-620, doi:10.1016/j.neuron.2007.09.009 (2007). 
486 Burgess, R. W. et al. Evidence for a conserved function in synapse 
formation reveals Phr1 as a candidate gene for respiratory failure in 
newborn mice. Mol Cell Biol 24, 1096-1105 (2004). 
487 Grill, B. et al. C. elegans RPM-1 regulates axon termination and 
synaptogenesis through the Rab GEF GLO-4 and the Rab GTPase GLO-1. 
Neuron 55, 587-601, doi:10.1016/j.neuron.2007.07.009 (2007). 
488 Opperman, K. J. & Grill, B. RPM-1 is localized to distinct subcellular 
compartments and regulates axon length in GABAergic motor neurons. 
Neural Dev 9, 10, doi:10.1186/1749-8104-9-10 (2014). 
489 Abrams, B., Grill, B., Huang, X. & Jin, Y. Cellular and molecular 
determinants targeting the Caenorhabditis elegans PHR protein RPM-1 to 
282 
 
perisynaptic regions. Dev Dyn 237, 630-639, doi:10.1002/dvdy.21446 
(2008). 
490 Wu, C., Wairkar, Y. P., Collins, C. A. & DiAntonio, A. Highwire function at 
the Drosophila neuromuscular junction: spatial, structural, and temporal 
requirements. J Neurosci 25, 9557-9566, doi:10.1523/JNEUROSCI.2532-
05.2005 (2005). 
491 Han, S. et al. Pam (Protein associated with Myc) functions as an E3 
ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal 20, 1084-
1091, doi:10.1016/j.cellsig.2008.01.020 (2008). 
492 Saiga, T. et al. Fbxo45 forms a novel ubiquitin ligase complex and is 
required for neuronal development. Mol Cell Biol 29, 3529-3543, 
doi:10.1128/MCB.00364-09 (2009). 
493 Babetto, E., Beirowski, B., Russler, E. V., Milbrandt, J. & DiAntonio, A. The 
Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell 
Rep 3, 1422-1429, doi:10.1016/j.celrep.2013.04.013 (2013). 
494 Holland, S. et al. The ubiquitin ligase MYCBP2 regulates transient receptor 
potential vanilloid receptor 1 (TRPV1) internalization through inhibition of 
p38 MAPK signaling. J Biol Chem 286, 3671-3680, 
doi:10.1074/jbc.M110.154765 (2011). 
495 Xiong, X. et al. The Highwire ubiquitin ligase promotes axonal 
degeneration by tuning levels of Nmnat protein. PLoS Biol 10, e1001440, 
doi:10.1371/journal.pbio.1001440 (2012). 
496 Milde, S., Gilley, J. & Coleman, M. P. Axonal trafficking of NMNAT2 and its 
roles in axon growth and survival in vivo. Bioarchitecture 3, 133-140, 
doi:10.4161/bioa.27049 (2013). 
497 McIntyre, M. C., Frattini, M. G., Grossman, S. R. & Laimins, L. A. Human 
papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for 
zinc binding, dimerization, and transformation but not for Rb binding. 
Journal of virology 67, 3142-3150 (1993). 
498 Wang, X. et al. Ubiquitination of serine, threonine, or lysine residues on 
the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J 
Cell Biol 177, 613-624, doi:10.1083/jcb.200611063 (2007). 
499 van Wijk, S. J. et al. A comprehensive framework of E2-RING E3 
interactions of the human ubiquitin-proteasome system. Mol Syst Biol 5, 
295, doi:10.1038/msb.2009.55 (2009). 
500 Metzger, M. B., Pruneda, J. N., Klevit, R. E. & Weissman, A. M. RING-type 
E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and 
ubiquitination. Biochim Biophys Acta 1843, 47-60, 
283 
 
doi:10.1016/j.bbamcr.2013.05.026 (2014). 
501 Koliopoulos, M. G., Esposito, D., Christodoulou, E., Taylor, I. A. & Rittinger, 
K. Functional role of TRIM E3 ligase oligomerization and regulation of 
catalytic activity. EMBO J 35, 1204-1218, doi:10.15252/embj.201593741 
(2016). 
502 Wright, J. D., Mace, P. D. & Day, C. L. Secondary ubiquitin-RING docking 
enhances Arkadia and Ark2C E3 ligase activity. Nat Struct Mol Biol 23, 45-
52, doi:10.1038/nsmb.3142 (2016). 
503 Allen, G. F., Toth, R., James, J. & Ganley, I. G. Loss of iron triggers 
PINK1/Parkin-independent mitophagy. EMBO Rep 14, 1127-1135, 
doi:10.1038/embor.2013.168 (2013). 
504 Irwin, D. J., Lee, V. M. & Trojanowski, J. Q. Parkinson's disease dementia: 
convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat 
Rev Neurosci 14, 626-636, doi:10.1038/nrn3549 (2013). 
505 Stefanis, L. alpha-Synuclein in Parkinson's disease. Cold Spring Harb 
Perspect Med 2, a009399, doi:10.1101/cshperspect.a009399 (2012). 
506 Arora, A. & Scholar, E. M. Role of tyrosine kinase inhibitors in cancer 
therapy. J Pharmacol Exp Ther 315, 971-979, 
doi:10.1124/jpet.105.084145 (2005). 
507 Gross, S., Rahal, R., Stransky, N., Lengauer, C. & Hoeflich, K. P. Targeting 
cancer with kinase inhibitors. J Clin Invest 125, 1780-1789, 
doi:10.1172/JCI76094 (2015). 
508 Cohen, P. & Tcherpakov, M. Will the ubiquitin system furnish as many drug 
targets as protein kinases? Cell 143, 686-693, 
doi:10.1016/j.cell.2010.11.016 (2010). 
509 Huang, X. & Dixit, V. M. Drugging the undruggables: exploring the 
ubiquitin system for drug development. Cell Res 26, 484-498, 
doi:10.1038/cr.2016.31 (2016). 
510 Zhao, R. et al. DDB2 modulates TGF-beta signal transduction in human 
ovarian cancer cells by downregulating NEDD4L. Nucleic Acids Res 43, 
7838-7849, doi:10.1093/nar/gkv667 (2015). 
511 Qu, M. H. et al. miR-93 promotes TGF-beta-induced epithelial-to-
mesenchymal transition through downregulation of NEDD4L in lung 
cancer cells. Tumour Biol 37, 5645-5651, doi:10.1007/s13277-015-4328-8 
(2016). 
512 Kito, Y. et al. Pathobiological properties of the ubiquitin ligase Nedd4L in 
melanoma. Int J Exp Pathol 95, 24-28, doi:10.1111/iep.12051 (2014). 
513 Veeriah, S. et al. Somatic mutations of the Parkinson's disease-associated 
284 
 
gene PARK2 in glioblastoma and other human malignancies. Nat Genet 
42, 77-82, doi:10.1038/ng.491 (2010). 
514 Poulogiannis, G. et al. PARK2 deletions occur frequently in sporadic 
colorectal cancer and accelerate adenoma development in Apc mutant 
mice. Proc Natl Acad Sci U S A 107, 15145-15150, 
doi:10.1073/pnas.1009941107 (2010). 
515 Cesari, R. et al. Parkin, a gene implicated in autosomal recessive juvenile 
parkinsonism, is a candidate tumor suppressor gene on chromosome 
6q25-q27. Proc Natl Acad Sci U S A 100, 5956-5961, 
doi:10.1073/pnas.0931262100 (2003). 
516 Cappadocia, L. & Lima, C. D. Ubiquitin-like Protein Conjugation: 
Structures, Chemistry, and Mechanism. Chem Rev 118, 889-918, 
doi:10.1021/acs.chemrev.6b00737 (2018). 
517 Guidotti, G., Brambilla, L. & Rossi, D. Cell-Penetrating Peptides: From Basic 
Research to Clinics. Trends Pharmacol Sci 38, 406-424, 
doi:10.1016/j.tips.2017.01.003 (2017). 
518 Kristensen, M., Birch, D. & Morck Nielsen, H. Applications and Challenges 
for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and 
Protein Cargos. Int J Mol Sci 17, doi:10.3390/ijms17020185 (2016). 
519 Ellis, H. R. & Poole, L. B. Roles for the two cysteine residues of AhpC in 
catalysis of peroxide reduction by alkyl hydroperoxide reductase from 
Salmonella typhimurium. Biochemistry 36, 13349-13356, 
doi:10.1021/bi9713658 (1997). 
520 Alpi, A. F., Chaugule, V. & Walden, H. Mechanism and disease association 
of E2-conjugating enzymes: lessons from UBE2T and UBE2L3. Biochem J 
473, 3401-3419, doi:10.1042/BCJ20160028 (2016). 
521 McDowell, G. S. & Philpott, A. Non-canonical ubiquitylation: mechanisms 
and consequences. Int J Biochem Cell Biol 45, 1833-1842, 
doi:10.1016/j.biocel.2013.05.026 (2013). 
522 Wang, X., Herr, R. A. & Hansen, T. H. Ubiquitination of substrates by 
esterification. Traffic 13, 19-24, doi:10.1111/j.1600-0854.2011.01269.x 
(2012). 
523 Coscoy, L. & Ganem, D. PHD domains and E3 ubiquitin ligases: viruses 
make the connection. Trends Cell Biol 13, 7-12 (2003). 
524 Hewitt, E. W. et al. Ubiquitylation of MHC class I by the K3 viral protein 
signals internalization and TSG101-dependent degradation. EMBO J 21, 
2418-2429, doi:10.1093/emboj/21.10.2418 (2002). 
525 Cadwell, K. & Coscoy, L. Ubiquitination on nonlysine residues by a viral E3 
285 
 
ubiquitin ligase. Science 309, 127-130, doi:10.1126/science.1110340 
(2005). 
526 Williams, C., van den Berg, M., Geers, E. & Distel, B. Pex10p functions as 
an E3 ligase for the Ubc4p-dependent ubiquitination of Pex5p. Biochem 
Biophys Res Commun 374, 620-624, doi:10.1016/j.bbrc.2008.07.054 
(2008). 
527 Platta, H. W. et al. Pex2 and pex12 function as protein-ubiquitin ligases in 
peroxisomal protein import. Mol Cell Biol 29, 5505-5516, 
doi:10.1128/MCB.00388-09 (2009). 
528 Vosper, J. M. et al. Ubiquitylation on canonical and non-canonical sites 
targets the transcription factor neurogenin for ubiquitin-mediated 
proteolysis. J Biol Chem 284, 15458-15468, doi:10.1074/jbc.M809366200 
(2009). 
529 Wang, Y. & Tjandra, N. Structural insights of tBid, the caspase-8-activated 
Bid, and its BH3 domain. J Biol Chem 288, 35840-35851, 
doi:10.1074/jbc.M113.503680 (2013). 
530 Tait, S. W. et al. Apoptosis induction by Bid requires unconventional 
ubiquitination and degradation of its N-terminal fragment. J Cell Biol 179, 
1453-1466, doi:10.1083/jcb.200707063 (2007). 
531 Ishikura, S., Weissman, A. M. & Bonifacino, J. S. Serine residues in the 
cytosolic tail of the T-cell antigen receptor alpha-chain mediate 
ubiquitination and endoplasmic reticulum-associated degradation of the 
unassembled protein. J Biol Chem 285, 23916-23924, 
doi:10.1074/jbc.M110.127936 (2010). 
532 Bays, N. W., Gardner, R. G., Seelig, L. P., Joazeiro, C. A. & Hampton, R. Y. 
Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-
associated degradation. Nat Cell Biol 3, 24-29, doi:10.1038/35050524 
(2001). 
533 Shimizu, Y., Okuda-Shimizu, Y. & Hendershot, L. M. Ubiquitylation of an 
ERAD substrate occurs on multiple types of amino acids. Mol Cell 40, 917-
926, doi:10.1016/j.molcel.2010.11.033 (2010). 
534 Herr, R. A., Harris, J., Fang, S., Wang, X. & Hansen, T. H. Role of the RING-
CH domain of viral ligase mK3 in ubiquitination of non-lysine and lysine 
MHC I residues. Traffic 10, 1301-1317, doi:10.1111/j.1600-
0854.2009.00946.x (2009). 
535 Song, J. et al. Stability of thioester intermediates in ubiquitin-like 
modifications. Protein Sci 18, 2492-2499, doi:10.1002/pro.254 (2009). 
536 Holland, S. & Scholich, K. Regulation of neuronal functions by the E3-
286 
 
ubiquitinligase protein associated with MYC (MYCBP2). Commun Integr 
Biol 4, 513-515, doi:10.4161/cib.4.5.15967 (2011). 
537 Ji, R. R., Samad, T. A., Jin, S. X., Schmoll, R. & Woolf, C. J. p38 MAPK 
activation by NGF in primary sensory neurons after inflammation 
increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36, 57-68 
(2002). 
538 Nakata, K. et al. Regulation of a DLK-1 and p38 MAP kinase pathway by 
the ubiquitin ligase RPM-1 is required for presynaptic development. Cell 
120, 407-420, doi:10.1016/j.cell.2004.12.017 (2005). 
539 Sakuma, H. et al. Molecular cloning and functional expression of a cDNA 
encoding a new member of mixed lineage protein kinase from human 
brain. J Biol Chem 272, 28622-28629 (1997). 
540 Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and 
inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4, 648-657, 
doi:10.1038/ncb839 (2002). 
541 Swaney, D. L. et al. Global analysis of phosphorylation and ubiquitylation 
cross-talk in protein degradation. Nat Methods 10, 676-682, 
doi:10.1038/nmeth.2519 (2013). 
542 Ordureau, A. et al. Quantitative proteomics reveal a feedforward 
mechanism for mitochondrial PARKIN translocation and ubiquitin chain 
synthesis. Mol Cell 56, 360-375, doi:10.1016/j.molcel.2014.09.007 (2014). 
543 Heap, R. E., Gant, M. S., Lamoliatte, F., Peltier, J. & Trost, M. Mass 
spectrometry techniques for studying the ubiquitin system. Biochem Soc 
Trans 45, 1137-1148, doi:10.1042/BST20170091 (2017). 
544 Sylvestersen, K. B., Young, C. & Nielsen, M. L. Advances in characterizing 
ubiquitylation sites by mass spectrometry. Curr Opin Chem Biol 17, 49-58, 
doi:10.1016/j.cbpa.2012.12.009 (2013). 
545 Ohsaki, Y., Cheng, J., Fujita, A., Tokumoto, T. & Fujimoto, T. Cytoplasmic 
lipid droplets are sites of convergence of proteasomal and autophagic 
degradation of apolipoprotein B. Mol Biol Cell 17, 2674-2683, 
doi:10.1091/mbc.E05-07-0659 (2006). 
546 Yoshida, Y. et al. E3 ubiquitin ligase that recognizes sugar chains. Nature 
418, 438-442, doi:10.1038/nature00890 (2002). 
547 Pao, K. C. et al. Activity-based E3 ligase profiling uncovers an E3 ligase 
with esterification activity. Nature 556, 381-385, doi:10.1038/s41586-018-
0026-1 (2018). 
548 Udeshi, N. D. et al. Refined preparation and use of anti-diglycine remnant 
(K-epsilon-GG) antibody enables routine quantification of 10,000s of 
287 
 
ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 
12, 825-831, doi:10.1074/mcp.O112.027094 (2013). 
 
